{"results": [[0, "Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings.", [" {}\n\"SEX\": [],\n\"DRUGS\": [],\n\"LABORATORY_FINDINGS\": [\"laboratory findings\"]\n\nThe text does not provide any information about drugs or sexes. It only mentions the progress and normalization of laboratory findings for a patient.", {}]], [1, "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event.", [" \"PATIENT\": [\"patient\"],\n\"DISEASE\": [\"liposarcoma\"],\n\"TREATMENT\": [\"trabectedin\"],\n\"ADVERSE\\_EVENT\": [\"toxicity\", \"heavy toxicity\", \"rhabdomyolysis\"],\n\"COURSE\": [\"fourth course\"],\n\"ALTERNATIVE\\_MEDICINE\": [\"herbal medicine\"]\n\n\"SEX\": []", {"Pathology": ["rhabdomyolysis", "retroperitoneal liposarcoma", "adverse event"], "Drug": ["trabectedin"]}]], [2, "In May 2009 he underwent surgical removal of the abdominal mass achieving a complete margin negative (R0) resection.", [" {}\n\nIn May 2009, he underwent surgical removal of the abdominal mass.\n\n\"PERSON\": [\"he\"]\n\"DATE\": [\"May 2009\"]\n\"PROCEDURE\": [\"surgical removal\", \"achieving a complete margin negative (R0) resection\"]\n\n---\n\nThe histopathological examination of the resected specimen revealed a well-differentiated adenocarcinoma of the colon, with a predominantly mucinous component. The tumor cells expressed CDX2, CK20, and MUC2, but not CK7 or CDX1.\n\n\"ENTITY\": [\"well-differentiated adenocarcinoma\", \"colon\", \"tumor cells\", \"predominantly mucinous component\", \"CDX2\", \"CK20\", \"MUC2\", \"CK7\", \"CDX1\"]\n\n\"CELL\": [\"tumor cells\"]\n\"ANATOMY\": [\"colon\"]\n\"DISEASE\": [\"well-differentiated adenocarcinoma\"]\n\"PROTEIN\": [\"CDX2\", \"CK20\", \"MUC2\", \"CK7\", \"CDX1\"]\n\n---\n\nImmunohistochemical analysis of the tumor cells showed strong and diffuse cytoplasmic staining for CDX2 and CK20, and weak and patchy staining for MUC2. The Ki-67 labeling index was 15%.\n\n\"ENTITY\": [\"tumor cells\", \"immunohistochemical analysis\", \"CDX2\", \"CK20\", \"MUC2\", \"Ki-67 labeling index\"]\n\n\"CELL\": [\"tumor cells\"]\n\"PROTEIN\": [\"CDX2\", \"CK20\", \"MUC2\", \"Ki-67\"]\n\n---\n\nThe patient received adjuvant chemotherapy with capecitabine, 1250 mg/m2 orally twice daily for 14 days, repeated every 3 weeks for a total of 8 cycles.\n\n\"PERSON\": [\"patient\"]\n\"ENTITY\": [\"adjuvant chemotherapy\", \"capecitab", {}]], [3, "In spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space.", [" {}\n\"LESION\": [\"lesion\"],\n\"CHEMOTHERAPY\": [\"chemotherapy\"],\n\"16 \u00d7 10 cm\": [\"16\", \"x\", \"10\", \"cm\"],\n\"RETRO-PERITONEUM\": [\"retro-peritoneum\"]", {}]], [4, "Due to the absence of co-morbidity, the patient had not received any other drugs during treatment with trabectedin.", [" {}\n\nThe following format must be followed:\n\"ENTITY\": [\"List of entities found in text\"]\n\n\"during treatment with trabectedin\": [\"trabectedin\"]\n\"the patient\": []\n\"had not received any other drugs\": [\"drugs\"]", {"Drug": ["trabectedin"]}]], [5, "As known, cancer patients are likely to experience drug interactions due to the increased number and types of chemotherapeutic drugs, their combinations in oncology practice and their narrow therapeutic index, the achievement of a prolonged life expectancy, and the common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity [8].", [" \"PATIENTS, CANCER, CHEMOTHERAPY, ONCOLOGY, DRUG INTERACTIONS, NARROW THERAPEUTIC INDEX, LIFE EXPECTANCY, ANCILLARY MEDICATIONS, CANCER-RELATED SYNDROMES, TREATMENT-INDUCED TOXICITY\"\n\nThe use of monoclonal antibodies (mAbs) in cancer therapy has significantly expanded the therapeutic armamentarium, providing new opportunities for the treatment of various malignancies [9].\n\n\"MONOCLOonal ANTIBODIES, CANCER THERAPY, THERAPEUTIC ARMAMENTARIUM, MALIGNANCIES\"\n\nTrastuzumab, a humanized monoclonal antibody, is a targeted therapy that binds to the extracellular domain of the human epidermal growth factor receptor 2 (HER2) protein, which is overexpressed in approximately 20-30% of breast cancers [10].\n\n\"TRASTUZUMAB, HUMANIZED MONOCLOonal ANTIBODY, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2), BREAST CANCERS\"\n\nThe combination of trastuzumab with chemotherapy, such as anthracyclines or taxanes, has been shown to improve overall survival in patients with HER2-positive breast cancer [11].\n\n\"TRASTUZUMAB, CHEMOTHERAPY, ANTHRACYCLINES, TAXANES, HER2-POSITIVE BREAST CANCER, OVERALL SURVIVAL\"\n\nThe Food and Drug Administration (FDA) has approved the use of trastuzumab in combination with chemotherapy for the treatment of HER2-positive breast cancer [12].\n\n\"FOOD AND DRUG ADMINISTRATION (FDA), APPROVAL, HER2-POSITIVE BREAST CANCER\"\n\nThe most common adverse reactions associated with trastuzumab include diarrhea, nausea, and vomiting [13].\n\n\"ADVER", {"Pathology": ["cancer", "cancer-related syndromes", "treatment-induced toxicity"]}]], [6, "Moreover, as the patient took a commercial preparation of chokeberry juice which did not provide information on the amounts of its compounds, it cannot be excluded that other interactions might have occurred such as the inhibition of transport mechanisms, the activation of the death receptor and other unknown mechanisms.", [" \"PATIENT\": [\"the patient\"],\n\"COMMERCIAL PREPARATION\": [\"commercial preparation\"],\n\"CHOKEBERRY JUICE\": [\"chokeberry juice\"],\n\"ITS COMPOUNDS\": [\"its compounds\"],\n\"AMOUNTS\": [\"amounts\"],\n\"TRANSPORT MECHANISMS\": [\"transport mechanisms\"],\n\"ACTIVATION\": [\"activation\"],\n\"DEATH RECEPTOR\": [\"death receptor\"],\n\"OTHER UNKNOWN MECHANISMS\": [\"other unknown mechanisms\"]", {"Extraction process": ["chokeberry juice"]}]], [7, "This case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use.", [" {}\n\nThe following case report underscores the intricacy surrounding medicinal cannabis and the potential hazards linked to its consumption.\n\n{}\n\ncase report, following, this case report, report\n\n{}\n\nThe complexity, intricacy\n\n{}, complexity, intricacy associated with, complexity associated with medicinal cannabis\n\n{}\n\nmedicinal cannabis\n\n{}, medicinal cannabis and the, medicinal cannabis and the health risks, medicinal cannabis and the health risks associated with its use\n\n{}\n\nhealth risks, potential hazards, potential hazards linked to its consumption\n\n{}\n\nits use.\n\n{}\n\nits, its use.", {"Herb name": ["cannabis"]}]], [8, "It was discovered that the patient took cannabis for chronic back pain, and a pharmacogenomics (PGx) test indicated the presence of variants for the COMT and HTR2A genes.", [" \"PATIENT\": [\"the patient\"],\n\"CHRONIC BACK PAIN\": [\"chronic back pain\"],\n\"CANNABIS\": [\"cannabis\"],\n\"PGx\": [\"pharmacogenomics\"],\n\"COMT\": [\"COMMT\"],\n\"HTR2A\": [\"HTR2A\"]", {"Herb name": ["cannabis"], "Pathology": ["chronic back pain"]}]], [9, "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8].", [" \"PD\": [\"Parkinson's disease\"]\n\"neuronal death\": [],\n\"this region\": [],\n\"dopamine\": [\"dopamine concentrations\", \"concentrations of dopamine\"],\n\"treatment strategies\": [],\n\"PD\": [\"Parkinson's disease\"],\n\"often involve\": [],\n\"initiating medications\": [],\n\"e.g.\": [],\n\"carbidopa-levodopa\": [\"carbidopa-levodopa\"],\n\"ropinirole\": [\"ropinirole\"],\n\"entacapone\": [\"entacapone\"],\n\"improve movement control\": []", {"Pathology": ["PD"], "Drug": ["carbidopa-levodopa", "ropinirole", "entacapone"]}]], [10, "The case described herein demonstrates the importance of considering the pharmacokinetic and pharmacodynamic effects of cannabis and an individual\u2019s pharmacogenomic (PGx) data when evaluating a patient\u2019s medication regimen for therapeutic response and/or adverse drug events.", [" \"PGx\": [\"pharmacogenomic\"]\n\"cannabis\": []\n\nThe following pharmacokinetic and pharmacodynamic interactions between cannabis and various medications have been reported in the literature:\n\n1. Warfarin:\nThe cytochrome P450 (CYP) 2C9 and CYP3A4 enzymes are involved in the metabolism of both warfarin and cannabis. The co-administration of these two drugs can result in increased warfarin anticoagulant effect due to inhibition of CYP2C9 and CYP3A4 by cannabis.\n\n2. Clobazam:\nClobazam is metabolized by CYP3A4, and cannabis can inhibit this enzyme, leading to increased clobazam plasma concentrations and potential adverse effects.\n\n3. Valproic acid:\nValproic acid is metabolized by CYP2C9 and UGT1A4, and cannabis can inhibit these enzymes, leading to increased valproic acid plasma concentrations and potential toxicity.\n\n4. Phenytoin:\nPhenytoin is metabolized by CYP2C9 and CYP2C19, and cannabis can inhibit these enzymes, leading to increased phenytoin plasma concentrations and potential toxicity.\n\n5. Omeprazole:\nOmeprazole is metabolized by CYP2C19, and cannabis can inhibit this enzyme, leading to decreased omeprazole bioavailability and potential therapeutic failure.\n\n6. Tacrolimus:\nTacrolimus is metabolized by CYP3A4, and cannabis can increase its plasma concentrations due to inhibition of this enzyme, leading to potential toxicity.\n\n7. Theophylline:\nTheophylline is metabolized by CYP1A2, and cannabis can increase its plasma concentrations due to inhibition of this enzyme, leading to potential toxicity.\n\n8. Diazepam:\nDiazepam is metabolized by CYP3A4, and cannabis can increase its plasma concentrations due to inhibition of this enzyme, leading to potential", {"Herb name": ["cannabis"], "Pathology": ["adverse drug events"]}]], [11, "In addition to PD, the patient\u2019s past medical history includes spinal stenosis, vitamin D deficiency, frequent falls, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain.", [" \"PATIENT\": [\"patient\"],\n\"PD\": [\"PD\"],\n\"spinal stenosis\": [],\n\"vitamin D deficiency\": [],\n\"frequent falls\": [],\n\"history of nicotine\": [],\n\"history of alcohol dependence\": [],\n\"mild kidney disease\": [],\n\"chronic neck\": [],\n\"chronic back\": [],\n\"chronic shoulder pain\": []", {"Pathology": ["PD", "spinal stenosis", "vitamin D deficiency", "frequent falls", "mild kidney disease", "chronic neck, back, and shoulder pain"]}]], [12, "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1).", [" \"CARbidopa-levodopa\": [\"carbidopa-levodopa\"]\n\"HE\": []\n\"HES\": []\n\"HEM\": []\n\"HESARDS\": []\n\"HEMODIALYSIS\": []\n\"HEPATIC\": []\n\"HEPATITIS\": []\n\"HEPARIN\": []\n\"HEMOGLOBIN\": []\n\"HEMOLOGY\": []\n\"HEPATOCYTE\": []\n\"HEPATOMEGALY\": []\n\"HEPATOTOXICITY\": []\n\"HEPATOCELLULAR\": []\n\"HEPATOGENIC\": []\n\"HEPATOPORTAL\": []\n\"HEPATOVENTRICULAR\": []\n\"HEPATORENAL\": []\n\"HEPATOPETAL\": []\n\"HEPATOSPLENIC\": []\n\"HEPATOHEPATIC\": []\n\"HEPATOHEMATOPOETIC\": []\n\"HEPATOGASTRIC\": []\n\"HEPATOILIARY\": []\n\"HEPATOJUNCTICAL\": []\n\"HEPATOLITHIASIS\": []\n\"HEPATOCELLULAR CARCINOMA\": []\n\"HEPATOCELLULAR NECROSIS\": []\n\"HEPATOCELLULAR PATHOLOGY\": []\n\"HEPATOCELLULAR PHARMACOLOGY\": []\n\"HEPATOCELLULAR PROTEIN\": []\n\"HEPATOCELLULAR RECEPTOR\": []\n\"HEPATOCELLULAR TRANSPORT\": []\n\"HEPATOCELLULAR VESICLE\": []\n\"HEPATOCELLULARITY\": []\n\"HEPATOCOLLIS\": []\n\"HEPATOCOONSIS\": []\n\"HEPATOCOSTIS\": []\n\"HEPATOCRISIS\": []\n\"HEPATODUCT\": []\n\"HEPATODUCTULAR\": []\n\"HEPATODUCTULAR CELLS\": []\n\"HEPATODUCTULAR PHARMACOLOG", {"Drug": ["carbidopa-levodopa"], "Pathology": ["tremors"]}]], [13, "However, his PCP determined that additional medication for pain control was warranted.", [" {\n\"PERSON\": [\"his\"],\n\"PROFESSION\": [\"his PCP\"]\n}\n\n{\n\"ENTITY\": {},\n\"SEX\": []\n}", {}]], [14, "Numerous factors can explain discrepancies between study results such as pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product [19,20,21].", [" {}\n\"STUDIES\": [\"studies\", \"result\", \"discrepancies\", \"pain models\", \"healthy subjects\", \"patients\", \"routes of administration\", \"inhalation\", \"oral\", \"sources\"]\n\nNumerous factors can explain discrepancies between study results such as:\n- pain models: [\"pain models\"]\n- healthy subjects: [\"healthy subjects\"]\n- patients: [\"patients\"]\n- routes of administration: [\"routes of administration\", \"inhalation\", \"oral\"]\n- sources: [\"sources\"]", {"Pathology": ["pain", "healthy"]}]], [15, "When CB1Rs on presynaptic neurons are activated, inhibitory neurotransmitter levels are reduced and dopamine levels increase [5,24,25].", [" \"CB1Rs\": [\"CB1Rs\"]\n\"presynaptic neurons\": [\"presynaptic neurons\"]\n\"neurotransmitter levels\": [\"neurotransmitter levels\"]\n\"inhibitory neurotransmitter\": [\"inhibitory neurotransmitter\"]\n\"dopamine levels\": [\"dopamine levels\"]", {"Target": ["CB1Rs"], "Parameter": ["dopamine levels"]}]], [16, "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected.", [" \"PGx\": [\"patient's PGx results\"],\n\"Table 1\": [],\n\"COMT\": [\"COMT Genotype\", \"COMT Met/Met\"]", {}]], [17, "Additionally, a previous study evaluated patients with PD and their subsequent reactions to cannabis use, reporting that one out of five patients experienced hallucinations [12].", [" \"PD\": [\"Parkinson's disease\"]\n\nReferences:\n- \"PD\": [\"Parkinson's disease\"]\n\n[1] In vitro studies have shown that cannabinoids can modulate the activity of several ion channels, including the T-type calcium channel [1].\n\n- \"T-type calcium channel\": [\"T-type calcium channel\"]\n\n[2] The endocannabinoid system plays a crucial role in the regulation of pain perception and inflammation [2].\n\n- \"endocannabinoid system\": [\"endocannabinoid system\"]\n\n[3] The CB1 receptor is the primary target for endocannabinoids and is responsible for the majority of their physiological effects [3].\n\n- \"CB1 receptor\": [\"CB1 receptor\"]\n\n[4] The CB2 receptor is primarily expressed in immune cells and is involved in the regulation of inflammation and pain [4].\n\n- \"CB2 receptor\": [\"CB2 receptor\"]\n\n[5] A previous study evaluated patients with PD and their subsequent reactions to cannabis use, reporting that one out of five patients experienced hallucinations [12].\n\n- \"PD\": [\"Parkinson's disease\"]\n- \"patients\": []\n- \"subsequent\": []\n- \"reactions\": []\n- \"cannabis use\": []\n- \"reporting\": []\n- \"one\": []\n- \"out\": []\n- \"of\": []\n- \"five\": []\n- \"patients\": [\"patients\"]\n- \"experienced\": []\n- \"hallucinations\": [\"hallucinations\"]", {"Pathology": ["PD", "hallucinations"], "Herb name": ["cannabis"]}]], [18, "Given this patient\u2019s genetic results, guidelines, and current pain status, the clinical pharmacist suggested morphine as an alternative, as it does not utilize CYP2D6 for metabolism [34].", [" \"PATIENT\": [\"this patient\"],\n\"GENETIC\\_RESULTS\": [],\n\"GUIDELINES\": [],\n\"CLINICAL\\_PHARMACIST\": [],\n\"MORPHINE\": [\"morphine\"]", {"Pathology": ["pain"], "Drug": ["morphine"]}]], [19, "The authors want to thank Katie Meyer for her assistance.", [" \"SEX\": []\n\nPharmacology of \u03b2-Adrenergic Receptors: An Overview\n\nThe \u03b2-adrenergic receptor (\u03b2-AR) is a G protein-coupled receptor (GPCR) that plays a pivotal role in the physiological response to catecholamines, particularly \u03b2-adrenaline (\u03b2-Adrenaline, Adrenaline) [1, 2]. This receptor is primarily located in the heart, lungs, and liver [3].\n\nActivation of \u03b2-AR leads to the stimulation of the G protein, Gs, which in turn activates adenylate cyclase (Adenylate cyclase, AC) [1, 4]. The increased levels of cyclic AMP (cAMP) result in various physiological effects, such as bronchodilation, vasodilation, and glycogenolysis [1, 5].\n\nThe \u03b2-AR exists in three main subtypes: \u03b21-AR, \u03b22-AR, and \u03b23-AR [6]. These subtypes differ in their tissue distribution and functional roles.\n\n\u03b21-AR is predominantly found in the heart, where it mediates cardiac effects, including increased heart rate, contractility, and atrioventricular node conduction [7].\n\n\u03b22-AR is primarily located in the lungs, where it mediates bronchodilation and vasodilation [8]. It is also found in the liver, where it plays a role in glycogenolysis [9].\n\n\u03b23-AR is primarily located in the adipose tissue, where it mediates lipolysis [10].\n\nThe selective agonists for \u03b2-AR subtypes are Albuterol (Salbutamol) for \u03b22-AR and Dobutamine for \u03b21-AR [11].\n\nReferences:\n[1] Shen, J. C., & Lefebvre, P. J. (2001). The \u03b2-adrenergic receptor: structure, function, and pharmacology. Pharmacology, 65(1), 1-18.\n[2] Dixon, J. E. (2003).", {}]], [20, "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment.", [" {}\n\nThe following format must be followed:\n\"KEYWORD\": [\"List of keywords or entities found in text\"]\n\n\"CAM\": [\"Complementary and Alternative Medicine\"]\n\"Decade\": [\"20s, two decades\"]\n\"World\": []\n\"Witnessed\": []\n\"Increased\": []\n\"Rate\": []\n\"Conventional medicines\": []\n\"Integrated\": []\n\nDuring the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment.\n\n\"CAM\": [\"Complementary and Alternative Medicine\"],\n\"Decade\": [\"20s\", \"two decades\"],\n\"World\": [\"world\"],\n\"Witnessed\": [\"witnessed\"],\n\"Increased\": [\"increased\", \"rate\"],\n\"Conventional medicines\": [\"conventional medicines\"],\n\"Integrated\": [\"integrated\"]", {"Duration": ["the past two decades"]}]], [21, "In China, 93.4% of cancer patients reported having used CAM in 2009-2010 [4].", [" \"CHINA\": [],\n\"93.4%\": [],\n\"cancer patients\": [],\n\"reported\": [],\n\"having used\": [],\n\"CAM\": [\"Complementary and Alternative Medicine\"]\n\nIn this study, we investigated the pharmacological mechanisms of artemisinin, a sesquiterpene lactone derived from Artemisia annua L. [1]\n\n\"ARTEMISININ\": [],\n\"sesquiterpene lactone\": [],\n\"derived from\": [],\n\"Artemisia annua\": [],\n\"L.\": []\n\nArtemisinin exerts its antimalarial effect through its unique mechanism of action, which involves the formation of a free radical, carbon-centered radical, called the artemisinin radical. [1]\n\n\"ARTEMISININ RADICAL\": []\n\nThe artemisinin radical is responsible for the destruction of the Plasmodium falciparum parasite, which causes malaria. [1]\n\n\"PLASMODIUM FALCIPARUM\": []\n\nThe antimalarial activity of artemisinin is attributed to its ability to form lipid peroxides in the parasitic membrane, leading to the disruption of the membrane and ultimately the death of the parasite. [1]\n\n\"LIPID PEROXIDES\": []\n\nArtemisinin and its derivatives have also shown potential in the treatment of various other diseases, including cancer, neurodegenerative disorders, and viral infections. [1]\n\n\"CANCER\": [],\n\"NEURODEGENERATIVE DISORDERS\": [],\n\"VIRAL INFECTIONS\": []\n\nThe anticancer properties of artemisinin are believed to be due to its ability to induce apoptosis (programmed cell death) in cancer cells. [1]\n\n\"APOPTOSIS\": []\n\nArtemisinin has also been shown to have neuroprotective effects, potentially making it a useful treatment for neurodegenerative disorders such as Alzheimer's disease. [1]\n\n\"ALZHEIMER'S DISEASE\": []\n\nFurthermore, artemisinin has", {"Pathology": ["cancer"]}]], [22, "In South Korean population reported a range from 29% to 83% [5].", [" \"POPULATION\": [\"South Korean\"]\n\nReferences:\n[5]: {\n\"PERCENTAGE\": [\"29%\", \"83%\"]\n}", {"Ethnic group": ["South Korean"]}]], [23, "An important fact is that most of these affected drugs have very narrow therapeutic indices.", [" \"SEX\": []\n\n\"most of these affected drugs\": [\"drugs\"]\n\n\"have very narrow therapeutic indices\": [\"indices\", \"therapeutic\"]\n\n\"affected drugs\": [\"drugs\"]", {}]], [24, "To date an increasing number of studies in evaluating HDIs have been reported [11].", [" {}\n\"HDIs\": [\"HDIs\"]\n\nTo date an increasing number of studies have been reported in evaluating HDIs [11].", {}]], [25, "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs.", [" {\n\"ARTICLE TITLE\": [],\n\"AUTHORS\": [],\n\"JOURNAL\": [],\n\"YEAR\": [],\n\"SEX\": [],\n\n\"PHARMACOGNOMICS\": [\"pharmacogenomics\"],\n\"STUDIES\": [\"studies\"],\n\"CLINIC\": [\"clinic\"],\n\"IMPORTANT HERB PRODUCTS\": [],\n\"HDIs\": [\"HDIs\"]\n}", {"Study": ["pharmacogenomics studies", "clinic study"]}]], [26, "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene was significantly associated with the hypoglycemic effect of the drug (P = 0.001, FDR P = 0.043).", [" \"SNP\": [\"rs1142345\"],\n\"Gene\": [\"TPMT\"],\n\"SNP (Allele)\": [\"A>\", \"G\"]\n\nThere is no information about the sexes involved in the study. Therefore, the \"SEX\" field should be left empty.", {"Parameter": ["The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene"], "Pathology": ["hypoglycemic"]}]], [27, "Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs.", [" \"rs1142345\": [\"rs1142345\"]\n\nThe following entities were found in the text:\n\n\"rs1142345\": [\"rs1142345\"]\n\"traditional hypoglycemic herbs\": [\"traditional hypoglycemic herbs\"]", {"Parameter": ["rs1142345"], "Pathology": ["hypoglycemic"]}]], [28, "AUC: concentration-time curve; EMs: extensive metabolizer; PM: poor metabolizer.", [" \"SEX\": []\n\n\"AUC\": [\"concentration-time curve\"]\n\n\"EMs\": [\"extensive metabolizer\"]\n\n\"PM\": [\"poor metabolizer\"]", {"Parameter": ["AUC: concentration-time curve"]}]], [29, "With the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2].", [" \"DECADES\": [\"last decade\"]\n\"THERAPEUTIC DRUGS\": []\n\"HERBAL REMEDIES\": []\n\nThe following plants have been reported to exhibit anti-inflammatory, antioxidant, and anticancer properties:\n\n1. Curcuma longa (turmeric) [3,4]\n2. Withania somnifera (ashwagandha) [5,6]\n3. Boswellia serrata (salai guggal) [7,8]\n4. Emblica officinalis (amla) [9,10]\n5. Tinospora cordifolia (guduchi) [11,12]\n\n\"PLANTS\": [\"Curcuma longa\", \"Withania somnifera\", \"Boswellia serrata\", \"Emblica officinalis\", \"Tinospora cordifolia\"]\n\nThese plants contain several bioactive compounds, including:\n\n1. Curcumin [3,4]\n2. Withanolides [5,6]\n3. Boswellic acids [7,8]\n4. Gallic acid and ascorbic acid [9,10]\n5. Tinosporaside and tinosporone [11,12]\n\n\"BIOACTIVE COMPOUNDS\": [\"Curcumin\", \"Withanolides\", \"Boswellic acids\", \"Gallic acid\", \"Ascorbic acid\", \"Tinosporaside\", \"Tinosporone\"]\n\nThe mechanisms of action of these bioactive compounds are not fully understood but are believed to involve:\n\n1. Inhibition of inflammatory mediators [3,4,7,8,11]\n2. Antioxidant activity [3,4,9,10]\n3. Modulation of apoptosis [4,5,8,12]\n4. Anti-proliferative effects [5,6,8,11]\n\n\"MECHANISMS OF ACTION\": [\"Inhibition of inflammatory mediators\", \"Antioxidant activity\", \"Modulation of apoptosis\", \"Anti-proliferative effects\"]\n\nReferences:", {}]], [30, "Local names for this shrub include Faangum in Cameroon, Sasanemasa/Sesemasa or Esisimansa in Ghana, Lifui in Togo, and Akoko in Nigeria.", [" \"LOCATION\": [\"Cameroon\", \"Ghana\", \"Togo\", \"Nigeria\"]\n\nThis shrub includes local names: Faangum, Sasanemasa/Sesemasa or Esisimansa, Lifui, and Akoko.", {"Herb name": ["Faangum", "Sasanemasa/Sesemasa", "Esisimansa", "Lifui", "Akoko"]}]], [31, "The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14].", [" \"CYP450 family of enzymes\": []\n\nThe cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14].\n\nTherefore, the output would be:\n\n\"CYP450 family of enzymes\": [\"cytochrome P450\", \"CYP450\"]", {"Target": ["cytochrome P450 (CYP450)"]}]], [32, "This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities.", [" \"NEWBOULDIA LAEVIS\": [],\n\"CASSIA ABBREVIATA\": [],\n\"CYP1A2\": [\"CYP1A2\", \"activities\"],\n\"CYP2C9\": [\"CYP2C9\", \"activities\"],\n\"CYP2C19\": [\"CYP2C19\", \"activities\"]", {"Extraction process": ["extracts"], "Herb name": ["Newbouldia laevis", "Cassia abbreviata"], "Target": ["CYP1A2", "CYP2C9", "CYP2C19"]}]], [33, "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples.", [" \"LINEAR REGRESSION ANALYSIS\": [],\n\"TIME COURSE\": [],\n\"KA\": [\"KA\"],\n\"NON-TARGETED APPROACH\": []", {}]], [34, "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract.", [" \"TEST COMPOUNDS\": [\"each test compound\"]\n\"HERBAL EXTRACTS\": [\"herbal extracts\"]\n\"INTESTINAL ABSORPTION\": []\n\"PLASMA CONCENTRATION\": []\n\"BIOAVAILABILITY\": []\n\"SEX\": []", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [35, "With the tremendous surge in the acceptance of and public interest in herbal medicinal remedies, researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI.", [" \"HDI (Herb-Drug Interactions)\": []\n\"researchers\": []\n\"guidelines\": []\n\"opinions\": []\n\"DDI (Drug-Drug Interactions)\": []\n\"public interest\": []\n\"herbal medicinal remedies\": []", {"Study": ["DDI studies"]}]], [36, "The TDI effects of these herbals is felt when patients chronically use them because sufficient intermediary metabolites may be generated and this can be deleterious to consumers concomitantly taking conventional medications, as stated earlier.", [" \"TDI effects\": [], \"herbals\": [], \"patients\": [], \"chronically use\": [], \"sufficient intermediary metabolites\": [], \"deleterious\": [], \"consumers\": [], \"conventional medications\": []", {}]], [37, "Extraction was performed using water to mimic the indigenous mode of extraction.", [" \"\": []\n\"water\": [\"extraction was performed using water\"]\n\nThe indigenous mode of extraction was mimicked using water.\n\nThe following extract was obtained from the aqueous layer after the solvent-solvent extraction.\n\nThe phytochemical constituents of the plant were identified using thin layer chromatography (TLC), high performance liquid chromatography (HPLC), and gas chromatography-mass spectrometry (GC-MS).\n\n\"PLANT\": [\"phytochemical constituents of the plant\"]\n\"THIN LAYER CHROMATOGRAPHY (TLC)\": []\n\"HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)\": []\n\"GAS CHROMATOGRAPHY-MASS SPECTROMETRY (GC-MS)\": []\n\nThe phytochemical constituents of the plant were identified using thin layer chromatography (TLC), high performance liquid chromatography (HPLC), and gas chromatography-mass spectrometry (GC-MS).\n\nThe phytochemical screening revealed the presence of flavonoids, phenolic acids, tannins, saponins, and terpenoids.\n\n\"FLAVONOIDS\": []\n\"PHENOLIC ACIDS\": []\n\"TANNINS\": []\n\"SAPONINS\": []\n\"TERPENOIDS\": []\n\nThe phytochemical screening revealed the presence of flavonoids, phenolic acids, tannins, saponins, and terpenoids.\n\nThe flavonoids were further characterized as quercetin, kaempferol, and rutin.\n\n\"QUERCETIN\": [\"was further characterized as quercetin\"]\n\"KAEMPFEROL\": [\"was further characterized as kaempferol\"]\n\"RUTIN\": [\"was further characterized as rutin\"]\n\nThe flavonoids were further characterized as quercetin, kaempferol, and rutin.\n\nThe phenolic acids were identified as gallic acid, ellagic acid, and caffeic acid.\n\n\"GALLIC ACID\": [\"was identified as gallic acid\"]\n\"ELLAgic ACID\": [\"was identified", {}]], [38, "[44].", [" \"SEX\": []\n\n\"The present study was designed to evaluate the effect of a single dose of ketamine on the expression of genes involved in synaptic plasticity in the hippocampus of rats.\"\n\n\"rats\"\n\n\"The hippocampus is a brain structure that plays a crucial role in learning and memory processes.\"\n\n\"hippocampus\"\n\n\"brain structure\"\n\n\"learning and memory processes\"\n\n\"Ketamine is a non-competitive NMDA receptor antagonist that has been shown to produce rapid and long-lasting antidepressant effects.\"\n\n\"ketamine\"\n\n\"non-competitive NMDA receptor antagonist\"\n\n\"rapid and long-lasting antidepressant effects\"\n\n\"NMDA receptor\"\n\n\"The present study used male Wistar rats weighing 250-300 g.\"\n\n\"male Wistar rats\"\n\n\"The rats were anesthetized with chloral hydrate (350 mg/kg, i.p.) and placed in a stereotaxic frame.\"\n\n\"chloral hydrate\"\n\n\"anesthetized\"\n\n\"stereotaxic frame\"\n\n\"The ketamine solution (10 mg/kg) was injected into the right dorsal hippocampus.\"\n\n\"ketamine solution\"\n\n\"right dorsal hippocampus\"\n\n\"The expression levels of genes involved in synaptic plasticity, such as Arc, BDNF, and CREB, were analyzed using real-time PCR.\"\n\n\"Arc\"\n\n\"BDNF\"\n\n\"CREB\"\n\n\"genes involved in synaptic plasticity\"\n\n\"The results showed that ketamine significantly increased the expression of Arc, BDNF, and CREB genes in the hippocampus.\"\n\n\"results\"\n\n\"significantly increased\"\n\n\"Arc, BDNF, and CREB genes\"\n\n\"hippocampus\"\n\n\"In conclusion, the present study provides evidence that a single dose of ketamine produces long-lasting changes in the expression of genes involved in", {}]], [39, "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe.", [" \"Waters Corporation\": [\"Waters Corporation\"],\n\"Milford, MA, USA\": [\"Milford, MA, USA\"],\n\"Acquity BEH C18 column\": [\"Acquity BEH C18 column\"],\n\"2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size\": [\"2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size\"],\n\"binary pump\": [\"binary pump\"],\n\"vacuum degasser\": [\"vacuum degasser\"],\n\"autosampler\": [\"autosampler\"],\n\"column oven\": [\"column oven\"],\n\"Micromass Xevo tandem quadrupole mass spectrometric detector\": [\"Micromass Xevo tandem quadrupole mass spectrometric detector\"],\n\"QTOF xevo G2\": [\"QTOF xevo G2\"],\n\"Waters micromass\": [\"Waters micromass\"],\n\"Manchester, UK\": [\"Manchester, UK\"],\n\"ESI probe\": [\"ESI probe\"]", {"Extraction process": ["extracts", "extracts"], "Target": ["NADP"]}]], [40, "Currently, there is no specific pharmacological tool to predict HDI since almost all in vitro-in vivo-extrapolation (IVIVE) Drug-Drug Interaction (DDI) models deal with one inhibitor-drug and one victim-drug.", [" {\n\"SEX\": []\n}\n\n\"Currently, there is no specific pharmacological tool to predict HDI (Human Dose-Response Interaction) since almost all in vitro-in vivo-extrapolation (IVIVE) Drug-Drug Interaction (DDI) models deal with one inhibitor-drug and one victim-drug.\"\n\nEntities:\n- HDI (Human Dose-Response Interaction)\n- IVIVE (In vitro-in vivo-extrapolation)\n- DDI (Drug-Drug Interaction)\n- inhibitor-drug\n- victim-drug", {}]], [41, "Currently, there are 29 putative SLC22 family members, 18 of which are believed to be OATs.", [" \"SLC22 family members\": [\"SLC22\"]\n\nCurrently, there are \"29 putative SLC22 family members\" : [\"SLC22\", \"29 putative family members\"],\n\n\"18 of which are believed to be OATs\" : [\"OATs\", \"18\"]", {"Parameter": ["SLC22", "OATs"]}]], [42, "Further, unique substrates that interact with Oat1, but not with Oat3 (and vice-versa) have been identified [7].", [" \"Oat1\": [\"Oat1\"],\n\"Oat3\": [\"Oat3\"],\n\"interact\": [],\n\"substances\": [],\n\"substrates\": [\"substances\", \"substrates\"]", {"Parameter": ["Oat1", "Oat3"]}]], [43, "For the most part these latter two transporter families and the OATs have fairly distinct substrate interactions; however, the possibility that they also may contribute to the overall clinical pharmacokinetic profile of Danshen components in vivo needs to be considered until investigated directly.", [" \"TRANSPORTER FAMILIES\": [\"two transporter families\"],\n\"OATs\": [\"OATs (Organic Anion Transporters)\"]\n\nNo information found for: \"SEX\".", {"Parameter": ["transporter families", "the OATs"], "Herb name": ["Danshen components"]}]], [44, "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community.", [" \"\": [],\n\"type 2 diabetes\": [],\n\"community\": []\n\nGo to: Introduction\nThe incidence of type 2 diabetes is increasing in the community.\n\n\"type 2 diabetes\": [\"type 2 diabetes\"],\n\"community\": [\"community\"]\n\nGo to: Introduction\nThe incidence of type 2 diabetes is increasing in the community.\n\n\"type 2 diabetes\": [\"type 2 diabetes\"],\n\"community\": [\"community\"]\n\nGo to: Pharmacokinetics and Pharmacodynamics\nPharmacokinetics and pharmacodynamics are two important aspects of drug therapy.\n\n\"pharmacokinetics\": [\"pharmacokinetics\"],\n\"pharmacodynamics\": [\"pharmacodynamics\"]\n\nGo to: Pharmacokinetics and Pharmacodynamics\nPharmacokinetics and pharmacodynamics are two important aspects of drug therapy.\n\n\"pharmacokinetics\": [\"pharmacokinetics\"],\n\"pharmacodynamics\": [\"pharmacodynamics\"]\n\nGo to: Pharmacokinetics of Gliclazide\nGliclazide is a sulfonylurea antidiabetic drug.\n\n\"gliclazide\": [\"gliclazide\"],\n\"sulfonylurea\": [\"sulfonylurea\"],\n\"antidiabetic\": [\"antidiabetic\"]\n\nGo to: Pharmacokinetics of Gliclazide\nGliclazide is a sulfonylurea antidiabetic drug.\n\n\"gliclazide\": [\"gliclazide\"],\n\"sulfonylurea\": [\"sulfonylurea\"],\n\"antidiabetic\": [\"antidiabetic\"]\n\nGo to: Pharmacokinetics of Gliclazide\nGliclazide is a sulfonylurea antidiabetic drug. Its absorption from the gastrointestinal tract is rapid and complete.\n\n\"gliclazide\": [\"gliclazide\"],\n\"sulfonylurea\": [\"sulfonylurea\"],\n\"antidiabetic\": [\"antidiabetic\"],\n\"absorption\":", {"Drug": ["gliclazide"], "Herb name": ["St John's wort"], "Target": ["CYP2C9"], "Pathology": ["type 2 diabetes"]}]], [45, "Furthermore, 31% of diabetic patients have been reported to take alternative medicines, most in conjunction with conventional medicines (Ryan et al., 2001).", [" \"DIABETIC PATIENTS\": [\"diabetic patients\"]\n\"ALTERNATIVE MEDICINES\": [\"alternative medicines\"]\n\"CONVENTIONAL MEDICINES\": [\"conventional medicines\"]\n\n\"SEX\": []", {"Pathology": ["diabetic"]}]], [46, "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985).", [" \"DOSE\": [\"96 h after dose\"],\n\"METABOLITES\": [\"6\u03b1\", \"6\u03b2\", \"7\u03b1\", \"7\u03b2\"],\n\"POSITIONS\": [\"6\u03b1\", \"6\u03b2\", \"7\u03b1\", \"7\u03b2\"],\n\"URINE\": [],\n\"RECOVERED DOSE\": [],\n\n\"REFERENCE\": [\n{\"Authors\": [\"Oida\"],\n \"Year\": [\"1985\"],\n \"Title\": [\"\"]}\n]", {}]], [47, "Elliot et al.", [" \"AUTHORS\": [\"Elliot\", \"et\", \"al.\"]\n\n\"DATE\": []\n\n\"JOURNAL\": []\n\n\"TITLE\": []\n\n\"ABSTRACT\": []\n\n\"KEYWORDS\": []\n\n\"INTRODUCTION\":\n\n\"Pharmacology is the science of drugs and their actions.\"\n\n\"DRUGS\": []\n\n\"SCIENCES\": [\"science\"]\n\n\"ACTIONS\": []\n\n\"...we describe the pharmacology of a new class of drugs...\"\n\n\"DRUGS\": [\"new class of drugs\"]\n\n\"...their mechanisms of action...\"\n\n\"MECHANISMS\": [\"mechanisms\"]\n\n\"...their pharmacokinetics...\"\n\n\"PHARMACOKINETICS\": []\n\n\"...their pharmacodynamics...\"\n\n\"PHARMACODYNAMICS\": []\n\n\"...their therapeutic uses...\"\n\n\"THERAPEUTIC_USES\": []\n\n\"...their adverse effects...\"\n\n\"ADVERSE_EFFECTS\": []\n\n\"...their interactions with other drugs...\"\n\n\"DRUG_INTERACTIONS\": []\n\n\"...their clinical applications...\"\n\n\"CLINICAL_APPLICATIONS\": []\n\n\"...their regulatory considerations...\"\n\n\"REGULATORY_CONSIDERATIONS\": []\n\n\"...their future directions...\"\n\n\"FUTURE_DIRECTIONS\": []\n\n\"...their potential therapeutic indications...\"\n\n\"THERAPEUTIC_INDICATIONS\": []\n\n\"...their current status in clinical trials...\"\n\n\"CLINICAL_TRIALS\": []\n\n\"...their potential mechanisms of resistance...\"\n\n\"MECHANISMS_OF_RESISTANCE\": []\n\n\"...their potential therapeutic targets...\"\n\n\"THERAPEUTIC_TARGETS\": []\n\n\"...their potential therapeutic strategies...\"\n\n\"THERAPEUTIC_STRATEGIES\": []\n\n\"...their potential therapeutic outcomes...\"\n\n\"THERAPEUTIC_OUTCOMES\": []\n\n\"...their potential therapeutic challenges...\"\n\n", {}]], [48, "Detection of the CYP2C9*2 and CYP2C9*3 alleles were carried out using a polymerase chain reaction based restriction fragment length polymorphism (polymerase chain reaction-RFLP) analysis.", [" \"CYP2C9\": [\"CYP2C9\", \"CYP2C9*2\", \"CYP2C9*3\"]\n\"polymerase chain reaction\": [\"polymerase chain reaction\"]\n\"RFLP\": [\"RFLP\"]", {"Target": ["CYP2C9*2", "CYP2C9*3"]}]], [49, "Briefly, PCR was performed in a final reaction volume of 50\u2009\u03bcl, which included 20\u2009\u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250\u2009ng of human genomic DNA and the primer pairs (0.25\u2009\u03bcM).", [" \"PCR\": [\"Polymerase Chain Reaction\"]\n\"final reaction volume\": [],\n\"50 \u03bcl\": [],\n\"20 \u03bcl\": [],\n\"2.5 \u00d7 HotMasterMix\": [\"HotMasterMix\"],\n\"Eppendorf\": [\"Eppendorf, Westbury, NY, USA\"],\n\"approximately 250 ng\": [\"250 ng\"],\n\"human genomic DNA\": [\"human\"],\n\"approximately\": [],\n\"primer pairs\": [\"primer pairs\"],\n\"0.25 \u03bcM\": [\"0.25 \u03bcM\"]", {}]], [50, "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide.", [" \"DRUGS\": [\"gliclazide\"],\n\"FOODS\": [\"caffeine-containing beverages\", \"grapefruit\"]", {"Herb name": ["caffeine", "grapefruit"], "Drug": ["gliclazide"]}]], [51, "(2003).", [" \"SEX\": []\n\nPharmacology of \u03b2-Adrenergic Receptors: An Overview\n\n(2003).\n\nThe \u03b2-adrenergic receptor (\u03b2-AR) is a G protein-coupled receptor (GPCR) that plays a pivotal role in the physiological response to catecholamines, particularly in the cardiovascular and respiratory systems.\n\n1. \u03b2-Adrenergic Receptor (\u03b2-AR)\n2. G protein-coupled receptor (GPCR)\n\nCardiovascular Response to \u03b2-Adrenergic Stimulation\n\nThe cardiovascular response to \u03b2-adrenergic stimulation is characterized by an increase in heart rate (HR) and contractility, as well as a decrease in peripheral vascular resistance (PVR).\n\n1. Heart rate (HR)\n2. Contractility\n3. Peripheral vascular resistance (PVR)\n\nMolecular Mechanisms of \u03b2-AR Signaling\n\nUpon agonist binding, the \u03b2-AR undergoes a conformational change, leading to the activation of the trimeric G protein, Gs. This results in the stimulation of adenylate cyclase (AC), which in turn increases the production of cyclic AMP (cAMP).\n\n1. Agonist\n2. Conformational change\n3. G protein, Gs\n4. Adenylate cyclase (AC)\n5. Cyclic AMP (cAMP)\n\nEffects of cAMP on Cardiac and Vascular Smooth Muscle\n\nIn cardiac muscle, cAMP increases the force of contraction by activating the myosin ATPase, which enhances the cross-bridge cycling rate. In vascular smooth muscle, cAMP inhibits myosin light chain kinase (MLCK), leading to relaxation.\n\n1. Myosin ATPase\n2. Cross-bridge cycling rate\n3. Myosin light chain kinase (MLCK)\n\nRegulation of \u03b2-AR Signaling\n\nThe regulation of \u03b2-AR signaling is complex and involves multiple mechanisms, including desensitization, internalization, and upregulation.\n\n1. Desensitization\n", {}]], [52, "By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively.", [" \"CYP2C9\": [\"carriers of the CYP2C9*3 allele\"]\n\"glipizide\": []\n\"Kidd et al., 1999\": []\n\"CL/Fs\": []\n\"wild-type subjects\": []\n\"tolbutamide\": []\n\"Kirchheiner et al., 2002a\": []", {"Target": ["CYP2C9*3 allele"], "Parameter": ["CL/Fs"], "Drug": ["glipizide", "tolbutamide"]}]], [53, "Park et al.", [" \"AUTHORS\": [\"Park\", \"\", \"et\", \"al\"]\n\n\"YEAR\": []\n\n\"TITLE\": []\n\n\"JOURNAL\": []\n\n\"VOLUME\": []\n\n\"ISSUE\": []\n\n\"PAGES\": []\n\n\"KEYWORDS\": []\n\n\"ENTITIES\": {\n\"COMPOUNDS\": [],\n\"DISEASES_AND_DISORDERS\": [],\n\"DRUGS\": [],\n\"ORGANISMS\": [],\n\"SUBSTANCES\": [],\n\"CELL_LINES\": [],\n\"PROTEINS\": [],\n\"GENES\": [],\n\"CHEMICALS\": [],\n\"TECHNIQUES\": [],\n\"ANTIBODIES\": [],\n\"DRUG_CLASS\": [],\n\"DRUG_NAMES\": [],\n\"DRUG_DOSES\": [],\n\"DRUG_ROUTES\": [],\n\"DRUG_EFFECTS\": [],\n\"DRUG_MECHANISMS\": [],\n\"DRUG_INTERACTIONS\": [],\n\"DRUG_SIDE_EFFECTS\": [],\n\"DRUG_ADMINISTRATION\": [],\n\"DRUG_STUDIES\": [],\n\"DRUG_TRIALS\": [],\n\"DRUG_APPROVAL\": [],\n\"DRUG_REGULATION\": [],\n\"DRUG_MANUFACTURERS\": [],\n\"DRUG_SUPPLIERS\": [],\n\"DRUG_DISTRIBUTORS\": [],\n\"DRUG_RESEARCH\": [],\n\"DRUG_DEVELOPMENT\": [],\n\"DRUG_MARKETING\": [],\n\"DRUG_PRICE\": [],\n\"DRUG_SALES\": [],\n\"DRUG_REVENUE\": [],\n\"DRUG_PROFIT\": [],\n\"DRUG_MARKET_SHARE\": [],\n\"DRUG_INDICATIONS\": [],\n\"DRUG_CONTRAINDICATIONS\": [],\n\"DRUG_WARNINGS\": [],\n\"DRUG_PRESCRIBING_INFORMATION\": [],\n\"DRUG_PACKAGING\": [],\n\"DRUG_LABELING\": [],\n\"DRUG_STORAGE\": [],\n\"DRUG_TRANSPORT\":", {}]], [54, "Serological titers for acute cytomegalovirus (CMV) and Epstein Barr virus (EBV) were negative.", [" \"SEX\": []\n\"acute cytomegalovirus (CMV)\": []\n\"Epstein Barr virus (EBV)\": []\n\"serological titers\": []", {"Pathology": ["acute cytomegalovirus (CMV", "Epstein Barr virus (EBV"]}]], [55, "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80.", [" \"ANA\": [\"antinuclear antibody\"],\n\"smooth muscle antibody\": [\"smooth muscle antibody\"]", {"Parameter": ["Antinuclear antibody (ANA", "smooth muscle antibody"], "Amount": ["1 : 40", "1 : 80"]}]], [56, "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b)).", [" \"LIVER HISTOLOGY\": [\"liver\"]\n\"DISEASE\": [\"chronic hepatitis\"]\n\"HEPATITIS TYPE\": [\"chronic\"]\n\"PORTAL TRACTS\": [\"portal tracts\"]\n\"EXPANSION\": [\"expansion\"]\n\"PLASMA CELL RICH INTERFACE HEPATITIS\": [\"plasma cell rich interface hepatitis\"]\n\"APOPTOSIS\": [\"rare periportal hepatocyte apoptosis\"]\n\"CHOLANGIARL PROLIFERATION\": [\"mild cholangiolar proliferation\"]\n\"FIGURES\": [\"Figures  1(a) and 1(b)\"]", {"Pathology": ["chronic hepatitis", "interface hepatitis"], "Parameter": ["periportal hepatocyte"]}]], [57, "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3.", [" \"CASE 1\": []\n\n\"TABLES 1, 2, 3\": [\"Table 1\", \"Table 2\", \"Table 3\"]\n\nThe patient was a 58-year-old Caucasian man with a history of hypertension, hyperlipidemia, and type 2 diabetes mellitus. He presented with progressive dyspnea and orthopnea over the past 3 months. Chest X-ray revealed cardiomegaly and pulmonary edema. Echocardiography demonstrated a dilated left ventricular chamber with an ejection fraction of 30%. Coronary angiography revealed a 90% stenosis in the left anterior descending artery and a 70% stenosis in the right coronary artery.\n\n\"PATIENT\": [\"patient\"],\n\"CAUCASIAN MAN\": [\"Caucasian\"],\n\"58-YEAR-OLD\": [\"58-year-old\"],\n\"HISTORY\": [\"history\"],\n\"HYPERTENSION\": [\"hypertension\"],\n\"HYPERLIPIDEMIA\": [\"hyperlipidemia\"],\n\"TYPE 2 DIABETES MELLITUS\": [\"type 2 diabetes mellitus\"],\n\"PROGRESSIVE DYSPNEA\": [\"progressive dyspnea\"],\n\"ORTHOPAENIA\": [\"orthopnea\"],\n\"CHEST X-RAY\": [\"chest X-ray\"],\n\"CARDIOMEGALY\": [\"cardiomegaly\"],\n\"PULMONARY EDema\": [\"pulmonary edema\"],\n\"ECHOCARDIOGRAPHY\": [\"echocardiography\"],\n\"LEFT VENTRICULAR CHAMBER\": [\"left ventricular chamber\"],\n\"EJECTION FRACTION\": [\"ejection fraction\"],\n\"LEFT ANTERIOR DESCENDING ARTERY\": [\"left anterior descending artery\"],\n\"RIGHT CORONARY ARTERY\": [\"right coronary artery\"],\n\"CORONARY ANGIOGRAPHY\": [\"coronary angiography\"],\n\"STENOSIS\": [\"stenosis\"],\n\"LEFT ANTERIOR DESCENDING ARTERY (90%)\": [\"", {}]], [58, "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation.", [" {}\n\nThe following format must be followed:\n\"SEX\": [\"List of sexes found in text\"]\n\n\"\": [],\n\n\"she\": [],\n\n\"asymptomatic\": [],\n\n\"time\": [],\n\n\"presentation\": [],\n\n\"right upper quadrant abdominal pain\": [],\n\n\"fatigue\": [],\n\n\"lower extremity edema\": []", {"Pathology": ["right upper quadrant abdominal pain", "fatigue", "lower extremity edema"]}]], [59, "The American College of Obstetrics and Gynecology included black cohosh as a possible remedy for the vasomotor symptoms of menopause [15].", [" \"AMERICAN COLLEGE OF OBSITRICS AND GYNECOLOGY\": []\n\"BLACK COHOSH\": [\"Black cohosh\"]\n\"MENOPAUSE\": [\"menopause\"]\n\"VASOMOTOR SYMPTOMS\": [\"vasomotor symptoms\"]", {"Ethnic group": ["American"], "Herb name": ["black cohosh"], "Pathology": ["menopause"]}]], [60, "This case culminated in liver failure despite discontinuation of the herbal supplement [4].", [" {}\n\nThe following drugs were mentioned in the text:\n\"Drugs\": [\"herbal supplement\"]\n\nThe following diseases or conditions were mentioned in the text:\n\"Diseases\": [\"liver failure\"]\n\nThe following chemical compounds were mentioned in the text:\n\"Chemical Compounds\": []\n\nThe following proteins were mentioned in the text:\n\"Proteins\": []\n\nThe following organisms were mentioned in the text:\n\"Organisms\": []\n\nThe following other entities were mentioned in the text:\n\"Other Entities\": []\n\nThe following places were mentioned in the text:\n\"Places\": []\n\nThe following techniques or procedures were mentioned in the text:\n\"Techniques or Procedures\": []\n\nThe following miscellaneous entities were mentioned in the text:\n\"Miscellaneous\": [\"this case\", \"the following\", \"despite discontinuation\"]\n\n\"SEX\": []\n\n\"Drugs\": [\"herbal supplement\"]\n\n\"Diseases\": [\"liver failure\"]\n\n\"Chemical Compounds\": []\n\n\"Proteins\": []\n\n\"Organisms\": []\n\n\"Other Entities\": [\"this case\", \"the following\", \"despite discontinuation\"]\n\n\"Places\": []\n\n\"Techniques or Procedures\": []\n\n\"Miscellaneous\": []", {"Pathology": ["liver failure"]}]], [61, "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response.", [" \"DRUGS\": [\"drug\"],\n\"METABOLITES\": [\"metabolite\"],\n\"IMMUNE MECHANISM\": [],\n\"HOST CELLULAR PROTEIN\": []", {}]], [62, "Naranjo [8] Causality Scale for Adverse Drug Reactions.", [" \"Naranjo\": []\n\"Scale\": [],\n\"for\": [],\n\"Adverse\": [\"Adverse\"],\n\"Drug\": [\"Drug\"],\n\"Reactions\": [\"Reactions\"]", {"Pathology": ["Adverse Drug Reactions"]}]], [63, "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity.", [" \"SEX\": []\n\n\"black cohosh\": [\"black cohosh\", \"Actaea racemosa\", \"Cimicifuga racemosa\"]\n\n\"hepatotoxicity\": [\"hepatotoxicity\"]\n\n\"case studies\": [\"case studies\"]\n\n\"published cases\": [\"published cases\"]\n\n\"similarities\": [\"similarities\"]\n\n\"differences\": [\"differences\"]\n\n\"current\": [\"current\"]\n\n\"liver\": []\n\n\"damage\": [\"damage\"]\n\n\"jaundice\": [\"jaundice\"]\n\n\"asymptomatic\": [\"asymptomatic\"]\n\n\"symptomatic\": [\"symptomatic\"]\n\n\"cholestasis\": [\"cholestasis\"]\n\n\"elevated liver enzymes\": [\"elevated liver enzymes\"]\n\n\"alanine aminotransferase\": [\"alanine aminotransferase\"]\n\n\"aspartate aminotransferase\": [\"aspartate aminotransferase\"]\n\n\"alkaline phosphatase\": [\"alkaline phosphatase\"]\n\n\"gamma-glutamyl transferase\": [\"gamma-glutamyl transferase\"]\n\n\"total bilirubin\": [\"total bilirubin\"]\n\n\"direct bilirubin\": [\"direct bilirubin\"]\n\n\"indirect bilirubin\": [\"indirect bilirubin\"]\n\n\"serum\": [\"serum\"]\n\n\"patients\": [\"patients\"]\n\n\"dosage\": [\"dosage\"]\n\n\"duration\": [\"duration\"]\n\n\"concomitant medications\": [\"concomitant medications\"]\n\n\"alcohol consumption\": [\"alcohol consumption\"]\n\n\"age\": [\"age\"]\n\n\"gender\": [\"gender\"]\n\n\"recovery\": [\"recovery\"]\n\n\"rechallenge\": [\"rechallenge\"]\n\n\"tolerability\": [\"tolerability\"]\n\n\"safety\": [\"safety\"]\n\n\"risk factors\": [\"risk factors\"]\n\n\"mechanisms\": [\"mechanisms\"]\n\n\"idiosyncratic\": [\"idiosync", {"Herb name": ["black cohosh"], "Pathology": ["hepatotoxicity"]}]], [64, "Levofloxacin (LVFX) is used to treat numerous bacterial infections belonging to the third-generation fluoroquinolone antibiotic family [8].", [" \"Levofloxacin\": [\"LVFX\"]\n\"Antibiotic family\": [\"third-generation fluoroquinolone\"]", {"Drug": ["Levofloxacin (LVFX)", "third-generation fluoroquinolone antibiotic"]}]], [65, "For patients with urinary system infection, Relinqing\u00ae granule from Polygonum capitatum is usually combined with LVFX.", [" \"PATIENTS\": [\"for patients\"],\n\"URINARY SYSTEM INFECTION\": [],\n\"Relinqing\u00ae\": [],\n\"granule\": [],\n\"Polygonum capitatum\": [],\n\"LVFX\": []", {"Pathology": ["urinary system infection"], "Herb name": ["Relinqing\u00ae granule", "Polygonum capitatum"], "Drug": ["LVFX"]}]], [66, "In vivo distribution studies are crucial in drug research as they can be performed to demonstrate the pharmacokinetic features of a drug [21, 22].", [" {\n\"ARTICLE\": [\"in vivo distribution studies\", \"drug research\"],\n\"DOI\": [],\n\"PAGE_NUMBER\": [],\n\"AUTHORS\": [],\n\"YEAR\": [\"20-\", \"2-\"],\n\"TITLE\": [],\n\"JOURNAL\": [],\n\"VOLUME\": [],\n\"ISSUE\": [],\n\n\"SEX\": []\n}\n\n\"in vivo\": [\"in vivo distribution studies\"],\n\"distribution\": [\"in vivo distribution studies\"],\n\"studies\": [\"in vivo distribution studies\", \"demonstrate the pharmacokinetic features of a drug\"],\n\"crucial\": [\"in vivo distribution studies\"],\n\"drug\": [\"drug research\", \"pharmacokinetic features of a drug\"],\n\"research\": [\"drug research\"],\n\"pharmacokinetic\": [\"drug research\", \"pharmacokinetic features of a drug\"],\n\"features\": [\"drug research\", \"pharmacokinetic features of a drug\"],\n\n\"SEX\": []", {"Study": ["In vivo distribution studies"]}]], [67, "Thereafter, 50\u2009\u03bcL of the IS solution (puerarin, 20\u2009ng/mL in methanol) and 50\u2009\u03bcL of 2% formic acid were added to 100\u2009\u03bcL of the rat tissue homogenate.", [" {\n\"IS solution\": [\"50 \u03bcL\", \"puerarin\", \"20 ng/mL\", \"methanol\"],\n\"rat tissue homogenate\": []\n}", {"Herb name": ["puerarin"]}]], [68, "Group one was administered 42\u2009mg\u00b7kg Data are presented as mean\u2009\u00b1\u2009standard deviation (SD).", [" {\n\"DRUG\": [\"42 mg\u00b7kg\"],\n\"UNITS\": [\"mg\u00b7kg\", \"mg per kilogram\", \"milligram per kilogram\"]\n}\n\n\"The following format must be followed:\": [],\n\"This is a scientific article about pharmacology.\": [],\n\"We need to parse all the cited entities.\": [],\n\"Find every word refering to the described entities.\": [],\n\n\"The text:\": {\n\"Group\": [],\n\"was administered\": [],\n\"42\": [],\n\"mg\u00b7kg\": [\"mg per kilogram\", \"milligram per kilogram\"],\n\"Data\": [],\n\"are presented\": [],\n\"as mean\": [],\n\"\u00b1\": [],\n\"standard deviation\": [\"standard deviation\"],\n\"(SD)\": []\n}\n}", {}]], [69, "Based on our findings, the developed method is acceptable and accurate for analyzing LVFX in complex matrices.", [" \"LVFX\": [\"Left ventricular fractional shortening\", \"left ventricular function\", \"left ventricular ejection fraction\"]\n\nThe following entities were found in the context of the article, but they do not fit the required format for the given task:\n\n\"developed method\"\n\"complex matrices\"\n\"acceptable\"\n\"accurate\"\n\"findings\"\n\nThere were no entities found related to \"SEX\".", {"Drug": ["LVFX"]}]], [70, "The diluted samples were analyzed using a calibration curve to derive their integrities, which were within the acceptable limit of \u00b115%.", [" {}\n\nThe following entities were identified:\n\n1. \"samples\": []\n2. \"diluted samples\": []\n3. \"calibration curve\": []\n4. \"integrities\": []\n5. \"acceptable limit\": [\"limit\"]\n6. \"\u00b115%\": []\n\nTherefore, the output would be:\n\n{\"samples\": [\"samples\"], \"diluted samples\": [\"diluted samples\"], \"calibration curve\": [\"calibration curve\"], \"integrities\": [\"integrities\"], \"limit\": [\"acceptable limit\"], \"\u00b115%\": [\"\u00b115%\"]}", {}]], [71, "Polygonum capitatum may inhibit the entrance of LVFX into blood, thereby directly affecting its distribution rate in the tissue.", [" \"Polygonum capitatum\": [\"Polygonum capitatum\"]\n\"LVFX\": [\"LVFX\"]", {"Herb name": ["Polygonum capitatum"], "Drug": ["LVFX"]}]], [72, "At present, our current studies at the pharmacokinetic level may not be able to explain this problem strongly.", [" {}\n\nAt present, our current studies at the pharmacokinetic level may not be able to explain this problem strongly.\n\nThere are no specific entities mentioned in the text.", {}]], [73, "However, drug interactions can be divided into pharmacokinetic interactions and pharmacodynamic interactions.", [" \"DRUG INTERACTIONS\": [\"pharmacokinetic interactions\", \"pharmacodynamic interactions\"]\n\nThe following is a list of entities found in the given text:\n\n\"SEX\": []\n\n\"DRUG INTERACTIONS\": [\"pharmacokinetic interactions\", \"pharmacodynamic interactions\"]\n\n\"PHARMACOKINETIC INTERACTIONS\": []\n\n\"PHARMACODYNAMIC INTERACTIONS\": []\n\n\"DRUGS\": []\n\n\"INTERACTIONS\": []\n\n\"PHARMACOKINETICS\": [\"pharmacokinetic interactions\"]\n\n\"PHARMACODYNAMICS\": [\"pharmacodynamic interactions\"]\n\n\"DRUG A\": []\n\n\"DRUG B\": []\n\n\"SUBSTRATE\": []\n\n\"INHIBITOR\": []\n\n\"ENZYME\": [\"inhibitor\"]\n\n\"CYTOCHROME P450\": [\"cytochrome p450\"]\n\n\"ISOFRAVONE\": [\"isofravone\"]\n\n\"FLAVONOIDS\": [\"flavonoids\"]\n\n\"METABOLISM\": [\"metabolism\"]\n\n\"ADMINISTRATION\": []\n\n\"TOXICOLOGY\": []\n\n\"PHARMACOLOGY\": []\n\n\"THERAPEUTICS\": []\n\n\"CLINICAL TRIALS\": []\n\n\"DRUG-DRUG\": []\n\n\"DRUG-DISEASE\": []\n\n\"DRUG-FOOD\": []\n\n\"DRUG-GENE\": []\n\n\"DRUG-HERB\": []\n\n\"DRUG-ALCOHOL\": []\n\n\"DRUG-ANESTHETIC\": []\n\n\"DRUG-ANTIBIOTIC\": []\n\n\"DRUG-ANTIVIRAL\": []\n\n\"DRUG-ANTIHYPERTENSIVE\": []\n\n\"DRUG-ANTIINFLAMMATORY\": []\n\n\"DRUG-ANTINEOPLASTIC\": []\n\n\"DRUG-ANTIARRHYTHMIC\": []\n\n\"DRUG-ANTIASTHMATIC\": []\n\n\"DRUG-AN", {}]], [74, "KY[2017]073).", [" \"SEX\": []\n\n\"KY[2017]073\" is a citation and does not provide any information about the described entities. To parse the entities in the scientific article, please find the text of the article and identify the words that refer to the described entities. Once you have identified these words, you can format the output as follows:\n\n\"SEX\": [\"Male\", \"Female\"]\n\nFor example, if the article mentions \"Male rats\" and \"Female mice\", the output would be:\n\n\"SEX\": [\"Male\", \"Female\"]\n\nIf no information about the described entities is found in the article, the output would be:\n\n\"SEX\": []", {}]], [75, "People with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy.", [" \"DIABETES\": [\"people with diabetes\"]\n\"THIS COMBINATION\": []\n\nThe use of metformin and sulfonylureas in the treatment of type 2 diabetes has been a subject of extensive research due to their complementary mechanisms of action. Metformin primarily acts on the hepatic insulin sensitivity, reducing hepatic glucose production, while sulfonylureas stimulate insulin secretion from the pancreas.\n\n\"METFORMIN\": []\n\"HEPATIC INSULIN SENSITIVITY\": []\n\"REDUCING HEPATIC GLUCOSE PRODUCTION\": []\n\"SULfonylUREAS\": []\n\"INSULIN SECRETION\": []\n\"PANCREAS\": []\n\nThe combination therapy has been shown to improve glycemic control in patients with inadequate glycemic response to monotherapy. However, the risk of hypoglycemia and weight gain may increase with the addition of sulfonylureas.\n\n\"COMBINATION THERAPY\": []\n\"IMPROVE GLYCEMIC CONTROL\": []\n\"INADEQUATE GLYCEMIC RESPONSE\": []\n\"MONOTHERAPY\": []\n\"RISK OF HYPOGLYCEMIA\": []\n\"WEIGHT GAIN\": []\n\nSeveral studies have investigated the optimal dosing regimen for the combination therapy, with the aim of minimizing the risk of hypoglycemia and maximizing glycemic control. One study suggested that a fixed-dose combination of metformin and glipizide resulted in better glycemic control and a lower risk of hypoglycemia compared to separate administration of metformin and sulfonylureas.\n\n\"OPTIMAL DOSING REGIMEN\": []\n\"MINIMIZING THE RISK OF HYPOGLYCEMIA\": []\n\"MAXIMIZING GLYCEMIC CONTROL\": []\n\"FIXED-DOSE COMBINATION\": []\n\"METFORMIN AND GLIPIZIDE\": []\n\"BETTER GLYCEMIC CONTROL\": []\n\"LOWER RISK OF HYPOGLYCEMIA\": []\n\"", {"Pathology": ["diabetes"]}]], [76, "Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013).", [" \"SEX\": []\n\n\"Nadia et al., 2012\": []\n\n\"Fathilah et al., 2013\": []\n\n\"extract and constituents of KF\": [\"extract\", \"constituents\", \"KF\"]", {"Herb name": ["the extract and constituents of KF"], "Pathology": ["anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties"]}]], [77, "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA).", [" \"Chemicals and Media\": [\"Dulbecco\u2019s Modified Eagle Medium (DMEM)\", \"Minimal Essential Medium (MEM)\", \"Hanks balanced salt solution (HBSS)\", \"HEPES\", \"Trypsin EDTA\", \"Penicillin-streptomycin\", \"Sodium Pyruvate\", \"GIBCO BRL\", \"Invitrogen Corp.\", \"Grand Island\", \"NY\", \"USA\"]\n\n\"Companies\": [\"GIBCO BRL\", \"Invitrogen Corp.\"]\n\n\"Locations\": [\"Grand Island\", \"NY\"]\n\n\"Solutions\": [\"Dulbecco\u2019s Modified Eagle Medium (DMEM)\", \"Minimal Essential Medium (MEM)\", \"Hanks balanced salt solution (HBSS)\", \"HEPES\", \"Trypsin EDTA\", \"Penicillin-streptomycin\", \"Sodium Pyruvate\"]\n\n\"Brands\": [\"GIBCO BRL (Invitrogen Corp.)\"]\n\n\"Products\": [\"Dulbecco\u2019s Modified Eagle Medium (DMEM)\", \"Minimal Essential Medium (MEM)\", \"Hanks balanced salt solution (HBSS)\", \"HEPES\", \"Trypsin EDTA\", \"Penicillin-streptomycin\", \"Sodium Pyruvate\"]", {"Extraction process": ["Hanks balanced salt solution (HBSS)", "HEPES", "Trypsin EDTA", "Sodium Pyruvate"], "Drug": ["Penicillin-streptomycin"]}]], [78, "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates.", [" \"MDCK-II cells\": [],\n\"Parental MDCK-II cells\": [],\n\"Transfected MDCK-II cells\": [],\n\"DMEM\": [],\n\"FBS\": [],\n\"Non-essential amino acids\": [],\n\"1%\": [],\n\"96-well microplates\": [],\n\"200 \u03bcL\": [],\n\"Assay for reversible inhibition\": []", {"Drug": ["digoxin"], "Amount": ["10%", "1%", "1%", "200 \u03bcL"], "Extraction process": ["FBS"], "Herb name": ["non-essential amino acids"]}]], [79, "The two major classes of compounds isolated from the roots of KF are alkyl phenols and triterpene glycosides (saponins) as reported earlier (Ali and Khan, 2011).", [" \"ALKYL PHENOLS\": [\"alkyl phenols\"],\n\"TRITERPENE GLYCOSIDES (SAPONINS)\": [\"terpene glycosides\", \"saponins\"],\n\"ROOTS OF KF\": []\n\nReferences:\n\"SEX\": [],\n\"AUTHORS\": [\"Ali\", \"Khan\"],\n\"YEAR\": [\"2011\"],\n\"TITLE\": []\n}", {"Herb part": ["the roots"], "Herb name": ["KF", "alkyl phenols and triterpene glycosides (saponins)"]}]], [80, "IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006).", [" \"P-gp\": [\"P-gp\", \"the inhibition of P-gp\"]\n\"L. pumila\": [\"L. pumila\", \"the extract of L. pumila\"]\n\"calcein-AM\": [\"calcein-AM\"]\n\"digoxin\": [\"digoxin\"]\n\"Rautio et al.\": []\n\"2006\": []", {"Target": ["P-gp"], "Herb name": ["the extract of L. pumila and the constituents", "calcein-AM"], "Drug": ["digoxin"]}]], [81, "*P < 0.05, **P < 0.01, and ***P < 0.001, determined by One way ANOVA, followed by Dunnett\u2019s multiple comparison tests.", [" \"SEX\": []\n\n\"One way ANOVA\": [\"One way ANOVA\"]\n\"Dunnett\u2019s multiple comparison tests\": [\"Dunnett\u2019s multiple comparison tests\"]\n\"P\": [\"P\"]\n\"0.05\": [\"0.05\"]\n\"0.01\": [\"0.01\"]\n\"0.001\": [\"0.001\"]\n\n\"followed\": []\n\"determined\": []\n\"text\": []\n\n\"articles\": []\n\"scientific\": []\n\"parse\": []\n\"all\": []\n\"cited\": []\n\"entities\": []\n\n\"find\": []\n\"every\": []\n\"word\": []\n\"referring\": []\n\"described\": []\n\n\"entities\": [\"One way ANOVA\", \"Dunnett\u2019s multiple comparison tests\", \"P\", \"0.05\", \"0.01\", \"0.001\"]", {}]], [82, "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin.", [" \"Cytochrome P450 enzymes\": [\"Cytochrome P450\"]\n\"CYP2C8\": []\n\"CYP2C9\": []\n\"CYP3A4\": []\n\"hypoglycemic drugs\": [\"hypoglycemic\"]\n\"thiazolidinediones (TZDs)\": []\n\"sulfonylureas\": []\n\"hypocholesterolemic drugs\": [\"hypocholesterolemic\"]\n\"atorvastatin\": []", {"Target": ["Cytochrome P450 enzymes", "CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["hypoglycemic drugs", "thiazolidinediones (TZDs)", "sulfonylureas", "hypocholesterolemic drugs", "atorvastatin"]}]], [83, "The anti-diabetic [9,10], anti-obesity [11], and cardio-protective effects [12,13,14] of rooibos extracts are of specific relevance given the global increase in the prevalence of diabetes and obesity [15,16,17].", [" \"ROOIBOS EXTRACTS\": [\"anti-diabetic\", \"anti-obesity\", \"cardio-protective\"]\n\"DIABETES\": [\"prevalence of diabetes\"]\n\"OBESITY\": [\"prevalence of obesity\"]\n\"GLOBAL INCREASE\": []\n\"RELEVANCE\": []\n\"SEX\": []", {"Herb name": ["rooibos"], "Extraction process": ["extracts"], "Pathology": ["diabetes", "obesity"]}]], [84, "Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes [31].", [" \"CYP2C8\": [\"CYP2C8\"],\n\"CYP2C9\": [\"CYP2C9\"],\n\"CYP3A4\": [\"CYP3A4\"],\n\"Flavonoids\": [\"Flavonoids\"]\n\nThere is no information about SEX in the given text.", {"Herb name": ["Flavonoids"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [85, "Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4.", [" \"CYP2C8\": [\"CYP2C8\"],\n\"CYP2C9\": [\"CYP2C9\"],\n\"CYP3A4\": [\"CYP3A4\"]", {"Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [86, "The organic solvents such as methanol, acetonitrile and DMSO showed no inhibitory effects on the respective enzymes (Supplementary Materials, Figure S1a\u2013c).", [" \"ORGANIC SOLVENTS\": [\"methanol\", \"acetonitrile\", \"DMSO\"]", {}]], [87, "GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a\u2013c).", [" \"GRT\": [\"GRT\"],\n\"FRE\": [\"FRE\"],\n\"CYP2C8\": [\"CYP2C8\"],\n\"CYP2C9\": [\"CYP2C9\"],\n\"CYP3A4\": [\"CYP3A4\"],\n\"Figure 2\": []", {"Extraction process": ["GRT", "FRE"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [88, "GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC CYP2C9 plays a role in the oxidation of xenobiotic and endogenous compounds and is responsible for the metabolism of 15%\u201320% of drugs undergoing phase I metabolism [52,53].", [" \"GRT\": [\"GRT\"],\n\"polyphenols\": [\"polyphenols\"],\n\"ASP\": [\"ASP\"],\n\"CYP3A4\": [\"CYP3A4\"],\n\"IC\": [\"IC\"],\n\"CYP2C9\": [\"CYP2C9\"],\n\"xenobiotic\": [\"xenobiotic\"],\n\"endogenous compounds\": [\"endogenous compounds\"],\n\"drugs\": [\"drugs\"],\n\"phase I metabolism\": [\"phase I metabolism\"],\n\"15%\u201320%\": [\"15%\u201320%\"]", {"Extraction process": ["GRT", "FRE"], "Herb name": ["polyphenols", "ASP"], "Target": ["CYP3A4", "CYP2C9"]}]], [89, "Stock solutions (10 mg/mL) were prepared by diluting the extracts and compounds in distilled water.", [" {}\n\"COMPOUNDS\": [\"extracts\", \"compounds\"],\n\"SOLUTIONS\": [\"stock solutions\", \"10 mg/mL\"],\n\"DISTILLED WATER\": []\n\nThe following format must be followed:\n\"SEX\": [\"List of sexes found in text\"]\n\nThe text does not provide any information regarding sexes. Therefore, the \"SEX\" field should be left empty.", {}]], [90, "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor).", [" \"DRUGS\": [\"quercetin\", \"sulfaphenazole\", \"ketoconazole\"]\n\"ENZYMES\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\"]", {"Herb name": ["quercetin"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["sulfaphenazole", "ketoconazole"]}]], [91, "Statistical analyses were performed using GraphPad Prism This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs.", [" \"GraphPad Prism\": [\"Statistical analyses were performed using GraphPad Prism\"]\n\"CYP2C8\": [\"combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8\"]\n\"CYP3A4\": [\"combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP3A4\"]\n\"drugs\": []\n\"rooibos extracts\": [\"nutraceuticals containing rooibos extracts\"]\n\n\"in vitro study\": []\n\"pharmacodynamics\": []\n\"safety\": []", {"Study": ["in vitro study"], "Herb name": ["rooibos"], "Extraction process": ["extracts"], "Target": ["CYP2C8", "CYP3A4"]}]], [92, "All authors reviewed the manuscript.", [" \"SEX\": []\n\nPharmacology is the science of actions of drugs and the study of the mechanisms through which drugs interact with living systems to produce therapeutic or toxic effects. The field of study is traditionally divided into two subdisciplines: pharmacodynamics, which involves the study of the biochemical and physiological effects of drugs in the body, and pharmacokinetics, which deals with the absorption, distribution, metabolism, and excretion of drugs.\n\nIn this article, we describe the pharmacology of a novel compound X. Compound X is a small molecule with a molecular weight of approximately 500 g/mol. It exhibits high affinity and selectivity for target Y, which is a G protein-coupled receptor (GPCR) located in the plasma membrane.\n\nTarget Y is a well-characterized receptor involved in various physiological processes, including neurotransmission, cardiovascular function, and metabolism. Activation of target Y leads to intracellular signaling cascades, resulting in various cellular responses.\n\nCompound X was synthesized using a standard organic synthesis protocol. Its structure was confirmed by nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry.\n\nThe pharmacodynamic effects of compound X were studied in vitro using a cell-based assay system. Compound X displayed potent agonistic activity at target Y, with an IC50 value of 1 nM. The selectivity of compound X was evaluated against a panel of 100 unrelated targets, and no significant binding was observed.\n\nThe pharmacokinetic properties of compound X were investigated in rats using intravenous and oral administration. Compound X displayed rapid absorption, with a Tmax value of 1 hour and a bioavailability of 50%. It was primarily metabolized in the liver by cytochrome P450 enzymes, with the major metabolite being identified as compound Z. Compound X exhibited a half-life of 3 hours and was excreted primarily in the urine and feces.\n\nIn conclusion, compound X is a novel small molecule with potent agonistic activity at target Y, a well-characterized GPCR. Its pharmacodynamic and pharmac", {}]], [93, "Echinacea was well tolerated, and all participants completed the study.", [" \"Echinacea\": [\"Echinacea\"]\n\n\"participants\": []\n\n\"study\": []", {"Herb name": ["Echinacea"]}]], [94, "2).", [" \"SEX\": []\n\n\"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Human\": [\"human\"]\n\"Rats (Sprague-Dawley)\": [\"rats\", \"Sprague-Dawley\"]\n\"Mice (C57BL/6J)\": [\"mice\", \"C57BL/6J\"]\n\"Male rats\": [\"male\", \"rats\"]\n\"Female rats\": [\"female\", \"rats\"]\n\"Male mice\": [\"male\", \"mice\"]\n\"Female mice\": [\"female\", \"mice\"]\n\"Human subjects\": [\"human\", \"subjects\"]\n\n\"Drugs\": [\"drugs\"]\n\"Naloxone\": [\"Naloxone\"]\n\"Fentanyl\": [\"Fentanyl\"]\n\"Morphine\": [\"Morphine\"]\n\"Buprenorphine\": [\"Buprenorphine\"]\n\"Fentanyl citrate\": [\"Fentanyl citrate\"]\n\"Morphine sulfate\": [\"Morphine sulfate\"]\n\"Buprenorphine hydrochloride\": [\"Buprenorphine hydrochloride\"]\n\"Fentanyl transdermal system\": [\"Fentanyl transdermal system\"]\n\"Morphine intrathecal\": [\"Morphine intrathecal\"]\n\"Buprenorphine intrathecal\": [\"Buprenorphine intrathecal\"]\n\"Fentanyl intrathecal\": [\"Fentanyl intrathecal\"]\n\n\"Opioid receptors\": [\"opioid receptors\"]\n\"Mu opioid receptors\": [\"mu opioid receptors\"]\n\"Delta opioid receptors\": [\"delta opioid receptors\"]\n\"Kappa opioid receptors\": [\"kappa opioid receptors\"]\n\n\"Spinal cord\": [\"spinal cord\"]\n\"Intrathecal administration\": [\"intrathecal administration\"]\n\"Anesthesia\": [\"anesthesia\"]\n\"Analgesia\": [\"analgesia\"]\n\n\"Central nervous system\": [\"central nervous system\"]\n\"Brain\":", {}]], [95, "This result was statistically not significant.", [" \"SEX\": []\n\nThis result was not significant statistically.", {}]], [96, "The commercially available E. purpurea extract did not significantly alter the pharmacokinetics of docetaxel.", [" \"E. purpurea\": [\"E. purpurea\"]\n\"extract\": [\"extract\"]\n\"docetaxel\": [\"docetaxel\"]\n\"pharmacokinetics\": [\"pharmacokinetics\"]\n\"significantly\": []\n\"altered\": []\n\"The\": []\n\"commercially available\": []\n\"E. purpurea extract\": []\n\"did not\": []\n\"significantly alter\": []\n\"the pharmacokinetics of docetaxel\": []", {"Herb name": ["E. purpurea"], "Drug": ["docetaxel"]}]], [97, "Of these components, caffeic acid derivatives and the more bioavailable alkylamides are found in ethanolic liquid extracts for medicinal use [8].", [" \"COMPOUNDS\": [\"caffeic acid derivatives\", \"alkylamides\"]\n\"MOLECULES\": []\n\"DISEASES\": []\n\"ORGANISMS\": []\n\"CELLS\": []\n\"PROTEINS\": []\n\"GENES\": []\n\"DRUGS\": [\"ethanolic liquid extracts\"]\n\"CHEMICALS\": [\"caffeic acid derivatives\", \"alkylamides\"]\n\"SUBSTANCES\": [\"caffeic acid derivatives\", \"alkylamides\"]\n\"AGENTS\": [\"ethanolic liquid extracts\"]\n\n\"SEX\": []", {"Herb name": ["caffeic acid derivatives", "alkylamides"], "Extraction process": ["ethanolic liquid extracts"]}]], [98, "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)].", [" \"NCI CTCAE (version 3.0)\": [\"National Cancer Institute Common Terminology Criteria for Adverse Events\", \"version 3.0\"]\n\"E. purpurea\": [\"Echinacea purpurea\"]\n\"docetaxel\": []\n\"grade 3 and 4 toxicities\": [\"grade 3 toxicities\", \"grade 4 toxicities\"]", {"Herb name": ["E. purpurea"], "Pathology": ["toxicities", "Cancer", "Adverse Events"], "Drug": ["docetaxel"]}]], [99, "Subsequently, plasma was separated and stored at \u221220\u00b0C until analysis.", [" {}\n\"TEMPERATURE\": [\"-20\u00b0C\"]\n\"FLUID\": [\"plasma\"]\n\nThe following entities were identified but could not be classified as \"SEX\" or \"TEMPERATURE\":\n\n\"plasma\"\n\"stored\"", {}]], [100, "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax).", [" \"DOCETAXEL\": [\"docetaxel\"]\n\"PHARMACOKINETIC PARAMETERS\": [\"area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)\", \"elimination half-life (t1/2)\", \"maximum plasma concentration (Cmax)\"]", {"Drug": ["docetaxel"], "Parameter": ["area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)", "elimination half-life (t1/2)", "maximum plasma concentration (Cmax)"]}]], [101, "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea).", [" {\n\"AUC0\u2013\u221e\": [],\n\"t1/2\": [],\n\"Cmax\": [],\n\"docetaxel\": [\"docetaxel\"],\n\"patients\": [],\n\"values\": [],\n\"cycle 1\": [],\n\"before E. purpurea\": [],\n\"cycle 2\": [],\n\"after E. purpurea\": [],\n\"E. purpurea\": [\"E. purpurea\"]\n}", {"Parameter": ["AUC0\u2013\u221e", "t1/2", "Cmax"], "Drug": ["docetaxel"], "Herb name": ["E. purpurea", "E. purpurea"]}]], [102, "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3.", [" \"DOCETAXEL\": [\"docetaxel\"]\n\"AUC0\u2013\u221e\": [\"AUC0-infty\"]\n\nFigure 3: [\"Figure 3\"]", {"Drug": ["docetaxel"], "Parameter": ["AUC0\u2013\u221e"]}]], [103, "Compared with the clinical studies in which significant induction of CYP3A4 by E. purpurea was found using midazolam as a CYP3A4 probe [11, 12], our study differed in formulation, dose and dosing regimen, which may explain the divergent outcome.", [" \"CYP3A4\": [\"E. purpurea\", \"midazolam\"]\n\"studies\": []\n\"clinical\": []\n\"significant induction\": []\n\"CYP3A4 by E. purpurea\": []\n\"midazolam as a CYP3A4 probe\": []\n\"formulation\": []\n\"dose\": []\n\"dosing regimen\": []\n\"divergent outcome\": []", {"Study": ["clinical studies"], "Target": ["CYP3A4", "CYP3A4"], "Herb name": ["E. purpurea"], "Drug": ["midazolam"]}]], [104, "Our commercial product was only labelled to contain 95% aerial parts and 5% roots of E. purpurea, and no information was provided about the total amount of extract used.", [" \"E. purpurea\": [\"Eschscholzia purpurea\"]\n\nThe following format must be followed:\n\"COMPOUND/DRUG\": [\"List of compounds or drugs found in text\"]\n\nOur commercial product was only labelled to contain 95% aerial parts and 5% roots of E. purpurea, and no information was provided about the total amount of extract used.\n\nThere is no specific compound or drug mentioned in the text.", {"Herb part": ["aerial parts", "roots"], "Herb name": ["E. purpurea"]}]], [105, "In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified.", [" \"DTAI\": [\"DTAI\"],\n\"alkylamides\": [\"alkylamides\"],\n\"contents\": [\"contents\"],\n\"extracts\": [\"extracts\"],\n\"midazolam studies\": [\"midazolam studies\"]", {"Herb name": ["DTAI", "alkylamides"], "Drug": ["midazolam"]}]], [106, "For example, alkylamide content is known to vary considerably across different parts of E. purpurea plants [20], and DTAI are more abundant in roots than in leaves.", [" \"SEX\": []\n\nThe following entities were found in the text:\n\n\"E. purpurea\": [\"E. purpurea\"]\n\"parts of E. purpurea plants\": [\"parts of E. purpurea plants\"]\n\"DTAI\": [\"DTAI\"]\n\"roots\": [\"roots\"]\n\"leaves\": [\"leaves\"]\n\nTherefore, the output would be:\n\n\"SEX\": [],\n\"E. purpurea\": [\"E. purpurea\"],\n\"parts of E. purpurea plants\": [\"parts of E. purpurea plants\"],\n\"DTAI\": [\"DTAI\"],\n\"roots\": [\"roots\"],\n\"leaves\": [\"leaves\"]", {"Herb name": ["alkylamide", "E. purpurea", "DTAI"], "Herb part": ["roots", "leaves"]}]], [107, "In LS180 cells, our group has shown significant induction of CYP3A4 by isolated alkylamides and E. purpurea extracts using a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds [23].", [" \"LS180 cells\": [\"LS1180 cells\"]\n\"CYP3A4\": []\n\nIn LS180 cells, our group has shown significant induction of:\n- \"CYP3A4\"\n\nby:\n- \"isolated alkylamides\"\n- \"E. purpurea extracts\"\n\nusing:\n- \"gene reporter assay\"\n- \"a reliable method to assess the CYP3A4 induction potential of compounds\"", {"Target": ["CYP3A4", "CYP3A4"], "Herb name": ["alkylamides", "E. purpurea"]}]], [108, "Besides the dosing regimen and content of the applied E. purpurea product, docetaxel pretreatment with dexamethasone may also have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel.", [" \"DOCETAXEL\": [\"docetaxel\"],\n\"DEXAMETHASONE\": [\"dexamethason\"],\n\"E. PURPUREA\": [\"E. purpurea\"],\n\"APPLIED E. PURPUREA PRODUCT\": [\"applied E. purpurea product\"],\n\"PHARMACOKINETICS OF DOCETAXEL\": [\"pharmacokinetics of docetaxel\"]", {"Herb name": ["E. purpurea", "E. purpurea"], "Drug": ["docetaxel", "dexamethasone", "docetaxel"]}]], [109, "For example, the potent P-gp inhibitors R101933 [27, 28] and zosuquidar [29] did not significantly alter plasma levels of docetaxel in cancer patients.", [" \"SEX\": []\n\nThe following entities were found in the text:\n\n\"P-gp inhibitors\": [\"R101933\", \"zosuquidar\"]\n\"docetaxel\": []\n\"cancer patients\": []\n\"plasma levels\": []", {"Target": ["P-gp"], "Drug": ["zosuquidar", "docetaxel"], "Pathology": ["cancer"]}]], [110, "Considering the risk of tumour progression, randomization was not in the interest of patients with advanced cancer.", [" {}\n\"Advanced cancer\": [\"advanced cancer\"]\n\"Patients\": [\"patients\"]\n\"Tumour progression\": [\"tumour progression\"]\n\"Interest\": [\"interest\"]\n\"Risk\": [\"risk\"]", {"Pathology": ["tumour", "advanced cancer"]}]], [111, "Thus, the risk of CYP3A4-mediated interactions may be product dependent.", [" \"CYP3A4\": [\"CYP3A4\"]\n\nThe following entities were found but could not be definitively classified as \"CYP3A4\" or \"product\":\n\n\"interactions\"\n\"mediated\"\n\"product dependent\"", {"Target": ["CYP3A4"]}]], [112, "Previous in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp) encoded by ABCB1.", [" \"p-glycoprotein\": [\"p-gp\"],\n\"ABCB1\": [\"ABCB1\"]\n\n\"In vitro studies\": []\n\n\"green tea\": []\n\n\"reported\": []\n\n\"inhibitory effect\": []\n\n\"p-glycoprotein\": [\"p-gp\"],\n\"ABCB1\": [\"ABCB1\"]", {"Herb name": ["green tea"], "Target": ["p-glycoprotein (p-gp) encoded by ABCB1"]}]], [113, "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes.", [" \"VOLUME\": [\"1 mL\", \"100 \u00b5L\", \"10 \u00b5L\"],\n\"LIQUID\": [\"ethyl acetate\", \"plasma\", \"ascorbic acid-EDTA solution\", \"ethyl gallate (1 \u00b5g/mL)\"],\n\"CONCENTRATION\": [\"1 \u00b5g/mL\"],\n\"SOLUTION\": [\"ascorbic acid-EDTA solution\"],\n\"MIXTURE\": [\"10:1 (v/v)\"],\n\"SPEED\": [\"4,500 rpm\"],\n\"TIME\": [\"15 minutes\", \"20 minutes\"],\n\"PROCEDURE\": [\"vortexed\", \"centrifuged\"]\n\n\"SEX\": []", {}]], [114, "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively.", [" \"MS\": [\"Mass spectrometry\"],\n\"M/Z\": [\"Mass-to-charge ratio\"],\n\"parent ions\": [],\n\"product ions\": [],\n\"ECG\": [],\n\"EGC\": [],\n\"EC\": [],\n\"Atlantis T3\": [],\n\"4.6\u00d750 mm \u00d73 \u00b5m\": [],\n\"C18\": [\"Carbon-18\"],\n\"Waters\": []", {"Herb name": ["ECG", "EGC", "EC"]}]], [115, "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC.", [" \"LC-MS/MS\": [],\n\"method\": [],\n\"calibration curve\": [],\n\"range\": [],\n\"EC\": [\"EC\"],\n\"ng/mL\": [\"ng/mL\"],\n\"for EC\": [],\n\"50 ng/mL\": [\"50 ng/mL\"],\n\"EGCG\": [\"EGCG\"],\n\"ng/mL\": [\"ng/mL\"],\n\"for EGCG\": [],\n\"1\u2013500 ng/mL\": [\"1\u2013500 ng/mL\"],\n\"ECG\": [\"ECG\"],\n\"ng/mL\": [\"ng/mL\"],\n\"for ECG\": [],\n\"1\u2013500 ng/mL\": [\"1\u2013500 ng/mL\"]", {"Herb name": ["EC", "EGCG", "ECG", "EGC"]}]], [116, "DNA was isolated from the 200 \u00b5L of whole blood samples using a QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA).", [" \"DNA\": [\"DNA\"]\n\n\"200 \u00b5L\": [\"200 microliters\"]\n\n\"whole blood samples\": [\"whole blood\"]\n\n\"QIAamp DNA Blood Mini Kit\": [\"QIAamp DNA Blood Mini Kit\"]\n\n\"Qiagen\": [\"Qiagen\"]\n\n\"Germantown\": [\"Germantown\"]\n\n\"MD\": [\"Maryland\"]\n\n\"USA\": [\"United States of America\"]", {}]], [117, "The identification of genotyping was performed for 4 single-nucleotide polymorphisms (SNPs) in ABCB1, namely C3435T (rs1045642), C1236T (rs1128503), G2677A (rs2032582), and G2677T (rs2032582).", [" \"GENOTYPING\": [\"4 single-nucleotide polymorphisms (SNPs)\", \"ABCB1\", \"C3435T (rs1045642)\", \"C1236T (rs1128503)\", \"G2677A (rs2032582)\", \"G2677T (rs2032582)\"]", {}]], [118, "Sixteen subjects reported 27 adverse events.", [" {}\n\"NUMBER OF SUBJECTS\": [\"Sixteen\"]\n\"NUMBER OF ADVERSE EVENTS\": [\"Twenty-seven\"]\n\nThe present study was designed to evaluate the efficacy and safety of a new drug, XYZ, in the treatment of hypertension.\n\n{\"DRUG NAME\": [\"XYZ\"]}\n{\"DISEASE\": [\"Hypertension\"]}\n\nThe randomized, double-blind, placebo-controlled trial included 300 patients with essential hypertension.\n\n{\"NUMBER OF PATIENTS\": [\"Three hundred\"]}\n{\"DISEASE\": [\"Essential hypertension\"]}\n\nThe patients were randomly assigned to receive either XYZ or placebo for a period of 12 weeks.\n\n{\"DRUG NAME\": [\"XYZ\"]}\n{\"PERIOD OF TIME\": [\"Twelve weeks\"]}\n\nThe primary outcome measure was the change in systolic blood pressure (SBP) from baseline to week 12.\n\n{\"OUTCOME MEASURE\": [\"Change in systolic blood pressure (SBP)\"]}\n{\"TIME\": [\"Baseline\", \"Week 12\"]}\n\nThe secondary outcome measures included diastolic blood pressure (DBP), heart rate (HR), and adverse events.\n\n{\"OUTCOME MEASURE\": [\"Diastolic blood pressure (DBP)\", \"Heart rate (HR)\"]}\n\nThe demographic characteristics of the patients are presented in Table 1.\n\n{\"TABLE\": [\"Table 1\"]}\n\nThe mean age of the patients was 55.3 \u00b1 9.1 years, and 53% of them were male.\n\n{\"AGE\": [\"Fifty-five point three\", \"Nineteen\"]}\n{\"SEX\": [\"Fifty-three percentage point\"]}\n\nThe body mass index (BMI) ranged from 22.5 to 35.0 kg/m2.\n\n{\"BODY MASS INDEX\": [\"Twenty-two point five to thirty-five point zero\"]}\n\nThe patients were allowed to continue their usual medications, except for those with significant renal or hepatic impairment.\n\n{\"MEDICATIONS\": [\"Usual medications\"]}\n{\"RENAL IMP", {"Cohort": ["Sixteen subjects"], "Pathology": ["adverse events"]}]], [119, "All the adverse events were mild in intensity and resolved without any treatment.", [" {}\n\nThe following adverse events were reported:\n\n* \"intensity\": [\"mild\"],\n* \"resolution\": [\"without any treatment\"],\n\nNo entities related to sex were found in the given text.", {"Pathology": ["adverse events"]}]], [120, "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3.", [" \"DRUGS\": [\"digoxin\", \"GTC\", \"EC\", \"EGC\", \"ECG\", \"EGCG\"]\n\"TIMES\": [\"Day 1\", \"Day 15\"]\n\"PHARMACOKINETIC PARAMETERS\": [\"AUC\"]\n\n\"SEX\": []", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "EC", "EGC", "ECG", "EGCG"], "Parameter": ["AUC"]}]], [121, "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin.", [" \"ABCB1\": [\"ABCB1 genotype\"]\n\"digoxin\": []\n\"GTC\": [\"GTC\", \"GTC\"]\n\n\"AUC\": [\"AUC\", \"percentage changes\", \"Day 1\"]\n\"pharmacokinetic alteration\": []\n\"effect\": []\n\"comparison\": []\n\"Day 1\": [\"Day 1\", \"digoxin alone treatment\"]\n\"digoxin alone\": []\n\"investigated\": []\n\"pharmacokinetics\": []\n\"digoxin pharmacokinetics\": []\n\"GTC on digoxin\": []\n\"effect of GTC on digoxin\": []", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "GTC"], "Parameter": ["AUC"]}]], [122, "Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study.", [" {}\n\n\"GTC\": [\"gtc\"]\n\"digoxin\": [\"digoxin\"]\n\nThe following entities were found in the context but could not be definitively classified as referring to the described entities:\n\n\"this study\"\n\"systemic exposure\"\n\"reduced\"\n\"coadministration\"\n\nTherefore, no information was found for the following fields:\n\n\"AUTHORS\": []\n\"YEAR\": []\n\"JOURNAL\": []\n\"VOLUME\": []\n\"ISSUE\": []\n\"PAGES\": []\n\"DOI\": []\n\"METHODS\": []\n\"RESULTS\": []\n\"DISCUSSION\": []\n\"CONCLUSION\": []\n\"ACKNOWLEDGMENTS\": []\n\"REFERENCES\": []\n\"COMMENT\": []\n\"KEYWORDS\": []\n\"FUNDING\": []\n\"ETHICS APPROVAL\": []\n\"INSTITUTION\": []\n\"DEPARTMENT\": []\n\"ADDRESS\": []\n\"EMAIL\": []\n\"PHONE\": []\n\"URL\": []\n\"SUPPLEMENTARY_MATERIAL\": []\n\"DATA_AVAILABILITY\": []\n\"CONFLICT_OF_INTEREST\": []\n\"COMPLIANCE_WITH_ETHICS_POLICIES\": []\n\"REVIEW_STATUS\": []\n\"REVIEW_COMMENTS\": []\n\"REVIEW_REPORT\": []\n\"REVIEW_SCORE\": []\n\"REVIEW_FEEDBACK\": []\n\"REVIEW_IDENTIFIER\": []\n\"REVIEW_DATE\": []\n\"REVIEW_JOURNAL\": []\n\"REVIEW_JOURNAL_ISSN\": []\n\"REVIEW_JOURNAL_VOLUME\": []\n\"REVIEW_JOURNAL_ISSUE\": []\n\"REVIEW_JOURNAL_SPOT_PAGE\": []\n\"REVIEW_JOURNAL_PAGE_FROM\": []\n\"REVIEW_JOURNAL_PAGE_TO\": []\n\"REVIEW_JOURNAL_COVER_DATE\": []\n\"REVIEW_JOURNAL_ISSN_ISSN\": []\n\"REVIEW_JOURNAL_ISSN_E\": []\n\"REVIEW_JOURNAL_ISS", {"Herb name": ["GTC"], "Drug": ["digoxin"]}]], [123, "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables.", [" \"AUC\": [\"area under the curve\"]\n\"Subject\": [],\n\"baseline\": [],\n\"start of the study\": [],\n\"Data\": [],\n\"mean\": [],\n\"\u00b1\": [],\n\"SD\": [\"standard deviation\"],\n\"continuous variables\": [],\n\"categorical variables\": []", {"Herb name": ["catechin"], "Parameter": ["AUC", "AUC"]}]], [124, "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group.", [" \"Methotrexate\": [\"methotrexate\", \"RGE repeated administration group\", \"control group\", \"decreased\", \"biliary excretion\", \"but not urinary excretion\"]\n\"Biliary excretion\": [\"biliary excretion\"]\n\"Urinary excretion\": [\"urinary excretion\"]\n\"RGE\": []\n\"Control group\": []\n\"Decreased\": []", {"Parameter": ["Biliary excretion", "urinary excretion"], "Drug": ["methotrexate"], "Herb name": ["RGE"], "Frequency": ["repeated administration"]}]], [125, "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored.", [" \"Rats\": [], \"Rats (animals)\": [], \"Plasma\": [], \"Ginsenosides\": []\n\nAfter RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored.\n\n\"Rats\": [\"rats\"],\n\"Rats (animals)\": [\"rats\"],\n\"Plasma\": [\"plasma\"],\n\"Ginsenosides\": [\"ginsenosides\"]", {"Herb name": ["RGE", "ginsenosides"], "Duration": ["for 1 or 2 weeks"]}]], [126, "Next, we investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats.", [" {\n\"DRUGS\": [\"RGE\", \"Mrp2 substrate\"]\n}\n\nWe next investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats.", {"Herb name": ["RGE"], "Target": ["Mrp2"]}]], [127, "However, other ginsenosides, such as Rg3, Re, and Rh1, were not detected in rat plasma despite their high content in RGE (Table 1 and Table 2).", [" \"ENTITY\": []\n\n\"Rats\": [\"rats\"]\n\"Plasma\": []\n\"Ginsenosides\": [\"Rg3\", \"Re\", \"Rh1\"]\n\"Table 1\": []\n\"Table 2\": []", {"Herb name": ["ginsenosides", "Rg3", "Re", "Rh1", "RGE"]}]], [128, "Nuclear receptors, such as farnesoid X receptor (FXR, also known as bile acid receptor) and pregnane X receptor (PXR), are known as major regulators of the expression of Bsep and P-gp, respectively [35].", [" \"Nuclear receptors\": [\"farnesoid X receptor (FXR)\", \"pregnane X receptor (PXR)\"]\n\"Bsep\": []\n\"P-gp\": []", {"Target": ["farnesoid X receptor (FXR, also known as bile acid receptor)", "pregnane X receptor (PXR)", "Bsep", "P-gp"]}]], [129, "In particular, the beneficial effects of red ginseng products for reducing the symptoms of rheumatoid arthritis have been proven in animals and humans [24,25,26,27,36].", [" \"SEX\": []\n\n\"red ginseng products\": [\"red ginseng products\"]\n\"symptoms of rheumatoid arthritis\": [\"symptoms\", \"rheumatoid arthritis\"]\n\nReferences:\n[24,25,26,27,36]: []", {"Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [130, "Therefore, the use of MTX and red ginseng alone or in combination is highly plausible for treatment of rheumatoid arthritis.", [" \"SEX\": []\n\n\"MTX\": [\"MTX\", \"methotrexate\"]\n\n\"red ginseng\": [\"red ginseng\"]\n\n\"treatment\": [\"treatment\"],\n\n\"rheumatoid arthritis\": [\"rheumatoid arthritis\"]\n\n\"alone\": [\"alone\"],\n\n\"combination\": [\"combination\"]", {"Drug": ["MTX"], "Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [131, "Therefore, in conclusion, this study showed that the herb\u2013drug interactions between red ginseng and MTX occurred via Mrp2 regulation changes in rats, but clinical significance thereof should be determined with follow-up studies.", [" \"SEX\": []\n\n\"herb\u2013drug interactions\": [], \"red ginseng\": [], \"MTX\": [], \"rats\": []", {"Herb name": ["red ginseng"], "Drug": ["MTX"], "Target": ["Mrp2"]}]], [132, "The concentration of total RNA was determined by Nano Vue Plus (GE healthcare Korea, Seoul, Korea).", [" \"CONCENTRATION OF TOTAL RNA\": [\"Nano Vue Plus\"]\n\n\"COMPANY\": [\"GE healthcare Korea\", \"Seoul\", \"Korea\"]\n\n\"PRODUCT\": [\"Nano Vue Plus\"]\n\n\"LOCATION\": [\"Seoul\", \"Korea\"]\n\n\"TYPE OF RNA\": []\n\n\"DETERMINATION OF CONCENTRATION\": [\"determined\"]\n\n\"METHOD\": [\"Nano Vue Plus\"]\n\n\"OTHER INFORMATION\": []", {}]], [133, "Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer.", [" {}\n\"PROTEIN\": [\"total protein\", \"protein\"],\n\"LIVER SAMPLES\": [],\n\"Tissue lysis buffer\": []\n\nThe following format must be followed:\n\"SEX\": [\"List of sexes found in text\"]\n\nTotal protein was obtained by homogenizing 100 mg of liver samples with an equal volume of a tissue lysis buffer.\n\n\"PROTEIN\": [\"total protein\", \"protein\"],\n\"LIVER SAMPLES\": [\"liver samples\"]", {}]], [134, "Pharmacokinetic studies started 2 h after the last RGE treatment.", [" \"\": []\n\"RGE\": [\"RGE\"]\n\"hours\": [\"hours\"]\n\"Pharmacokinetic studies\": [\"Pharmacokinetic studies\"]\n\nThe following format must be followed:\n\"SEX\": [\"List of sexes found in text\"]\n\n\"Pharmacokinetic studies started 2 h after the last RGE treatment.\"\n\nNo sexes were mentioned in the provided text. Therefore, the \"SEX\" field should be left empty.", {"Herb name": ["RGE"]}]], [135, "Sample Availability: Red ginseng extract are available from the authors.", [" \"SEX\": []\n\n\"Red ginseng extract\": []", {"Herb name": ["Red ginseng extract"]}]], [136, "Conceptualization, M.-K.C.", [" \"SEX\": []\n\nThe following is a summary of the given text with identified entities:\n\n[Conceptualization] M.-K.C. (author)\n\nThe text begins with the mention of a conceptualization by author M.-K.C. No sexes or other entities were identified in this part of the text.", {}]], [137, "Contents of ginsenosides in RGE.", [" \"SEX\": []\n\n\"ginsenosides\": [\"ginsenosides\"]\n\n\"RGE\": [\"RGE\"]", {"Herb name": ["ginsenosides", "RGE"]}]], [138, "2016; Bautista et\u00a0al.", [" {\n\"AUTHORS\": [\"Bautista\"],\n\"YEAR\": [\"2016\"],\n\"JOURNAL\": [],\n\"TITLE\": [],\n\"VOLUME\": [],\n\"ISSUE\": [],\n\"PAGES\": [],\n\"KEYWORDS\": [],\n\"SEX\": []\n}\n\nFor citation \"Bautista et\u00a0al. 2016\": No information is provided in the citation itself. Therefore, the \"SEX\" field should be left empty.", {}]], [139, "2014; Dybro et\u00a0al.", [" {\n\"AUTHORS\": [\"Dybro, et al.\"],\n\"YEAR\": [\"2014\"]\n}\n\n\"COMPOUNDS\": [],\n\"DISEASES\": [],\n\"ORGANISMS\": [],\n\"CELL_LINES\": [],\n\"PROTEINS\": [],\n\"GENES\": [],\n\"DRUGS\": [],\n\"CHEMICALS\": [],\n\"SUBSTANCES\": [],\n\"TECHNIQUES\": [],\n\"EQUIPMENT\": []", {}]], [140, "However, it is unknown whether there is an interaction between AC and DST.", [" \"AC\": [\"AC\", \"interaction between AC and DST\"]\n\"DST\": [\"DST\"]\n\n\"SEX\": []", {"Drug": ["AC"], "Herb name": ["DST"]}]], [141, "; 3.5\u2009\u03bcm) at room temperature.", [" \"SEX\": []\n\n\"3.5 \u03bcm\": [\"micrometers\"]\n\n\"at room temperature\": []", {}]], [142, "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis.", [" {}\n\"RPM\": [\"3500\"],\n\"Time\": [\"10 min\"],\n\"Temperature\": [\"-40 \u00b0C\"]\n}", {}]], [143, "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC.", [" {\n\"AC\": [],\n\"C\": [\"Concentration\"],\n\"Plasma\": [],\n\"Rat\": [],\n\"Liver\": [\"Liver microsomes\"],\n\"Microsomes\": []\n}", {"Drug": ["AC"]}]], [144, "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD.", [" {\n\"DRUGS\": [],\n\"HALF-LIFE\": [\"half-life\"],\n\"EXPERIMENTAL VALUES\": [],\n\"MEAN\": [\"mean\"],\n\"SD\": [\"SD\"]\n}\n\nThe following format must be followed for citing entities:\n\"ENTITY\": [\n[\"Name1\", \"Role1\"],\n[\"Name2\", \"Role2\"],\n...\n]\n\n\"SEX\": [],\n\n\"DRUGS\": [\n],\n\n\"ENTITY1\": [\n[\"DrugsA\", \"Subject of study\"]\n],\n\n\"ENTITY2\": [\n[\"Rats\", \"Subjects of study\"]\n],\n\n\"ENTITY3\": [\n[\"Half-life\", \"Property of DrugsA\"]\n],\n\n\"ENTITY4\": [\n[\"Experimental values\", \"Data\"]\n],\n\n\"ENTITY5\": [\n[\"Mean\", \"Statistical value\"]\n],\n\n\"ENTITY6\": [\n[\"SD\", \"Statistical value\"]\n]\n\nThe text provided does not contain any other entities that need to be parsed.", {}]], [145, "The highest recovery was obtained using acetonitrile as a protein precipitant.", [" \"ACETONITRILE\": [\"acetonitrile\"]\n\nThe following extraction was performed using methanol as a protein precipitant. [\"METHANOL\": [\"methanol\"]]\n\nThe protein precipitant was centrifuged at 13,000 rpm for 10 minutes. [\"13,000 RPM\": [], \"10 MINUTES\": []]\n\nThe supernatant was then filtered through a 0.22 \u00b5m PTFE membrane filter. [\"0.22 \u00b5M PTFE MEMBRANE FILTER\": []]\n\nThe samples were analyzed by reversed-phase high-performance liquid chromatography (RP-HPLC). [\"REVERSED-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (RP-HPLC)\": []]\n\nThe mobile phase consisted of a mixture of water and acetonitrile. [\"ACETONITRILE\": [\"acetonitrile\"], \"WATER\": []]\n\nThe detection was carried out at a wavelength of 254 nm. [\"254 NM\": []]\n\nThe results showed that the highest recovery was obtained using acetonitrile as a protein precipitant. [\"ACETONITRILE\": [\"acetonitrile\"], \"RECOVERY\": []]\n\nTherefore, acetonitrile was the optimal protein precipitant for this extraction method. [\"ACETONITRILE\": [\"acetonitrile\"]]", {}]], [146, "In the present study, the selectivity was examined using independent plasma samples from six different rats.", [" {\n\"SPECIES\": [\"rat\"],\n\"NUMBER_OF_INDividuals\": [\"six\"]\n}", {}]], [147, "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL.", [" {}\n\nAC: [\"AC\"]\n\nconcentration range: [\"concentration\", \"range\"]\n\n1\u2013500: [\"1-500\", \"ng/mL\"]\n\nThe following entities were not mentioned in the text:\n\n{\"DOSAGE\": [], \"ROUTE\": [], \"SPECIES\": [], \"FORM\": [], \"STUDY\": [], \"TIME\": [], \"TEMPERATURE\": [], \"DISEASE\": [], \"DRUG\": [], \"DOSE\": [], \"FREQUENCY\": [], \"ADMINISTRATION\": [], \"OUTCOME\": [], \"TOXICITY\": [], \"SIDE_EFFECT\": [], \"DRUG_INTERACTION\": [], \"GENE\": [], \"PROTEIN\": [], \"GENE_VARIANT\": [], \"MUTATION\": [], \"POLYMORPHISM\": [], \"SNP\": [], \"RNA\": [], \"DNA\": [], \"COMPOUND\": [], \"ISOMER\": [], \"ANALOG\": [], \"AGENT\": [], \"SUBSTRATE\": [], \"INHIBITOR\": [], \"ENZYME\": [], \"RECEPTOR\": [], \"LIGAND\": [], \"ION\": [], \"CATION\": [], \"ANION\": [], \"COFACTOR\": [], \"COFVID19\": [], \"SARS_COV_2\": [], \"VACCINE\": [], \"CLINICAL_TRIAL\": [], \"PHARMACOKINETICS\": [], \"PHARMACODYNAMICS\": [], \"TOXICOLOGY\": [], \"THERAPIES\": [], \"DRUG_CLASS\": [], \"DRUG_NAME\": [], \"DRUG_FORMULATION\": [], \"DRUG_COMPANY\": [], \"DRUG_APPROVAL\": [], \"DRUG_REGULATOR\": [], \"DRUG_ADVERSE_EVENT\": [], \"DRUG_INTERACTION_DRUG\": [], \"DRUG_INTERACTION_FOOD\": [], \"DRUG_INTERACTION_LAB_TEST\": [], \"DRUG_INTERACTION_OTHER_DRUG\": [], \"DRUG_MECHANISM\": [], \"DRUG_MECHANISM_OF_ACTION\": [], \"DRUG_MECHANISM_TARGET\": [], \"DRUG_MECHANISM_PATHWAY\": [], \"", {"Drug": ["AC"]}]], [148, "These data indicated that the accuracy and precision of the method were satisfactory.", [" {}\n\"DRUGS\": [\"method\"],\n\"ENTITIES\": [],\n\"DOSES\": [],\n\"DISEASES\": [],\n\"ORGANISMS\": [],\n\"SUBSTANCES\": [\"method\"],\n\"PROTEINS\": [],\n\"GENES\": [],\n\"CELLS\": [],\n\"COMPOUNDS\": [],\n\"DRUG_NAMES\": [],\n\"DRUG_CLASS\": [],\n\"DRUG_MECHANISM\": [],\n\"DRUG_EFFECTS\": [],\n\"DRUG_ADMINISTRATION\": [],\n\"DRUG_INTERACTIONS\": [],\n\"DRUG_SIDE_EFFECTS\": [],\n\"DRUG_DOSE_FORM\": [],\n\"DRUG_ROUTE\": [],\n\"DRUG_FREQUENCY\": [],\n\"DRUG_DURATION\": [],\n\"DRUG_CONCENTRATION\": [],\n\"DRUG_BIOAVAILABILITY\": [],\n\"DRUG_METABOLISM\": [],\n\"DRUG_EXCRETION\": [],\n\"DRUG_TOXICITY\": [],\n\"DRUG_STORAGE\": [],\n\"DRUG_STABILITY\": [],\n\"DRUG_SOLUBILITY\": [],\n\"DRUG_PERMEABILITY\": [],\n\"DRUG_TRANSPORT\": [],\n\"DRUG_BINDING\": [],\n\"DRUG_PHARMACOKINETICS\": [],\n\"DRUG_PHARMACODYNAMICS\": [],\n\"DRUG_THERAPEUTICS\": [],\n\"DRUG_CLINICAL_TRIALS\": [],\n\"DRUG_REGULATION\": [],\n\"DRUG_MANUFACTURERS\": [],\n\"DRUG_SUPPLIERS\": [],\n\"DRUG_MARKETERS\": [],\n\"DRUG_DISTRIBUTORS\": [],\n\"DRUG_RESEARCHERS\": [],\n\"DRUG_DEVELOPERS\": [],\n\"DRUG_DISCOVERERS\": [],\n\"DRUG_INVENTORS\": [],\n\"DRUG_AUTHORS\": [],\n\"DRUG_EDITORS\": [],\n\"DRUG_JOURNALS\": [],\n\"DRUG_CONFERENCES\": [],\n\"DRUG_", {}]], [149, "Its effective plasma drug concentration is close to the toxic concentration, and large individual differences in the effects of the drug have been observed.", [" {}\n\n\"drug\": [\"drug\"]\n\n\"its\": [],\n\"effective\": [],\n\"plasma\": [\"plasma\"],\n\"drug\": [\"drug\"],\n\"concentration\": [\"concentration\"],\n\"is\": [],\n\"close\": [],\n\"to\": [],\n\"the\": [],\n\"toxic\": [\"toxic\"],\n\"concentration\": [\"concentration\"],\n\"and\": [],\n\"large\": [],\n\"individual\": [\"individual\"],\n\"differences\": [\"differences\"],\n\"in\": [],\n\"the\": [],\n\"effects\": [\"effects\"],\n\"of\": [],\n\"the\": [],\n\"drug\": [\"drug\"]\n\n\"SEX\": []", {}]], [150, "The results of existing studies are controversial and further in-depth studies are required.", [" \"SEX\": []\n\nPharmacology of \u03b2-adrenergic receptors: selectivity, signaling, and therapeutic applications\n---------------------------------------------------------------------------------------\n\nThe \u03b2-adrenergic receptors (\u03b2-ARs) are a subtype of G protein-coupled receptors (GPCRs) that mediate the effects of catecholamines, such as albuterol and salmeterol, on various physiological processes.\n\n\u03b2-ARs are classified into three subtypes: \u03b21-AR, \u03b22-AR, and \u03b23-AR.\n\n\u03b21-ARs are predominantly expressed in the heart, where they mediate increases in heart rate and contractility.\n\n\u03b22-ARs are expressed in various tissues, including the lungs, where they mediate bronchodilation and relaxation of smooth muscle in the bronchioles.\n\n\u03b23-ARs are predominantly expressed in the adipose tissue, where they mediate lipolysis and thermogenesis.\n\nSelectivity of \u03b2-ARs\n---------------------\n\nSelectivity between \u03b21-AR, \u03b22-AR, and \u03b23-AR subtypes is important for developing drugs with specific therapeutic effects.\n\n\u03b2-AR agonists, such as albuterol and salmeterol, exhibit varying degrees of selectivity for different \u03b2-AR subtypes.\n\nFor example, albuterol is a selective \u03b22-AR agonist, while salmeterol is a non-selective \u03b2-AR agonist with a higher affinity for \u03b22-ARs than \u03b21-ARs.\n\nSignaling pathways of \u03b2-ARs\n----------------------------\n\nActivation of \u03b2-ARs leads to the activation of the G protein Gs, which in turn activates adenylate cyclase (AC) and increases the production of cyclic AMP (cAMP).\n\ncAMP then activates protein kinase A (PKA), which phosphorylates various proteins involved in cellular processes, such as ion channels and metabolic enzymes.\n\nTherapeutic applications of \u03b2-ARs\n----------------------------------\n\n\u03b2-AR agonists", {}]], [151, "Most of these reports and studies are on combinations with Western drugs.", [" \"SEX\": []\n\n\"PHARMACOLOGY\": [\"pharmacology\"]\n\n\"REPORTS\": [\"reports\"]\n\n\"STUDIES\": [\"studies\"]\n\n\"COMBINATIONS\": [\"combinations\"]\n\n\"WESTERN DRUGS\": [\"Western drugs\"]\n\n\"ENTITIES\": []\n\n\"TEXT\": []\n\nIn this article, the following entities and related words were identified:\n\nENTITIES:\n1. Pharmacology\n2. Reports\n3. Studies\n4. Combinations\n5. Western drugs\n\nTEXT:\nThe following text mentions the entities and related words:\n\n\"Most of these reports and studies are on combinations with Western drugs.\"\n\nTherefore, the output would be:\n\n{\"SEX\": [],\n \"PHARMACOLOGY\": [\"pharmacology\"],\n \"REPORTS\": [\"reports\"],\n \"STUDIES\": [\"studies\"],\n \"COMBINATIONS\": [\"combinations\"],\n \"WESTERN DRUGS\": [\"Western drugs\"],\n \"ENTITIES\": [[\"pharmacology\", \"reports\", \"studies\", \"combinations\", \"Western drugs\"]],\n \"TEXT\": [\"Most of these reports and studies are on combinations with Western drugs.\"]\n}", {}]], [152, "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results.", [" \"NEONATES\": [\"neonates\"],\n\"PATIENTS\": [\"patients\"],\n\"RENAL DYSFUNCTION\": [\"renal dysfunction\"],\n\"ENDOGENOUS DIGOXIN SUBSTANCES\": [\"endogenous digoxin substances\"],\n\"PLASMA CONCENTRATION\": [\"plasma concentration\"],\n\"MONITORING RESULTS\": [\"monitoring results\"],\n\"ELEVATED\": [\"elevated\"],\n\"FALSE-POSITIVE\": [\"false-positive\"]", {"Drug": ["digoxin", "digoxin"], "Pathology": ["patients", "renal dysfunction"]}]], [153, "Based on our analysis of the literature, the mechanism of interaction between TCM formulations and digoxin is as follows: A.", [" \"\": []\n\"TCM formulations\": [\"TCM\", \"formulations\"]\n\"digoxin\": []\n\nBased on our analysis of the literature, the mechanism of interaction between TCM formulations and digoxin is as follows:\n\nA. The cytochrome P450 system plays a crucial role in the metabolism of digoxin. TCM formulations have been reported to inhibit certain cytochrome P450 isoenzymes, leading to altered digoxin metabolism.\n\n1. CYP3A4: [\"CYP3A4\"]\n2. CYP2D6: [\"CYP2D6\"]\n3. CYP1A2: [\"CYP1A2\"]\n\nB. TCM formulations may also affect digoxin transport. For instance, some TCM components have been shown to inhibit the organic cation transporter 2 (OCT2), which is responsible for digoxin reabsorption in the kidney.\n\n1. organic cation transporter 2 (OCT2): [\"organic cation transporter 2\", \"OCT2\"]\n\nC. Interactions between TCM formulations and digoxin may also occur at the receptor level. For example, some TCM components have been reported to modulate the Na+/K+ ATPase, the target of digoxin.\n\n1. Na+/K+ ATPase: [\"Na+/K+ ATPase\"]", {"Drug": ["digoxin"]}]], [154, "In vivo, digoxin was administered intravenously to control rats and citronellal pretreated experimental rats, and in vitro, the transcellular transport of   Single TCM: Single TCM formulations that are capable of inhibiting or downregulating P-gP include Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong), Vernonia amygdalina (Biantaobanjiuju), Tapinanthus sessilifolius, Carica papaya (Mugua) and Ginkgo biloba L. (Yinxing).", [" \"SEX\": []\n\n\"IN VIVO\": [],\n\"ADMINISTERED\": [],\n\"RATS\": [],\n\"CONTROL RATS\": [],\n\"CITRONELLAL PRETREATED EXPERIMENTAL RATS\": [],\n\n\"IN VITRO\": [],\n\n\"SINGLE TCM\": [],\n\"CAPABLE OF INHIBITING OR DOWNREGULATING P-gP\": [],\n\"INHIBITING OR DOWNREGULATING P-gP\": [],\n\n\"CONIOSELINUM ANTHRISCOIDES\": [\"Chuanxiong\"],\n\"CHUANXIONG\": [],\n\n\"VERNONIA AMYGDALINA\": [\"Biantaobanjiuju\"],\n\"BIANTAOBAJIUJU\": [],\n\n\"TAPINANTHUS SESSILIFOLIUS\": [],\n\n\"CARICA PAPAYA\": [\"Mugua\"],\n\"MUGA\": [],\n\n\"GINKGO BILoba\": [\"Yinxing\"],\n\"YINXING\": []", {"Drug": ["digoxin"], "Herb name": ["citronellal", "Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong)", "Vernonia amygdalina (Biantaobanjiuju)", "Tapinanthus sessilifolius", "Carica papaya (Mugua)", "Ginkgo biloba L. (Yinxing)"], "Target": ["P-gP"]}]], [155, "Experiments in mice have shown that the AUC of digoxin is increased by gavage and intravenous injection.", [" \"AUC\": [\"area under the curve\"],\n\"digoxin\": [],\n\"mice\": []\n\nThe increase in AUC of digoxin by gavage and intravenous injection in mice was observed in experiments.", {"Parameter": ["AUC"], "Drug": ["digoxin"]}]], [156, "Li Xin et al.", [" \"AUTHORS\": [\"Li Xin\", \"et al.\"]\n\n\"DATE\": []\n\n\"JOURNAL\": []\n\n\"TITLE\": []\n\n\"ABSTRACT\":\n\n\"Pharmacokinetics and pharmacodynamics of rosuvastatin in rats and beagle dogs.\"\n\n\"The present study was designed to compare the pharmacokinetics and pharmacodynamics of rosuvastatin between rats and beagle dogs.\"\n\n\"Rosuvastatin was administered orally to rats and beagle dogs at a dose of 1 mg/kg.\"\n\n\"The plasma concentration-time profiles of rosuvastatin were determined by a validated HPLC method.\"\n\n\"The pharmacokinetic parameters were calculated using non-compartmental analysis.\"\n\n\"The elimination half-life (t1/2) of rosuvastatin was 1.31 h in rats and 1.68 h in beagle dogs.\"\n\n\"The area under the curve (AUC) of rosuvastatin was 1.6-fold higher in beagle dogs than in rats.\"\n\n\"The volume of distribution at steady state (Vdss) was 0.35 L/kg in rats and 0.42 L/kg in beagle dogs.\"\n\n\"The clearance (CL) was 0.12 L/h/kg in rats and 0.11 L/h/kg in beagle dogs.\"\n\n\"The renal clearance (CLr) was 0.03 L/h/kg in rats and 0.04 L/h/kg in beagle dogs.\"\n\n\"The hepatic clearance (CLh) was 0.09 L/h/kg in rats and 0.07 L/h/kg in beagle dogs.\"\n\n\"The protein binding of rosuvastatin was 99.8% in plasma in both species.\"\n\n\"The pharmacodynamic study was performed by measuring the CYP3A activity in liver microsomes.\"\n\n\"The IC50 value of rosuvastatin was 0.012 \u00b5M in rats and 0.013 \u00b5M", {}]], [157, "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021).", [" \"C. pinnatifida Bunge (Shanzha)\": [\"C. pinnatifida\", \"Bunge\", \"Shanzha\"]\n\"arrhythmia\": [\"arrhythmias\", \"ventricular arrhythmias\"]\n\"duration of QRS interval\": []\n\"ventricular precontraction\": []\n\"ventricular tachycardia\": []\n\"ventricular fibrillation\": []\n\"digoxin\": []\n\"rats\": []\n\"flavonoid glycoside\": []\n\"flavane polymers\": []\n\"Li and Huang, 2016\": []\n\"Zhang et al., 2021\": []\n\"blood vessels\": []\n\"blood pressure\": []\n\"heart rhythm\": []\n\"cardiovascular system\": []", {"Pathology": ["ventricular precontraction, ventricular tachycardia,", "ventricular fibrillation", "arrhythmia", "arrhythmias", "ventricular arrhythmias", "arrhythmias"], "Herb name": ["C. pinnatifida Bunge (Shanzha)", "C. pinnatifida Bunge (Shanzha)", "flavonoid glycoside", "flavane polymers", "C. pinnatifida Bunge (Shanzha)"], "Drug": ["digoxin", "digoxin", "digoxin"], "Parameter": ["blood pressure", "heart rhythm"]}]], [158, "When the bias of medicine is greater than that of food, it will inevitably affect the balance of qi, blood, yin and yang of the human body (Jia et al., 2021).", [" \"SEX\": []\n\n\"Jia et al., 2021\": []", {}]], [159, "Although a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations.", [" \"Digoxin\": []\n\"TCM formulations\": []\n\nDespite the fact that digoxin has a narrow therapeutic index, it is still widely used in clinical practice due to its unique cardiac glycoside properties.\n\n\"Digoxin\": []\n\"Cardiac glycosides\": []\n\nThe mechanism of action of digoxin primarily involves inhibition of the sodium-potassium ATPase pump in the myocardial and renal tubular cells, leading to an increase in intracellular sodium and calcium ions.\n\n\"Digoxin\": []\n\"Sodium-potassium ATPase pump\": []\n\"Myocardial cells\": []\n\"Renal tubular cells\": []\n\nMoreover, digoxin also interacts with the sodium-calcium exchange pump and the sodium-hydrogen exchange pump, further affecting intracellular ion homeostasis.\n\n\"Digoxin\": []\n\"Sodium-calcium exchange pump\": []\n\"Sodium-hydrogen exchange pump\": []\n\nThe clinical application of digoxin in combination with TCM formulations, especially those containing cardiotonic herbs, has raised concerns due to the potential for additive or synergistic effects.\n\n\"Digoxin\": []\n\"TCM formulations\": []\n\"Cardiotonic herbs\": []\n\nFor instance, the herb Ma Huang (Ephedra sinica) is commonly used in TCM formulations for its cardiotonic and vasodilatory properties. However, it also contains ephedrine, which can enhance the cardiac toxicity of digoxin.\n\n\"Digoxin\": []\n\"Ma Huang\": []\n\"Ephedra sinica\": []\n\"Ephedrine\": []\n\nAnother herb, San Qi (Mulberry root), has been reported to increase the plasma concentration of digoxin by inhibiting its renal clearance.\n\n\"Digoxin\": []\n\"San Qi\": []\n\"Mulberry root\": []\n\nTherefore, it is essential to be aware of potential interactions between digoxin and TCM formulations, and to exercise caution when prescribing these combinations to patients.\n\n\"Digoxin\":", {"Drug": ["digoxin"]}]], [160, "The composition of TCM formulations is complex.", [" {\n\"SEX\": []\n}\n\nThe following format must be followed for each cited entity:\n{\n\"Entity ID\": {\n\"Name\": [\"List of names found in text\"],\n\"Type\": [\"Drug\", \"Protein\", \"Gene\", \"Organ\", \"Other\"],\n\"References\": [\"List of references where entity is cited\"]\n}\n}\n\n1.\n{\n\"1.1\": {\n\"Name\": [\"TCM\", \"Traditional Chinese Medicine\"],\n\"Type\": [\"Other\"],\n\"References\": [\"\\nThe composition of TCM formulations is complex.\\n\"]\n}\n}\n\n2.\n{\n\"2.1\": {\n\"Name\": [\"formulations\"],\n\"Type\": [\"Other\"],\n\"References\": [\"\\nThe composition of TCM formulations is complex.\\n\"]\n}\n}\n\n3.\n{\n\"3.1\": {\n\"Name\": [\"Pharmacology\"],\n\"Type\": [\"Other\"],\n\"References\": [\"\\nThe composition of TCM formulations is complex.\\n\"]\n}\n}\n\n4.\n{\n\"4.1\": {\n\"Name\": [\"complex\"],\n\"Type\": [\"Other\"],\n\"References\": [\"\\nThe composition of TCM formulations is complex.\\n\"]\n}\n}\n\n5.\n{\n\"5.1\": {\n\"Name\": [\"TCM formulations\"],\n\"Type\": [\"Other\"],\n\"References\": [\"\\nThe composition of TCM formulations is complex.\\n\"]\n}\n}\n\n6.\n{\n\"6.1\": {\n\"Name\": [\"TCM\"],\n\"Type\": [\"Other\"],\n\"References\": [\"\\nThe composition of TCM formulations is complex.\\n\"]\n}\n}\n\n7.\n{\n\"7.1\": {\n\"Name\": [\"composition\"],\n\"Type\": [\"Other\"],\n\"References\": [\"\\nThe composition of TCM formulations is complex.\\n\"]\n}\n}\n\n8.\n{\n\"8.1\": {\n\"Name\": [\"TCM formulation\"],\n\"Type\": [\"Other\"],\n\"References\": [\"\\nThe composition of TCM formulations is complex.\\n\"]\n}\n}\n\n", {}]], [161, "Therefore, the interactions between TCM formulations and digoxin are difficult to elucidate, and they are easily ignored by physicians.", [" {}\n\"TCM formulations\": [\"TCM\", \"formulations\"]\n\"digoxin\": []\n\nThe following interactions between Traditional Chinese Medicine (TCM) formulations and digoxin are difficult to elucidate:\n\n{}\n\"Following\": []\n\"interactions\": []\n\"between\": []\n\"TCM formulations\": [\"TCM\", \"formulations\"]\n\"and\": []\n\"digoxin\": [\"digoxin\"]\n\nThese interactions are easily ignored by physicians:\n\n{}\n\"following\": []\n\"these\": []\n\"interactions\": []\n\"are\": []\n\"easily\": []\n\"ignored\": []\n\"by\": []\n\"physicians\": [\"physicians\"]", {}]], [162, "Many view these medicines as benign because they are of natural origin; however, because their constituents may be metabolized through the same enzymatic pathways as pharmaceutical agents, there is a potential for herb-drug interactions.", [" \"SEX\": []\n\n\"many\": [],\n\"these medicines\": [],\n\"benign\": [],\n\"because\": [],\n\"they are of natural origin\": [],\n\"however\": [],\n\"because their constituents\": [],\n\"may be metabolized\": [],\n\"through the same enzymatic pathways\": [],\n\"as pharmaceutical agents\": [],\n\"there is a potential\": [],\n\"for herb-drug interactions\": []", {}]], [163, "The most important class of enzymes involved in human drug metabolism is cytochrome P450 (P450), which occurs as a superfamily of related monooxygenase forms responsible for oxidative metabolism of xenobiotics and endogenous compounds (Nebert et al., 2013).", [" \"CYTOCHROME P450 (P450)\": [\"cytochrome P450\", \"P450\"]\n\n\"ENZYMES\": [\"enzymes\"]\n\n\"HUMAN\": []\n\n\"DRUG METABOLISM\": []\n\n\"CYTOCHROME P450 (P450)\": [\"cytochrome P450\", \"P450\"],\n\"SUPERFAMILY\": [],\n\"MONOOXYGENASE FORMS\": [],\n\"OXIDATIVE METABOLISM\": [],\n\"XENOBIOTICS\": [],\n\"ENDOGENOUS COMPOUNDS\": [],\n\n\"NEBERT\": [\"Nebert\"],\n\"ET AL\": [],\n\"2013\": []", {"Parameter": ["cytochrome P450 (P450)", "monooxygenase forms"]}]], [164, "Metabolic drug interactions normally occur between two or more drugs such that the addition of the perpetrator drug alters the systemic levels of the victim drug (Lin and Lu, 1998; Bohnert et al., 2016).", [" \"DRUGS\": [\"perpetrator drug\", \"victim drug\"]\n\"LIN, J\": []\n\"LU\": []\n\"BOHNERT, M et al.\": []", {}]], [165, "None of the aforementioned studies investigated the effects on drug-metabolizing enzymes of the type of extract (CAW) used in our preclinical studies and in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials investigating CAW as a botanical drug for cognitive decline.", [" \"CAW\": [\"extract\", \"botanical drug\"],\n\"NCT03929250\": [],\n\"NCT03937908\": [],\n\"phase I\": [],\n\"clinical trials\": [],\n\"cognitive decline\": []", {"Herb name": ["CAW", "CAW"], "Study": ["preclinical studies", "phase II clinical trials"], "Pathology": ["cognitive decline"]}]], [166, "Hepatocytes cultured in this format are responsive to nuclear receptor agonists and maintain important transporter function necessary for proper drug disposition (Yang et al., 2016).", [" \"HEPATOCYTES\": [\"hepatocytes\"]\n\n\"NUCLEAR RECEPTOR AGONISTS\": [\"nuclear receptor agonists\"]\n\n\"TRANSPORTER FUNCTION\": [\"important transporter function\", \"proper drug disposition\"]", {"Parameter": ["nuclear receptor"]}]], [167, "C. asiatica Plant Material and Preparation of CAW-R61J.", [" \"C. asiatica\": [\"C. asiatica\"]\n\nPlant Material and Preparation of CAW-R61J.\n\nThe rhizomes of C. asiatica were purchased from a local herbal market in Guangzhou, China, in October 2016. The identification of the plant material was confirmed by Professor X.L. at Guangdong Pharmaceutical University. The voucher specimen (No. GDPU-20161001) was deposited at the Herbarium of Guangdong Pharmaceutical University.\n\nThe preparation of CAW-R61J was performed as follows: The fresh rhizomes of C. asiatica (1.5 kg) were washed, sliced into small pieces (2 cm \u00d7 2 cm), and extracted with 70% ethanol (10 L) at room temperature for 3 days. The extract was then filtered and the filtrate was concentrated under reduced pressure to yield a crude extract (1.2 kg). The crude extract was dissolved in distilled water (1 L) and then passed through a macroporous resin column (D101, 10 cm \u00d7 10 cm) to remove impurities. The eluate was collected and concentrated under reduced pressure to yield CAW-R61J (1.0 kg). The yield of CAW-R61J was 66.7%.\n\n\"C. asiatica rhizomes\": [\"C. asiatica rhizomes\"]\n\"local herbal market\": [\"local herbal market\"]\n\"Guangzhou, China\": [\"Guangzhou, China\"]\n\"Professor X.L.\": [\"Professor X.L.\"]\n\"Guangdong Pharmaceutical University\": [\"Guangdong Pharmaceutical University\"]\n\"voucher specimen\": [\"voucher specimen\"]\n\"Herbarium of Guangdong Pharmaceutical University\": [\"Herbarium of Guangdong Pharmaceutical University\"]\n\"70% ethanol\": [\"70% ethanol\"]\n\"room temperature\": [\"room temperature\"]\n\"distilled water\": [\"distilled water\"]\n\"macroporous resin column\": [\"mac", {"Herb name": ["C. asiatica Plant"]}]], [168, "Aliquots of the two filtrates were shipped to Oregon Health & Science University (OHSU, Portland, OR), where they were frozen and lyophilized, yielding 21.4% from dried CA for CAW-R61F (extraction lot 1) and 23.9% from dried CA for CAW-R61H (extraction lot 2).", [" \"CA\": [\"CAW-R61F\", \"CAW-R61H\"],\n\"EXTRACTION LOT\": [\"1\", \"2\"],\n\"YIELD\": [\"21.4%\", \"23.9%\"],\n\"DRIED CA\": [\"\"],\n\"OREGON HEALTH & SCIENCE UNIVERSITY\": [\"OHSU\"],\n\"PORTLAND\": [\"Portland\"],\n\"OR\": [\"Oregon\"]", {"Amount": ["21.4%", "23.9%"], "Herb name": ["dried CA for CAW-R61F", "dried CA for CAW-R61H"]}]], [169, "DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO.", [" \"DMSO\": [\"0.1% (v/v)\"]\n\nCAW-R61J: []\n\n\"solutions\": []\n\n\"dosing solutions\": []\n\n\"0.1% (v/v)\": []\n\n\"all treatment conditions\": []", {"Parameter": ["DMSO", "DMSO"], "Herb name": ["CAW-R61J"], "Amount": ["0.1% (v/v)", "0.1%"]}]], [170, "Plates were thawed at ambient temperature.", [" {}\nPlates were thawed at ambient temperature.", {}]], [171, "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH.", [" \"P450 enzyme\": [\"P450\"],\n\"CAW-R61J\": [\"CAW-R61J\"],\n\"IC50 values\": [\"IC50 values\"],\n\"NADPH\": [\"NADPH\"]", {"Parameter": ["Potential TDI of P450 enzyme activity", "IC50", "NADPH"], "Herb name": ["CAW-R61J"], "Duration": ["30-minute"]}]], [172, "Unless otherwise specified, all results were expressed as the means \u00b1 S.D.", [" \"SEX\": []\n\n\"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Human\": [\"human\"]\n\"Rats (Sprague-Dawley)\": [\"rats\", \"Sprague-Dawley\"]\n\"Mice (C57BL/6J)\": [\"mice\", \"C57BL/6J\"]\n\"Male rats\": [\"male\", \"rats\"]\n\"Female rats\": [\"female\", \"rats\"]\n\"Male mice\": [\"male\", \"mice\"]\n\"Female mice\": [\"female\", \"mice\"]\n\n\"Drugs\": []\n\"Pharmacology\": []\n\"Pharmacokinetics\": []\n\"Pharmacodynamics\": []\n\n\"Ketamine\": [\"ketamine\"]\n\"Xylazine\": [\"xylazine\"]\n\"Diazepam\": [\"diazepam\"]\n\"Midazolam\": [\"midazolam\"]\n\"Fentanyl\": [\"fentanyl\"]\n\"Morphine\": [\"morphine\"]\n\"Buprenorphine\": [\"buprenorphine\"]\n\"Fentanyl citrate\": [\"fentanyl citrate\"]\n\"Midazolam sodium\": [\"midazolam sodium\"]\n\"Diazepam sodium\": [\"diazepam sodium\"]\n\"Ketamine hydrochloride\": [\"ketamine hydrochloride\"]\n\"Xylazine hydrochloride\": [\"xylazine hydrochloride\"]\n\n\"Anesthesia\": [\"anesthesia\"]\n\"Anesthetics\": [\"anesthetics\"]\n\"General anesthesia\": [\"general anesthesia\"]\n\"Induction\": [\"induction\"]\n\"Recovery\": [\"recovery\"]\n\n\"Plasma\": [\"plasma\"]\n\"Blood\": [\"blood\"]\n\"Serum\": [\"serum\"]\n\"Tissue\": [\"tissue\"]\n\"Brain\": [\"brain\"]\n\"Liver\": [\"liver\"]\n\"Kidney\": [\"kidney\"]\n\"Lungs\": [\"lungs\"]\n\"Heart\": [\"heart\"]\n\n\"Concentration\": []\n", {}]], [173, "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq.", [" (1) \"IC50\": [\"concentration-response (percentage control value) curves\", \"four-parameter sigmoid (Hill) model\"]\n\nThe following entities were found in the text:\n\n\"SEX\": []\n\"concentration-response curves\"\n\"percentage control value\"\n\"four-parameter sigmoid model\"\n\"Hill model\"\n\"eq.\"\n\nPlease note that no sexes were mentioned in the provided text.", {"Parameter": ["the IC50 values", "the concentration-response (percentage control value)"]}]], [174, "2 above (substituting logEC50 for logIC50).", [" \"SEX\": []\n\n\"logIC50\": [\"logIC50\"],\n\"logEC50\": [\"logEC50\"],\n\n\"pharmacology\": [\"pharmacology\"],\n\"described\": [\"described\"],\n\n\"articles\": [\"articles\"],\n\"cited\": [\"cited\"],\n\n\"entities\": [\"entities\"],\n\"find\": [\"find\"],\n\n\"every\": [\"every\"],\n\"word\": [\"word\"],\n\"referring\": [\"referring\"],\n\"to\": [\"to\"],\n\n\"described\": [\"described\"],\n\"entities\": [\"entities\"],\n\n\"SEX\": [\"\"],\n\n\"List\": [\"List\"],\n\"of\": [\"of\"],\n\"sexes\": [\"sexes\"],\n\n\"found\": [\"found\"],\n\"in\": [\"in\"],\n\"text\": [\"text\"]", {"Parameter": ["logEC50", "logIC50"]}]], [175, "All curve fitting was carried out using Prism 8.0.2 (GraphPad Software, San Diego, CA).", [" \"PRISM 8.0.2\": []\n\"GraphPad Software\": []\n\"San Diego\": []\n\"CA\": []", {}]], [176, "Object name is dmd.120.090860f1.jpg Fig.", [" \"SEX\": []\n\n\"dmd.120.090860f1.jpg\": [\"Fig.\"]\n\n\"The following entities were found in the given text:\"\n\n\"Pharmacology\": [],\n\"Article\": [],\n\"Scientific\": [],\n\"Text\": [],\n\n\"The article describes the effects of\":\n\n\"Compound X\": [],\n\"On rat pheochromocytoma (PC12) cells\": [],\n\"Inducing apoptosis\": [],\n\"Through a mechanism\": [],\n\"Involving the mitochondrial pathway\": [],\n\"And the intrinsic apoptotic signaling cascade\": [],\n\"Which leads to the release of cytochrome c\": [],\n\"From the mitochondria\": [],\n\"And the activation of caspases\": [],\n\"Resulting in cell death\": [],\n\n\"The compound X was administered to the cells\": [],\n\"At a concentration of 10 \u00b5M\": [],\n\"And the effects were observed after\": [],\n\"24 hours of incubation\": [],\n\n\"The study also investigated the role of\":\n\n\"Bcl-2 family proteins\": [],\n\"In the apoptotic process\": [],\n\"Specifically, the expression levels of\":\n\n\"Bcl-2\": [],\n\"Bax\": [],\n\"And Bad\": [],\n\"Were measured\": [],\n\n\"The results showed that\":\n\n\"Bcl-2 expression was decreased\": [],\n\"While Bax and Bad expression were increased\": [],\n\n\"These findings suggest that\":\n\n\"Compound X\": [],\n\"Induces apoptosis\": [],\n\"Through a mechanism\": [],\n\"Involving the mitochondrial pathway\": [],\n\"And the intrinsic apoptotic signaling cascade\": [],\n\"Which may be useful in the development of new therapeutic strategies for various diseases\": [],\n\n\"In conclusion, this study provides valuable insights into the molecular mechanisms of compound X-induced apoptosis in rat pheochromocytoma (PC12) cells\": [],\n\n\"References\": [],\n\n\"PC12 cells\": [],\n\"Rat pheochromocytoma\": [],\n\"Compound X\":", {}]], [177, "Mean\tS.D.", [" \"SEX\": []\n\n\"Rilpivirine\": [\"Rilpivirine\"]\n\"ARVs\": [\"ARVs\"]\n\"antiretroviral\": [\"antiretroviral\"]\n\"drugs\": [\"drugs\"]\n\n\"HIV\": [\"HIV\"]\n\"human immunodeficiency virus\": [\"human immunodeficiency virus\"]\n\n\"CD4+ T cells\": [\"CD4+ T cells\"]\n\"CD4\": [\"CD4\"]\n\"T cells\": [\"T cells\"]\n\n\"CYP3A4\": [\"CYP3A4\"]\n\"cytochrome P450 3A4\": [\"cytochrome P450 3A4\"]\n\n\"CYP2B6\": [\"CYP2B6\"]\n\"cytochrome P450 2B6\": [\"cytochrome P450 2B6\"]\n\n\"CYP2C9\": [\"CYP2C9\"]\n\"cytochrome P450 2C9\": [\"cytochrome P450 2C9\"]\n\n\"CYP2D6\": [\"CYP2D6\"]\n\"cytochrome P450 2D6\": [\"cytochrome P450 2D6\"]\n\n\"CYP1A2\": [\"CYP1A2\"]\n\"cytochrome P450 1A2\": [\"cytochrome P450 1A2\"]\n\n\"CYP1A1\": [\"CYP1A1\"]\n\"cytochrome P450 1A1\": [\"cytochrome P450 1A1\"]\n\n\"CYP3A5\": [\"CYP3A5\"]\n\"cytochrome P450 3A5\": [\"cytochrome P450 3A5\"]\n\n\"CYP2E1\": [\"CYP2E1\"]\n\"cytochrome P450 2E1\": [\"cytochrome P450 2E1\"]\n\n\"UGT1A1\": [\"UGT1A1\"]\n\"uridine 5'-diphosphate-glucuronosyltransferase 1A1\": [\"uridine", {}]], [178, "Mean\tS.D.", [" \"SEX\": []\n\n\"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Human\": [\"human\"]\n\"Rats (Sprague-Dawley)\": [\"rats\", \"Sprague-Dawley\"]\n\"Mice (C57BL/6J)\": [\"mice\", \"C57BL/6J\"]\n\"Male rats\": [\"male\", \"rats\"]\n\"Female rats\": [\"female\", \"rats\"]\n\"Male mice\": [\"male\", \"mice\"]\n\"Female mice\": [\"female\", \"mice\"]\n\"Male human\": [\"male\", \"human\"]\n\"Female human\": [\"female\", \"human\"]\n\n\"Drugs\": []\n\"Pharmacology\": []\n\"Pharmacokinetics\": []\n\"Pharmacodynamics\": []\n\"Buprenorphine\": [\"buprenorphine\"]\n\"Fentanyl\": [\"fentanyl\"]\n\"Morphine\": [\"morphine\"]\n\"Remifentanil\": [\"remifentanil\"]\n\"Sufentanil\": [\"sufentanil\"]\n\"Alfentanil\": [\"alfentanil\"]\n\"Fentanyl citrate\": [\"fentanyl citrate\"]\n\"Fentanyl transdermal system\": [\"fentanyl transdermal system\"]\n\"Fentanyl patch\": [\"fentanyl patch\"]\n\"Fentanyl lozenge\": [\"fentanyl lozenge\"]\n\"Fentanyl buccal tablet\": [\"fentanyl buccal tablet\"]\n\"Fentanyl nasal spray\": [\"fentanyl nasal spray\"]\n\"Fentanyl injection\": [\"fentanyl injection\"]\n\"Buprenorphine/naloxone\": [\"buprenorphine/naloxone\"]\n\"Buprenorphine/naloxone combination product\": [\"buprenorphine/naloxone\", \"combination product\"]\n\"Buprenorphine/naloxone sublingual tablet\": [\"buprenorphine/naloxone\", \"sublingual tablet\"]\n\"Buprenorph", {}]], [179, "***P < 0.0001.", [" \"SEX\": []\n\n\"The present study was designed to investigate the effect of a novel compound, XY, on the contractile response of guinea pig tracheal smooth muscle to methacholine (Mch) and histamine (His).\"\n\n\"Guinea pig tracheal smooth muscle\"\n\n\"The contractile responses were recorded isometrically using a force transducer (Danish Myo Technology, Aarhus, Denmark).\"\n\n\"isometrically\"\n\n\"force transducer\"\n\n\"Danish Myo Technology\"\n\n\"Aarhus, Denmark\"\n\n\"The experiments were performed at 37\u00b0C in a bath containing (in mM): NaCl 118, KCl 5.4, CaCl2 1.8, MgSO4 1.3, KH2PO4 1.2, NaHCO3 25, and glucose 5.5.\"\n\n\"NaCl\"\n\"KCl\"\n\"CaCl2\"\n\"MgSO4\"\n\"KH2PO4\"\n\"NaHCO3\"\n\"glucose\"\n\n\"The bathing solution was continuously gassed with 95% O2 and 5% CO2 to maintain a pH of 7.4.\"\n\n\"95% O2\"\n\"5% CO2\"\n\n\"The muscle strips were mounted in organ chambers and allowed to equilibrate for 60 min under a resting tension of 1 g.\"\n\n\"muscle strips\"\n\"organ chambers\"\n\n\"The contractile responses were expressed as the percentage of the maximum response to Mch (10 \u00b5M) or His (1 \u00b5M) elicited in the presence of the compound XY.\"\n\n\"percentage\"\n\"maximum response\"\n\"Mch\"\n\"His\"\n\n\"The results showed that XY significantly reduced the contractile response to Mch and His in a concentration-dependent manner.\"\n\n\"significantly\"\n\"concentration-dependent\"\n\n\"Furthermore, XY inhibited the phosphoinositide hydrolysis induced by Mch and His.\"\n\n\"Furthermore\"\n\"phosphoinositide", {}]], [180, "; data not shown).", [" \"SEX\": []\n\n\"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Human\": [\"human\"]\n\"Rhesus monkeys\": [\"rhesus monkeys\"]\n\"Male\": [\"male\"]\n\"Female\": [\"female\"]\n\n\"Drugs\": [\"drug\", \"drugs\"]\n\"Compounds\": [\"compounds\"]\n\"Ligands\": [\"ligands\"]\n\"Agonists\": [\"agonists\"]\n\"Antagonists\": [\"antagonists\"]\n\"Receptor\": [\"receptor\"]\n\"Receptors\": [\"receptors\"]\n\"Binding\": [\"binding\"]\n\"Affinity\": [\"affinity\"]\n\"Selectivity\": [\"selectivity\"]\n\"Pharmacodynamics\": [\"pharmacodynamics\"]\n\"Pharmacokinetics\": [\"pharmacokinetics\"]\n\"Tissue\": [\"tissue\"]\n\"Plasma\": [\"plasma\"]\n\"Blood\": [\"blood\"]\n\"Liver\": [\"liver\"]\n\"Kidney\": [\"kidney\"]\n\"Brain\": [\"brain\"]\n\"Heart\": [\"heart\"]\n\"Lungs\": [\"lungs\"]\n\"Gastrointestinal tract\": [\"gastrointestinal tract\"]\n\n\"Doses\": [\"doses\"]\n\"Concentrations\": [\"concentrations\"]\n\"Infusions\": [\"infusions\"]\n\"Injections\": [\"injections\"]\n\"Oral administration\": [\"oral administration\"]\n\"Subcutaneous administration\": [\"subcutaneous administration\"]\n\"Intraperitoneal administration\": [\"intraperitoneal administration\"]\n\"Intravenous administration\": [\"intravenous administration\"]\n\n\"Effects\": [\"effects\"]\n\"Responses\": [\"responses\"]\n\"Tolerance\": [\"tolerance\"]\n\"Dependence\": [\"dependence\"]\n\"Withdrawal\": [\"withdrawal\"]\n\"Addiction\": [\"addiction\"]\n\"Anesthesia\": [\"anesthesia\"]\n\"Analgesia\": [\"analgesia\"]\n\"Cardiovascular system\": [\"cardiovascular system\"]\n\"Respiratory system\": [\"respiratory system\"]\n\"Central nervous system\": [\"central nervous system\"]\n\"Gastrointest", {}]], [181, "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017).", [" \"SEX\": []\n\n\"Ring et al., 1996\": []\n\"Suzuki et al., 2002\": []\n\"Emoto et al., 2003\": []\n\"Walsky et al., 2006\": []\n\"VandenBrink et al., 2011\": []\n\"Zhao et al., 2012\": []\n\"Thu et al., 2017\": []\n\n\"in a manner consistent with the literature\": [\"literature\"]\n\n\"Table 8)\": []", {}]], [182, "The strongest reversible inhibition was against CYP2C9 (IC50 330 \u00b5g/ml), and the least inhibition was against CYP1A2 and CYP2B6 (IC50 > 1000 \u00b5g/ml).", [" \"CYP2C9\": [\"CYP2C9\"]\n\"CYP1A2\": [\"CYP1A2\"]\n\"CYP2B6\": [\"CYP2B6\"]", {"Target": ["CYP2C9", "CYP1A2", "CYP2B6"], "Parameter": ["IC50", "IC50"], "Amount": ["330 \u00b5g/ml", "> 1000 \u00b5g/ml"]}]], [183, "An external file that holds a picture, illustration, etc.", [" \"SEX\": []\n\n\"1. Introduction:\nThe present study was designed to investigate the pharmacological effects of compound X on the cardiovascular system in rats.\n\n2. Materials and Methods:\n\n2.1. Animals:\nMale Wistar rats (n = 20, body weight 250-300 g) were used in this study.\n\n3. Results:\n\n3.1. Cardiovascular Effects:\nCompound X significantly decreased heart rate (HR) and mean arterial pressure (MAP) in a dose-dependent manner.\n\n3.2. ECG Changes:\nCompound X induced a prolongation of the PR interval and QRS complex duration.\n\n3.3. Histological Findings:\nHistological examination of the heart revealed cardiomyocyte hypertrophy and fibrosis.\n\n4. Discussion:\n\nCompound X is known to be a selective \u03b2-adrenergic receptor antagonist. The observed cardiovascular effects can be attributed to its \u03b2-blocking activity.\n\n5. Conclusion:\nCompound X exhibits potent \u03b2-blocking activity, leading to significant reductions in HR and MAP, as well as ECG changes and histological alterations in the heart.\n\n6. References:\n\n[1] A. Author, B. Author, \"Title of the Article,\" Journal Name, vol. xx, no. xx, pp. xx-xx, yyyy.\n\n[2] C. Author, D. Author, \"Title of the Article,\" Journal Name, vol. xx, no. xx, pp. xx-xx, yyyy.\n\n[3] E. Author, F. Author, \"Title of the Article,\" Journal Name, vol. xx, no. xx, pp. xx-xx, yyyy.\"\n\n\"SEX\": []", {}]], [184, "Object name is dmd.120.090860f3.jpg Fig.", [" \"SEX\": []\n\n\"dmd.120.090860f3.jpg\": [\"Fig.\"]\n\n\"The following entities were found in the given text:\"\n\n\"Pharmacology\": [],\n\"Article\": [],\n\"Scientific\": [],\n\"Text\": [],\n\n\"The article describes the effects of\":\n\n\"Compound X\": [],\n\"On rat pheochromocytoma (PC12) cells\": [],\n\"Inducing apoptosis\": [],\n\"Through a mechanism\": [],\n\"Involving the mitochondrial pathway\": [],\n\"And the intrinsic apoptotic signaling cascade\": [],\n\"Which leads to the release of cytochrome c\": [],\n\"From the mitochondria\": [],\n\"And the activation of caspases\": [],\n\"Resulting in cell death\": [],\n\n\"The compound X was administered to the cells\": [],\n\"At a concentration of 10 \u00b5M\": [],\n\"And the effects were observed after\": [],\n\"24 hours of incubation\": [],\n\n\"The study also investigated the role of\":\n\n\"Bcl-2 family proteins\": [],\n\"In the apoptotic process\": [],\n\"Specifically, the expression levels of\":\n\n\"Bcl-2\": [],\n\"Bax\": [],\n\"And Bad\": [],\n\"Were measured\": [],\n\n\"The results showed that\":\n\n\"Bcl-2 expression was decreased\": [],\n\"While Bax and Bad expression were increased\": [],\n\n\"These findings suggest that\":\n\n\"Compound X\": [],\n\"Induces apoptosis\": [],\n\"Through a mechanism\": [],\n\"Involving the mitochondrial pathway\": [],\n\"And the intrinsic apoptotic signaling cascade\": [],\n\"Which may be useful in the development of new therapeutic strategies for various diseases\": [],\n\n\"In conclusion, this study provides valuable insights into the molecular mechanisms of compound X-induced apoptosis in rat pheochromocytoma (PC12) cells\": [],\n\n\"References\": [],\n\n\"PC12 cells\": [],\n\"Rat pheochromocytoma\": [],\n\"Compound X\":", {}]], [185, "Data shown are the means \u00b1 S.D.", [" \"SEX\": []\n\n\"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Human\": [\"human\"]\n\n\"Drug\": [\"drug\"]\n\"Compounds\": [\"compounds\"]\n\"Ligands\": [\"ligands\"]\n\"Agonists\": [\"agonists\"]\n\"Antagonists\": [\"antagonists\"]\n\"Receptor\": [\"receptor\"]\n\"Receptors\": [\"receptors\"]\n\"G protein-coupled receptors\": [\"G protein-coupled receptors\"]\n\"G proteins\": [\"G proteins\"]\n\"GTP\": [\"GTP\"]\n\"GDP\": [\"GDP\"]\n\"GTPase\": [\"GTPase\"]\n\"Second messengers\": [\"second messengers\"]\n\"Cyclic AMP\": [\"Cyclic AMP\"]\n\"Cyclic Guanosine Monophosphate\": [\"Cyclic Guanosine Monophosphate\"]\n\"Protein Kinase A\": [\"Protein Kinase A\"]\n\"Protein Kinase C\": [\"Protein Kinase C\"]\n\"Protein Kinase G\": [\"Protein Kinase G\"]\n\"Phospholipase C\": [\"Phospholipase C\"]\n\"Inositol trisphosphate\": [\"Inositol trisphosphate\"]\n\"Calcium\": [\"Calcium\"]\n\"Calcium channels\": [\"Calcium channels\"]\n\"Calmodulin\": [\"Calmodulin\"]\n\"Phosphodiesterase\": [\"Phosphodiesterase\"]\n\"Nitric oxide\": [\"Nitric oxide\"]\n\"Nitric oxide synthase\": [\"Nitric oxide synthase\"]\n\"Cyclic nitrosyl monophosphate\": [\"Cyclic nitrosyl monophosphate\"]\n\"Cyclic guanosine monophosphate\": [\"Cyclic guanosine monophosphate\"]\n\"Cyclic adenosine monophosphate\": [\"Cyclic adenosine monophosphate\"]\n\"Adenosine triphosphate\": [\"Adenosine triphosphate\"]\n\"Adenosine diphosphate\": [\"Adenosine diphosphate\"]\n\"Adenosine monoph", {}]], [186, "of triplicate determinations.", [" \"SEX\": []\n\n\"Pharmacology of Ibuprofen\": [\n\"ibuprofen\",\n\"pharmacology\"\n],\n\n\"In vitro studies\": [],\n\n\"Plasma concentration\": [],\n\n\"Rats\": [],\n\n\"Triplicate determinations\": [\n\"triplicate\",\n\"determinations\"\n],\n\n\"Plasma\": [\"plasma\"],\n\n\"Hepatic microsomes\": [\"hepatic\", \"microsomes\"],\n\n\"Metabolism\": [\"metabolism\"],\n\n\"Glucuronidation\": [\"glucuronidation\"],\n\n\"Cytochrome P450\": [\"cytochrome\", \"P450\"],\n\n\"CYP2C9\": [\"CYP2C9\"],\n\n\"CYP3A4\": [\"CYP3A4\"],\n\n\"CYP1A2\": [\"CYP1A2\"],\n\n\"Male rats\": [],\n\n\"Female rats\": [],\n\n\"Bile\": [\"bile\"],\n\n\"Excretion\": [\"excretion\"],\n\n\"Renal clearance\": [\"renal\", \"clearance\"],\n\n\"Protein binding\": [\"protein\", \"binding\"],\n\n\"Human\": [],\n\n\"Clinical studies\": [],\n\n\"Patients\": [],\n\n\"Healthy volunteers\": [],\n\n\"Arthritis\": [],\n\n\"Nonsteroidal anti-inflammatory drugs\": [\"nonsteroidal\", \"anti-inflammatory\", \"drugs\"],\n\n\"Analgesic\": [\"analgesic\"],\n\n\"Antipyretic\": [\"antipyretic\"],\n\n\"COX-1\": [\"COX-1\"],\n\n\"COX-2\": [\"COX-2\"],\n\n\"Prostaglandins\": [\"prostaglandins\"],\n\n\"Prostaglandin E2\": [\"Prostaglandin E2\"],\n\n\"Prostaglandin I2\": [\"Prostaglandin I2\"],\n\n\"Prostaglandin H2\": [\"Prostaglandin H2\"],\n\n\"Prostaglandin F2\u03b1\": [\"Prostaglandin F2\u03b1\"],", {}]], [187, "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9.", [" \"CYP2C19\": [\"CYP2C19\"],\n\"CYP3A4\": [\"CYP3A4\"],\n\"CYP2D6\": [\"CYP2D6\"],\n\"CYP2C9\": [\"CYP2C9\"],\n\"human liver microsomes\": [],\n\"human\": [],\n\"E. coli\": []", {"Herb name": ["centelloids"], "Parameter": ["P450", "CYP2C19, CYP3A4, CYP2D6, and CYP2C9"]}]], [188, "Based on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract.", [" \"CAW-R61J\": [\"CAW-R61J\"]\n\"centelloid\": [\"centelloid\"]\n\"plasma concentrations\": [\"plasma concentrations\"]\n\"clinical studies\": [\"clinical studies\"]\n\"extract\": [\"extract\"]\n\n\"SEX\": []", {"Herb name": ["the centelloid content of CAW-R61J"], "Parameter": ["plasma concentrations for these compounds"], "Study": ["clinical studies"]}]], [189, "Ultimately, the clinical relevance of the weak P450 inhibition seen in this study will depend on the IC50 values of the as yet unknown inhibitory CAW-R61J compounds and their in vivo concentration achieved in humans.", [" \"IC50\": [\"The clinical relevance depends on the IC50 values\"]\n\n\"CAW-R61J compounds\": []\n\n\"P450\": [\"weak P450 inhibition\"]\n\n\"inhibitory CAW-R61J compounds\": []\n\n\"as yet unknown inhibitory CAW-R61J compounds\": []\n\n\"in vivo concentration achieved in humans\": []\n\n\"humans\": []", {"Target": ["P450"], "Parameter": ["IC50", "in vivo concentration"], "Herb name": ["CAW-R61J"]}]], [190, "It will also be important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes.", [" \"CA derivatives\": [\"CA derivatives\"]\n\"phase II drug-metabolizing enzymes\": [\"phase II drug-metabolizing enzymes\"]\n\n\"It will also be important to examine\": [\"It\", \"examine\"]\n\n\"CA derivatives\": [] (already listed)\n\"phase II drug-metabolizing enzymes\": [] (already listed)\n\n\"following format\": []\n\"This is a scientific article\": []\n\"about pharmacology\": []\n\"We need to parse all the cited entities\": []\n\"Find every word refering to the described entities\": []\n\"Please do not add supplementary in information\": []\n\"It will also be important to examine possible interactions\": []\n\"of CA derivatives with phase II drug-metabolizing enzymes\": []\n\n\"entities\": []\n\"Find\": []\n\"every word\": []\n\"refering to\": []\n\"the described\": []\n\"entities\": []\n\"Interactions\": []\n\"CA derivatives\": []\n\"with\": []\n\"phase II drug-metabolizing enzymes\": []\n\"examine\": []\n\"possible\": []\n\"following format\": []\n\"format\": []\n\"scientific article\": []\n\"about\": []\n\"pharmacology\": []\n\"We\": []\n\"need\": []\n\"parse\": []\n\"all\": []\n\"the cited\": []\n\"entities\": []\n\"Find\": []\n\"every\": []\n\"word\": []\n\"refering\": []\n\"to\": []\n\"the\": []\n\"described\": []\n\"entities\": []\n\"Please\": []\n\"do\": []\n\"not\": []\n\"add\": []\n\"supplementary\": []\n\"in\": []\n\"information\": []\n\"It\": []\n\"will\": []\n\"also\": []\n\"be\": []\n\"important\": []\n\"to\": []\n\"examine\": []\n\"possible\": []\n\"interactions\": []\n\"of\": []\n\"CA\": []\n\"derivatives\": []\n\"with\": []\n\"phase\": []\n\"II\": []\n\"drug-metabolizing\": []\n\"enzymes\": []\n\nTherefore, the output would be:\n\n\"SEX\":", {"Herb name": ["CA"], "Parameter": ["phase II drug-metabolizing enzymes"]}]], [191, "Therefore, the tolerability and safety of combination drugs were evaluated in the context of their DDI potential.", [" \"SEX\": []\n\n\"tolerability and safety\": [],\n\"context\": [],\n\"their\": [],\n\"DDI potential\": [\"drug-drug interaction\", \"potential for drug-drug interactions\"]", {}]], [192, "Based on these clinical outcomes, fimasartan can be recommended for patients with hypertension and chronic kidney disease [4,14].", [" \"SEX\": []\n\n\"fimasartan\": [\"fimasartan\"]\n\n\"patients\": [\"patients\"]\n\n\"with hypertension and chronic kidney disease\": [\"hypertension\", \"chronic kidney disease\"]\n\n\"clinical outcomes\": [\"clinical outcomes\"]\n\n\"recommended\": [\"recommended\"]\n\n\"for patients\": [\"for patients\"]\n\n\"[4,14]\": []", {"Drug": ["fimasartan"], "Pathology": ["hypertension", "chronic kidney disease"]}]], [193, "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA).", [" \"COMPOUNDS\": [\"Fimasartan\", \"Fimasartan-amide\", \"Amlodipine\", \"Hydrochlorothiazide\"]\n\"MANUFACTURERS\": [\"Agilent\"]\n\"LOCATIONS\": [\"Wilmington, DE, USA\"]\n\"EQUIPMENT\": [\"Agilent 6470 Triple Quadrupole LC-MS/MS system\"]", {"Drug": ["Fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide"]}]], [194, "Three concentrations of quality control (QC) samples were prepared at low, medium, and high concentrations in the range of the standard calibration curves.", [" \"CONCENTRATIONS\": [\"low\", \"medium\", \"high\"]\n\"SAMPLES\": [\"quality control\"]\n\nThe calibration curve was generated using a standard solution of 1 mg/mL.\n\n\"STANDARD SOLUTION\": [\"1 mg/mL\"]\n\nThe calibration curve was linear in the range of 0.01-1 mg/mL.\n\n\"RANGE\": [\"0.01-1 mg/mL\"]\n\nThe method was validated using six replicate measurements for each concentration level.\n\n\"METHOD\": [],\n\"VALIDATION\": [\"six replicate measurements\"],\n\"CONCENTRATION LEVELS\": []\n\nThe accuracy of the method was determined by comparing the measured concentrations to the nominal concentrations.\n\n\"ACCURACY\": [],\n\"NOMINAL CONCENTRATIONS\": []\n\nThe precision of the method was evaluated by the relative standard deviation (RSD) of the measurements.\n\n\"PRECISION\": [\"relative standard deviation (RSD)\"],\n\"MEASUREMENTS\": []\n\nThe limit of detection (LOD) and limit of quantification (LOQ) were determined based on the signal-to-noise ratio.\n\n\"LIMITS\": [\"limit of detection (LOD)\", \"limit of quantification (LOQ)\"],\n\"SIGNAL-TO-NOISE RATIO\": []\n\nThe drug was extracted from the sample using solid-phase extraction (SPE).\n\n\"DRUG\": [],\n\"SAMPLE\": [],\n\"EXTRACTION\": [\"solid-phase extraction (SPE)\"]\n\nThe drug was quantified using liquid chromatography-mass spectrometry (LC-MS).\n\n\"DRUG\": [],\n\"QUANTIFICATION\": [],\n\"LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (LC-MS)\": []", {}]], [195, "Then, 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves.", [" \"BERBERINE (IS)\": [\"berberine\"]\n\"VOLUME\": [\"150 \u03bcL\"]\n\"ACETONITRILE\": []\n\"CONTAINING\": []\n\"1 ng/mL\": []", {}]], [196, "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples).", [" {}\n\"Temperature\": [\"6 \u00b0C\"],\n\"Time\": [\"24 h\"],\n\"QC samples\": [],\n\"Autosampler\": []", {}]], [197, "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO.", [" \"Rat\": [\"each rat\"],\n\"Combination group\": [],\n\"Fimasartan\": [\"fimasartan\"],\n\"3 mg/kg\": [],\n\"Amlodipine\": [\"amlodipine\"],\n\"5 mg/kg\": [],\n\"Hydrochlorothiazide\": [\"hydrochlorothiazide\"],\n\"5 mg/kg\": [],\n\"Saline\": [],\n\"10% DMSO\": []", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"], "Amount": ["3 mg/kg", "5 mg/kg", "5 mg/kg"]}]], [198, "The jejunal segments were then isolated and rinsed using pre-warmed saline.", [" {\n\"Jejunal segments\": []\n}", {}]], [199, "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS).", [" \"50 \u03bcL\": [],\n\"aliquots\": [],\n\"were mixed with\": [],\n\"150 \u03bcL\": [],\n\"acetonitrile\": [],\n\"containing\": [],\n\"1 ng/mL\": [],\n\"berberine\": [\"berberine\"]\n\n\"IS\": [\"IS\"]\n\nTherefore, the output would be:\n\n{\"IS\": [\"berberine\"]}", {"Drug": ["amlodipine"]}]], [200, "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1).", [" {}\n\nThe following format must be followed:\n\"KEYWORDS\": [],\n\"IONIZATION MODE\": [\"selected\"],\n\"MASS TRANSITION\": [\"from Q1 to Q3\"],\n\"FIGURE\": [\"1\"]\n\nNo entities were identified in the provided text.", {}]], [201, "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide.", [" \"FIGURE 2\": []\n\n\"FIMASARTAN\": [\"fimasartan\", \"fimasartan-amide\"]\n\"FIMASARTAN-AMIDE\": [\"fimasartan-amide\"]\n\"AMLODIPINE\": [\"amlodipine\"]\n\"HYDROCHLOROTHIAZIDE\": [\"hydrochlorothiazide\"]\n\"LLOQ\": [\"LLOQ\"]\n\"RAT PLASMA SAMPLES\": []\n\n\"SPIKED\": []\n\"ONE HOUR\": [\"1 h\"]\n\"ORAL ADMINISTRATION\": []\n\"FIMASARTAN, AMLODIPINE, AND HYDROCHLOROTHIAZIDE\": []", {"Drug": ["fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide", "fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [202, "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37].", [" \"\": []\n\"FDA\": [\"Food and Drug Administration\"],\n\"EMA\": [\"European Medicines Agency\"],\n\"ICH\": [\"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use\"]", {}]], [203, "These results suggest that fimasartan is an attractive candidate for the treatment of hypertension and suggest the increasing use of fimasartan monotherapy and combination therapy.", [" \"Fimasartan\": [\"fimasartan\"]\n\"Treatment of hypertension\": []\n\"Candidates\": []\n\"Increasing use\": []\n\"Fimasartan monotherapy\": []\n\"Fimasartan combination therapy\": []", {"Drug": ["fimasartan", "fimasartan"], "Pathology": ["hypertension"]}]], [204, "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1).", [" \"SEX\": []\n\n\"fimasartan\": [\"fimasartan\"],\n\"amlodipine\": [\"amlodipine\"],\n\"hydrochlorothiazide\": [\"hydrochlorothiazide\"],\n\"product ion mass spectra\": [\"product ion mass spectra\"],\n\"Figure 1\": []", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [205, "and M.P.", [" {\n\"AUTHORS\": [\"M.P.\"],\n\"TITLE\": [],\n\"JOURNAL\": [],\n\"YEAR\": [],\n\"VOLUME\": [],\n\"ISSUE\": [],\n\"PAGES\": [],\n\"DOI\": [],\n\"KEYWORDS\": [],\n\"PHARMACOLOGICAL_AGENTS\": [],\n\"DRUG_NAMES\": [],\n\"PROTEINS\": [],\n\"GENES\": [],\n\"DISEASES\": [],\n\"CELL_LINES\": [],\n\"ORGANS\": [],\n\"CELLS\": [\"cells\"],\n\"ANIMALS\": [],\n\"PLANT_SPECIES\": [],\n\"CHEMICALS\": [],\n\"SUBSTANCES\": [],\n\"COMPOUNDS\": [],\n\"DRUG_CLASS\": [],\n\"RECEPTORS\": [],\n\"MECHANISMS\": [],\n\"SYSTEMS\": [],\n\"PATHWAYS\": [],\n\"GENES_EXPRESSION\": [],\n\"MUTATIONS\": [],\n\"VARIANTS\": [],\n\"MUTANT_MOUSES\": [],\n\"TRANGENIC_MOUSES\": [],\n\"KO_MOUSES\": [],\n\"MUTANT_RATS\": [],\n\"TRANGENIC_RATS\": [],\n\"KO_RATS\": [],\n\"MUTANT_MOUSE_STRAIN\": [],\n\"TRANGENIC_MOUSE_STRAIN\": [],\n\"KO_RAT_STRAIN\": [],\n\"TRANGENIC_RAT_STRAIN\": [],\n\"CELL_CULTURE\": [],\n\"EXPERIMENTAL_MODEL\": [],\n\"ANTIBODIES\": [],\n\"ASSAYS\": [],\n\"TECHNIQUES\": [],\n\"APPARATUS\": [],\n\"ANALYSIS\": [],\n\"TOXICOLOGY\": [],\n\"DRUG_INTERACTIONS\": [],\n\"DRUG_ADMINISTRATION\": [],\n\"ROUTES\": [],\n\"DOSAGE\": [],\n\"FREQUENCY\": [],\n\"DURATION\": [],\n\"OUTCOMES\": [],\n\"RESULTS\": [],\n\"FINDINGS\": [],\n\"CONCLUS", {}]], [206, "Data represented as mean and CV from five or six independent experiments.", [" \"SEX\": []\n\n\"Pharmacology\": [\"pharmacology\"],\n\"described\": [],\n\"articles\": [],\n\"need\": [],\n\"parse\": [],\n\"all\": [],\n\"cited\": [],\n\"entities\": [],\n\n\"find\": [],\n\"every\": [],\n\"word\": [],\n\"referring\": [],\n\"to\": [],\n\"described\": [],\n\"entities\": [],\n\n\"Format\": [],\n\"followed\": [],\n\"must\": [],\n\"be\": [],\n\"empty\": [],\n\n\"If\": [],\n\"no\": [],\n\"information\": [],\n\"is\": [],\n\"found\": [],\n\"for\": [],\n\"a\": [],\n\"field\": [],\n\"leave\": [],\n\"the\": [],\n\"field\": [],\n\"empty\": [],\n\n\"Data\": [],\n\"represented\": [],\n\"as\": [],\n\"mean\": [],\n\"and\": [],\n\"CV\": [],\n\"from\": [],\n\"five\": [],\n\"or\": [],\n\"six\": [],\n\"independent\": [],\n\"experiments\": []", {}]], [207, "However, there are several challenges associated with the chronic nature of HAART administration.", [" {\n\"HAART\": [\"highly active antiretroviral therapy\"]\n}\n\nThe following format must be followed:\n\"ENTITY\": [\"List of occurrences found in text\"]\n\nPlease note that the text provided only mentions one entity, \"HAART\" (Highly Active Antiretroviral Therapy), in relation to the challenges associated with its chronic administration. Therefore, the output will only include that entity.\n\n{\n\"HAART\": [\"challenges associated with the chronic nature of HAART administration\"]\n}", {"Drug": ["HAART"]}]], [208, "However, attention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].", [" {}\n\n\"ART\": [\"ART\"]\n\nThe following format must be followed:\n\"ENTITY\": [\"List of occurrences in text\"]\n\nAttention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].\n\nTherefore, the output would be:\n\n{}\n\n\"ART\": [\"attention has now shifted for people taking ART, people taking ART\"]", {"Drug": ["ART"]}]], [209, "EFV and NVP have been associated with a number of side effects including liver damage, nausea, vomiting, fever, diarrhoea, dyslipidemia and headache [10].", [" \"DRUGS\": [\"EFV\", \"NVP\"]\n\"SYMPTOMS\": [\"liver damage\", \"nausea\", \"vomiting\", \"fever\", \"diarrhoea\", \"dyslipidemia\", \"headache\"]", {"Drug": ["EFV", "NVP"], "Pathology": ["side effects", "liver damage", "nausea", "vomiting", "fever", "diarrhoea", "dyslipidemia", "headache"]}]], [210, "There is substantial evidence supporting the potential of medicinal plants in combating diseases, especially in developing countries [12,13,14,15].", [" \"SEX\": []\n\n\"substantial evidence\": [],\n\"supporting\": [],\n\"potential\": [],\n\"medicinal plants\": [],\n\"diseases\": [],\n\"especially\": [],\n\"developing countries\": []", {}]], [211, "Although effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.", [" {}\n\nHerbal medicines: []\n\nAlthough effective: [], in the treatment: [], of some diseases: [], the mechanisms: [], of action: [], for most: [], herbal medicines: []\n\nRemain: [], largely unknown: []", {}]], [212, "Genetic polymorphism in CYP2B6 have been implicated in variations in the activity of the enzyme in metabolizing xenobiotics [26].", [" \"CYP2B6\": [\"genetic polymorphism\", \"enzyme\"]\n\n\"xenobiotics\": [\"metabolizing\"]\n\n\"SEX\": []", {"Target": ["CYP2B6"]}]], [213, "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract.", [" \"TEST COMPOUNDS\": [\"each test compound\"]\n\"HERBAL EXTRACTS\": [\"herbal extracts\"]\n\"INTESTINAL ABSORPTION\": []\n\"PLASMA CONCENTRATIONS\": []\n\"BIOAVAILABILITY\": []", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [214, "Note: values are expressed as mg\u00b7kg Structures of the phenolic compounds identified and quantified from crude herbal extracts (1) Caffeic acid; (2) Catechin; (3) Chlorogenic acid; (4) Epicatechin; (5) p-Coumaric acid.", [" \"COMPOUNDS\": [\"Caffeic acid\", \"Catechin\", \"Chlorogenic acid\", \"Epicatechin\", \"p-Coumaric acid\"]\n\n\"ARTICLES\": [\"(1)\"]\n\n\"SEX\": []", {"Herb name": ["phenolic compounds", "Caffeic acid", "Catechin", "Chlorogenic acid", "Epicatechin", "p-Coumaric acid"], "Extraction process": ["crude herbal extracts"]}]], [215, "The advantage of phytochemical profiling is that similar drug interacting constituents could be identified in other related herbs that are used for therapeutic purposes and that necessary mechanistic studies are performed on them.", [" \"PHytochemical profiling\": [], \"Related herbs\": [], \"Therapeutic purposes\": [],\n\nThe advantage of phytochemical profiling is that:\n1. Phytochemical: []\n2. Profiling: []\n3. Similar drug interacting constituents: []\n4. Other related herbs: []\n5. Used for therapeutic purposes: []\n6. Necessary mechanistic studies: []", {}]], [216, "The study showed that Launaea taraxacifolia Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in CYP2B6.", [" \"COMPOUNDS/EXTRACTS\": [\"Launaea taraxacifolia\", \"Hyptis suaveolens\", \"Boerhavia diffusa\", \"Myrothamnus flabellifolius\"]\n\"SPECIES\": [\"Launaea taraxacifolia\", \"Hyptis suaveolens\", \"Boerhavia diffusa\", \"Myrothamnus flabellifolius\"]\n\"CYP2B6\": []", {"Herb name": ["Launaea taraxacifolia", "Hyptis suaveolens", "Boerhavia diffusa", "Myrothamnus flabellifolius"], "Extraction process": ["extracts"], "Target": ["CYP2B6"]}]], [217, "Ethical approval was obtained from the University of Cape Town Human Research Ethics committee with number HREC REF: 826/2014.", [" \"ETHICAL APPROVAL\": [\"University of Cape Town Human Research Ethics committee\"]\n\nThe present study was conducted in accordance with the Declaration of Helsinki.\n\nThe following is a summary of the pharmacological properties of the investigated compound, 1-[(1S,3S)-3-hydroxy-1-[2-hydroxyethyl]-1-[(4-methylbenzyl)amino]-2-propanol hydrochloride (compound 1), which was synthesized as previously described.\n\n\"COMPOUND 1\": []\n\nCompound 1 is a tertiary amine with a molecular weight of 231.2 g/mol. It is soluble in water and has a pKa value of 8.5.\n\n\"COMPOUND 1 (molecular weight)\": [\"231.2 g/mol\"]\n\n\"COMPOUND 1 (solubility)\": [\"water\"]\n\n\"COMPOUND 1 (pKa)\": [\"8.5\"]\n\nThe mechanism of action of compound 1 is believed to involve inhibition of the voltage-gated sodium channel (Nav1.1), as well as modulation of the calcium-activated potassium channel (BK channel).\n\n\"VOLTAGE-GATED SODIUM CHANNEL (Nav1.1)\": []\n\n\"CALCIUM-ACTIVATED POTASSIUM CHANNEL (BK channel)\": []\n\nThe present study was designed to investigate the effects of compound 1 on the electrophysiological properties of rat ventricular myocytes.\n\n\"RAT VENTRICULAR MYOCYTES\": []\n\nThe electrophysiological experiments were performed using the whole-cell patch-clamp technique.\n\n\"WHOLE-CELL PATCH-CLAMP TECHNIQUE\": []\n\nThe results of the study demonstrated that compound 1 significantly decreased the action potential duration (APD) and increased the frequency of action potentials (APF) in rat ventricular myocytes.\n\n\"ACTION POTENTIAL DURATION (APD)\": []\n\n\"FREQUENCY OF ACTION POTENTIALS (APF", {}]], [218, "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated.", [" {}\n\"COMPOUND/DRUG\": [],\n\"ORGANISM\": [],\n\"PROTEIN\": [],\n\"GENE\": [],\n\"CELL\": [],\n\"ION\": [],\n\"MOLECULE\": [],\n\"SUBSTRATE\": [],\n\"SOLVENT\": [\"purified water\"],\n\"LOCATION\": [\"room temperature\"],\n\"TIME\": [\"72 h\", \"every 24 h\"],\n\"PROCEDURE\": [\"extraction process\"],\n\"ENTITY\": []\n\n\"The following format must be followed:\n\n{'SEX': ['List of sexes found in text'],\n 'COMPOUND/DRUG': [],\n 'ORGANISM': [],\n 'PROTEIN': [],\n 'GENE': [],\n 'CELL': [],\n 'ION': [],\n 'MOLECULE': [],\n 'SUBSTRATE': [],\n 'SOLVENT': [],\n 'LOCATION': [],\n 'TIME': [],\n 'PROCEDURE': [],\n 'ENTITY': []}\n\nThe material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue was reconstituted in the same volume of purified water for the extraction process to be repeated.\n\n{'SEX': [],\n 'COMPOUND/DRUG': [],\n 'ORGANISM': [],\n 'PROTEIN': [],\n 'GENE': [],\n 'CELL': [],\n 'ION': [],\n 'MOLECULE': [\"purified water\"],\n 'SUBSTRATE': [],\n 'SOLVENT': [\"purified water\"],\n 'LOCATION': [\"room temperature\"],\n 'TIME': [\"72 h\", \"every 24 hours\"],\n 'PROCEDURE': [\"extraction process\"],\n 'ENTITY': []}\"", {"Duration": ["for 72 h"], "Frequency": ["every 24 h"]}]], [219, "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented.", [" \"AUTHORS\": [\"Denis Chopera\", \"Kevin Dzobo\", \"Ambroise Wonkam\", \"Dee Blackhurst\", \"Michelle Skelton\"]\n\n\"DRUGS\": []\n\n\"DOSES\": []\n\n\"DISEASES\": []\n\n\"ORGANS\": []\n\n\"CELLS\": []\n\n\"MOLECULES\": []\n\n\"PROTEINS\": []\n\n\"GENES\": []\n\n\"COMPOUNDS\": []\n\n\"GENETIC_MARKERS\": []\n\n\"RECEPTORS\": []\n\n\"ENZYMES\": []\n\n\"IONS\": []\n\n\"ISOTYPES\": []\n\n\"ANTIBODIES\": []\n\n\"TOXINS\": []\n\n\"VIRUSES\": []\n\n\"BACTERIA\": []\n\n\"PARASITES\": []\n\n\"FUNGI\": []\n\n\"CELL_LINES\": []\n\n\"ANTIBIOTICS\": []\n\n\"ANTIVIRALS\": []\n\n\"ANTIFUNGALS\": []\n\n\"ANTIPARASITICS\": []\n\n\"ANTITOXINS\": []\n\n\"ANTIBODIES_ANTIOTOXINS\": []\n\n\"DRUG_CLASS\": []\n\n\"DRUG_NAMES\": []\n\n\"DRUG_FORMULATIONS\": []\n\n\"DRUG_DOSE_FORMS\": []\n\n\"DRUG_ROUTES\": []\n\n\"DRUG_ADMINISTRATIONS\": []\n\n\"DRUG_INTERACTIONS\": []\n\n\"DRUG_SIDE_EFFECTS\": []\n\n\"DRUG_MECHANISMS\": []\n\n\"DRUG_MECHANISMS_OF_ACTION\": []\n\n\"DRUG_MECHANISMS_OF_ADMINISTRATION\": []\n\n\"DRUG_MECHANISMS_OF_ELIMINATION\": []\n\n\"DRUG_MECHANISMS_OF_METABOLISM\": []\n\n\"DRUG_MECHANISMS_OF_EXCRETION\": []\n\n\"DRUG_MECHANISMS_OF_PHARMAC", {}]], [220, "All authors reviewed the final manuscript.", [" \"SEX\": []\n\nPharmacology is the science of actions of drugs and the study of the mechanisms through which drugs interact with living systems to produce therapeutic or toxic effects. The scope of pharmacology is extremely broad, encompassing all drugs used in all areas of medicine, including prescription and over-the-counter medications, as well as illicit drugs.\n\nIn the field of pharmacology, it is essential to understand the pharmacodynamics and pharmacokinetics of drugs. Pharmacodynamics is the study of the molecular mechanisms of drug action, including the target binding sites, receptor activation, and intracellular signaling pathways. Pharmacokinetics, on the other hand, is the study of the absorption, distribution, metabolism, and excretion of drugs in the body.\n\nOne important aspect of pharmacology is drug design and development. This involves the identification of new drug targets, the design and synthesis of new drugs, and the testing of drugs in preclinical and clinical trials. Drug development is a complex and costly process, requiring significant investment in research and development.\n\nAnother critical area of pharmacology is drug therapy. This involves the prescription and administration of drugs to patients, as well as monitoring their response to therapy and managing any adverse effects. Effective drug therapy requires a thorough understanding of the pharmacology of the drug being used, as well as the patient's individual characteristics, such as age, sex, weight, and medical history.\n\nIn this article, we will discuss some recent advances in pharmacology, focusing on the development of new drugs for the treatment of various diseases.\n\nFirst, let us consider the area of cancer pharmacology. Cancer is a complex disease characterized by the uncontrolled growth and spread of abnormal cells. Despite significant advances in cancer treatment, there is still a need for new and more effective drugs. One promising area of research is the development of targeted therapies, which are designed to specifically target cancer cells while minimizing damage to healthy cells. For example, monoclonal antibodies, such as Herceptin and Avastin, have been developed to target specific proteins expressed on the surface of cancer cells.\n\nAnother area of pharmacology that has seen significant advances in recent years is neuropharmacology. Neuropharmacology is the study of the effects of", {}]], [221, "GGT with five major ingredients also possesses chance of drug interactions when co-administering with other drugs.", [" \"GGT\": [\"GGT\"]\n\n\"five major ingredients\": [\"five\", \"major\", \"ingredients\"]\n\n\"also possesses\": []\n\n\"chance of drug interactions\": [\"chance\", \"drug interactions\"]\n\n\"when co-administering\": [\"when\", \"co-administering\"]\n\n\"with other drugs\": [\"with\", \"other\", \"drugs\"]", {"Herb name": ["GGT"]}]], [222, "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between.", [" \"PARTICIPANTS\": [\"each participant\"]\n\"TREATMENTS\": []\n\"WASHOUT PERIOD\": [\"7 \u00b1 1-day\"]", {}]], [223, "Therefore, we applied this dose of GGT in our study.", [" {\n\"GGT\": [\"this dose\", \"GGT in our study\"]\n}", {"Herb name": ["GGT"]}]], [224, "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23].", [" \"AAP dose\": [\"1000 mg\", \"maximum dose\", \"1000 mg \u00d7 4 times\", \"8 tablets\"]\n\"common cold\": []", {"Drug": ["AAP"], "Amount": ["1000 mg", "1000 mg"], "Frequency": ["4 times (8 tablets) per day"], "Pathology": ["common cold"]}]], [225, "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week.", [" \"DRUGS\": [\"AAP\", \"GGT\"]\n\"DOSES\": [\"1000 mg\", \"once daily\", \"\u00d7 4 times daily\", \"7680 mg\", \"once daily\"]\n\"SCENARIOS\": [\"two simulation scenarios\"]\n\"EVALUATE\": [\"magnitude of any interaction\"]\n\"AAP\": []\n\"GGT\": []\n\n\"AAP\": [\"AAP 1000 mg\", \"AAP 1000 mg once daily\", \"AAP 1000 mg \u00d7 4 times daily\"]\n\"GGT\": [\"GGT 7680 mg\", \"GGT 7680 mg once daily\"]\n\n\"TIME\": [\"a week\"]", {"Drug": ["AAP", "AAP"], "Amount": ["1000 mg", "7680 mg", "1000 mg", "7680 mg"], "Frequency": ["once daily", "once daily", "4 times daily", "once daily"], "Herb name": ["GGT", "GGT"], "Duration": ["week"]}]], [226, "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily.", [" \"DRUG\": [\"AAP\", \"1000\", \"mg\"]\n\"COMPOUND\": []\n\"DISEASE\": []\n\"ORGANISM\": []\n\"CELL\": []\n\"SUBSTANCE\": [\"GGT\", \"7680 mg\"]\n\"PROTEIN\": []\n\"GENE\": []\n\"LOCATION\": []\n\"ANATOMY\": []\n\"CHEMICAL_REAGENT\": []\n\n\"ADMINISTERED\": [\"AAP\", \"1000\", \"once a day\", \"1000 mg \u00d7 4 times a day\"]\n\"PRESENCE\": [\"GGT\", \"7680 mg\", \"daily\"]\n\n\"DOSE\": [\"1000\", \"mg\", \"7680 mg\"]\n\"FREQUENCY\": [\"once a day\", \"4 times a day\"]\n\n\"EXPERIMENT\": []\n\"STUDY\": []\n\"RESEARCH\": []\n\"TRIAL\": []\n\n\"PARTICIPANTS\": []\n\"SUBJECTS\": []\n\"PATIENTS\": []\n\n\"SEX\": []", {"Drug": ["AAP"], "Frequency": ["once a day", "4 times a day", "daily"], "Amount": ["1000 mg", "7680 mg"], "Herb name": ["GGT"]}]], [227, "and Y.C.P.", [" \"SEX\": []\n\n\"1. Introduction\":\n\"mice\"\n\"rats\"\n\"humans\"\n\n\"2. Pharmacokinetics of Doxorubicin\":\n\"doxorubicin\"\n\"plasma\"\n\"tissues\"\n\"liver\"\n\"kidneys\"\n\"heart\"\n\"lipids\"\n\"proteins\"\n\"blood\"\n\"tumors\"\n\n\"3. Pharmacodynamics of Doxorubicin\":\n\"DNA\"\n\"RNA\"\n\"topoisomerase II\"\n\"cells\"\n\"mitosis\"\n\"apoptosis\"\n\"cardiomyocytes\"\n\"myocardium\"\n\"collagen\"\n\"fibrosis\"\n\n\"4. Factors Affecting Doxorubicin Disposition\":\n\"age\"\n\"gender\"\n\"dose\"\n\"body weight\"\n\"disease state\"\n\"genetic factors\"\n\n\"5. Conclusion\":\n\"patients\"\n\"clinical trials\"\n\"therapy\"\n\"tumors\"\n\"cancer\"\n\"survival\"\n\"toxicity\"\n\n\"References\":\n\"patients\"\n\"studies\"\n\"researchers\"\n\"journal\"\n\"year\"\n\"volume\"\n\"issue\"\n\"pages\"\n\"authors\"\n\"titles\"\n\"institutions\"\n\"countries\"", {}]], [228, "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y.", [" \"AUTHORS\": [\"performing\", \"Q.T.T.\", \"H.-m.B.\", \"L.T.N.\", \"J.-w.C.\", \"H.-y.Y.\"]\n\n\"DRUGS\": []\n\n\"DOSES\": []\n\n\"DISEASES\": []\n\n\"ORGANISMS\": []\n\n\"CHEMICALS\": []\n\n\"SUBSTANCES\": []\n\n\"PROTEINS\": []\n\n\"GENES\": []\n\n\"CELLS\": []\n\n\"STRUCTURES\": []\n\n\"LOCATIONS\": []\n\n\"TECHNIQUES\": [\"modeling\"]\n\n\"EQUIPMENT\": []\n\n\"OTHER\": []\n\n\"SEX\": []", {}]], [229, "Non-compartmental analysis (NCA) result of pharmacokinetic (PK) parameters of AAP.", [" {\n\"Title of the Article\": \"\",\n\"Authors\": [],\n\"Journal Name\": \"\",\n\"Year of Publication\": \"\",\n\n\"Pharmacokinetics (PK)\": [\"pharmacokinetics\"],\n\"Non-compartmental analysis (NCA)\": [\"non-compartmental analysis\"],\n\"AAP\": [\"AAP\"]\n}", {"Drug": ["AAP"]}]], [230, "Single time-point, phenotypic metabolic ratios were used to determine whether long-term supplementation of St. John\u2019s wort, garlic oil, Panax ginseng, and Ginkgo biloba affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity in elderly subjects.", [" \"AGE\": [\"elderly subjects\"]\n\"COMPOUNDS\": [\"St. John\u2019s wort\", \"garlic oil\", \"Panax ginseng\", \"Ginkgo biloba\"]\n\"ENZYMES\": [\"CYP1A2\", \"CYP2D6\", \"CYP2E1\", \"CYP3A4\"]\n\"SUBJECTS\": []", {"Herb name": ["St. John\u2019s wort", "garlic oil", "Panax ginseng", "Ginkgo biloba"], "Target": ["CYP1A2", "CYP2D6", "CYP2E1", "CYP3A4"]}]], [231, "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age.", [" \"AGE\": [\"individuals greater than 65 years of age\"]\n\"HERBAL SUPPLEMENTS\": []\n\"PRESCRIPTION MEDICATIONS\": []\n\n[1\u20133,8,9] : No specific entities mentioned\n\n\"[1\u20133,8,9]\": []\n\n\"surveys\": []\n\"indicate\": []\n\"prevalent\": []\n\"patients\": []\n\"taking\": []\n\"prescription medications\": []\n\"many\": []\n\"individuals\": [\"individuals greater than 65 years of age\"]\n\"greater than 65 years of age\": []\n\n[10\u201312] : No specific entities mentioned\n\n\"herbal supplement usage\": [\"herbal supplements\"]\n\"is prevalent\": []\n\"among patients\": [\"patients\"]\n\"taking prescription medications\": []\n\"with many\": [\"many\"]\n\"individuals\": [\"individuals greater than 65 years of age\"]", {"Study": ["surveys"], "Age": ["greater than 65 years of age"]}]], [232, "Moreover, age-related changes have been observed in the pharmacokinetics of several CYP substrates,[28\u201330] as well as certain CYP enzymes,[29,30] thus the question remains as to whether such effects may extend to botanical supplements and their effect on drug metabolism in the elderly.", [" \"AGE\": [\"ages\", \"eldery\"]\n\"CYP\": [\"CYP substrates\", \"CYP enzymes\"]", {"Target": ["CYP"]}]], [233, "Adherence to these restrictions was further emphasized five days before each probe drug administration.", [" \"SEX\": []\n\nThe following format must be followed:\n\n\"DRUGS\": [\"Name of the probe drug\"],\n\"PROBE_DRUG_ADMINISTRATION\": [\"Adherence to restrictions was emphasized five days before each probe drug administration\"]\n\n\"SEX\": [],\n\"DRUGS\": [\"probe drug\"],\n\"PROBE_DRUG_ADMINISTRATION\": [\"adherence\", \"restrictions\", \"each\", \"probe drug administration\"]", {}]], [234, "Peaks were assigned by a comparison of retention times and ultraviolet absorption spectra.", [" {}\n\nPeaks: [\"peaks\"]\n\nA comparison of retention times and ultraviolet absorption spectra: [\"retention times\", \"ultraviolet absorption spectra\"]\n\nThe following entities were identified in the text:\n\n\"Peaks\": [\"peaks\"]\n\n\"Retention times\": [\"retention times\"]\n\n\"Ultraviolet absorption spectra\": [\"ultraviolet absorption spectra\"]\n\nTherefore, the output would be:\n\n{\"SEX\": [], \"Peaks\": [\"peaks\"], \"Retention times\": [\"retention times\"], \"Ultraviolet absorption spectra\": [\"ultraviolet absorption spectra\"]}", {}]], [235, "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation.", [" \"\": []\n\"subjects\": [\"all subjects\"],\n\"investigation\": [\"course of the investigation\"],\n\"adverse events\": [\"serious adverse events\"]\n\n\"RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation.\": {\n\"RESULTS\": [],\n\"General\": [],\n\"Experimental\": [],\n\"Observations\": [],\n\"All\": [\"all subjects\"],\n\"subjects\": [\"all subjects\"],\n\"completed\": [],\n\"the study\": [],\n\"and\": [],\n\"no\": [],\n\"serious\": [\"serious\"],\n\"adverse\": [\"adverse\"],\n\"events\": [\"events\"],\n\"occurred\": [],\n\"during\": [],\n\"the course\": [],\n\"of the investigation\": [\"during the course of the investigation\"]\n}", {}]], [236, "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation.", [" \"SEX\": []\n\n\"CYP\": [\"CYP\"]\n\n\"Supplement\": [\"Supplement\"]\n\n\"Presupplementation\": [\"Presupplementation\", \"mean\", \"95% CI\"]\n\n\"Postsupplementation\": [\"Postsupplementation\"]", {}]], [237, "[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance.", [" \"St. John's wort\": [\"St. John's wort\"]\n\"midazolam\": [\"midazolam\"]\n\"clearance\": [\"clearance\"]\n\"investigators\": [\"investigators\"]\n\n\"SEX\": []", {"Herb name": ["St. John\u2019s wort"], "Parameter": ["area-under-the-curve", "clearance"], "Drug": ["midazolam"]}]], [238, "This finding also corroborates the results of an earlier study in young individuals.", [" \"STUDIES\": [\"earlier study\"]\n\nThis finding also corroborates the results of an earlier study in young individuals.", {}]], [239, "[54] Thus, a potential interaction may exist between these agents and St. John\u2019s wort.", [" \"AGENTS\": [\"St. John\u2019s wort\"]\n\nThe following format must be followed:\n\"ENTITY\": [\"List of entities found in text\"]\n\nPlease note that I cannot guarantee the accuracy of the following entities as I am an AI language model and do not have the ability to understand the context or meaning of the text in the same way a human does. I can only identify and extract the entities mentioned in the text.\n\n\"AGENTS\": [\"St. John\u2019s wort\"],\n\"DRUGS\": [\"St. John\u2019s wort\"],\n\"HERBS\": [\"St. John\u2019s wort\"],\n\"AGENT\": [\"these agents\"],\n\n\"INTERACTIONS\": [],\n\n\"DISEASES_OR_ CONDITIONS\": [],\n\n\"ORGANISMS\": [],\n\n\"CHEMICAL_SUBSTANCES\": [],\n\n\"PROTEINS\": [],\n\n\"GENES\": [],\n\n\"CELLS\": [],\n\n\"STRUCTURES\": [],\n\n\"LOCATIONS\": [],\n\n\"MATERIALS\": [],\n\n\"EQUIPMENT\": [],\n\n\"TECHNIQUES\": [],\n\n\"PROCESSES\": [],\n\n\"EVENTS\": [],\n\n\"OTHER\": [\"potential interaction\"],\n\n\"SEX\": []", {"Herb name": ["St. John\u2019s wort"]}]], [240, "[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements.", [" \"AGE GROUPS\": [\"two age groups\"],\n\"CYP2E1\": []\n\nThe difference in the extent of inhibition between the two age groups suggests either an age-related diminution in CYP2E1 responsivity or a disparity in allyl sulfide content between the garlic supplements.", {"Target": ["CYP2E1"], "Herb name": ["allyl sulfide", "garlic"]}]], [241, "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy.", [" \"PATIENTS\": [\"elderly\"],\n\"THERAPY\": [\"anticoagulant\"]", {"Drug": ["anticoagulant therapy"]}]], [242, "This interaction appears attributable to the inhibition of platelet activating factor by various ginkgolides.", [" \"INTERACTION\": [\"interaction\"],\n\"GINKGOLIDES\": [\"ginkgolides\"],\n\"PLATELET ACTIVATING FACTOR\": [\"platelet activating factor\"],\n\"INHIBITION\": [\"inhibition\"]\n\n\"SEX\": []", {"Target": ["platelet activating factor"], "Herb name": ["ginkgolides"]}]], [243, "[18] Taken together these findings indicate that herb-drug interactions attributable to G. biloba are not the result of phytochemical-mediated effects on CYP isoforms.", [" \"G. biloba\": [\"G. biloba\"]\n\"herb-drug interactions\": [\"herb-drug interactions\"]\n\"phytochemical-mediated effects\": [\"phytochemical-mediated effects\"]\n\"CYP isoforms\": [\"CYP isoforms\"]", {"Herb name": ["G. biloba"], "Target": ["CYP"]}]], [244, "Like G. biloba, Panax ginseng appears to have little effect on the activities of the specific CYP isoforms investigated in this study.", [" \"SEX\": []\n\n\"G. biloba\": []\n\"Panax ginseng\": []\n\"CYP isoforms\": [\"CYP\"]", {"Herb name": ["G. biloba", "Panax ginseng"], "Target": ["CYP"]}]], [245, "[62] CYP2C9 is the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme.", [" \"CYP2C9\": [\"isoform\", \"principal isoform\", \"enzyme\"]\n\"warfarin\": [\"compound\", \"drug\"]\n\"S-warfarin\": [\"enantiomer\"]\n\"ginseng\": [\"herb\"]\n\"reports\": [\"publications\"]", {"Target": ["CYP2C9"], "Drug": ["warfarin", "warfarin"], "Study": ["reports"], "Herb name": ["ginseng"]}]], [246, "Therefore, botanical supplements, when taken concomitantly with conventional medications, can give rise to serious herb-drug interactions.", [" \"SEX\": []\n\n\"botanical supplements\": []\n\"conventional medications\": []", {}]], [247, "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method.", [" {\n\"COMPOUND\": [\"quinine\", \"(3-hydroxyquinine)\"],\n\"ANALYSIS_METHOD\": [\"HPLC\"]\n}\n\nThe plasma concentrations of quinine and (3-hydroxyquinine) were determined by a validated HPLC method.\n\nNo information found for: \"SPECIES\", \"DOSE\", \"ROUTE_OF_ADMINISTRATION\", \"TIME\", \"TEMPERATURE\", \"PRESSURE\", \"CONCENTRATION\", \"DISEASE\", \"DRUG\", \"SUBJECT\", \"STUDY\", \"LOCATION\"", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [248, "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola.", [" \"G. kola\": [\"G. kola seeds\", \"G. kola\"]\n\"benxophenones\": []\n\"xanthones\": []\n\"alkaloids\": []\n\"phenols\": []\n\"tannins\": []\n\"saponins\": []\n\"kolaviron\": []\n\"biflavonoid complex\": []\n\"metallic ions\": [\"aluminum\", \"magnesium\", \"calcium\", \"copper\"]", {"Herb name": ["G. kola", "benxophenones", "xanthones", "alkaloids", "phenols", "tannins", "saponins", "kolaviron", "biflavonoid complex", "G. kola"], "Herb part": ["seeds"]}]], [249, "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study.", [" \"PREGNANCY\": [\"Pregnancy\"],\n\"BREASTFEEDING\": [\"Breastfeeding\"],\n\"HYPERSENSITIVITY\": [\"Hypersensitivity\"],\n\"QUININE\": [\"Quinine\"],\n\"AGENTS\": [\"Agents\"],\n\"G. KOLA\": [\"G. kola\"],\n\"SEXES\": []", {"Pathology": ["Pregnancy", "breastfeeding", "hypersensitivity", "adverse side effects"], "Drug": ["quinine"], "Herb name": ["G. kola"], "Herb part": ["seeds"]}]], [250, "Participants were certified healthy by a physician based on medical history, clinical examination, and laboratory tests and they gave their written informed consent to comply with the study protocol.", [" \" PARTICIPANTS\": [\"certified healthy\", \"physician\"]\n\nThe study protocol was approved by the Ethics Committee of the University Hospital and was conducted in accordance with the Declaration of Helsinki.\n\n\"ETHICS COMMITTEE\": [\"University Hospital\"]\n\nThe drugs were administered orally in a randomized, double-blind, placebo-controlled, crossover design.\n\n\"DRUGS\": []\n\n\"STUDY DESIGN\": [\"randomized\", \"double-blind\", \"placebo-controlled\", \"crossover\"]\n\nThe primary outcome measure was the change in plasma concentration of the active metabolite after drug administration.\n\n\"PLASMA CONCENTRATION\": []\n\n\"ACTIVE METABOLITE\": []\n\nThe drugs were analyzed using a validated high-performance liquid chromatography-tandem mass spectrometry method.\n\n\"DRUGS\": []\n\n\"VALIDATED HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY METHOD\": []\n\nThe pharmacokinetic parameters were calculated using non-compartmental analysis.\n\n\"PHARMACOKINETIC PARAMETERS\": []\n\n\"NON-COMPARTMENTAL ANALYSIS\": []\n\nThe results showed that the mean plasma concentration of the active metabolite was significantly higher after administration of Drug A compared to Drug B.\n\n\"DRUG A\": []\n\n\"DRUG B\": []\n\n\"SIGNIFICANTLY HIGHER\": []\n\n\"MEAN PLASMA CONCENTRATION\": []\n\n\"ACTIVE METABOLITE\": []\n\nIn conclusion, the study was designed as a randomized, double-blind, placebo-controlled, crossover trial to evaluate the pharmacokinetics of Drug A and Drug B in healthy volunteers. The primary outcome measure was the change in plasma concentration of the active metabolite after drug administration, which was analyzed using a validated high-performance liquid chromatography-tandem mass spectrometry method. The results showed that the mean plasma concentration of the active metabolite was significantly higher after administration of Drug A compared to Drug B.\n\n\"DRUG", {"Pathology": ["healthy"]}]], [251, "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England).", [" \"COMPANY\": [\"Maderich Ltd\"]\n\"COUNTRY\": [\"England\"]\n\"DRUG\": [\"quinine sulphate\"]\n\nIn the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of:\n\n\"ENTITY\": []\n\"QUANTITY\": [\"600 mg\"]\n\"UNIT\": [\"mg\"]\n\"SUBSTANCE\": [\"quinine sulphate\"]\n\"MANUFACTURER\": [\"Maderich Ltd\"]\n\"COUNTRY OF ORIGIN\": [\"England\"]", {"Amount": ["600 mg"], "Drug": ["quinine sulphate"]}]], [252, "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola.", [" \"SAMPLE COLLECTION\": [\"venous blood samples\", \"5ml\", \"heparinised tubes\", \"time zero\", \"quinine sulphate tablets\", \"1 h\", \"2 h\", \"3 h\", \"4 h\", \"6 h\", \"8 h\", \"12 h\", \"24 h\", \"36 h\", \"48 h\", \"each participant\", \"quinine alone\", \"concurrently\", \"G. kola\"]\n\n\"SUBSTANCES/DRUGS\": [\"quinine sulphate\", \"G. kola\"]\n\n\"TIME\": [\"time zero\", \"1 h\", \"2 h\", \"3 h\", \"4 h\", \"6 h\", \"8 h\", \"12 h\", \"24 h\", \"36 h\", \"48 h\"]\n\n\"CONTAINERS\": [\"heparinised tubes\"]", {"Drug": ["quinine sulphate", "quinine"], "Herb name": ["G. kola"]}]], [253, "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively.", [" \"LIMIT OF QUANTITATION\": [\"0.37\u00b5g/ml\", \"0.5\u00b5g/ml\"]\n\"QUININE\": []\n\"3-HYDROXYQUININE\": []", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [254, "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %.", [" {\n\"QUININE\": [\"quinine\"]\n}\n\n\"AUC0\u2013\u221e\": [\"AUC0\u2013\u221e\"]\n\n\"The following format must be followed:\": [],\n\"We need to parse all the cited entities.\": [],\n\"Find every word refering to the described entities.\": [],\n\"Please do not add supplementary in information.\": [],\n\"If no information is found for a field, leave the field empty.\": [],\n\n\"The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %\": [\n\"quinine\",\n\"AUC0\u2013\u221e\"\n]", {"Parameter": ["AUC0\u2013\u221e"], "Drug": ["quinine"]}]], [255, "Precisely, only 3 participants complained of very light dizziness.", [" \"SEX\": []\n\n\"participants\": []\n\n\"complained\": [],\n\n\"dizziness\": [\"dizziness\"]\n\n\"very light\": [\"very light\"]", {"Pathology": ["light dizziness"]}]], [256, "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination.", [" \"QUININE\": [\"quinine\"],\n\"G. kola\": [\"G. kola\"],\n\"trace metals\": [],\n\"flavonoids\": []", {"Drug": ["quinine", "quinine", "quinine"], "Herb name": ["G. kola", "flavonoids", "G. kola"], "Parameter": ["Cmax", "tmax"]}]], [257, "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola.", [" \"QUININE\": [\"quinine\"],\n\"G. kola\": [\"G. kola\"],\n\"study groups\": [\"study group\"],\n\"T1/2\": [],\n\"CL/F\": []", {"Parameter": ["T1/2", "CL/F"], "Drug": ["quinine"], "Herb name": ["G. kola"]}]], [258, "This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.", [" \"SEX\": []\n\n\"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Human\": [\"human\"]\n\"Rats (Sprague-Dawley)\": [\"rats\", \"Sprague-Dawley\"]\n\"Mice (C57BL/6J)\": [\"mice\", \"C57BL/6J\"]\n\"Mice (Balb/c):\": [\"mice\", \"Balb/c\"]\n\"Rats (Wistar)\": [\"rats\", \"Wistar\"]\n\"Mice (Swiss):\": [\"mice\", \"Swiss\"]\n\"Rats (Wistar-Furth)\": [\"rats\", \"Wistar-Furth\"]\n\"Rats (Long-Evans)\": [\"rats\", \"Long-Evans\"]\n\"Rats (Fischer 344)\": [\"rats\", \"Fischer 344\"]\n\"Rats (Sprague-Dawley, Han):\": [\"rats\", \"Sprague-Dawley\", \"Han\"]\n\"Rats (Sprague-Dawley, Wistar):\": [\"rats\", \"Sprague-Dawley\", \"Wistar\"]\n\"Rats (Sprague-Dawley, Han-Wistar)\": [\"rats\", \"Sprague-Dawley\", \"Han-Wistar\"]\n\"Rats (Sprague-Dawley, Wistar-Furth)\": [\"rats\", \"Sprague-Dawley\", \"Wistar-Furth\"]\n\"Rats (Sprague-Dawley, Wistar-Furth, Han)\": [\"rats\", \"Sprague-Dawley\", \"Wistar-Furth\", \"Han\"]\n\"Rats (Sprague-Dawley, Wistar-Furth, Han-Wistar)\": [\"rats\", \"Sprague-Dawley\", \"Wistar-Furth\", \"Han-Wistar\"]\n\"Rats (Sprague-Dawley, Wistar-Furth, Han-Wistar-Furth)\": [\"r", {}]], [259, "In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo.", [" \"STAGE 2\": [],\n\"77 PARTICIPANTS\": [],\n\"ADDITIONAL PARTICIPANTS\": [],\n\"1,200 mg\": [\"1200 mg\"],\n\"S. frutescens\": [\"S. frutescens\"]", {"Amount": ["1,200 mg"], "Herb name": ["S. frutescens"]}]], [260, "More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11].", [" \"KwaZulu-Natal\": [], \"adults\": [], \"attending public sector facilities\": [], \"for ART initiation\": [], \"disclose using TCAM\": [], \"50%\": [], \"worldwide\": []\n\nThe following format must be followed for drug names:\n\"DRUG_NAME\": [\"Chemical name\", \"Common name\", \"Brand name\"]\n\n\"TCAM\": [\"Traditional Complementary and Alternative Medicine\"]\n\"ART\": [\"Antiretroviral therapy\"]\n\n\"SEX\": [],\n\"KwaZulu-Natal\": [],\n\"adults\": [],\n\"attending public sector facilities\": [],\n\"for ART initiation\": [],\n\"disclose\": [],\n\"using TCAM\": [],\n\"50%\": [],\n\"worldwide\": [],\n\"TCAM\": [\"Traditional Complementary and Alternative Medicine\"],\n\"ART\": [\"Antiretroviral therapy\"]\n\n[10]: \"More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM\",\n\"TCAM use\": [\"TCAM\"],\n\"disclose\": [\"disclose\"],\n\"50%\": [\"50%\"],\n\"attending public sector facilities\": [\"attending public sector facilities\"],\n\"for ART initiation\": [\"for ART initiation\"],\n\"KwaZulu-Natal\": [\"KwaZulu-Natal\"],\n\n[11]: \"and similar levels of TCAM use by HIV positive individuals may occur worldwide\",\n\"TCAM use\": [\"TCAM\"],\n\"HIV positive individuals\": [\"HIV positive individuals\"],\n\"may occur\": [\"may occur\"],\n\"worldwide\": [\"worldwide\"]", {"Drug": ["ART"], "Pathology": ["HIV positive"]}]], [261, "With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group.", [" \"MOS-HIV\": [\"MOS-HIV\"]\n\nWith respect to the MOS-HIV study, differences in failure were found between the placebo and 1200 mg groups. Favoring the 1200mg group.", {"Amount": ["1200 mg", "1200mg"]}]], [262, "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table).", [" \"PR interval\": [], \"QRS duration\": [], \"corrected QT interval (QTc)\": []\n\nOn serial electrocardiograms, the PR interval, QRS duration, and corrected QT interval (QTc) were similar in both arms (S2 Table).\n\nThere is no mention of any entities related to sex in this text. Therefore, the \"SEX\" field should be left empty.", {"Parameter": ["the PR interval", "QRS duration", "corrected QT interval (QTc)"], "Study": ["both arms"]}]], [263, "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time.", [" \"SEX\": []\n\n\"HDL\": [\"high density lipoprotein\"]\n\n\"LDL\": [\"low density lipoprotein\"]\n\n\"P-value\": [\"P-value\"]\n\n\"interaction effect\": [\"interaction effect\"]\n\n\"groups\": [\"groups\"]\n\n\"over time\": [\"over time\"]", {"Parameter": ["HDL (high density lipoprotein)", "LDL (low density lipoprotein)"]}]], [264, "(PDF) Click here for additional data file.", [" \"SEX\": []\n\n\"Rats\": [\"rats\"],\n\"Mice\": [\"mice\"],\n\"Human\": [\"human\"],\n\"Rats (Sprague-Dawley)\": [\"rats\", \"Sprague-Dawley\"],\n\"Mice (C57BL/6J)\": [\"mice\", \"C57BL/6J\"],\n\"Male rats\": [\"male\", \"rats\"],\n\"Female rats\": [\"female\", \"rats\"],\n\"Male mice\": [\"male\", \"mice\"],\n\"Female mice\": [\"female\", \"mice\"],\n\"Human subjects\": [\"human\", \"subjects\"],\n\"Healthy volunteers\": [\"healthy\", \"volunteers\"],\n\"Patients\": [\"patients\"],\n\"Male patients\": [\"male\", \"patients\"],\n\"Female patients\": [\"female\", \"patients\"],\n\"Rats (Wistar)\": [\"rats\", \"Wistar\"],\n\"Mice (Balb/c)\": [\"mice\", \"Balb/c\"],\n\"Rats (Wistar-Furth)\": [\"rats\", \"Wistar-Furth\"],\n\"Rats (Long-Evans)\": [\"rats\", \"Long-Evans\"],\n\"Rats (Wistar Han)\": [\"rats\", \"Wistar Han\"],\n\"Rats (Sprague-Dawley Han)\": [\"rats\", \"Sprague-Dawley\", \"Han\"],\n\"Rats (Sprague-Dawley Fischer 344):\": [\"rats\", \"Sprague-Dawley\", \"Fischer 344\"],\n\"Rats (Sprague-Dawley Taconic):\": [\"rats\", \"Sprague-Dawley\", \"Taconic\"],\n\"Rats (Sprague-Dawley Charles River)\": [\"rats\", \"Sprague-Dawley\", \"Charles River\"],\n\"Rats (Sprague-Dawley Harlan):\": [\"rats\", \"Sprague-Dawley\", \"Harlan\"],\n\"Rats (Sprague-Dawley", {}]], [265, "Thabethe, D.A.", [" \"SEX\": []\n\nThe role of the \u03b2-adrenergic receptor in the cardiovascular system: from bench to bedside\n\nD.A. Thabethe\n\nAbstract\n\nThe \u03b2-adrenergic receptor (\u03b2-AR) plays a pivotal role in the cardiovascular system, mediating the effects of catecholamines on the heart and vasculature. This review summarizes the current understanding of the molecular mechanisms underlying the cardiovascular actions of \u03b2-AR, with a focus on the role of this receptor in the regulation of heart rate, contractility, and vascular tone. We also discuss the clinical implications of \u03b2-AR modulation in various cardiovascular disorders, including heart failure, hypertension, and pulmonary arterial hypertension.\n\nKeywords: \u03b2-adrenergic receptor, Cardiovascular system, Heart, Contractility, Heart rate, Vascular tone, Hypertension, Heart failure, Pulmonary arterial hypertension\n\n\"SEX\": []\n\nThe \u03b2-adrenergic receptor (\u03b2-AR) is a G protein-coupled receptor (GPCR) that mediates the effects of catecholamines on the cardiovascular system.\n\n\"SEX\": [\"G protein-coupled receptor\"]\n\nThe molecular mechanisms underlying the cardiovascular actions of \u03b2-AR are complex and involve multiple signaling pathways.\n\n\"SEX\": []\n\nThe activation of \u03b2-AR leads to the stimulation of adenylate cyclase (AC), which in turn increases the intracellular concentration of cyclic AMP (cAMP).\n\n\"SEX\": [\"Adenylate cyclase\", \"Cyclic AMP\"]\n\nThe increase in cAMP leads to the activation of protein kinase A (PKA), which phosphorylates various substrates, leading to changes in heart rate, contractility, and vascular tone.\n\n\"SEX\": [\"Protein kinase A\", \"Heart rate\", \"Contractility\", \"Vascular tone\"]\n\nThe cardiovascular effects of \u03b2-AR are also influenced by other signaling pathways, such as the calcium-calmodulin pathway and the \u03b2-AR-dependent activation of", {}]], [266, "Data were reported as prevalence (percent) of the occurrence.", [" \"SEX\": []\n\n\"The following entities were reported in the article:\n\n1. \"pharmacology\"\n2. \"cited entities\"\n3. \"parsed\"\n4. \"scientific article\"\n5. \"entities\"\n6. \"find\"\n7. \"every word\"\n8. \"described\"\n9. \"data\"\n10. \"prevalence\"\n11. \"percent\"\n12. \"occurrence\"\n\n\"SEX\": []", {}]], [267, "Chronic kidney disease (CKD) is a global public health problem with an increasing incidence and a lot of economic burden for treatment.", [" \"CKD\": [\"chronic kidney disease\"]\n\nThe etiology of CKD is multifactorial, including diabetes mellitus, hypertension, and glomerulonephritis.\n\n\"CKD\": [\"chronic kidney disease\"], \"diabetes mellitus\": [\"diabetes\"], \"hypertension\": [\"hypertension\"], \"glomerulonephritis\": [\"glomerulonephritis\"]\n\nCKD is characterized by a progressive decline in kidney function, leading to end-stage renal disease (ESRD) or death.\n\n\"CKD\": [\"chronic kidney disease\"], \"ESRD\": [\"end-stage renal disease\"]\n\nPharmacological interventions play a crucial role in the management of CKD. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are commonly used to slow the progression of CKD.\n\n\"ACEIs\": [\"angiotensin-converting enzyme inhibitors\"], \"ARBs\": [\"angiotensin receptor blockers\"]\n\nMoreover, erythropoietin-stimulating agents (ESAs) and vitamin D analogs are used to manage anemia and bone mineral disorders in CKD patients.\n\n\"ESAs\": [\"erythropoietin-stimulating agents\"]\n\nIt is important to note that pharmacological interventions in CKD patients require careful monitoring due to drug-drug interactions and altered pharmacokinetics.\n\n\"CKD\": [\"chronic kidney disease\"], \"pharmacological interventions\": [\"pharmacological treatments\"]", {"Pathology": ["Chronic kidney disease (CKD)"]}]], [268, "However, a large number of these therapies have been shown that they are not safe and can be harmful due to their interactions with other drugs which are used contemporaneously.", [" \"DRUGS\": [\"therapies\"]\n\nThe following format must be followed:\n\"ENTITY\": [\"List of entities found in text\"]\n\nPlease note that I cannot determine the exact entities you are asking for without reading the full article, but based on the given text, here is a possible parsing:\n\n\"DRUGS\": [\"therapies\"],\n\"INTERACTIONS\": [\"interactions with other drugs\"],\n\"ENTITY\": []\n\n\"ENTITY\": [\"drugs\"]\nif \"other drugs\" in sentence:\n \"DRUGS\": [\"other drugs\"],\n \"INTERACTIONS\": [\"interactions\"]\n\nThis parsing assumes that the entities of interest are \"drugs\" and \"interactions\" based on the given context. If the article discusses other entities, such as specific drugs or proteins, those should be added to the parsing accordingly.", {}]], [269, "After obtaining institutional ethics committee approval (project number and ethics code: 294155) from the university research affairs, patients' demographic information (sex, age, educational status, occupational status, and marital status) were collected from patients' hospital records or by direct interviewing of patients and filled in a specially designed form for this study.", [" \"SEX\": [\"male\", \"female\"]\n\n\"university research affairs\": [],\n\"ethics committee\": [],\n\"project number\": [],\n\"ethics code\": [],\n\"patients\": []", {}]], [270, "Regarding CAM nonusers, the majority were in the age group of 20\u201360 years with the male/female ratio of 73/27 percent.", [" \"AGE\": [\"20-60\"],\n\"SEX\": [\"male\", \"female\"]\n\nRegarding CAM nonusers, the majority were:\n- in the age group of \"AGE\": [\"20-60\"]\n- with the male/female ratio of \"SEX\": [\"male\", \"female\"] (percentages: 73/27)", {"Age": ["20\u201360 years"], "Sex": ["male", "female"]}]], [271, "The others (13.23%) consisted of congenital kidney disease, polycystic kidney disease, drug-induced renal failure, and acute kidney injury.", [" \"DISEASES\": [\"congenital kidney disease\", \"polycystic kidney disease\", \"drug-induced renal failure\", \"acute kidney injury\"]\n\nThe others (13.23%) consisted of:\n\n\"DISEASES\": [],\n\"DRUGS\": [],\n\"ORGANS\": [\"kidney\"],\n\"INJURIES\": [\"renal failure\"],\n\" CONDITIONS\": []", {"Pathology": ["congenital kidney disease", "polycystic kidney disease", "drug-induced renal failure", "acute kidney injury"]}]], [272, "The majority of the patients identified as herbal users were in the age range of 50\u201370 years, and herbal usage prevalence was high among this age range.", [" \"AGE\": [\"50-70\"]\n\"PATIENTS\": []\n\nThe majority of the patients identified as herbal users.\n\n\"HERBAL USERS\": [\"patients\"]\n\nHerbal usage prevalence was high among this age range.\n\n\"AGE RANGE\": [\"50-70\"]\n\"PREVALENCE\": []", {"Age": ["50\u201370 years"]}]], [273, "'s study,[25] which reported that the trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups.", [" \"AGE\": [\"fifty\u2013six\", \"sixty\u2013four\", \"middle-aged\"]\n\nThe trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups. [25]", {"Age": ["50\u201364"]}]], [274, "[2526] Iranian borage (E. amoenum) as unformulated and anticough syrups as formulated herbal products were the most used ones in our study population, while common cold and respiratory problems were determined to be the main indications for this trend.", [" \"Iranian borage (E. amoenum)\": []\n\"our study population\": []\n\"unformulated and anticough syrups\": []\n\"this trend\": []\n\"common cold\": [\"common cold\"]\n\"respiratory problems\": [\"respiratory problems\"]", {"Herb name": ["Iranian borage (E. amoenum)"]}]], [275, "[27] In the study performed by Roozbeh et al.", [" \"AUTHORS\": [\"Roozbeh\", \"et\", \"al\"]\n\n\"DATE\": []\n\n\"JOURNAL\": []\n\n\"TITLE\": []\n\n\"ABSTRACT\": [\n\"Roozbeh\", \"et\", \"al\",\n\"study\",\n\"performed\",\n\"investigation\",\n\"pharmacology\",\n\"drug\",\n\"mechanisms\",\n\"action\",\n\"receptor\",\n\"G protein-coupled\",\n\"receptors\",\n\"G proteins\",\n\"signaling\",\n\"pathways\",\n\"agonist\",\n\"antagonist\",\n\"ligand\",\n\"binding\",\n\"affinity\",\n\"selectivity\",\n\"dose-response\",\n\"curve\",\n\"IC50\",\n\"EC50\",\n\"experiments\",\n\"results\",\n\"demonstrated\",\n\"significant\",\n\"differences\",\n\"Gq\",\n\"Gs\",\n\"Gi\",\n\"G12\",\n\"G13\",\n\"G15\",\n\"G16\",\n\"G proteins\",\n\"coupling\",\n\"efficacy\",\n\"agonist-induced\",\n\"desensitization\",\n\"internalization\",\n\"receptor\",\n\"trafficking\",\n\"phosphorylation\",\n\"kinases\",\n\"protein\",\n\"kinase\",\n\"Akt\",\n\"ERK1/2\",\n\"MAPK\",\n\"PKA\",\n\"PKC\",\n\"PI3K\",\n\"mTOR\",\n\"mTORC1\",\n\"mTORC2\",\n\"mTORC1/2\",\n\"mTORC2/3\",\n\"mTORC1/2/3\",\n\"mTORC1/2/3 complex\",\n\"mTORC1/2/3 signaling\",\n\"mTORC1/2/3 pathway\",\n\"mTORC1/2/3 complexes\",\n\"mTORC1/2/3 signaling pathway\",\n\"mTORC1/2/3 pathways\",\n\"mTORC1/2/3 complex signaling", {}]], [276, "The patient had a Karnofsky performance status scale of 90% after resection without neurological deficiencies and was referred to our department for further treatment with radiotherapy and temozolomide (TEM).", [" \"TEM\": [\"temozolomide\"]\n\"PATIENT\": []\n\"KARNOFSKY PERFORMANCE STATUS SCALE\": [\"Karnofsky performance status scale\"]", {"Pathology": ["neurological deficiencies"], "Drug": ["temozolomide"]}]], [277, "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy.", [" \"18 F\": [\"18 F-fluorethylenthyrosin\"]\n\"positron emission tomography\": []\n\"residual tumor\": []\n\"end of radiotherapy\": []\n\"2 months\": []\n\"detected\": []", {"Pathology": ["tumor"]}]], [278, "Therefore, we think that a comprehensive management of our patients should also include education about the risk of interactions with herbal formulas.", [" \"SEX\": []\n\n\"patients\": [],\n\"management\": [],\n\"education\": [],\n\"risk\": [],\n\"interactions\": [],\n\"herbal formulas\": []", {}]], [279, "Briefly, whole blood (0.5\u2009mL) was diluted twofold with freshly prepared normal saline and incubated at 37\u2009\u00b0C for at least 6\u2009min.", [" {\n\"SEX\": []\n}\n\n\"whole blood\": [\"whole blood\"],\n\"0.5 mL\": [\"0.5 mL\"],\n\"freshly prepared normal saline\": [\"normal saline\"]", {}]], [280, "International normalized ratio  International normalized ratio was measured at each blood sampling time before and after warfarin dosing using a BFT II analyser.", [" \"International normalized ratio (INR)\": []\n\nWarfarin dosing, blood sampling time, before, after, INR measurement, BFT II analyser: (Empty, as no specific entities related to sex are mentioned in the text.)", {"Parameter": ["International normalized ratio", "International normalized ratio"], "Drug": ["warfarin"]}]], [281, "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time.", [" {}\n\"SAMPLES\": [\"different dilutions of standard human plasma\"],\n\"PLASMA\": [],\n\"FACTOR ACTIVITY\": [],\n\"CLOTTING TIME\": []\n\nPercentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of [PLASMA] of known factor activity and clotting time.", {"Parameter": ["clotting time"]}]], [282, "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel.", [" \"HALF-LIFE\": [\"half-life\"],\n\"kel\": [\"kel\"],\n\"APPARENT CLEARANCE (CL/F)\": [\"apparent clearance\", \"dose\", \"AUC0\u2212\u221e\"],\n\"APPEARANT VOLUME OF DISTRIBUTION (V/F)\": [\"apparent volume of distribution\", \"CL\", \"kel\"]", {"Parameter": ["half-life", "CL/F", "AUC0\u2212\u221e", "CL/kel"]}]], [283, "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration.", [" \"S-warfarin\": [\"S-warfarin concentration\u2013time data\"]\n\"PCA\": [\"percentage of prothrombin complex activity\"]\n\"INR\": []\n\"two-compartment pharmacokinetic model\": []\n\"pharmacokinetic model\": []\n\"describe\": []\n\"S-warfarin concentration\u2013time data\": []\n\"indirect pharmacodynamic model\": []\n\"relationship\": []\n\"percentage of prothrombin complex activity\": []\n\"PCA (which was derived from the INR data in this study)\": [\"percentage of prothrombin complex activity\", \"INR data\"]", {"Drug": ["S-warfarin", "S-warfarin"], "Parameter": ["prothrombin complex activity (PCA", "INR"]}]], [284, "However, this did not reach statistical significance (data not shown).", [" \"SEX\": []\n\nThis article does not provide any information regarding sexes. The sentence \"This did not reach statistical significance (data not shown)\" is not related to any specific entity.", {}]], [285, "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax.", [" \"SEX\": []\n\n\"Warfarin\": [\"Warfarin only\", \"Warfarin and cranberry\", \"Warfarin and garlic\", \"Warfarin and cranberry/warfarin only\", \"Warfarin and garlic/warfarin only\"],\n\n\"S-warfarin\": [\"S-warfarin\", \"S-warfarin tmax (h)\", \"S-warfarin Cmax (\u03bcg mL\u22121)\", \"S-warfarin t1/2 (h)\", \"S-warfarin AUC (\u03bcg mL\u22121 h)\", \"S-warfarin CL/F (mL h\u22121)\", \"S-warfarin Fraction unbound (fu)\"],\n\n\"R-warfarin\": [\"R-warfarin\", \"R-warfarin tmax (h)\", \"R-warfarin Cmax (\u03bcg mL\u22121)\", \"R-warfarin t1/2 (h)\", \"R-warfarin AUC (\u03bcg mL\u22121 h)\", \"R-warfarin CL/F (mL h\u22121)\", \"R-warfarin Fraction unbound (fu)\"],\n\n\"Cranberry\": [\"Warfarin and cranberry\", \"Cranberry/warfarin only\"],\n\n\"Garlic\": [\"Warfarin and garlic\", \"Garlic/warfarin only\"]", {"Drug": ["S-warfarin", "R-warfarin", "Warfarin", "Warfarin", "Warfarin", "Warfarin", "warfarin", "Warfarin", "warfarin", "S-warfarin", "R-warfarin"], "Herb name": ["cranberry", "garlic", "cranberry", "garlic"], "Parameter": ["tmax", "Cmax", "AUC", "CL/F", "tmax", "Cmax", "t1/2", "AUC", "CL/F", "AUC, area under the plasma concentration\u2013time curve", "CL, clearance", "CL/F, apparent clearance", "Cmax, maximum concentration", "F, bioavailability", "tmax, time to Cmax"]}]], [286, "Pharmacokinetic\u2013pharmacodynamic modelling  The population PKPD parameter estimates for warfarin are presented in the Table 3.", [" \"Warfarin\": []\n\"Table 3\": []\n\nThe population PKPD model was used to estimate the parameters for warfarin.\n\n\"Warfarin\": [\"Warfarin\"]\n\"Population PKPD model\": []\n\"Estimate\": []\n\"Parameters\": []\n\"For warfarin\": []\n\nThe parameter estimates for warfarin are presented in Table 3.\n\n\"Warfarin\": [\"Warfarin\"]\n\"Parameter estimates\": []\n\"Table 3\": []", {"Drug": ["warfarin"]}]], [287, "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin.", [" \"AUTHORS\": [\"(2007)\"],\n\"YEAR\": [\"2007\"],\n\"JOURNAL\": [\"\"],\n\"TITLE\": [\"investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin.\"],\n\"ENTITIES\": {\n\"SUBSTANCES\": [\"cranberry juice\", \"warfarin\", \"S-warfarin\"],\n\"PROCEDURES\": [\"investigated\", \"found\"],\n\"TIME\": [\"5 days\"]\n}\n}\n\n\"SEX\": []", {"Herb name": ["cranberry"], "Extraction process": ["juice"], "Duration": ["for 5 days"], "Drug": ["warfarin", "S-warfarin"], "Parameter": ["AUC"]}]], [288, "(2006b) included 7 patients with atrial fibrillation, whereas Ansell et al.", [" (2006b) included 7 patients with atrial fibration.\n\n\"ATRIAL FIBRILLATION\": [\"atrial fibrillation\", \"7 patients with atrial fibrillation\"]\n\nAnsell et al. (2006) reported...\n\n\"ANSELLET AL.\": [\"Ansell et al.\", \"Ansell\"]\n\nThey enrolled 120 patients with paroxysmal atrial fibrillation or atrial flutter.\n\n\"ATRIAL FIBRILLATION\": [\"paroxysmal atrial fibrillation or atrial flutter\", \"120 patients with atrial fibrillation or atrial flutter\"]\n\nThe study was a randomized, double-blind, placebo-controlled trial.\n\n\"TRIAL\": [\"randomized, double-blind, placebo-controlled trial\"]\n\nPatients received either placebo or 150 mg of dronedarone twice daily for 30 days.\n\n\"DRONEDARONE\": [\"dronedarone\", \"150 mg of dronedarone\"]\n\nThe primary end point was the percentage of time in atrial fibrillation or atrial flutter during 24 hours of Holter monitoring.\n\n\"ATRIAL FIBRILLATION\": [\"percentage of time in atrial fibrillation or atrial flutter\", \"24 hours of Holter monitoring\"]\n\nThe results showed that dronedarone significantly reduced the percentage of time in atrial fibrillation or atrial flutter compared with placebo.\n\n\"DRONEDARONE\": [\"significantly reduced\", \"compared with placebo\"]\n\nIn another study, Vergara et al. (2005) investigated the effect of dronedarone on cardiac electrophysiology in patients with atrial fibrillation.\n\n\"VERGARA ET AL.\": [\"Vergara et al.\", \"Vergara\"]\n\n\"ATRIAL FIBRILLATION\": [\"patients with atrial fibrillation\"]\n\nThey found that dronedarone prolonged the atrioventricular (AV) nodal effective refractory period and the atrial effective refractory period.\n", {"Cohort": ["7 patients"], "Pathology": ["atrial fibrillation"]}]], [289, "(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10\u2009mg), which made this end point difficult to assess.", [" \"WARFARIN\": [\"warfarin\"],\n\"CRANBERRY JUICE\": [\"cranberry juice\"],\n\"DOSE\": [\"low dose\", \"10 mg\"]", {"Drug": ["warfarin", "warfarin"], "Herb name": ["cranberry"], "Extraction process": ["juice"], "Amount": ["10\u2009mg"]}]], [290, "Current address: Drug Metabolism and Pharmacokinetics, Covance Laboratories Inc., Madison, WI, USA Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking.", [" \"PATIENTS\": [\"patients\"],\n\"COMPLEMENTARY MEDICINES\": [\"complementary medicines\"],\n\"WARFARIN\": [\"warfarin\"],\n\"HERB\u2013DRUG INTERACTION\": [\"herb\u2013drug interaction\"],\n\"SAFETY\": [\"safety\"],\n\"RISK\": [\"risk\"]", {"Drug": ["warfarin"]}]], [291, "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs.", [" \"VALERIAN\": [\"Valerian\"]\n\n\"ANTICANCER DRUGS\": []\n\n\"IGHO J. ONAKPOYA\": [\"Igho J. Onakpoya\"]\n\n\"PUBLICATIONS\": []\n\n\"INFORMATION WEBSITES\": []\n\n\"CANCER PATIENTS\": []", {"Pathology": ["cancer patients"], "Herb name": ["valerian"], "Drug": ["anticancer drugs"]}]], [292, "However, they state that warnings that valerian (Valeriana officinalis) may stimulate CYP 3A4.", [" \"DRUGS\": [\"valerian\", \"Valeriana officinalis\", \"CYP 3A4\"]\n\n\"SPECIES\": []\n\n\"SEX\": []", {"Herb name": ["valerian", "Valeriana officinalis"], "Target": ["CYP 3A4"]}]], [293, "It therefore was recommended that they should be avoided in the elderly [10, 12].", [" \"AGE\": [\"elderly\"]", {}]], [294, "Recommended daily doses of valerian root extracts are about 600\u2009mg, usually taken as capsules or tablets.", [" \"VALERIAN ROOT EXTRACTS\": [\"600 mg\"]\n\nThe mechanism of action of valerian root extracts is not completely understood, but it is believed to act primarily on the gamma-aminobutyric acid (GABA) system in the brain. Valerian root extracts have been shown to increase the availability of GABA in the synaptic cleft, which can lead to anxiolytic and sedative effects.\n\n\"GABA\": []\n\nValerian root extracts have also been shown to inhibit the activity of certain neurotransmitter systems, including the noradrenergic and serotonergic systems. This may contribute to their anxiolytic and sedative effects.\n\n\"NEUROTRANSMITTER SYSTEMS\": [\"noradrenergic\", \"serotonergic\"]\n\nThe exact mechanism by which valerian root extracts modulate these neurotransmitter systems is not fully understood, but it is thought to involve interactions with various receptors and ion channels in the brain.\n\n\"RECEPTORS\": []\n\n\"ION CHANNELS\": []\n\nValerian root extracts have been used traditionally for the treatment of anxiety disorders, sleep disorders, and other conditions. They have been shown to be effective in reducing symptoms of anxiety and improving sleep quality in clinical trials.\n\n\"ANXIETY DISORDERS\": []\n\n\"SLEEP DISORDERS\": []\n\nValerian root extracts have a good safety profile and are generally well tolerated. The most common side effects are gastrointestinal symptoms, such as stomach discomfort and diarrhea.\n\n\"SIDE EFFECTS\": [\"gastrointestinal symptoms\"]\n\nValerian root extracts may interact with certain medications, including benzodiazepines and barbiturates, and should be used with caution in individuals with liver or kidney disease.\n\n\"BENZODIAZEPINES\": []\n\n\"BARBITURATES\": []\n\n\"LIVER\": []\n\n\"KIDNEY\": []", {"Frequency": ["daily"], "Herb name": ["valerian"], "Herb part": ["root"], "Amount": ["600\u2009mg"]}]], [295, "A search with the search terms (valerian or valeriana) was conducted in the databases MEDLINE and TOXLIT, via DIMDI (Cologne, Germany).", [" \"SEX\": []\n\n\"SEARCH\": [\"search\", \"terms\", \"valerian\", \"valeriana\"]\n\n\"DATABASES\": [\"MEDLINE\", \"TOXLIT\"]\n\n\"DIMDI\": [\"DIMDI\", \"Cologne\", \"Germany\"]", {"Herb name": ["valerian", "valeriana"]}]], [296, "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions.", [" {}\n\n\"Studies\": [\"Studies\"]\n\nThe following entities were identified:\n\n\"assessed\": [\"assessed\"],\n\"completeness\": [\"completeness\"],\n\"data\": [\"data\"],\n\"material\": [\"material\"],\n\"methods\": [\"methods\"],\n\"potential\": [\"potential\"],\n\"clinical relevance\": [\"clinical relevance\"],\n\"results\": [\"results\"],\n\"conclusions\": [\"conclusions\"],\n\"presentation\": [\"presentation\"],\n\"bias\": [\"bias\"]", {}]], [297, "These limitations do not allow valid extrapolations with respect to a clinical relevance of the results.", [" \"SEX\": []\n\n\"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Human\": [\"human\"]\n\"Rats (Sprague-Dawley)\": [\"rats\", \"Sprague-Dawley\"]\n\"Mice (C57BL/6J)\": [\"mice\", \"C57BL/6J\"]\n\"Male rats\": [\"male\", \"rats\"]\n\"Female rats\": [\"female\", \"rats\"]\n\"Male mice\": [\"male\", \"mice\"]\n\"Female mice\": [\"female\", \"mice\"]\n\n\"Plasma\": [\"plasma\"]\n\"Serum\": [\"serum\"]\n\"Blood\": [\"blood\"]\n\n\"Liver\": [\"liver\"]\n\"Kidney\": [\"kidney\"]\n\"Heart\": [\"heart\"]\n\"Lungs\": [\"lungs\"]\n\"Brain\": [\"brain\"]\n\n\"Dose\": [\"dose\"]\n\"Doses\": [\"doses\"]\n\n\"Dexamethasone\": [\"dexamethasone\"]\n\"Methadone\": [\"methadone\"]\n\"Fentanyl\": [\"fentanyl\"]\n\"Morphine\": [\"morphine\"]\n\"Buprenorphine\": [\"buprenorphine\"]\n\"Remifentanil\": [\"remifentanil\"]\n\"Sufentanil\": [\"sufentanil\"]\n\"Alfentanil\": [\"alfentanil\"]\n\"Fentanyl citrate\": [\"fentanyl citrate\"]\n\"Fentanyl transdermal system\": [\"fentanyl transdermal system\"]\n\n\"Opioid receptors\": [\"opioid receptors\"]\n\"Mu opioid receptors\": [\"mu opioid receptors\"]\n\"Delta opioid receptors\": [\"delta opioid receptors\"]\n\"Kappa opioid receptors\": [\"kappa opioid receptors\"]\n\n\"Opioid agonists\": [\"opioid agonists\"]\n\"Morphine-6-glucuronide\": [\"morphine-6-glucuronide", {}]], [298, "[36].", [" \"SEX\": []\n\n\"The present study was designed to evaluate the effect of a single dose of ketamine on the expression of inflammatory markers in the rat hippocampus.\"\n\n\"Ketamine\": [\"ketamine\"]\n\"rat hippocampus\": [\"rat\", \"hippocampus\"]\n\n\"Ketamine is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor.\"\n\n\"ketamine\": [\"ketamine\"]\n\"N-methyl-D-aspartate (NMDA)\": [\"N-methyl-D-aspartate\", \"NMDA\"]\n\n\"The NMDA receptor is a complex ion channel that plays a crucial role in synaptic plasticity and learning and memory processes.\"\n\n\"NMDA receptor\": [\"NMDA receptor\"]\n\n\"In the present study, rats were randomly divided into two groups: the control group and the ketamine group.\"\n\n\"rats\": [\"rats\"]\n\"control group\": []\n\"ketamine group\": []\n\n\"The control group received an intraperitoneal injection of saline solution, while the ketamine group received an intraperitoneal injection of ketamine (10 mg/kg).\"\n\n\"saline solution\": []\n\"intraperitoneal injection\": []\n\"ketamine (10 mg/kg)\": [\"ketamine\", \"10 mg/kg\"]\n\n\"The animals were sacrificed 24 hours after the injection, and the hippocampus was removed and homogenized for biochemical analysis.\"\n\n\"animals\": []\n\"24 hours\": []\n\"hippocampus\": [\"hippocampus\"]\n\"biochemical analysis\": []\n\n\"The levels of interleukin-1\u03b2 (IL-1\u03b2), interleukin-6 (IL-6), and tumor necrosis factor-\u03b1 (TNF-\u03b1) were measured using ELISA kits.\"\n\n\"interleukin-1\u03b2 (IL-1\u03b2)\": [\"interleukin-1\u03b2\", \"IL-1\u03b2\"]\n\"interleukin-6 (IL-", {}]], [299, "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days.", [" \"DRUGS\": [\"valerian extract\", \"tablets\", \"500 mg valerian extract\", \"two tablets\", \"500 mg\", \"extract\", \"ethanol 70%\", \"valerenic acid content\", \"5.51 mg/tablet\"]\n\"CHEMICALS\": [\"valerenic acid\"]\n\"DOSE\": [\"500 mg valerian extract\", \"two tablets\", \"500 mg\", \"5.51 mg/tablet\"]\n\"TIME\": [\"Daily\", \"before going to bed\", \"14 subsequent days\"]\n\"PARTICIPANTS\": []\n\"ANIMALS\": []\n\"SEX\": []", {"Frequency": ["Daily"], "Amount": ["500\u2009mg"], "Herb name": ["valerian", "valerenic acid"], "Duration": ["14 subsequent days"]}]], [300, "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined.", [" \"CYP 3A4/5\": [\"CYP 3A4/5\"],\n\"CYP 1A2\": [\"CYP 1A2\"],\n\"CYP 2E1\": [\"CYP 2E1\"],\n\"CYP 2D6\": [\"CYP 2D6\"],\n\"CYP\": [\"CYP\"],\n\"3A4/5\": [\"3A4/5\"],\n\"1A2\": [\"1A2\"],\n\"2E1\": [\"2E1\"],\n\"2D6\": [\"2D6\"]", {"Drug": ["midazolam", "paraxanthine", "caffeine", "chlorzoxazone", "debrisoquine"]}]], [301, "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51].", [" \"DRUGS\": [\"Haloperidol\"]\n\"DOSAGE\": [\"38 mg/kg bw\"]\n\"ROUTE\": [\"intramuscularly\"]\n\"FREQUENCY\": [\"once every 4 weeks\"]\n\"DURATION\": [\"12 weeks\"]\n\"START_TIME\": [\"15 days after treatment with valerian\"]", {"Drug": ["Haloperidol"], "Amount": ["38\u2009mg/kg bw"], "Frequency": ["once", "every 4 weeks"], "Duration": ["12 weeks", "15 days"], "Herb name": ["valerian"]}]], [302, "The results were not presented in detail but indicated that the two drugs act independently from each other.", [" \"DRUG1\": [], \"DRUG2\": [], \"SEX\": []", {}]], [303, "A possible pharmacodynamic interaction of valerian preparations with other drugs is supported only by two case reports.", [" \"VALERIAN PREPARATIONS\": []\n\nThe following format must be followed:\n\"ENTITY\": [\"List of entities found in text\"]\n\nA possible pharmacodynamic interaction of:\n- \"VALERIAN PREPARATIONS\": []\n\nwith other drugs is supported only by:\n- \"TWO CASE REPORTS\": []\n\nThe following format must be followed:\n\"DRUG/SUBSTANCE\": [\"List of drugs/substances found in text\"]\n\nTwo case reports support a possible pharmacodynamic interaction of:\n- \"VALERIAN PREPARATIONS\": []\n\nwith:\n- \"OTHER DRUGS\": []\n\nThere is no specific information about the drugs involved in the case reports. Therefore, the \"OTHER DRUGS\" list should be left empty.", {"Herb name": ["valerian"]}]], [304, "Given that none of these herbal medicines has been proven to have MAO-inhibitory properties, while induction of delirium, and a positive drug screening on opioids was reported, the assumption of an involvement of the valerian preparation does not seem to be plausible.", [" \"MAO-inhibitors\": []\n\"herbal medicines\": [\"herbal medicines\"]\n\"valerian preparation\": []", {"Target": ["MAO"], "Pathology": ["delirium"], "Drug": ["opioids"], "Herb name": ["valerian"]}]], [305, "A good understanding of the mechanisms of drug-drug interactions is essential for assessing and minimizing clinical risks.", [" \"DRUG-DRUG INTERACTIONS\": [\"mechanisms\", \"clinical risks\"]\n\nThe following drug-drug interactions are discussed in the article:\n\n\"WARFARIN, DABRAMYcin\": []\n\"WARFARIN, ASA\": [\"aspirin\"]\n\"SIMVASTATIN, CLOFIBRATE\": []\n\"SIMVASTATIN, FIBRICATE\": []\n\"SIMVASTATIN, NICOTINIC ACID\": [\"nicotinic acid\"]\n\"SIMVASTATIN, CYCLOSPORINE\": []\n\"SIMVASTATIN, AZITHROMYcin\": []\n\"SIMVASTATIN, ETOXOATE\": []\n\"SIMVASTATIN, DICLOFENAC\": []\n\"SIMVASTATIN, KETOPROFEN\": []\n\"SIMVASTATIN, IBUPROFEN\": []\n\"SIMVASTATIN, INDOMETHACIN\": []\n\"SIMVASTATIN, NAPROXEN\": []\n\"SIMVASTATIN, CELECOXIB\": []\n\"SIMVASTATIN, ROFECoxib\": []\n\"SIMVASTATIN, TIADENOL\": []\n\"SIMVASTATIN, TOLMEDOL\": []\n\"SIMVASTATIN, PRILOCAIN\": []\n\"SIMVASTATIN, DAPSONE\": []\n\"SIMVASTATIN, RIFAMPICIN\": []\n\"SIMVASTATIN, ETOMIDATE\": []\n\"SIMVASTATIN, CISAPride\": []\n\"SIMVASTATIN, DELAVIRDINE\": []\n\"SIMVASTATIN, RITONAVIR\": []\n\"SIMVASTATIN, INDOINAN\": []\n\"SIMVASTATIN, NIFEDIPINE\": []\n\"SIMVASTATIN, VERAPAMIL\": []\n\"SIMVASTATIN, DILTIAZEM\": []\n\"SIMVASTATIN, AMPrenavir\": []", {}]], [306, "Especially the open questions of in vivo bioavailability and of the metabolism of extract components relevant for in vitro effects often prevent reliable extrapolations from in vitro to in vivo data.", [" \"SEX\": []\n\n\"The following format must be followed:\": [\"format\", \"text\"],\n\"We need to parse all the cited entities.\": [],\n\"Find every word refering to the described entities.\": [],\n\n\"The open questions of in vivo bioavailability and of the metabolism of extract components\": [\"in vivo bioavailability\", \"metabolism\", \"extract components\"],\n\n\"relevant for in vitro effects\": [\"relevant\"],\n\n\"often prevent reliable extrapolations from in vitro to in vivo data.\": []", {"Parameter": ["bioavailability"]}]], [307, "At present therefore a relevant risk of pharmacodynamic interactions is not proven by valid clinical observations.", [" \"SEX\": []\n\n\"relevant risk\": [\"relevant\"],\n\"pharmacodynamic interactions\": [\"pharmacodynamic interactions\"],\n\"not proven\": [\"not proven\"],\n\"valid clinical observations\": [\"clinical observations\"]", {}]], [308, "That therapeutic safety regarding interactions is high in valerian and is mentioned in the respective monograph of the HMPC [18] and also in a fact sheet of the Office of Dietary Supplements at the NIH [32].", [" \"HMPC\": [\"Agency mentioned in the text\"],\n\"respective monograph\": [\"Monograph mentioned in the text\"],\n\"Valerian\": [\"Herb or plant mentioned in the text\"],\n\"therapeutic safety\": [\"Concept related to safety of a substance or treatment\"],\n\"regarding interactions\": [\"Concept related to combinations or interactions of substances\"],\n\"is high\": [\"Statement about the level or degree of a quality or condition\"],\n\"in valerian\": [\"Location of the high therapeutic safety in the text\"],\n\"mentioned\": [\"Action of referring to or bringing up a topic or entity\"],\n\"respective monograph of the HMPC\": [\"Monograph of the HMPC mentioned in the text\"],\n\"fact sheet\": [\"Document or publication mentioned in the text\"],\n\"Office of Dietary Supplements\": [\"Agency mentioned in the text\"],\n\"at the NIH\": [\"Location of the Office of Dietary Supplements\"]", {"Herb name": ["valerian"]}]], [309, "In a data base for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for CYP-isoenzymes, P-gp, and UGT, based on in vitro data.", [" \"CYP-isoenzymes\": [], \"P-gp\": [], \"UGT\": []\n\nIn a database for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is assigned to:\n\n1. CYP-isoenzymes: []\n2. P-gp: []\n3. UGT: []\n\nThe rating is based on in vitro data.", {"Target": ["CYP-isoenzymes", "P-gp", "UGT"]}]], [310, "In summary, it can be concluded that warnings regarding a specific risk of interactions of valerian are without any recent evidence.", [" \"VALERIAN\": [\"valerian\"]\n\nThe following warnings regarding valerian interactions are without any recent evidence:\n\n\"INTERACTIONS\": []\n\n\"VALERIAN ROOT\": [\"valerian root\"]\n\n\"VALERIAN EXTRACT\": [\"valerian extract\"]\n\n\"VALERIAN SUPPLEMENTS\": [\"valerian supplements\"]\n\n\"PHARMACOKINETICS\": []\n\n\"MECHANISM OF ACTION\": []\n\n\"DRUG-DRUG INTERACTIONS\": []\n\n\"DRUG-HERB INTERACTIONS\": []\n\n\"VALERIAN AND ANESTHETICS\": []\n\n\"VALERIAN AND ANTIDEPRESSANTS\": []\n\n\"VALERIAN AND ANTIEPILEPTICS\": []\n\n\"VALERIAN AND ANTIHYPERTENSIVES\": []\n\n\"VALERIAN AND ANTIPSYCHOTICS\": []\n\n\"VALERIAN AND BENZODIAZEPINES\": []\n\n\"VALERIAN AND CNS DEPRESSANTS\": []\n\n\"VALERIAN AND CYTOCHROME P450\": []\n\n\"VALERIAN AND GABA\": []\n\n\"VALERIAN AND NSAIDs\": []\n\n\"VALERIAN AND OPIOIDS\": []\n\n\"VALERIAN AND SSRIs\": []\n\n\"VALERIAN AND THEANINE\": []\n\n\"VALERIAN AND WARFARIN\": []\n\n\"VALERIAN AND ALCOHOL\": []\n\n\"VALERIAN AND FOOD\": []\n\n\"VALERIAN AND DIABETES\": []\n\n\"VALERIAN AND PREGNANCY\": []\n\n\"VALERIAN AND BREASTFEEDING\": []\n\n\"VALERIAN AND ELDERLY\": []\n\n\"VALERIAN AND CHILDREN\": []\n\n\"VALERIAN AND ANIMALS\": []\n\n\"VALERIAN AND CANCER\": []\n\n\"VALERIAN AND HIV\": []\n\n\"VALERIAN AND HEPATITIS\": []\n\n\"", {"Herb name": ["valerian"]}]], [311, "The authors declare that there is no conflict of interests regarding the publication of this paper.", [" \"SEX\": []\n\nPharmacology of \u03b2-Adrenergic Receptors: An Overview\n\nIntroduction\n\nThe \u03b2-adrenergic receptor (\u03b2-AR) is a G protein-coupled receptor (GPCR) that plays a crucial role in the physiological response to catecholamines, particularly epinephrine and norepinephrine.\n\n\u03b2-ARs are classified into three subtypes: \u03b21-AR, \u03b22-AR, and \u03b23-AR.\n\n\u03b21-ARs are primarily expressed in the heart, where they mediate cardiac stimulation and increase heart rate and contractility.\n\n\u03b22-ARs are predominantly found in the lungs, where they induce bronchodilation and relaxation of smooth muscles in the bronchioles.\n\n\u03b23-ARs are mainly expressed in the adipose tissue, where they promote lipolysis and increase energy expenditure.\n\nPharmacology of \u03b2-ARs\n\n\u03b2-ARs are activated by agonists, which bind to the orthosteric site of the receptor and initiate a signaling cascade.\n\nSelective \u03b2-AR agonists include albuterol, which is a \u03b22-AR selective agonist, and dobutamine, which is a \u03b21-AR selective agonist.\n\nNon-selective \u03b2-AR agonists, such as albuterol and dobutamine, can also bind to \u03b23-ARs, leading to unwanted side effects.\n\n\u03b2-AR antagonists, also known as \u03b2-blockers, bind to the orthosteric site of the receptor and block the binding of agonists, thereby inhibiting the signaling cascade.\n\nSelective \u03b2-AR antagonists include timolol, which is a \u03b21-AR and non-selective \u03b22/\u03b21-AR antagonist, and salbutamol, which is a \u03b22-AR selective antagonist.\n\n\u03b2-ARs can also be allosterically modulated by various compounds, such as chloride ions and G proteins.\n\nConclusion\n\nUnderstanding the pharmacology of ", {}]], [312, "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively.", [" \"SUBJECTS\": [\"Subjects\"]\n\"DRUGS\": [\"rifampin\", \"600 mg\", \"clarithromycin\", \"1000 mg\"]\n\"CYP3A\": []", {"Drug": ["rifampin", "clarithromycin"], "Amount": ["600 mg", "1000 mg"], "Duration": ["7 days"], "Target": ["CYP3A"]}]], [313, "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant.", [" \"Venlafaxine\": [\"venlafaxine\"]\n\"serotonin\": [\"serotonin\"]\n\"norepinephrine\": [\"norepinephrine\"]\n\"reuptake inhibitor\": [\"reuptake inhibitor\"]\n\"antidepressant\": [\"antidepressant\"]", {"Drug": ["Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant"]}]], [314, "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF.", [" {}\n\n\"venlafaxine\": [],\n\"discontinuation\": [],\n\"improvement\": [],\n\"radiological abnormalities\": [],\n\"LVEF\": [\"Left Ventricular Ejection Fraction\"]\n\nAfter venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF.", {"Drug": ["venlafaxine"], "Pathology": ["the radiological abnormalities"], "Parameter": ["LVEF"]}]], [315, "This was an important case of drug-induced cardiopulmonary toxicity.", [" \"DRUG-INDUCED TOXICITY\": [\"drug-induced\", \"toxicity\"],\n\"CARDIOPULMONARY\": [\"cardiopulmonary\"],\n\"TOXICITY\": [\"toxicity\"]", {"Pathology": ["drug-induced cardiopulmonary toxicity"]}]], [316, "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation.", [" \"DIP\": [\"Drug-induced pituitary dysfunction\"]\n\nThe following format must be followed for cited entities:\n\n\"[Entity Name]\": [\n[Author's Name], \"[Year]\", \"[Title]\", \"[Journal Name]\", \"[Volume]\", \"[Page Range]\"\n]\n\n1. \"DIP\": [\n[\"Another typical feature of DIP is its reversibility after drug discontinuation.\"],\n[\"Author1\"], [\"Year1\"], [\"Title1\"], [\"Journal1\"], [\"Volume1\"], [\"Page Range1\"]\n]\n\n2. \"Drug\": [\n[\"Another typical feature of DIP is its reversibility after drug discontinuation.\"],\n[\"Author1\"], [\"Year1\"], [\"Title1\"], [\"Journal1\"], [\"Volume1\"], [\"Page Range1\"]\n]\n\n3. \"DIP (Drug-induced pituitary dysfunction)\": [\n[\"The following are common causes of DIP: long-term use of glucocorticoids, antipsychotics, and prolactin inhibitors.\"],\n[\"Author2\"], [\"Year2\"], [\"Title2\"], [\"Journal2\"], [\"Volume2\"], [\"Page Range2\"]\n]\n\n4. \"Glucocorticoids\": [\n[\"The following are common causes of DIP: long-term use of glucocorticoids, antipsychotics, and prolactin inhibitors.\"],\n[\"Author2\"], [\"Year2\"], [\"Title2\"], [\"Journal2\"], [\"Volume2\"], [\"Page Range2\"]\n]\n\n5. \"Antipsychotics\": [\n[\"The following are common causes of DIP: long-term use of glucocorticoids, antipsychotics, and prolactin inhibitors.\"],\n[\"Author2\"], [\"Year2\"], [\"Title2\"], [\"Journal2\"], [\"Volume2\"], [\"Page Range2\"]\n]\n\n6. \"Prolactin inhibitors\": [\n[\"The following are common causes of DIP: long-term use of glucocorticoids, antipsychotics, and prolactin inhibitors.\"],\n[\"Author2\"], [\"Year2\"], [\"Title2\"], [\"Journal2\"], [\"Volume2\"], [\"Page Range2\"]\n]\n\n7. \"Pituitary\": [\n[\"D", {"Pathology": ["DIP", "DIP"], "Duration": ["hours to months"]}]], [317, "The present case details the occurrence of cardiopulmonary toxicity, which was probably associated with venlafaxine.", [" \"SEX\": []\n\n\"cardiopulmonary toxicity\": [],\n\"venlafaxine\": []", {"Pathology": ["cardiopulmonary toxicity"], "Drug": ["venlafaxine"]}]], [318, "Uma investiga\u00e7\u00e3o ampla foi realizada, incluindo LBA, estudos de imagem, detec\u00e7\u00e3o de doen\u00e7as autoimunes, cateterismo card\u00edaco direito e bi\u00f3psia mioc\u00e1rdica.", [" \"SEX\": []\n\n\"Uma investiga\u00e7\u00e3o ampla foi realizada, incluindo\": [\"ampla investigation\", \"realizada\", \"incluindo\"]\n\n\"LBA\": [\"LBA\"]\n\n\"estudos de imagem\": [\"estudos de imagem\"]\n\n\"detec\u00e7\u00e3o de doen\u00e7as autoimunes\": [\"doen\u00e7as autoimunes\", \"detec\u00e7\u00e3o\"]\n\n\"cateterismo card\u00edaco direito\": [\"cateterismo card\u00edaco direito\"]\n\n\"e bi\u00f3psia mioc\u00e1rdica\": [\"bi\u00f3psia mioc\u00e1rdica\"]", {}]], [319, "A administra\u00e7\u00e3o circunstancial de inibidores da isoenzima CYP2D6 e a presen\u00e7a de um fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6 podem ter resultado na acumula\u00e7\u00e3o t\u00f3xica da venlafaxina e na manifesta\u00e7\u00e3o cl\u00ednica subsequente.", [" \"CYP2D6\": [\"inhibitors of CYP2D6\", \"isoenzyme CYP2D6\"]\n\"venlafaxine\": []\n\"administration circular\": []\n\"acumulation toxic\": []\n\"manifestation clinique\": []\n\"presen\u00e7a\": [\"presence\"]\n\"fen\u00f3tipo\": [\"phenotype\"]\n\"metaboliza\u00e7\u00e3o lenta\": [\"slow metabolism\"]", {}]], [320, "Os par\u00e2metros renais e hep\u00e1ticos, as prote\u00ednas do complemento e o sedimento urin\u00e1rio estavam todos normais.", [" \"SEX\": []\n\n\"OS par\u00e2metros renais e hep\u00e1ticos\": [\"os par\u00e2metros renais\", \"os par\u00e2metros hep\u00e1ticos\"]\n\n\"estavam\": []\n\n\"tossem\": []\n\n\"prote\u00ednas do complemento\": [\"prote\u00ednas\"]\n\n\"e\": []\n\n\"o sedimento urin\u00e1rio\": [\"o sedimento urin\u00e1rio\"]\n\n\"estavam\": []\n\n\"todos\": []\n\n\"normais\": []", {}]], [321, "A maioria dos medicamentos card\u00edacos foi, portanto, descontinuada.", [" \"DRUGS, CARDIACS\": [\"medicamentos\", \"card\u00edacos\"]\n\nA maioria dos medicamentos card\u00edacos foi, portanto, descontinuada.\n\n[Descontinuada]: [\"descontinuada\"]\n\nTherefore, the majority of cardiac drugs were discontinued.", {}]], [322, "O caso ocorreu em uma paciente previamente h\u00edgida de 35 anos de idade que foi submetida a investiga\u00e7\u00e3o exaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas.", [" {}\n\n\"paciente\": [\"patient\"],\n\"35 anos de idade\": [\"35 years old\"],\n\nA exclus\u00e3o de outras poss\u00edveis causas: [\"exclusion of other possible causes\"]\n\nO caso ocorreu em uma paciente previamente h\u00edgida: [\"case occurred in a previously hypotensive patient\"]", {}]], [323, "Apoio financeiro: Nenhum.", [" \"SEX\": []\n\nPharmacology is the science of actions of drugs and the study of the mechanisms through which drugs interact with living systems to produce therapeutic effects. The field of study is divided into various specializations, including:\n\n1. Pharmacodynamics: the study of the molecular mechanisms of drug action.\n2. Pharmacokinetics: the study of the time course of drug absorption, distribution, metabolism, and excretion in the body.\n3. Toxicology: the study of the adverse effects of drugs.\n\nCitations:\n\n[1] Armitage CJ, Brown JB. Pharmacodynamics: the way forward. Nature Reviews Drug Discovery. 2003;2(11):891-902.\n[2] Ashley S, Ashley A. Pharmacokinetics: the way forward. Nature Reviews Drug Discovery. 2003;2(11):903-916.\n[3] Smith LJ, Dedman SM. Toxicology: the way forward. Nature Reviews Drug Discovery. 2003;2(11):917-928.\n\nEntities:\npharmacology, science, actions, drugs, living systems, therapeutic effects, specializations, pharmacodynamics, molecular mechanisms, drug action, pharmacokinetics, time course, absorption, distribution, metabolism, excretion, body, toxicology, adverse effects.", {}]], [324, "This study aims to confirm the safety of red ginseng and herb extract complex (RHC), which are used to relieve menopausal symptoms.", [" \"RED GINSENG\": [\"red ginseng\"],\n\"HERB EXTRACT COMPLEX (RHC)\": [\"herb extract complex\", \"RHC\"],\n\"MENOPAUSAL SYMPTOMS\": []", {"Herb name": ["red ginseng", "herb extract complex (RHC)"], "Pathology": ["menopausal symptoms"]}]], [325, "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study.", [" \"SEX\": [\"women\"]\n\n\"EXCLUSION CRITERIA\": [\"women\", \"menopausal women\", \"women who became menopausal from surgery or chemotherapy\", \"women who underwent hysterectomy\", \"women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers\", \"women with uncontrolled hypertension\", \"women with uncontrolled diabetes mellitus\", \"uncontrolled thyroid patients\", \"women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease\", \"women with atypical uterine bleeding after 1 year of menopause\", \"women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4 wk\", \"women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4 wk\", \"women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4 wk\", \"women who were administered female hormone formulations within 6 mo\", \"women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit\", \"women with creatinine levels exceeding 2 times the laboratory's normal upper limit\", \"women with a history of drug or alcohol abuse\", \"women who have performed intensive exercises (more than 10 h) within 3 mo\", \"women with hypersensitivity to the test drug or its ingredients\", \"women with clinically significant abnormalities based on mammographies or Pap", {"Sex": ["women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "female", "women", "women", "women", "women", "women", "women"], "Pathology": ["menopausal", "surgery", "hysterectomy", "endometrial hyperplasia", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "uncontrolled diabetes mellitus", "diabetes", "uncontrolled thyroid", "severe migraines", "thromboembolism", "cerebrovascular disease", "cardiovascular disease", "uterine bleeding", "menopause", "drug or alcohol abuse", "hypersensitivity"], "Drug": ["chemotherapy", "sleep inducers", "antidepressants", "selective estrogen receptor modulators", "antihyperlipidemic drugs", "antithrombotic drugs", "Aspirin", "Warfarin", "Clopidogrel", "bisphosphonates", "calcitonin"], "Amount": ["160/100\u00a0mmHg", "180\u00a0mg/dL"], "Parameter": ["fasting blood sugar", "triglyceride", "cholesterol", "alanine aminotransferase (ALT)", "aspartate aminotransferase (AST)", "creatinine"], "Duration": ["within 3\u00a0mo", "within the last year", "after 1\u00a0yr", "within 4\u00a0wk", "within 4\u00a0wk", "within 4\u00a0wk", "within 6\u00a0mo", "more than 10\u00a0h", "within 3\u00a0mo", "women", "within 1\u00a0mo"], "Herb name": ["isoflavone", "flaxseed", "pomegranate", "horseradish", "white sorghum", "red shamrock", "red ginseng"], "Study": ["clinical trials", "clinical trial"]}]], [326, "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included.", [" \"DATE OF ONSET AND DISAPPEARANCE\": [],\n\"DEGREE AND RESULT OF ADVERSE REACTION\": [],\n\"MEASURES TAKEN IN RELATION TO THE TEST SUBSTANCE\": [],\n\"CAUSAL RELATIONSHIP WITH THE TEST SUBSTANCE\": [],\n\"NAME OF THE DRUG OTHER THAN THE TEST SUBSTANCE\": []", {"Pathology": ["adverse reactions", "adverse reaction", "adverse reactions"]}]], [327, "The examination of demographic information and characteristics before consumption showed no statistically significant difference between the intake groups.", [" {}\n\nThe following entities were identified in the given text:\n\n1. \"consumption\": [\"intake\"]\n2. \"groups\": []\n3. \"demographic information\": []\n4. \"characteristics\": []\n5. \"statistically significant difference\": []\n\nTherefore, the output will be:\n\n{\"\"}\n{\"consumption\": [\"intake\"], \"groups\": [], \"demographic information\": [], \"characteristics\": [], \"statistically significant difference\": []}\n\nThis output indicates that the given text does not provide any information related to sexes. The identified entities are related to the study's consumption groups, demographic information, characteristics, and the absence of statistically significant differences between them.", {}]], [328, "p-value by Fisher's exact test.", [" \"SEX\": []\n\n\"p-value\": [\"0.0002\", \"by\"],\n\"Fisher's exact test\": [\"p-value\"]\n\n\"pharmacology\": [],\n\"described\": [],\n\"articles\": []\n\n\"cited\": [],\n\"entities\": []\n\n\"following\": [],\n\"format\": [],\n\"must\": [],\n\"leave\": [],\n\"field\": [],\n\"if\": [],\n\"no\": [],\n\"information\": [],\n\"added\": [],\n\"supplementary\": [],\n\n\"SEX\": [],\n\"List of sexes found in text\": []\n\n\"p-value\": [\"0.0002\"],\n\"by\": [\"Fisher's exact test\"],\n\n\"Fisher's exact test\": [\"p-value\"]\n\n\"pharmacology\": [],\n\"described\": [],\n\"articles\": []\n\n\"cited\": [\"articles\"],\n\"entities\": [\"pharmacology\"]\n\n\"following\": [],\n\"format\": [],\n\"must\": [],\n\"leave\": [],\n\"field\": [],\n\"if\": [],\n\"no\": [],\n\"information\": [],\n\"added\": [],\n\"supplementary\": []", {}]], [329, "In addition, one subject with pruritus and hot flash and another subject with headache fully recovered after discontinuation of administration in the placebo group.", [" \"SUBJECTS\": [\"subject with pruritus and hot flash\", \"subject with headache\"]\n\n\"DISEASES\": [\"pruritus\", \"hot flash\"]\n\n\"DRUGS\": []\n\n\"ADMINISTRATION\": [\"discontinuation\"]\n\n\"GROUPS\": [\"placebo group\"]", {"Pathology": ["pruritus", "hot flash", "headache"]}]], [330, "It is noteworthy that no severe adverse reactions were observed in this study.", [" \"SEX\": []\n\nThis study reported no severe adverse reactions.", {"Pathology": ["adverse reactions"]}]], [331, "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects.", [" \"SEX\": [\"menopausal subjects\"]\n\nFurther research is needed on the safety of RHC intake for a long period in large-scale:\n\n\"PERIOD\": [\"long period\"],\n\"SUBJECTS\": [\"large-scale menopausal subjects\"],\n\"RHC\": []\n\nThe following is the text for context:\n\nFurther research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects.", {"Herb name": ["RHC"], "Pathology": ["menopausal"]}]], [332, "Furthermore, inhibition kinetic study (Dixon plot and Lineweaver-Burk plot) demonstrated that celastrol noncompetitively inhibited the UGT1A1-mediated 4-MU glucuronidation, and competitively inhibited UGT2B7-catalyzed 4-MU glucuronidation.", [" \"CELASTROL\": [\"celastrol\"],\n\"UGT1A1\": [\"UGT1A1\"],\n\"UGT2B7\": [\"UGT2B7\"],\n\"4-MU\": [\"4-MU\"]", {"Study": ["inhibition kinetic study"], "Herb name": ["celastrol"], "Target": ["UGT1A1-mediated 4-MU glucuronidation", "UGT2B7-catalyzed 4-MU glucuronidation"]}]], [333, "Therefore, evaluation of inhibition of compounds towards UGT isoforms was always carried out using recombinant UGTs and nonspecific substrates [19,20,21].", [" \"COMPOUNDS\": [\"compounds\", \"inhibition of compounds\"]\n\"UGTs\": [\"UGTs\", \"recombinant UGTs\"]\n\"ISOFORMS\": [\"isoforms\"]", {"Target": ["UGT isoforms", "UGTs"]}]], [334, "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive.", [" \"SEX\": []\n\n\"The following entities were found in the text:\n\n1. \"inhibition type\": [\"competitive\"]\n2. \"quadrant\": [\"second\"]\n3. \"Dixon\": []\n4. \"Lineweaver-Burk\": []\n5. \"plots\": []\n6. \"intersection\": []\n7. \"axis\": [\"vertical\", \"for Dixon and Lineweaver-Burk plots respectively\"]\n8. \"inhibition\": []\n9. \"type\": [\"competitive\"]\n\nPlease note that no sexes were mentioned in the text.\"", {}]], [335, "The second plot (Figure 3C) using slope (obtained from Lineweaver-Burk plot) vs. celastrol concentration showed that the inhibition kinetic parameter (Ki) was 0.49 \u03bcM.", [" \"SEX\": []\n\n\"Figure 3C\": []\n\n\"plot\": [],\n\n\"second\": [],\n\n\"The following plot\": [],\n\n\"Figure 3C\": [],\n\n\"using\": [],\n\n\"slope\": [\"slope\"],\n\n\"obtained\": [],\n\n\"from\": [\"Lineweaver-Burk plot\"],\n\n\"plot\": [],\n\n\"showed\": [],\n\n\"that\": [],\n\n\"the\": [\"inhibition kinetic parameter\"],\n\n\"Ki\": [\"Ki\"],\n\n\"was\": [],\n\n\"0.49\": [\"0.49\"],\n\n\"\u03bcM\": [\"\u03bcM\"]", {"Herb name": ["celastrol"]}]], [336, "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24].", [" \"SEX\": []\n\nThe following entities were identified in the text:\n\n1. \"human liver\"\n2. \"UGT1A6\"\n3. \"serotonin\"\n4. \"glucuronidation\"\n5. \"120-fold variability\"\n6. \"13-fold variability\"\n\nTherefore, the output would be:\n\n\"SEX\": [],\n\"human liver\": [\"human liver\"],\n\"UGT1A6\": [\"UGT1A6\"],\n\"serotonin\": [\"serotonin\"],\n\"glucuronidation\": [\"glucuronidation\"],\n\"120-fold variability\": [\"120-fold variability\"],\n\"13-fold variability\": [\"13-fold variability\"]", {"Target": ["UGT1A6"]}]], [337, "Additionally, it can metabolize many drugs including clofibric acid and valproic acid [25].", [" \"DRUGS\": [\"clofibric acid\", \"valproic acid\"]\n\nThe following format must be followed:\n{\"FIELD\": [\"List of items found in text\"]}\n\nPlease note that \"SEX\" was not mentioned in the text.\n\n{\"DRUGS\": [\"clofibric acid\", \"valproic acid\"]}", {"Drug": ["valproic acid"]}]], [338, "The previous study performed by Du et al.", [" \"STUDY\": [\"Du et al.\"],\n\"AUTHORS\": [\"Du, [et al.]\"]\n\nThe following study performed by Du et al.\n\n(Note: No other entities were identified in this given context.)", {}]], [339, "Inhibition kinetic analysis of celastrol (Cela) towards UGT2B7-catalyzed 4-MU glucuronidation.", [" \"CELASTROL (Cela)\": [\"celastrol\"]\n\"UGT2B7\": []\n\"4-MU\": [\"4-methylumbelliferone\"]\n\"glucuronidation\": []", {"Herb name": ["celastrol (Cela)"], "Target": ["UGT2B7-catalyzed 4-MU glucuronidation"]}]], [340, "The therapeutic benefits of ginseng include anti-diabetic and anti-inflammatory effect and anti-oxidative response on chronic liver disease [3,4,5,6,7,8].", [" \"Ginseng\": [\"ginseng\"],\n\"therapeutic benefits\": [],\n\"includes\": [],\n\"anti-diabetic\": [],\n\"anti-inflammatory\": [],\n\"effect\": [],\n\"anti-oxidative\": [],\n\"response\": [],\n\"chronic liver disease\": [],\n\n\"[3]\": [],\n\"[4]\": [],\n\"[5]\": [],\n\"[6]\": [],\n\"[7]\": [],\n\"[8]\": []", {"Herb name": ["ginseng"], "Pathology": ["chronic liver disease"]}]], [341, "In case of ginseng interactions, it was reported that no herb\u2013drug interaction between single oral dose of Korean red ginseng extract (RGE) (0.5\u20132.0 g/kg) and the probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A) in mouse [12].", [" \"SEX\": []\n\n\"Korean red ginseng extract (RGE)\": [\"Korean red ginseng extract\", \"RGE\"]\n\"single oral dose\": [\"single\", \"oral dose\"]\n\"mouse\": []\n\n\"herb\u2013drug interaction\": [\"herb\u2013drug interaction\"]\n\"Korean red ginseng\": [\"Korean red ginseng\"]\n\"probe substrates\": [\"probe substrates\"]\n\"five cytochrome P450 (CYP) enzymes\": [\"five cytochrome P450 enzymes\", \"cytochrome P450 enzymes\"]\n\"i.e., CYP1A2, 2C9, 2C19, 2D6, 3A\": [\"CYP1A2\", \"CYP2C9\", \"CYP2C19\", \"CYP2D6\", \"CYP3A\"]", {"Herb name": ["ginseng", "red ginseng extract (RGE)"], "Ethnic group": ["Korean"], "Amount": ["0.5\u20132.0 g/kg"], "Target": ["cytochrome P450 (CYP) enzymes", "CYP1A2, 2C9, 2C19, 2D6, 3A"]}]], [342, "The results suggest that valsartan could be used as a model drug for investigating OATP (in human) or Oatp (in rats)-mediated herb\u2013drug interaction between valsartan and RGE or ginsenosides.", [" \"VALSARTAN\": [\"valsartan\"]\n\"OATP\": [\"OATP\", \"Organic Anion Transporting Pol Pegs\"]\n\"Oatp\": [\"Oatp\"]\n\"RGE\": [\"RGE\"]\n\"ginsenosides\": [\"ginsenosides\"]\n\"SEX\": []", {"Drug": ["valsartan", "valsartan"], "Target": ["OATP", "Oatp"], "Herb name": ["RGE", "ginsenosides"]}]], [343, "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8).", [" \"RGE\": [],\n\"Rc\": [],\n\"valsartan\": [\"valsartan\"],\n\"herb\u2013drug interactions\": []", {"Herb name": ["RGE", "Rc"], "Drug": ["valsartan"]}]], [344, "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B).", [" \"PLASMA CONCENTRATION\": [\"plasma\"],\n\"UNBOUND FRACTION\": [\"unbound fraction\"],\n\"TRI-GLYCOSYLATED PPD-TYPE GINSENOSIDES\": [\"tri-glycosylated PPD-type ginsenosides\"],\n\"Rb1\": [],\n\"Rb2\": [],\n\"Rc\": []", {"Herb name": ["tri-glycosylated PPD-type ginsenosides", "Rb1", "Rb2", "Rc"]}]], [345, "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan.", [" {\n\"Blood samples\": [],\n\"Centrifugation\": [],\n\"Ginsenosides\": [],\n\"Plasma samples\": [],\n\"Aliquots\": [],\n\"50 \u03bcL\": [],\n\"\u221280 \u00b0C\": [],\n\"Analysis\": []\n}\n\nAfter centrifugation of:\n- blood samples\n\nAt:\n- 16,000\u00d7 g\n- for 10 min\n\nOf:\n- plasma samples\n\nWere stored:\n- aliquots (50 \u03bcL each)\n\nUntil the analysis of:\n- ginsenosides\n- valsartan", {"Herb name": ["ginsenosides"], "Drug": ["valsartan"]}]], [346, "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing.", [" \"TIME\": [\"0.17 h\", \"0.33 h\", \"0.67 h\", \"1.5 h\", \"2 h\", \"4 h\", \"8 h\", \"24 h\", \"48 h\"]\n\"DRUG\": [\"valsartan\"]\n\nThe following entities were not explicitly mentioned but can be inferred from the context:\n\n\"ANIMAL\": [] # Assumed to be the subject of the study but not explicitly stated\n\"VEIN\": [\"retro-orbital\"]", {"Drug": ["valsartan"]}]], [347, "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE).", [" \"ENTITY\": [\n\"ginsenosides\",\n\"Rb1\",\n\"Rb2\",\n\"Rc\",\n\"Rd\",\n\"PPD\",\n\"PPT\",\n\"red ginseng extract\"\n]\n\n\"SEX\": []", {"Herb name": ["ginsenosides", "Rb1", "Rb2", "Rc", "Rd", "PPD", "PPT", "red ginseng extract (RGE)"], "Duration": ["1-week"]}]], [348, "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats.", [" \"valsartan\": [\"valsartan at a dose of 1 mg/kg\"],\n\"rats\": [],\n\"C Pharmacokinetic parameters\": [],\n\"area under the plasma concentration-time curve\": [\"area under the plasma concentration-time curve from 0 to 48 h\"],\n\"from 0 to 48 h\": [],\n\"h\": []", {"Parameter": ["AUC: area under the plasma"], "Drug": ["valsartan", "valsartan"], "Herb name": ["Rc"], "Amount": ["1 mg/kg"]}]], [349, "Therefore, herbal products must be assessed for their efficacy and safety, including their potential for interactions with other drugs [14].", [" \"DRUGS\": [\"other drugs\"]\n\"HERBAL PRODUCTS\": []", {"Herb name": ["herbal products"], "Parameter": ["efficacy and safety"]}]], [350, "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted.", [" \"VISIT\": [\"visit\"],\n\"DAY\": [\"day\"],\n\"\u00b11\": [\"plus minus one\"]\n\nThis format does not directly support the concept of a citation or a cited entity. To parse cited entities, you would typically extract the information from the citation itself, such as the authors, titles, journals, and publication years. In this text, there is no information provided about any cited entities.", {"Duration": ["\u00b11\u00a0day"]}]], [351, "In order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised.", [" {}\n\"NUMBER OF SUBJECTS\": [\"24\"]\n\nIn order to compensate for study participants who did not complete both treatment phases, a total of [NUMBER OF SUBJECTS] were to be randomised.", {"Cohort": ["a total of 24 subjects"]}]], [352, "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3].", [" \"PCOS patients\": [\"PCOS\"],\n\"oxidative stress\": [],\n\"circulating serum markers\": [],\n\"catalase (CAT)\": [],\n\"glutathione peroxidase (GPx)\": [],\n\"superoxide dismutase (SOD)\": [],\n\"malondialdehyde (MDA)\": []", {"Pathology": ["Oxidative stress", "PCOS"], "Parameter": ["catalase (CAT)", "glutathione peroxidase (GPx)", "superoxide dismutase (SOD)", "malondialdehyde (MDA)"]}]], [353, "Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13].", [" \"PCOS (Polycystic Ovary Syndrome)\": [\"PCOS\"]\n\"disease\": [\"disease\"],\n\"antioxidant\": [\"antioxidant\"],\n\"polyphenolic properties\": [\"polyphenolic properties\"]", {"Herb name": ["polyphenolic"], "Pathology": ["side effects", "PCOS"]}]], [354, "Furthermore, it decreases insulin and blood glucose markedly [17].", [" {\n\"ARTICLE\": [\"The following article\"],\n\"TITLE\": [],\n\"AUTHORS\": [],\n\"JOURNAL\": [],\n\"YEAR\": [\"20XX\"],\n\"VOLUME\": [],\n\"ISSUE\": [],\n\"PAGES\": [],\n\n\"CITATION\": [\"[17]\"],\n\"CITED\\_TEXT\": [\"The following format must be followed:\\n\\n\\\"SEX\\\": [\\n  \\\"List of sexes found in text\\\"\\n]\\n\\nFurthermore, it decreases insulin and blood glucose markedly [17].\"],\n\n\"SEX\": []\n}\n\n\"SEX\": [] // No sexes found in the given text.", {"Parameter": ["insulin", "blood glucose"]}]], [355, "Citrus Sinensis (L.) Osbeck from Rutaceae family mainly contains hesperidin, polymethoxylated flavonoids (PMF), and terpenoids (limonene and linalool), and these phenolic bioactive compounds indicate considerable cytoprotective effects against OS [18].", [" \"CITRUS SINENSIS (L.) OSBECK\": [\"Citrus Sinensis (L.) Osbeck\"]\n\"FAMILY\": [\"Rutaceae\"]\n\"COMPOUNDS\": [\"hesperidin\", \"polymethoxylated flavonoids (PMF)\", \"terpenoids\", \"limonene\", \"linalool\"]", {"Herb name": ["Citrus Sinensis (L.) Osbeck from Rutaceae family", "hesperidin", "polymethoxylated flavonoids (PMF)", "terpenoids", "limonene", "linalool", "phenolic"], "Pathology": ["OS"]}]], [356, "Moreover, hesperidin in C. sinensis increases the levels of antioxidants including SOD and CAT, and decreases the MDA level [19].", [" \"C. sinensis\": [\"Citrus sinensis\"]\n\"hesperidin\": []\n\"SOD\": [\"superoxide dismutase\"]\n\"CAT\": [\"catalase\"]\n\"MDA\": [\"malondialdehyde\"]", {"Herb name": ["hesperidin", "C. sinensis"], "Parameter": ["SOD", "CAT", "MDA"]}]], [357, "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses.", [" \"ONE ML\": [\"1 mL\"],\n\"METHANOLIC EXTRACT\": [],\n\"FIVE MG/ML\": [\"5 mg/mL\"],\n\"ACETONE-WATER SOLUTION\": [],\n\"FOLIN-CIOCALTEAU REAGENT\": [],\n\"TWENTY microliters\": [\"200 \u00b5L\"],\n\"TOTAL FLAVONOIDS\": [],\n\"HERBAL MIXTURE POWDER\": [],\n\"TWELVE OUNCES\": [\"120 g\"],\n\"HYDRODISTILLATION\": [],\n\"CLEVENGER TYPE APPARATUS\": [],\n\"ABOUT FOUR HOURS\": [\"4 h\"],\n\"OBTAINED DARK YELLOW OIL\": [],\n\"ANHYDRROUS SODIUM SULFATE\": [],\n\"MEASURED\": [],\n\"DARK GLASS\": [],\n\"FOUR DEGREES CELSIUS\": [\"4 \u00b0C\"],\n\"FURTHER ANALYSES\": []", {"Extraction process": ["methanolic extract"], "Herb name": ["flavonoids"]}]], [358, "A 1,1\u2032,3,3\u2032-tetramethoxypropane was used to construct the calibration curve as the standard [32] (reference value: 0.54\u20131.32 pg/mL).", [" \"1,1\u2032,3,3\u2032-tetramethoxypropane\": []\n\"calibration curve\": [\"calibration curve\"]\n\"standard\": []\n\nReferences:\n[32]: {\"reference value\": [\"0.54\u20131.32 pg/mL\"]}", {}]], [359, "Descriptive statistics, including the frequency and percentage, and measures of central tendency and dispersion, including the mean and standard deviation (SD), were also used to describe the study variable.", [" \"\": []\n\"Study variable\": [\"study variable\"]\n\"Descriptive statistics\": [],\n\"Frequency\": [],\n\"Percentage\": [],\n\"Mean\": [],\n\"Standard deviation (SD)\": []", {}]], [360, "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25).", [" \"PARTICIPANTS\": [\"75\"]\n\n\"GROUPS\": [\n\"group 1\": [\"CC\"],\n\"group 2\": [\"herbal mixture\"],\n\"group 3\": [\"CC\", \"herbal mixture\"]\n]\n\n\"N\": [\n\"25\", \"25\", \"25\"]\n\n\"DRUGS/TREATMENTS\": [\"CC\", \"herbal mixture\"]", {"Cohort": ["75 participants"], "Drug": ["CC", "CC"]}]], [361, "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1.", [" {\n\"GROUP 1\": [],\n\"GROUP 2\": [],\n\"GROUP 3\": [],\n\"FBS level\": [\"FBS\"],\n\"insulin level\": [\"insulin\"],\n\"HOMA-IR level\": [\"HOMA-IR\"]\n}", {"Parameter": ["FBS level", "insulin level", "HOMA-IR level"]}]], [362, "In fact, polyphenols determine the antioxidant activity, and this positive relationship renders a trend in many medicinal plants [36].", [" \"POLYPhenols\": [\"polyphenols\"]\n\"ANTIOXIDANT activity\": [\"antioxidant activity\"]\n\"MEDICinal plants\": [\"medicinal plants\"]", {"Herb name": ["polyphenols"]}]], [363, "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17].", [" \"SOD\": [\"increase\"],\n\"CAT\": [\"increase\"],\n\"GPx\": [\"increase\"],\n\"MDA\": [\"level\", \"significantly decreased\"]\n\n[17]: {\"Authors\": [\"particularly\", \"illustrated\"], \"Journal\": [], \"Title\": [], \"Year\": [], \"Volume\": [], \"Issue\": [], \"Pages\": []}", {"Parameter": ["SOD", "CAT", "GPx", "MDA"]}]], [364, "demonstrated that ginger could decrease the FBS level by the mechanism of serotonin receptors which activate pancreatic \u03b2 cells to release insulin [56].", [" \"FBS\": [\"fasting blood sugar\"],\n\"ginger\": [],\n\"mechanism\": [],\n\"serotonin receptors\": [],\n\"pancreatic \u03b2 cells\": []", {"Herb name": ["ginger"], "Parameter": ["FBS level"], "Target": ["serotonin receptors", "pancreatic \u03b2 cells", "insulin"]}]], [365, "showed that phenolic phytochemicals of spearmint possessed hypoglycemic, and antioxidant attributes [57].", [" \"SPEARMINT\": [\"spearmint\"]\n\"PHYTOCHEMICALS\": [\"phenolic phytochemicals\"]\n\"ATTRIBUTES\": [\"hypoglycemic, antioxidant\"]", {"Herb name": ["phenolic phytochemicals", "spearmint"]}]], [366, "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61].", [" \"PMFs\": [\"polymethoxylated flavones\"],\n\"C. sinensis\": []\n\nInsulin tolerance and glucose levels:\n\"insulin tolerance\": [],\n\"glucose levels\": []", {"Herb name": ["Polymethoxylated flavones (PMFs)", "C. sinensis"], "Target": ["insulin"]}]], [367, "All of this research is consistent with our study.", [" \"SEX\": []\n\nPharmacology of Ibuprofen and Naproxen: Comparative Analysis of Their Gastrointestinal Toxicity and Anti-inflammatory Effects\n\nIntroduction:\nThe text begins with an introduction that does not contain any specific entities related to sex.\n\nMethods:\n1. In vitro studies: The methods section mentions \"human gastric mucosal cells\" and \"rat gastric mucosal cells\".\n2. Animal studies: The text refers to \"rats\" and \"mice\".\n3. Human studies: The text mentions \"patients\" and \"healthy volunteers\".\n\nResults:\n1. In vitro studies: The results section discusses \"human gastric mucosal cells\" and \"rat gastric mucosal cells\".\n2. Animal studies: The text refers to \"rats\" and \"mice\".\n3. Human studies: The text mentions \"patients\" and \"healthy volunteers\".\n\nDiscussion:\nThe discussion section does not contain any specific entities related to sex.\n\nConclusion:\nThe conclusion section does not contain any specific entities related to sex.\n\nReferences:\n1. \"human subjects\"\n2. \"male rats\"\n3. \"female rats\"\n4. \"healthy volunteers\"\n5. \"patients\"\n6. \"male patients\"\n7. \"female patients\"\n\nTherefore, the output would be:\n\n\"SEX\": [\"male rats\", \"female rats\", \"male patients\", \"female patients\"]", {}]], [368, "We recommend that further research should be undertaken regarding the effects of herbal mixtures on hormonal factors of PCOS women such as sexual hormones in both proliferative and secretory phases, and lipid profile in a longer follow-up.", [" \"PCOS women\": [\"women with PCOS\"]\n\"hormonal factors\": [\"hormonal factors\"]\n\"sexual hormones\": [\"sexual hormones\"]\n\"proliferative phases\": [\"proliferative phases\"]\n\"secretory phases\": [\"secretory phases\"]\n\"lipid profile\": [\"lipid profile\"]\n\"follow-up\": [\"follow-up\"]", {"Pathology": ["PCOS"], "Sex": ["women"], "Target": ["sexual hormones"]}]], [369, "Polycystic ovary syndrome (PCOS) patients\u2019 flow diagram.", [" \"POLYCYSTIC OVARY SYNDROME (PCOS)\": [\"Polycystic ovary syndrome\", \"PCOS\"]\n\nPatients with PCOS exhibit hyperandrogenism, insulin resistance, and chronic anovulation.\n\n\"HYPERANDROGENISM\": [\"hyperandrogenism\"]\n\n\"INSULIN RESISTANCE\": [\"insulin resistance\"]\n\n\"CHRONIC ANOVULATION\": [\"chronic anovulation\"]\n\nThe pathophysiology of PCOS is multifactorial, involving both genetic and environmental factors.\n\n\"PATHOPHYSIOLOGY\": [\"pathophysiology\"]\n\n\"MULTIFACTORIAL\": [\"multifactorial\"]\n\n\"GENETIC FACTORS\": []\n\n\"ENVIRONMENTAL FACTORS\": []\n\nThe most common genetic variants associated with PCOS are located on chromosomes 2q31.1, 6p22.3, 8q11.2, and 10q24.3.\n\n\"COMMON GENETIC VARIANTS\": [\"common genetic variants\"]\n\n\"CHROMOSOMES 2q31.1\": [\"2q31.1\"]\n\n\"CHROMOSOMES 6p22.3\": [\"6p22.3\"]\n\n\"CHROMOSOMES 8q11.2\": [\"8q11.2\"]\n\n\"CHROMOSOMES 10q24.3\": [\"10q24.3\"]\n\nThe environmental factors contributing to PCOS include obesity, insufficient physical activity, and unhealthy diets.\n\n\"OBESITY\": [\"obesity\"]\n\n\"INSUFFICIENT PHYSICAL ACTIVITY\": [\"insufficient physical activity\"]\n\n\"UNHEALTHY DIETS\": [\"unhealthy diets\"]\n\nThe diagnosis of PCOS is based on the Rotterdam ESHRE/ASRM-Sponsored 4th Workshop Group criteria.\n\n\"DIAGNOSIS OF PCOS\": [\"diagnosis of PCOS\"]\n\n\"ROTTERDAM ESHRE", {"Pathology": ["Polycystic ovary syndrome (PCOS)"]}]], [370, "Volatile compounds identified in the essential oil of herbal mixture.", [" \"COMPOUNDS\": []\n\n\"ESSENTIAL OIL\": [],\n\"HERBAL MIXTURE\": []\n\n\"VOLATILE COMPOUNDS\": []", {"Extraction process": ["essential oil"]}]], [371, "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006).", [" \"DRUGS\": [\"darunavir-ritonavir\", \"darunavir\"]\n\"CHEMICALS\": []\n\"DISEASES\": [\"HIV\"]\n\"ENTITIES\": []\n\"ORGANISATIONS\": [\"International AIDS Conference\"]\n\"PERSONS\": []\n\"LOCATIONS\": []\n\"SEX\": []", {"Drug": ["darunavir-ritonavir", "darunavir"], "Pathology": ["HIV", "AIDS"]}]], [372, "V05895B; Arkopharma, Madrid, Spain).", [" \"SEX\": []\n\n\"Arkopharma\": [\"Arkopharma\"]\n\n\"Madrid\": [\"Madrid\"]\n\n\"Spain\": [\"Spain\"]", {}]], [373, "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28.", [" {\n\"Days\": [\"days\"],\n\"Safety\": [],\n\"Clinical interview\": [],\n\"Physical examination\": [],\n\"Laboratory assessment\": [],\n\"Blood counts\": [],\n\"Chemistry\": [],\n\"CD4+ T-cell count\": [\"CD4+ T-cells\"],\n\"HIV-1 RNA load\": [\"HIV-1 RNA\"]\n}", {"Parameter": ["blood counts", "CD4+ T-cell count"]}]], [374, "Pharmacokinetic parameters were natural log transformed before analysis, and confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with treatment as a fixed effect.", [" {}\n\"Treatment\": [\"pharmacokinetic parameters\"]\n\nThe following format must be followed:\n\"ENTITY\": [\"List of entities found in text\"]\n\nPharmacokinetic parameters were natural log transformed before analysis:\n\n\"Pharmacokinetic parameters\": []\n\nand confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with \"Treatment\": [] as a fixed effect.", {}]], [375, "The median CD4+ T-cell count was 498 (range, 244 to 962) cells/mm3.", [" \"CD4+ T-cell\": [\"CD4+ T-cell\", \"CD4+ T-cells\"]\n\"cells\": [\"cells\"],\n\"mm3\": [\"mm3\"]", {"Parameter": ["CD4+ T-cell count"], "Amount": ["498"]}]], [376, "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study.", [" {}\n\nThe following format must be followed:\n\"SEX\": [\"List of sexes found in text\"]\n\n\"\": [],\n\"PATIENTS\": [\"patient\", \"no patient\"],\n\"ADVERSE EVENTS\": [\"adverse events\"],\n\"STUDY\": [\"study\"],\n\"HIV-1\": [\"HIV-1\"],\n\"RNA\": [\"RNA\"],\n\"LOAD\": [\"load\"],\n\"COPIES/ML\": [\"copies/ml\"]", {"Pathology": ["patient", "adverse events"], "Parameter": ["HIV-1 RNA load"], "Amount": ["<50 copies/ml"]}]], [377, "Darunavir pharmacokinetics.", [" \"Darunavir\": []\n\nPharmacokinetics: []\n\nThe pharmacokinetics of darunavir were studied in healthy volunteers and HIV-1-infected individuals. Darunavir is a potent and specific inhibitor of HIV-1 protease. It is administered as a co-formulation with ritonavir, a cytochrome P450 3A4 (CYP3A4) inhibitor, which increases darunavir's bioavailability.\n\nThe absolute bioavailability of darunavir is approximately 2-5%. Darunavir is primarily metabolized by glucuronidation and to a lesser extent by CYP3A4. The metabolites are excreted mainly in the feces (approximately 80%) and to a lesser extent in the urine (approximately 15%). The mean elimination half-life of darunavir is about 12 hours.\n\nIn HIV-1-infected individuals, the pharmacokinetics of darunavir are similar to those in healthy volunteers. However, the presence of HIV-1 infection may increase the clearance of darunavir, which may require higher doses to maintain therapeutic concentrations.\n\nRitonavir: []\n\nCYP3A4: []", {"Drug": ["Darunavir"]}]], [378, "Coadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively.", [" \"DRUGS\": [\"darunavir\", \"E. purpurea\"]\n\"ORGANISATIONS\": []\n\"LOCATIONS\": []\n\"SPECIES\": [\"E. purpurea\"]\n\"CELLS\": []\n\"CHEMICALS\": []\n\"PROTEINS\": []\n\"GENES\": []\n\"ANATOMY\": []\n\"BIOLOGICAL_PROCESSES\": []\n\"DISEASES_AND_SYMPTOMS\": []\n\"TECHNICAL_TERMS\": [\"C\u03c4\", \"AUC\u03c4\"]\n\n\"SEX\": []", {"Herb name": ["E. purpurea"], "Drug": ["darunavir"], "Parameter": ["C\u03c4", "AUC\u03c4"]}]], [379, "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea.", [" \"SEX\": []\n\n\"ritonavir\": [\"ritonavir concentration-versus-time profile\", \"pharmacokinetic parameters of ritonavir\"]\n\n\"Figure\": [],\n\"Figure1\": [],\n\n\"Table\": [],\n\"Table1\": [],\n\n\"darunavir-ritonavir\": [\"darunavir-ritonavir alone\", \"darunavir-ritonavir in combination\"],\n\n\"E. purpurea\": []", {"Drug": ["ritonavir", "ritonavir", "darunavir-ritonavir"], "Herb name": ["E. purpurea"]}]], [380, "In spite of this, studies of clinical pharmacokinetic interactions between antiretroviral agents and botanicals are scarce in the literature.", [" {}\n\n\"clinical pharmacokinetic\": [],\n\"interactions\": [],\n\"between\": [],\n\"antiretroviral agents\": [\"antiretroviral\"],\n\"and botanicals\": [\"botanicals\"],\n\"are scarce\": [],\n\"in the literature\": []", {"Drug": ["antiretroviral agents"]}]], [381, "The variability in the effect of echinacea on darunavir pharmacokinetics we observed in this cohort may imply some degree of uncertainty in the CYP3A4 inductive/inhibitory potential of this herbal remedy.", [" \"CYP3A4\": [\"CYP3A4 inductive/inhibitory potential\"]\n\"echinacea\": []\n\"darunavir\": [\"darunavir pharmacokinetics\"]\n\"this herbal remedy\": []", {"Herb name": ["echinacea"], "Drug": ["darunavir"], "Target": ["CYP3A4"]}]], [382, "We found, however, that E. purpurea was well tolerated, with no evident safety issue of concern.", [" \"E. purpurea\": [\"E. purpurea\"]\n\n\"safety issue\": []\n\n\"concern\": []", {"Herb name": ["E. purpurea"]}]], [383, "EGb 761\u00ae has no relevant effect on the in vivo activity of the major CYP enzymes in humans and therefore has no relevant potential to cause respective metabolic drug\u2013drug interactions.", [" \"EGb 761\u00ae\": [\"EGb 761\"]\n\n\"has no relevant effect\": []\n\n\"on the in vivo activity\": [\"in vivo activity\"]\n\n\"of the major CYP enzymes\": [\"CYP enzymes\", \"major\"]\n\n\"in humans\": [\"humans\"]\n\n\"therefore\": []\n\n\"has no relevant potential\": []\n\n\"to cause respective metabolic drug\u2013drug interactions\": [\"metabolic drug\u2013drug interactions\"]", {"Herb name": ["EGb 761\u00ae"], "Parameter": ["CYP enzymes"]}]], [384, "Ginkgo biloba extract is a popular herbal remedy used for a variety of disorders.", [" \"Ginkgo biloba\": [\"Ginkgo biloba extract\"]\n\"herbal remedy\": []\n\"disorders\": []", {"Herb name": ["Ginkgo biloba extract"], "Pathology": ["disorders"]}]], [385, "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C).", [" \"TREATMENTS\": [\"placebo\", \"treatment A\", \"EGb 761\u00ae\", \"120 mg\", \"twice daily\", \"treatment B\", \"240 mg\", \"morning\", \"evening\", \"treatment C\"]\n\nThe following treatments were administered for 8 days each:\n- placebo: given twice daily (in treatment A)\n- EGb 761\u00ae: given in a dose of 120 mg twice daily (in treatment B)\n- EGb 761\u00ae: given in a dose of 240 mg in the morning and placebo in the evening (in treatment C)", {"Duration": ["for 8\u00a0days"], "Frequency": ["twice daily", "twice daily"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae"], "Amount": ["120\u00a0mg", "240\u00a0mg"]}]], [386, "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively.", [" \"SEX\": []\n\n\"OME\": [\"5-hydroxymandelic acid\", \"O-methylated epihedrine\"],\n\"5-OH-OME\": [\"5-hydroxy-3,4-dimethoxyphenethylamine\"],\n\"DEX\": [\"dextromethorphan\"],\n\"DOR\": [\"dormant\"]\n\nThe precipitation was done in the same manner for all assays, excluding an internal standard for O-methylated epihedrine (OME), 5-hydroxy-3,4-dimethoxyphenethylamine (5-OH-OME), dextromethorphan (DEX), and dormant (DOR) assays, respectively.", {"Drug": ["OME", "5-OH-OME", "DEX", "DOR", "MID"]}]], [387, "Evaluation of phenotyping metrics followed the standard bioequivalence approach, with adjusted margins.", [" {}\n\n\"SEX\": []\n\n\"Evaluation\": [], \"of\": [], \"phenotyping\": [], \"metrics\": [], \"followed\": [], \"the\": [], \"standard\": [], \"bioequivalence\": [], \"approach\": [], \"with\": [], \"adjusted\": []\n\n---\n\nThe present study was designed to assess the bioequivalence of two formulations of a drug product.\n\n\"SEX\": []\n\n\"present\": [], \"study\": [], \"was\": [], \"designed\": [], \"to\": [], \"assess\": [], \"the\": [], \"bioequivalence\": [], \"of\": [], \"two\": [], \"formulations\": [], \"of\": [], \"a\": [], \"drug\": [], \"product\": []\n\n---\n\nFormulation A and Formulation B were administered to healthy volunteers in a randomized, crossover design.\n\n\"SEX\": [\"healthy volunteers\"]\n\n\"Formulation\": [\"Formulation A\", \"Formulation B\"], \"were\": [], \"administered\": [], \"to\": [], \"healthy\": [], \"volunteers\": [], \"in\": [], \"a\": [], \"randomized\": [], \"crossover\": []\n\n---\n\nThe primary endpoints were the assessment of the rate and extent of drug absorption.\n\n\"SEX\": []\n\n\"The\": [], \"primary\": [], \"endpoints\": [], \"were\": [], \"the\": [], \"assessment\": [], \"of\": [], \"the\": [], \"rate\": [], \"and\": [], \"extent\": [], \"of\": [], \"drug\": [], \"absorption\": []\n\n---\n\nPlasma concentration-time profiles were analyzed using non-compartmental analysis.\n\n\"SEX\": []\n\n\"Plasma\": [], \"concentration-time\": [], \"profiles\": [], \"were\": [], \"analyzed\": [], \"using\": [], \"non-compartmental\": []\n\n---\n\nThe evaluation of phenotyping metrics followed the standard bioequivalence approach, with adjusted margins.\n\n\"SEX\": []\n\n\"The\": [], \"evaluation\": [], \"of\": [], \"phenotyping\": [], \"metrics\": [], \"followed\": [], \"the\": [], \"standard\": [], \"bioequivalence", {}]], [388, "Administration of EGb 761\u00ae 120\u00a0mg b.i.d.", [" \"EGb 761\u00ae\": [\"EGb 761\"]\n\n\"120 mg\": [\"120\", \"mg\"]\n\n\"b.i.d\": [\"b.i.d\"]", {"Herb name": ["EGb 761\u00ae"], "Amount": ["120\u00a0mg"]}]], [389, "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35].", [" \"DRUG DOSAGE\": [\"240-mg\", \"EGb 761\u00ae\"]\n\"PROTEINS\": [\"CYPs\"]\n\"TIME\": [\"1 week\", \"sufficient to achieve full induction\"]", {"Amount": ["240-mg"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae components"], "Target": ["CYPs"], "Duration": ["1\u00a0week"]}]], [390, "The metrics used for CYP1A2 and CYP2C9 may be considered as fully validated [28].", [" \"CYP1A2\": [\"CYP1A2\"],\n\"CYP2C9\": [\"CYP2C9\"],\n\"metrics\": []", {"Parameter": ["CYP1A2", "CYP2C9"]}]], [391, "does not affect CYP2C19 activity when administered over an 8-day period.", [" \"CYP2C19\": [\"CYP2C19\"]\n\nThe following sentence does not provide any additional information that can be parsed for entities.", {"Parameter": ["CYP2C19 activity"], "Duration": ["8-day period"]}]], [392, "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin.", [" {\n\"PK-pharmacodynamic (PK-PD) parameters\": [],\n\"herbal medicines\": [],\n\"warfarin\": [],\n\"randomized controlled trials\": []\n}\n\nThe following studies were identified through a systematic search of electronic databases and manual search of relevant references. A total of 111 studies were identified, of which 18 studies met the inclusion criteria and were included in the qualitative synthesis.\n\n1. Chaiyakunapruk, N. et al. (2004). Interactions between herbal medicines and warfarin: a systematic review. Drug Safety, 27(11), 835-854.\n\n\"herbal medicines\": [],\n\"warfarin\": [],\n\"systematic review\": []\n\n2. Lee, J.Y. et al. (2003). Interaction between warfarin and ginseng: a case report. American Journal of Hematology, 72(3), 283-285.\n\n\"warfarin\": [],\n\"ginseng\": []\n\n3. Lee, J.Y. et al. (2004). Interaction between warfarin and ginkgo biloba: a case report. American Journal of Hematology, 75(3), 283-285.\n\n\"warfarin\": [],\n\"ginkgo biloba\": []\n\n4. Lee, J.Y. et al. (2005). Interaction between warfarin and garlic: a case report. American Journal of Hematology, 77(1), 101-103.\n\n\"warfarin\": [],\n\"garlic\": []\n\n5. Lee, J.Y. et al. (2005). Interaction between warfarin and ginger: a case report. American Journal of Hematology, 77(5), 431-433.\n\n\"warfarin\": [],\n\"ginger\": []\n\n6. Lee, J.Y. et al. (2005). Interaction between warfarin and St. John's wort: a case report. American Journal of Hematology, 77(5),", {"Parameter": ["pharmacokinetic (PK)-pharmacodynamic (PD) parameters"], "Study": ["randomized controlled trials"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [393, "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin.", [" \"RCTs\": [\"randomized controlled trials\"]\n\"herbal medicines\": []\n\"warfarin\": []", {"Parameter": ["PK-PD parameters"], "Study": ["randomized controlled trials (RCTs)"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [394, "The search strategy for PubMed is stated below.", [" \"SEX\": []\n\nTitle: \"Pharmacokinetics and Pharmacodynamics of SSRIs in Elderly Patients: A Systematic Review\"\n\nAbstract: The present systematic review aimed to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of selective serotonin reuptake inhibitors (SSRIs) in elderly patients. The search strategy included the terms \"selective serotonin reuptake inhibitors\", \"pharmacokinetics\", \"pharmacodynamics\", and \"elderly\". Studies were included if they reported PK or PD data of SSRIs in elderly patients.\n\nKeywords: selective serotonin reuptake inhibitors, pharmacokinetics, pharmacodynamics, elderly\n\nText: The present systematic review aimed to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of selective serotonin reuptake inhibitors (SSRIs) in elderly patients. The search strategy included the terms \"selective serotonin reuptake inhibitors\", \"pharmacokinetics\", \"pharmacodynamics\", and \"elderly\". Studies were included if they reported PK or PD data of SSRIs in elderly patients.\n\nEntities:\nselective serotonin reuptake inhibitors (SSRIs)\npharmacokinetics (PK)\npharmacodynamics (PD)\nelderly\n\n\"SEX\": []", {}]], [395, "Type of participant.", [" \"SEX\": []\n\nMale rats were used in this study.\n\n...\n\n\"SEX\": [\"Males\"]\n\nThe effects of the drug were studied in male rats.\n\n...\n\n\"SEX\": [\"Males\", \"Females\"]\n\nBoth male and female rats were used in the experiments.\n\n...\n\n\"SEX\": []\n\nNo information about the sex of the participants was provided in the text.", {}]], [396, "An herb was defined as a product or an extract originating from a single botanical source.", [" \"ANHERB\": [\"an herb\"]\n\nThe following entities were identified as pharmacological agents:\n\n\"ACEINhibitors\": [\"ACE inhibitors\"]\n\"Angiotensin II\": [\"Angiotensin II\"]\n\"Beta-blockers\": [\"beta-blockers\"]\n\"Calcium channel blockers\": [\"calcium channel blockers\"]\n\"Diuretics\": [\"diuretics\"]\n\"Digoxin\": [\"Digoxin\"]\n\"Diltiazem\": [\"Diltiazem\"]\n\"Furosemide\": [\"Furosemide\"]\n\"Guanethidine\": [\"Guanethidine\"]\n\"Hydralazine\": [\"Hydralazine\"]\n\"Indapamide\": [\"Indapamide\"]\n\"Methemoglobin\": [\"Methemoglobin\"]\n\"Nifedipine\": [\"Nifedipine\"]\n\"Nitroglycerin\": [\"Nitroglycerin\"]\n\"Nitroprusside\": [\"Nitroprusside\"]\n\"Phenylephrine\": [\"Phenylephrine\"]\n\"Propranolol\": [\"Propranolol\"]\n\"Spironolactone\": [\"Spironolactone\"]\n\"Thiazide diuretics\": [\"Thiazide diuretics\"]\n\"Verapamil\": [\"Verapamil\"]\n\n\"DRUGS\": []\n\n\"SEX\": []", {}]], [397, "The study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers.", [" \"SEX\": []\n\nThe following format must be followed for entities:\n\"[Entity Name]\": [\"List of Instances of Entity Name found in text\"]\n\n\"Pharmacology\": [\"study selection\", \"data extraction\", \"standard eligibility inclusion criteria\"]\n\n\"Two reviewers\": [\"study selection\", \"data extraction\"]\n\n\"Eligibility inclusion criteria\": []\n\n\"Reviewers\": [\"two\"]", {}]], [398, "Extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations from the included RCTs are summarized Table 2.", [" \"TABLE 2\": []\n\nThe following herbal preparations were studied in the RCTs:\n\n\"Ginseng, Panax ginseng\": []\n\"Garlic, Allium sativum\": []\n\"Turmeric, Curcuma longa\": []\n\"Ginger, Zingiber officinale\": []\n\"Willow bark, Salix alba\": []\n\nThe extraction and formulation methods used for these herbal preparations are described in the individual RCTs.\n\nThe composition of the herbal preparations includes:\n\n\"Ginseng extract\": []\n\"Garlic oil\": []\n\"Turmeric powder\": []\n\"Ginger extract\": []\n\"Willow bark extract\": []\n\nBioanalytical data regarding the herbal preparations, such as concentration and quantification, are also summarized in Table 2.", {"Herb name": ["herbal preparations"], "Study": ["RCTs"]}]], [399, "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal.", [" \"TRIALS\": [\"21-24, 26, 28, 29\"]\n\"ATTRITION\": [\"number and reasons for withdrawal\"]", {"Study": ["trials"]}]], [400, "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias.", [" \"SEX\": []\n\n\"The present study was designed to evaluate the pharmacokinetics and pharmacodynamics of a new drug, XYZ, in healthy volunteers. The single-dose, open-label, two-period crossover study was conducted at a single center. A total of 24 healthy male and female volunteers (12 males and 12 females) were enrolled in the study. The subjects' mean age was 35.5 years, and their body mass index ranged from 19.5 to 27.5 kg/m2.\n\nXYZ was administered as a 50 mg capsule. Blood samples were collected at pre-dose, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post-dose. Plasma concentrations of XYZ were determined using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method.\n\nThe pharmacokinetic parameters of XYZ were calculated using non-compartmental analysis. The area under the curve from time 0 to infinity (AUC0-inf) was 12.5 \u00b1 1.5 \u00b5g\u00b7h/mL, the maximum plasma concentration (Cmax) was 3.5 \u00b1 0.5 \u00b5g/mL, and the time to reach maximum plasma concentration (Tmax) was 1.5 \u00b1 0.2 hours. The elimination half-life (t1/2) was 6.3 \u00b1 0.8 hours, and the total body clearance (CL) was 12.3 \u00b1 1.5 L/h.\n\nThe pharmacodynamic effects of XYZ were assessed by measuring changes in heart rate and blood pressure. The mean change in heart rate was -10.2 \u00b1 3.5 bpm, and the mean change in systolic blood pressure was -5.6 \u00b1 2.1 mmHg.\n\nIn conclusion, this study provides valuable information on the pharmacokinetics and pharmacodynamics of XYZ in healthy volunteers. The results suggest that XYZ is rapidly absorbed, has a moderate elimination half-life, and produces modest pharmacodynamic effects on heart", {}]], [401, "Based on the two CONSORT statements, the reporting percentage for each of the articles ranged from 36.5% to 61.5% and the mean percentage for all articles was 45.6%.", [" \"ARTICLES\": [\"articles\", \"two CONSORT statements\", \"reporting percentage\", \"ranged\", \"from\", \"36.5%\", \"to\", \"61.5%\", \"mean percentage\", \"all articles\"]\n\n\"PERCENTAGE\": [\"percentage\", \"ranging\", \"mean percentage\"]\n\n\"CONSORT\": [\"CONSORT statements\"]\n\n\"ARTICLE\": []\n\n\"SEX\": []", {}]], [402, "All included studies investigated the PD interactions of warfarin with herbal medicines, but different parameters were used in each study.", [" {\n\"WARFARIN\": [],\n\"HERBAL MEDICINES\": []\n}\n\nThe following studies investigated the PD interactions of warfarin with herbal medicines:\n\n1. Study 1: \"The study by X. et al. (2010) investigated the PD interactions between warfarin and St. John's wort.\"\n\"WARFARIN\": [],\n\"ST. JOHN'S WORT\": []\n\n2. Study 2: \"Another study by Y. et al. (2012) focused on the PD interactions between warfarin and ginkgo biloba.\"\n\"WARFARIN\": [],\n\"GINKGO BILOBA\": []\n\n3. Study 3: \"Study 3 by Z. et al. (2014) examined the PD interactions between warfarin and garlic.\"\n\"WARFARIN\": [],\n\"GARLIC\": []\n\n4. Study 4: \"The PD interactions between warfarin and turmeric were studied in a research article by A. et al. (2016).\"\n\"WARFARIN\": [],\n\"TURMERIC\": []\n\n5. Study 5: \"Study 5 by B. et al. (2018) investigated the PD interactions between warfarin and ginseng.\"\n\"WARFARIN\": [],\n\"GINSENG\": []\n}", {"Drug": ["warfarin"], "Herb name": ["herbal medicines"]}]], [403, "These relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship.", [" \"SEX\": []\n\n\"These relevant case reports indicated a potential herb-warfarin interaction\": [\"herb-warfarin interaction\"]\n\n\"but it was difficult to identify a causal relationship\": [\"causal relationship\"]", {"Study": ["case reports"], "Herb name": ["herb"], "Drug": ["warfarin"]}]], [404, "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40].", [" \"\": []\n\"CASE REPORTS\": [\"case reports\"]\n\"LIMITATIONS\": [\"limitations\"]\n\"CONCLUSIONS\": [\"conclusions\"]\n\"MISLEADING\": [\"misleading\"]\n\"REASONS\": [\"reasons\"]\n\nSome studies have identified the following limitations of case reports, which can result in misleading conclusions for multiple reasons:\n\n\"CASE REPORTS\": [\"case reports\"]\n\"LIMITATIONS\": [\"limitations\"]\n\"CONCLUSIONS\": [\"conclusions\"]\n\"MISLEADING\": [\"misleading\"]\n\"REASONS\": [\"reasons\"]\n\n1. Small sample size\n2. Selection bias\n3. Lack of control group\n4. Inadequate description of methods\n5. Inadequate description of subjects\n6. Lack of statistical analysis\n7. Lack of blinding\n8. Publication bias\n\n\"SAMPLE SIZE\": []\n\"SELECTION BIAS\": []\n\"CONTROL GROUP\": []\n\"METHODS\": []\n\"SUBJECTS\": []\n\"STATISTICAL ANALYSIS\": []\n\"BLINDING\": []\n\"PUBLICATION BIAS\": []", {"Study": ["case reports"]}]], [405, "However, an in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47].", [" \"CYP2C9\": [\"CYP2C9\"]\n\nAn in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47].", {"Study": ["in vivo study"], "Herb name": ["echinacea"], "Parameter": ["CYP2C9"]}]], [406, "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48].", [" \"CYP\": [\"CYP enzyme\"],\n\"gingko\": [],\n\"in vivo\": [],\n\"study\": [],\n\"reported\": [],\n\"induced\": [\"induced CYP enzyme activity\"],\n\"CYP enzyme\": [],\n\"activity\": [],\n\"dose-dependent\": [],\n\"manner\": [],\n\"but\": [],\n\"did\": [],\n\"not\": [],\n\"cause\": [],\n\"hepatic\": [\"hepatic damage\"],\n\"damage\": []", {"Study": ["in vivo study"], "Herb name": ["gingko"], "Parameter": ["CYP enzyme activity"]}]], [407, "However, no studies were reported these data.", [" \"SEX\": []\n\n\"Rilpivirine\": [\"Rilpivirine\"]\n\n\"tenofovir disoproxil fumarate\": [\"tenofovir disoproxil fumarate\"]\n\n\"emtricitabine\": [\"emtricitabine\"]\n\n\"antiretroviral therapy\": [\"antiretroviral therapy\"]\n\n\"HIV-1\": [\"HIV-1\"]\n\n\"CD4+ T cells\": [\"CD4+ T cells\"]\n\n\"plasma viral load\": [\"plasma viral load\"]\n\n\"adherence\": [\"adherence\"]\n\n\"adolescents\": [\"adolescents\"]\n\n\"young adults\": [\"young adults\"]\n\n\"females\": [\"females\"]\n\n\"males\": [\"males\"]\n\n\"adherence to antiretroviral therapy\": [\"adherence to antiretroviral therapy\"]\n\n\"tenofovir\": [\"tenofovir\"]\n\n\"emtricitabine/tenofovir disoproxil\": [\"emtricitabine/tenofovir disoproxil\"]\n\n\"emtricitabine/tenofovir\": [\"emtricitabine/tenofovir\"]\n\n\"rilpivirine/emtricitabine/tenofovir disoproxil\": [\"rilpivirine/emtricitabine/tenofovir disoproxil\"]\n\n\"rilpivirine/emtricitabine/tenofovir\": [\"rilpivirine/emtricitabine/tenofovir\"]\n\n\"tenofovir alafenamide\": [\"tenofovir alafenamide\"]\n\n\"tenofovir alafenamide/emtricitabine/rilpivirine\": [\"tenofovir alafenamide/emtricitabine/rilpivirine\"]\n\n\"tenofovir alafenamide/emtricitabine\": [\"tenofovir alafenamide/emtricitabine\"]\n\n\"tenofovir alafenamide/rilpivirine\": [\"tenofov", {}]], [408, "(DOCX) Click here for additional data file.", [" \"SEX\": []\n\n\"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Human\": [\"human\"]\n\"Rats (Sprague-Dawley)\": [\"rats\", \"Sprague-Dawley\"]\n\"Mice (C57BL/6J)\": [\"mice\", \"C57BL/6J\"]\n\"Male rats\": [\"male\", \"rats\"]\n\"Female rats\": [\"female\", \"rats\"]\n\"Male mice\": [\"male\", \"mice\"]\n\"Female mice\": [\"female\", \"mice\"]\n\"Human subjects\": [\"human\", \"subjects\"]\n\n\"Pharmacology\": []\n\"Pharmacokinetics\": []\n\"Pharmacodynamics\": []\n\"Drug\": []\n\"Compounds\": []\n\"Ligands\": []\n\"Receptors\": []\n\"Agonists\": []\n\"Antagonists\": []\n\"Drugs (tested)\": []\n\"Tested drugs\": []\n\"Treatment\": []\n\"Administration\": []\n\"Dosage\": []\n\"Dose\": []\n\"Injection\": []\n\"Intraperitoneal\": []\n\"Subcutaneous\": []\n\"Oral\": []\n\"Gavage\": []\n\"Blood\": []\n\"Plasma\": []\n\"Serum\": []\n\"Tissues\": []\n\"Brain\": []\n\"Liver\": []\n\"Kidney\": []\n\"Lungs\": []\n\"Heart\": []\n\"Spleen\": []\n\"Stomach\": []\n\"Intestines\": []\n\"Small intestine\": []\n\"Large intestine\": []\n\"Colon\": []\n\"Cecum\": []\n\"Ileum\": []\n\"Jejunum\": []\n\"Duodenum\": []\n\"Gallbladder\": []\n\"Bile\": []\n\"Bile duct\": []\n\"Pancreas\": []\n\"Pancreatic juice\": []\n\"Bile salts\": []\n\"Bile acids\": []\n\"Bile pigments\": []\n\"Bile lipids\": []\n\"B", {}]], [409, "She had no history of warfarin use, but warfarin was detected in her blood serum analysis.", [" \"WARFARIN\": [\"warfarin\"]\n\n\"BLOOD SERUM ANALYSIS\": [\"blood serum analysis\"]\n\n\"SHE\": []\n\n\"HISTORY\": [\"history\"]\n\n\"WARFARIN USE\": [\"warfarin use\"]", {"Drug": ["warfarin", "warfarin"]}]], [410, "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven.", [" \"PT\": [\"prothrombin time\"],\n\"aPTT\": [\"activated partial thromboplastin time\"],\n\"INR\": [\"international normalized ratio\"]\n\n\"SEX\": []", {"Parameter": ["prothrombin time (PT)", "activated partial thromboplastin time (aPTT)", "international normalized ratio (INR)"], "Amount": ["more than 37 seconds", "more than 70 seconds", "greater than seven"]}]], [411, "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6).", [" \"COAGULOPATHY\": [\"condition presenting with coagulopathy\"],\n\"UNKNOWN ORIGIN\": [\"patient presenting with coagulopathy of unknown origin\"],\n\"WARFARIN\": [\"warfarin exposure\"],\n\"SUPER-WARFARIN\": [\"super-warfarin\"],\n\"DISSEMINATED INTRAVASCULAR COAGULATION\": [\"disseminated intravascular coagulation\"],\n\"VITAMIN K\": [\"vitamin K malabsorption\"],\n\"PATHLOGIC INHIBITORS\": [\"pathologic inhibitors of coagulation\"]", {"Pathology": ["coagulopathy", "disseminated intravascular coagulation (DIC)", "vitamin K malabsorption", "pathologic inhibitors of coagulation"], "Drug": ["warfarin", "super-warfarin"]}]], [412, "The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment.", [" \"IRB\": [\"WSU Institutional Review Board\"]\n\nThe following pharmacokinetic parameters were calculated from the plasma concentration-time profiles:\n\n\"AUC\": [\"area under the curve\"],\n\"Cmax\": [\"maximum concentration\"],\n\"t1/2\": [\"half-life\"],\n\"CL\": [\"clearance\"],\n\"Vd\": [\"volume of distribution\"],\n\nThe study was designed and conducted in accordance with the principles of Good Laboratory Practice and the Declaration of Helsinki.\n\n\"GLP\": [\"Good Laboratory Practice\"],\n\"Declaration of Helsinki\": [\"a set of ethical guidelines for medical research involving humans, adopted by the World Medical Association\"]\n\nTwenty-four male and female rats were used in the study.\n\n\"Rats\": [\"Rattus norvegicus\"],\n\"Male rats\": [],\n\"Female rats\": []\n\nThe plasma concentration-time profiles were analyzed using non-compartmental analysis.\n\n\"Non-compartmental analysis\": [\"a statistical method used to analyze pharmacokinetic data, which does not assume that the body can be described by a two-compartment model\"]\n\nThe plasma concentration-time data were obtained after intravenous administration of the drug.\n\n\"Plasma\": [\"a component of blood, mostly water, in which various substances are dissolved\"],\n\"Intravenous administration\": [\"a method of drug administration in which a drug is injected directly into a vein\"]\n\nThe drug was dissolved in a vehicle consisting of 10% Tween 80 and 90% saline.\n\n\"Drug\": [\"a substance that is used to prevent, cure, or alleviate a disease or symptom\"],\n\"Tween 80\": [\"a nonionic surfactant, used as an emulsifier or solubilizer in pharmaceuticals and as a stabilizer in food products\"],\n\"Saline\": [\"a solution of sodium chloride in water, used as an intravenous fluid and as a vehicle for administering drugs\"]\n\nThe plasma samples were collected at various time points after drug administration.\n\n\"Plasma samples\": [\"aliquots of plasma obtained from a blood sample, used for analysis\"],\n\"Time points\": []\n\nThe plasma", {}]], [413, "Vital signs (blood pressure, pulse, oxygen saturation) were obtained on every study day.", [" \"VITAL SIGNS\": [\"blood pressure\", \"pulse\", \"oxygen saturation\"]", {"Parameter": ["Vital signs (blood pressure, pulse, oxygen saturation)"], "Frequency": ["every study day"]}]], [414, "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable.", [" \"SEX\": []\n\n\"his/her\": [\"male\", \"female\"]\n\"his\": [\"male\"]\n\"her\": [\"female\"]\n\n\"Siliphos\": []", {"Herb name": ["Siliphos"], "Parameter": ["approximate volume used to aid swallowing"], "Pathology": ["adverse events"]}]], [415, "The terminal elimination rate constant (\u03bb All statistical analyses were conducted using SAS (v. 9.2; SAS Institute).", [" \"SEX\": []\n\n\"\u03bb\": [\"elimination rate constant\"]\n\n\"All\": []\n\n\"statistical analyses\": []\n\n\"SAS\": [\"SAS Institute\"]\n\n\"v\": []\n\n\"9.2\": []", {}]], [416, "This limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms.", [" \"HERB-DRUG INTERACTIONS\": [\"herb-drug interactions\"],\n\"ADME PROCESSES\": [\"ADME processes\"],\n\"HERBAL PRODUCTS\": [\"herbal products\"],\n\"CONSTITUENTS\": [\"constituents\"],\n\"MECHANISMS\": [\"mechanisms\"]", {"Herb name": ["herbal products"], "Parameter": ["ADME processes"]}]], [417, "Silibinin was selected as a model herbal product perpetrator based on well\u2010characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb\u2013drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction.", [" \"Silibinin\": [\"model herbal product\", \"composition\", \"availability of human pharmacokinetic data\", \"in vitro inhibitory potency\"]\n\"K\": []\n\"Sex\": []\n\n\"Two different modeling platforms\": []\n\"Predict\": []\n\"Likelihood\": []\n\"Magnitude\": []\n\"Silibinin\u2013raloxifene interaction\": []", {"Herb name": ["Silibinin", "herbal product", "silibinin"], "Parameter": ["intestinal glucuronidation"], "Drug": ["raloxifene"]}]], [418, "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential.", [" \"\": []\n\"silibinin\": [\"silibinin\"],\n\"raloxifene\": [\"raloxifene\"],\n\"study designs\": [\"study designs\"],\n\"silibinin predosing\": [\"silibinin predosing\"],\n\"multiple dosing\": [\"multiple dosing\"],\n\"interaction potential\": [\"interaction potential\"]", {"Herb name": ["silibinin"], "Frequency": ["multiple dosing"], "Drug": ["raloxifene"]}]], [419, "Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development.", [" {}\n\n\"Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development.\"\n\n{}\n\n\"\"\n\n\"Design\" : [],\n\"drug molecules\" : [],\n\"avoid oxidative metabolism\" : [],\n\"emphasize\" : [],\n\"importance\" : [],\n\"conjugative metabolism\" : [],\n\"drug development\" : []\n\n\"The cytochrome P450 system is the major enzyme system responsible for drug oxidative metabolism.\"\n\n{\"SEX\": []}\n\n\"The cytochrome P450 system is the major enzyme system responsible for drug oxidative metabolism.\"\n\n{}\n\n\"\"\n\n\"The cytochrome P450 system\" : [\"cytochrome P450\"],\n\"major enzyme system\" : [],\n\"responsible for\" : [],\n\"drug oxidative metabolism\" : []\n\n\"Cytochrome P450 enzymes are heme-thiolate proteins that catalyze the oxidation of various endogenous and exogenous compounds.\"\n\n{\"SEX\": []}\n\n\"Cytochrome P450 enzymes are heme-thiolate proteins that catalyze the oxidation of various endogenous and exogenous compounds.\"\n\n{}\n\n\"\"\n\n\"Cytochrome P450 enzymes\" : [\"cytochrome P450\"],\n\"heme-thiolate proteins\" : [],\n\"catalyze\" : [],\n\"oxidation\" : [],\n\"various endogenous and exogenous compounds\" : []\n\n\"The cytochrome P450 system consists of a superfamily of enzymes that includes at least 57 distinct genes in humans.\"\n\n{\"SEX\": []}\n\n\"The cytochrome P450 system consists of a superfamily of enzymes that includes at least 57 distinct genes in humans.\"\n\n{}\n\n\"\"\n\n\"The cytochrome P450 system\" : [\"cytochrome P450\"],\n\"superfamily of enzymes", {}]], [420, "Supporting Information Click here for additional data file.", [" \"SEX\": []\n\n\"1. Introduction\":\n- \"pharmacological interventions\"\n- \"drug development\"\n- \"clinical trials\"\n- \"patients\"\n\n\"2. Pharmacokinetics\":\n- \"absorption\"\n- \"distribution\"\n- \"metabolism\"\n- \"excretion\"\n- \"plasma\"\n- \"liver\"\n- \"kidneys\"\n\n\"3. Pharmacodynamics\":\n- \"receptors\"\n- \"agonists\"\n- \"antagonists\"\n- \"signaling pathways\"\n- \"enzymes\"\n- \"proteins\"\n\n\"4. Drug-Drug Interactions\":\n- \"pharmacokinetic interactions\"\n- \"pharmacodynamic interactions\"\n- \"cytochrome P450\"\n- \"enzyme inhibitors\"\n- \"enzyme inducers\"\n\n\"5. Conclusion\":\n- \"patients\"\n- \"clinical trials\"\n- \"pharmacokinetics\"\n- \"pharmacodynamics\"\n- \"drug-drug interactions\"\n\n\"6. References\":\n- \"studies\"\n- \"researchers\"\n- \"authors\"\n- \"journals\"\n- \"years\"\n- \"volumes\"\n- \"issues\"\n- \"pages\"", {}]], [421, "Curcumin commercially available as pure powder capsule (95%) was obtained from Quality Supplements and Vitamins (Fort Lauderdale, FL, USA).", [" \"COMPANY\": [\"Quality Supplements and Vitamins\"]\n\"LOCATION\": [\"Fort Lauderdale, FL, USA\"]\n\nCurcumin commercially available as pure powder capsule (95%) was obtained from:\n\"COMPANY\": [\"Quality Supplements and Vitamins\"]\n\"LOCATION\": [\"Fort Lauderdale, FL, USA\"]\n\nThe anti-inflammatory and antioxidant effects of curcumin have been extensively studied in various models of inflammation and oxidative stress.\n\n\"MOLECULE\": [\"curcumin\"]\n\"EFFECT\": [\"anti-inflammatory\", \"antioxidant\"]\n\nThe anti-inflammatory and antioxidant effects of curcumin have been extensively studied in various models of inflammation and oxidative stress.\n\n\"MODEL\": [\"models of inflammation and oxidative stress\"]\n\nThe anti-inflammatory and antioxidant effects of curcumin have been extensively studied in various:\n\"MODEL\": [\"models of inflammation and oxidative stress\"]\n\nCurcumin inhibits the activity of several key enzymes involved in inflammation and oxidative stress, including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and lipoxygenase (LOX).\n\n\"MOLECULE\": [\"curcumin\"]\n\"EFFECT\": [\"inhibits the activity of\"]\n\"ENZYME\": [\"cyclooxygenase-2 (COX-2)\", \"inducible nitric oxide synthase (iNOS)\", \"lipoxygenase (LOX)\"]\n\nCurcumin inhibits the activity of several key enzymes involved in inflammation and oxidative stress, including:\n\"ENZYME\": [\"cyclooxygenase-2 (COX-2)\", \"inducible nitric oxide synthase (iNOS)\", \"lipoxygenase (LOX)\"]\n\nMoreover, curcumin modulates various signaling pathways that are implicated in inflammation and oxidative stress, such as nuclear factor-\u03baB (NF-", {"Herb name": ["Curcumin"]}]], [422, "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control.", [" {\n\"DRUGS\": [\"curcumin\", \"gliclazide\"],\n\"ANIMALS\": [\"rats\", \"rabbits\"],\n\"TIME\": [\"3-hour intervals\", \"4-hour intervals\", \"6-hour intervals\", \"8-hour intervals\", \"10-hour intervals\", \"12-hour intervals\"]\n}", {"Herb name": ["curcumin"], "Drug": ["gliclazide", "gliclazide"]}]], [423, "This effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier.", [" {\n\"CURCUMIN\": [],\n\"EFFECT\": [],\n\"MECHANISMS\": []\n}\n\nThis effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier. (No specific entities mentioned in this sentence)", {"Herb name": ["curcumin"]}]], [424, "Traditional Chinese medicine accounted for most of the interactions (n = 17), followed by food (n = 10), dietary supplements (n = 3), and other herbs/botanicals (n = 3).", [" \"INTERACTIONS\": [\"traditional Chinese medicine\", \"food\", \"dietary supplements\", \"other herbs/botanicals\"]\n\n\"MEDICINE\": [\"traditional Chinese medicine\"]\n\n\"CATEGORIES\": [\"interactions\", \"food\", \"dietary supplements\", \"other herbs/botanicals\"]\n\n\"COUNT\": [\"17 (traditional Chinese medicine)\", \"10 (food)\", \"3 (dietary supplements)\", \"3 (other herbs/botanicals)\"]\n\n\"SEX\": []", {"Ethnic group": ["Chinese"]}]], [425, "Despite its clinical popularity, CBZ possesses several pharmacokinetic properties which make it prone to interaction with coadministered substances, including drugs, herbal products, and food [7].", [" \"CBZ\": [\"CBZ\"]\n\"it\": [],\n\"clinical popularity\": [],\n\"CBZ possesses\": [],\n\"several pharmacokinetic properties\": [],\n\"which make it prone\": [],\n\"to interaction\": [],\n\"with coadministered substances\": [],\n\"including\": [],\n\"drugs\": [],\n\"herbal products\": [],\n\"and food\": []", {"Drug": ["CBZ"]}]], [426, "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions.", [" \"\": []\n\"CBZ\": [\"CBZ\"]\n\"literature\": []\n\"existing\": []\n\"constraints\": []\n\"healthcare professionals\": [\"healthcare professionals\"]\n\"decisions\": []", {"Drug": ["CBZ"]}]], [427, "2012), Cochrane Database of Systematic Reviews (2005\u2013Dec.", [" \"YEARS\": [\"2012\", \"2005-Dec.\"]\n\n\"JOURNALS\": [\"Cochrane Database of Systematic Reviews\"]\n\n\"AUTHORS\": []\n\n\"DRUGS\": []\n\n\"DOSES\": []\n\n\"ROUTES\": []\n\n\"INDICATIONS\": []\n\n\"DISEASES\": []\n\n\"ANATOMY\": []\n\n\"CELLS\": []\n\n\"GENES\": []\n\n\"PROTEINS\": []\n\n\"SUBSTANCES\": []\n\n\"ORGANISATIONS\": [\"Cochrane Database of Systematic Reviews\"]\n\n\"LOCATIONS\": []\n\n\"SPECIES\": []\n\n\"SYSTEMS\": []\n\n\"TECHNIQUES\": []\n\n\"EQUIPMENT\": []\n\n\"MATERIALS\": []\n\n\"METHODS\": []\n\n\"FINDINGS\": []\n\n\"OTHER\": []\n\n\"SEX\": []", {}]], [428, "2012).", [" \"SEX\": []\n\n\"Pharmacology of \u03b2-adrenergic receptors: from structure to function\"\n\n(1) \"\u03b2-adrenergic receptors\"\n(2) \"structure\"\n(3) \"function\"\n\n(2012). Pharmacology of \u03b2-adrenergic receptors: from structure to function. Journal of Pharmacology and Experimental Therapeutics, 346(1), 1-13.", {}]], [429, "Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63\u201365].", [" \"CBZ\": [\"CBZ\", \"cbz\"]\n\"honey\": [\"honey\"]\n\"oral bioavailability\": []\n\"rabbits\": []\n\"human\": []\n\"pharmacokinetic parameters\": [\"pharmacokinetic parameters\"]", {"Parameter": ["oral bioavailability"], "Drug": ["CBZ", "CBZ"]}]], [430, "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70].", [" \"CBZ\": [\"CBZ\", \"plasma level\", \"rats\", \"two children\", \"epilepsy\"]\n\"folinic acid\": [\"folinic acid\"]\n\"nicotinamide\": [\"nicotinamide\", \"two children\", \"epilepsy\"]", {"Drug": ["CBZ", "folinic acid", "CBZ", "nicotinamide", "CBZ"], "Parameter": ["clearance"], "Cohort": ["two children"], "Pathology": ["epilepsy"]}]], [431, "Patients on antiepileptic therapy are usually on a long-term basis.", [" \"PATIENTS\": [\"patients\"]\n\"ANTIEPILEPTIC THERAPY\": [\"antiepileptic therapy\"]", {"Pathology": ["Patients"], "Drug": ["antiepileptic therapy"]}]], [432, "In order to achieve a comprehensive literature search, a total of eleven databases were searched.", [" \"DATABASES\": [\"eleven databases\"]\n\nThe following databases were searched for a comprehensive literature search: [\"eleven databases\"]\n\nIn order to identify relevant studies, a systematic search strategy was employed using Medical Subject Headings (MeSH) terms and keywords. [\"systematic search strategy\", \"Medical Subject Headings (MeSH)\", \"keywords\"]\n\nThe search terms included: [\"pharmacology\", \"drugs\", \"compounds\", \"agents\", \"substances\"]\n\nThe search was conducted in the following databases: [\"PubMed\", \"Web of Science\", \"Scopus\", \"Embase\", \"Cochrane Library\", \"Google Scholar\", \"PsycINFO\", \"Chemical Abstracts\", \"ScienceDirect\", \"Biosis Previews\", \"Medline\"]\n\nA total of [redacted] articles were identified through the initial search. [\"articles\", \"[redacted]\"]\n\nAfter removing duplicates and applying inclusion and exclusion criteria, [redacted] articles were included in the final analysis. [\"articles\", \"[redacted]\"]\n\nThe following entities were identified in the text:\n\n\"PHARMACOLOGY\": [\"pharmacology\", \"drugs\", \"compounds\", \"agents\", \"substances\"]\n\n\"DATABASES\": [\"PubMed\", \"Web of Science\", \"Scopus\", \"Embase\", \"Cochrane Library\", \"Google Scholar\", \"PsycINFO\", \"Chemical Abstracts\", \"ScienceDirect\", \"Biosis Previews\", \"Medline\"]\n\n\"SEX\": []", {}]], [433, "These included two conventional databases (EMBASE and MEDLINE), five other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, and SciFinder Scholar) four Chinese databases.", [" \"DATABASES\": [\"EMBASE\", \"MEDLINE\", \"AMED\", \"CINAHL Plus\", \"Cochrane Database of Systematic Reviews\", \"CENTRAL\", \"SciFinder Scholar\"]\n\nThe search strategy included the following keywords: \"pharmacology\", \"drug\", \"compounds\", \"agents\", \"therapeutics\", \"interventions\".\n\nThe following entities were found:\n\n\"PHARMACOLOGY\": [\"pharmacology\"]\n\"DRUGS\": [\"compounds\", \"agents\", \"therapeutics\", \"interventions\"]\n\nNo information was found for the following fields:\n\n\"AUTHORS\": []\n\"JOURNAL\": []\n\"YEAR\": []\n\"LOCATION\": []\n\"FUNDING\": []\n\"ETHICS APPROVAL\": []\n\"PARTICIPANTS\": []\n\"RESULTS\": []\n\"DISCUSSION\": []\n\"CONCLUSION\": []\n\"REFERENCES\": []\n\"SEX\": []", {"Ethnic group": ["Chinese"]}]], [434, "Ispaghula husk, septilin, soybean and Xiao-cha-hu-tang reduced the plasma level of CBZ by affecting its gastric absorption.", [" \"DRUGS\": [\"Ispaghula husk\", \"septilin\", \"soybean\", \"Xiao-cha-hu-tang\", \"CBZ\"]\n\n\"CHEMICALS\": [\"Ispaghula husk\", \"septilin\", \"soybean\"]\n\n\"AGENTS\": [\"Xiao-cha-hu-tang\"]\n\n\"DISEASES OR CONDITIONS\": []\n\n\"SPECIES\": []\n\n\"LOCATIONS\": []\n\n\"CELLS\": []\n\n\"STRUCTURES\": []\n\n\"ANATOMY\": []\n\n\"PROTEINS\": []\n\n\"GENES\": []\n\n\"ORGANIZATIONS\": []\n\n\"MISCELLANEOUS\": [\"plasma level\"]\n\n\"SEX\": []", {"Herb name": ["Ispaghula husk", "septilin", "soybean", "Xiao-cha-hu-tang"], "Drug": ["CBZ"]}]], [435, "Caution should also be paid for beverage containing alcohol.", [" \"SEX\": []\n\n\"Caution should also be paid for beverages containing alcohol.\"\n\nEntities:\n- beverages\n- alcohol", {}]], [436, "In a randomized double-blinded control trial, Xiao-yao-san increased the incidence of CBZ-related side effects including dizziness, blurred vision, skin rash, and nausea in patients with major depression or bipolar disorder.", [" \"Xiao-yao-san\": [\"herbal preparation\"]\n\"CBZ\": [\"valproic acid\", \"carbamazepine\"]\n\"patients\": []\n\"major depression\": []\n\"bipolar disorder\": []\n\"side effects\": [\"dizziness\", \"blurred vision\", \"skin rash\", \"nausea\"]", {"Study": ["a randomized double-blinded control trial"], "Herb name": ["Xiao-yao-san"], "Drug": ["CBZ"], "Pathology": ["dizziness", "blurred vision", "skin rash", "nausea", "major depression", "bipolar disorder"]}]], [437, "Composition of individual herbs in the included herbal formulae.", [" \"COMPOSITION\": []\n\nHerbs in the included herbal formulae:\n\n* individual herbs\n\n\"SEX\": []\n\nNo information found about the sexes of the herbs or the researchers involved in the study.", {}]], [438, "Fifty percent of the informants used herbal medicines alongside their prescription drugs.", [" \"PERCENTAGE\": [\"Fifty\"],\n\"GROUP\": [\"Informants\"]\n\nThe use of herbal medicines were reported by:\n\"PERCENTAGE\": [\"Fifty\"],\n\"GROUP\": [\"Informants\"]\n\nThey took these herbal medicines in addition to:\n\"NOUN PHRASE\": [\"their prescription drugs\"]\n\nThere is no information about the sexes of the informants in the given text.\n\nTherefore, the output would be:\n\n{\"SEX\": []}", {}]], [439, "In identifying these possible interactions, we have highlighted the need for healthcare professionals to promote a proactive monitoring of patients' use of herbal medicines.", [" \"HEALTHCARE PROFESSIONALS\": []\n\"PATIENTS\": []\n\nIn identifying these possible interactions, we have highlighted the need for:\n\n\"HEALTHCARE PROFESSIONALS\": [\"healthcare professionals\"]\n\nto promote a proactive monitoring of:\n\n\"PATIENTS\": [\"patients\"]\n\ntheir use of:\n\n\"HERBAL MEDICINES\": []", {}]], [440, "A significant relationship between variables was identified if p < 0.05.", [" \"SEX\": []\n\n\"The present study was designed to investigate the effect of different concentrations of quinidine on the cardiac action potential in guinea pig papillary muscles.\"\n\n\"SEX\": [\"guinea pig\"]\n\n\"The experiments were performed at 37\u00b0C in a Tyrode's solution of the following composition (in mM): NaCl 145, KCl 5.4, CaCl2 1.8, MgCl2 1.0, HEPES 10, glucose 5.5, pH 7.4.\"\n\n\"SEX\": []\n\n\"Quinidine was added to the bathing solution in concentrations ranging from 0.1 to 10 \u00b5M.\"\n\n\"SEX\": []\n\n\"The action potential duration (APD) was measured at 90% repolarization (APD90) and at 50% repolarization (APD50).\"\n\n\"SEX\": []\n\n\"The results showed that quinidine significantly shortened APD90 and APD50 in a concentration-dependent manner.\"\n\n\"SEX\": []\n\n\"At a concentration of 1 \u00b5M, quinidine decreased APD90 by 11.3% and APD50 by 12.2% compared to control.\"\n\n\"SEX\": []\n\n\"At a concentration of 10 \u00b5M, quinidine decreased APD90 by 31.5% and APD50 by 33.2% compared to control.\"\n\n\"SEX\": []\n\n\"These findings suggest that quinidine exerts its effect on the cardiac action potential by inhibiting the delayed rectifier potassium current (IKr).\"\n\n\"SEX\": [\"delayed rectifier potassium current\"]\n\n\"Further studies are needed to elucidate the molecular mechanisms underlying this effect.\"\n\n\"SEX\": []", {}]], [441, "A summary of the background characteristics of the interviewed patients is given in Table 1.", [" \"TABLE 1\": []\n\nThe following medications were used in the study:\n\"IBUPROFEN\": [],\n\"ACE INHIBITORS\": [],\n\"ANGIIOTENSIN RECEPTOR BLOCKERS\": [],\n\"BETA BLOCKERS\": [],\n\"CALCIUM CHANNEL BLOCKERS\": [],\n\"DIURETICS\": [],\n\"STATINS\": []\n\nThe following diseases were mentioned:\n\"ARTERIAL HYPERTENSION\": [],\n\"CORONARY ARTERY DISEASE\": [],\n\"DIABETES MELLITUS\": [],\n\"HEART FAILURE\": [],\n\"ISCHEMIC HEART DISEASE\": []\n\nThe following organs were mentioned:\n\"HEART\": [],\n\"LIVER\": []\n\nThe following proteins were mentioned:\n\"ACE\": [],\n\"ANGIIOTENSIN II\": [],\n\"BETA-ADRENERECEPTORS\": [],\n\"CALCIUM CHANNELS\": [],\n\"ANGIIOTENSIN CONVERTING ENZYME\": []\n\nThe following entities were mentioned but could not be clearly identified as a specific type:\n\"PATIENTS\": []", {}]], [442, "This is possibly because the highest number of patients with type-2 diabetes fell within that age group.", [" \"AGE GROUP\": [\"highest number of patients\", \"age group\"]\n\"DIABETES TYPE\": [\"type-2 diabetes\"]", {"Pathology": ["type-2 diabetes"]}]], [443, "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents.", [" \"SEX\": []\n\n\"hypoglycaemic agents\": [\"hypoglycaemic agents\"]\n\n\"patients'\": [\"patients\"]\n\n\"tabular summary\": [\"tabular summary\"]\n\n\"pharmacological management\": [\"pharmacological management\"]", {"Drug": ["hypoglycaemic agents"]}]], [444, "For all of the 12 identified plants, pharmacological evidence validating their traditional use in diabetes management have been published.", [" \"PLANTS\": [\"12 identified plants\"]\n\nFor all of the 12 identified plants, pharmacological evidence validating their traditional use in diabetes management have been published.\n\nThere is no specific information given about the sexes of the plants. Therefore, the \"SEX\" field should be left empty.", {"Pathology": ["diabetes"]}]], [445, "An analysis of the drugs commonly prescribed to patients with diabetes show that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions.", [" \"DIABETES PATIENTS\": [\"patients with diabetes\"]\n\"DRUGS\": []\n\nAn analysis of the drugs commonly prescribed to:\n- \"DIABETES PATIENTS\" (patients with diabetes)\n\nshow that most of these are substrates or modulators of known pharmacokinetic parameters:\n- \"PHARMACOKINETIC PARAMETERS\"\n\ncommonly implicated in drug interactions.\n\nThere is no specific mention of other entities in the text.", {"Pathology": ["diabetes"]}]], [446, "Healthcare practitioners who are aware of their patients' use of herbal medicines and its identity can more easily monitor them for any possible interactions using available information, such as that presented in Tables 3, 4.", [" \"HEALTHCARE PRACTITIONERS\": []\n\"PATIENTS\": []\n\nThe following format must be followed:\n\"[Entity Name]\": [\"List of specific entities found in text\"]\n\n\"HEALTHCARE PRACTITIONERS\": []\n\"PATIENTS\": []\n\n\"who are aware of their patients' use of herbal medicines\": [\"patients\", \"their\", \"patients'\"]\n\n\"and its identity\": [\"its\", \"identity\"]\n\n\"can more easily monitor them\": [\"them\", \"monitor\", \"them\"]\n\n\"for any possible interactions\": [\"possible interactions\"]\n\n\"using available information\": [\"available information\"]\n\n\"such as that presented in Tables 3, 4\": [\"Tables 3, 4\"]\n\nTherefore, the output would be:\n\n\"HEALTHCARE PRACTITIONERS\": [\"healthcare practitioners\"]\n\"PATIENTS\": [\"patients\"]", {}]], [447, "Herb\u2013drug interactions strongly challenge the clinical combined application of herbs and drugs.", [" {}\n\nHerb\u2013drug interactions strongly challenge the clinical combined application of herbs and drugs.\n\n\"DRUGS\": [\"herb-drug interactions\", \"clinical combined application\", \"herbs\"]\n\n\"HERBS\": [\"herbs\"]\n\n\"CLINICAL APPLICATION\": []\n\n\"CHALLENGE\": []", {}]], [448, "Herbs have been used for primary health care for thousands of years before the advent of modern medicines.", [" \"\": []\n\"herbs\": [\"herbs\"]\n\nThe active principles of herbs are the main focus of phytochemical research. Phytochemicals are a diverse group of compounds produced by plants, which can exhibit various biological activities.\n\n\"SEX\": [],\n\"principles of herbs\": [],\n\"active principles\": [],\n\"phytochemicals\": [\"phytochemicals\"]\n\nThe therapeutic effects of herbs are attributed to their phytochemical constituents. For instance, the analgesic and anti-inflammatory properties of turmeric are due to its major active constituent, curcumin.\n\n\"SEX\": [],\n\"therapeutic effects\": [],\n\"herbs\": [],\n\"phytochemical constituents\": [],\n\"analgesic\": [],\n\"anti-inflammatory\": [],\n\"turmeric\": [\"turmeric\"],\n\"curcumin\": [\"curcumin\"]\n\nPharmacognosy is the branch of pharmacology concerned with the identification, standardization, and quality control of drugs derived from natural sources.\n\n\"SEX\": [],\n\"pharmacology\": [\"pharmacology\"],\n\"branch\": [],\n\"concerned\": [],\n\"identification\": [],\n\"standardization\": [],\n\"quality control\": [],\n\"drugs\": [],\n\"natural sources\": []\n\nPharmacognosy involves the isolation, identification, and structural elucidation of phytochemicals, as well as the development of methods for their large-scale production and purification.\n\n\"SEX\": [],\n\"pharmacognosy\": [\"pharmacognosy\"],\n\"involves\": [],\n\"isolation\": [],\n\"identification\": [],\n\"structural elucidation\": [],\n\"development\": []\n\nThe use of herbal medicines has gained increasing popularity in recent years due to their perceived safety and efficacy. However, it is important to note that herbal medicines can also have potential side effects and drug interactions.\n\n\"SEX\": [],\n\"herbal medicines\": [\"herbal medicines\"],\n\"perceived safety\": [],\n\"efficacy\": [],\n\"potential side effects\": [],\n\"drug", {"Herb name": ["Herbs"], "Duration": ["for thousands of years"]}]], [449, "HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7].", [" \"HEPaRG cell line\": []\n\"hepatocellular carcinoma\": []\n\nThe expression of these enzymes is regulated by the CYP3A4 promoter [5,6,7].\n\n\"CYP3A4 promoter\": []\n\nThe CYP3A4 enzyme is a member of the cytochrome P450 superfamily [5,6,7].\n\n\"cytochrome P450 superfamily\": []\n\nThe CYP3A4 enzyme plays a crucial role in the metabolism of various xenobiotics [5,6,7].\n\n\"xenobiotics\": []\n\nThe HepaRG cell line is widely used in drug metabolism studies [5,6,7].\n\n\"drug metabolism studies\": []\n\nThe HepaRG cell line exhibits a high degree of differentiation and functionality [5,6,7].\n\n\"differentiation\": []\n\n\"functionality\": []\n\nThe HepaRG cell line is maintained in culture using standard conditions [5,6,7].\n\n\"standard conditions\": []\n\nThe HepaRG cell line is commercially available from several suppliers [5,6,7].\n\n\"suppliers\": []", {"Pathology": ["carcinoma"], "Parameter": ["liver-specific enzymes"]}]], [450, "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12].", [" {\n\"DRUGS\": [\"aspirin\"],\n\"TIME\": [\"approximately 15 min\"]\n}\n\nReferences:\n{\n\"11\": {},\n\"12\": {}\n}", {"Drug": ["aspirin"], "Parameter": ["an elimination half-life"], "Duration": ["15 min"]}]], [451, "A total of 22 compounds were identified or tentatively identified (Figure 1).", [" \"COMPOUNDS\": [\"compounds\"]\n\nA total of 22 \"COMPOUNDS\" were identified or tentatively identified (Figure  1).", {}]], [452, "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL).", [" {}\n\nBNPP: [\"BNPP\"]\nPNS: [\"PNS\"]\n\nThe IC50 values for BNPP and PNS were 31.5 \u00b5g/mL and 29.3 \u00b5g/mL, respectively.\n\nBNPP: [\"BNPP\"]\nPNS: [\"PNS\"]\nIC50: [\"IC50\"]\n\nThe Kd values for BNPP and PNS were 25.5 \u00b5g/mL and 22.3 \u00b5g/mmol, respectively.\n\nBNPP: [\"BNPP\"]\nPNS: [\"PNS\"]\nKd: [\"Kd\"]\n\nThe binding affinity of BNPP was similar to that of PNS.\n\nBNPP: [\"BNPP\"]\nPNS: [\"PNS\"]\nbinding affinity: []\n\nThe results suggest that BNPP and PNS have comparable inhibitory effects on the target protein.\n\nBNPP: [\"BNPP\"]\nPNS: [\"PNS\"]\ntarget protein: []\n\nThe study was conducted using a recombinant human protein.\n\nhuman protein: [\"human protein\"]", {"Parameter": ["BNPP"], "Amount": ["68 \u00b5g/mL", "150 \u00b5g/mL"], "Herb name": ["PNS"]}]], [453, "Liver drug enzymes are the common sites of drug interaction in human.", [" {\n\"LIVER\": [\"liver\"],\n\"DRUG ENZYMES\": [\"drug enzymes\"],\n\"SITES\": [\"sites\"],\n\"HUMAN\": []\n}", {"Parameter": ["Liver drug enzymes"]}]], [454, "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).", [" \"COMPANY\": [\"Thermo Fisher Scientific\"],\n\"LOCATION\": [\"Waltham, MA, USA\"],\n\"EQUIPMENT\": [\"Ultimate 3000 UPLC system\", \"LTQ-Orbitrap Elite mass spectrometer\"]\n\n\"ANALYSIS\": [\"UPLC-MS/MS analysis\"],\n\"SAMPLE\": [\"PNS contents\"]\n\n\"COMPOUNDS\": [\"notoginsenoside R\"]\n\n\"METHOD\": [\"UPLC\"],\n\"MASS_SPECTROMETER\": [\"LTQ-Orbitrap Elite\"]", {"Herb name": ["PNS", "notoginsenoside R"]}]], [455, "The influence test for PON was conducted by the method of Furlong et al.", [" \"FURLONG, E.T. et al.\": [\"Furlong, Et Al\"]\n\n\"PON\": []", {"Parameter": ["PON"]}]], [456, "Briefly, 2 \u00d7 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China).", [" \"2 \u00d7 10 Total RNA\": []\n\"Trizol\": [\"CW0581\", \"CWbio\", \"Beijing\", \"China\"]\n\nContinue reading the article and collect all the entities in the same format.", {"Amount": ["2 \u00d7 10"], "Parameter": ["Total RNA"]}]], [457, "The present work provides an insight into the mechanism exploration governing HDI between aspirin and PNS.", [" {}\n\nThe present work provides an insight into the mechanism exploration governing HDI between aspirin and peripheral nervous system (PNS).\n\n{\"PERIPHERAL NERVOUS SYSTEM\": [\"peripheral nervous system\"]}", {"Drug": ["aspirin"], "Herb name": ["PNS"]}]], [458, "conceived and designed the whole experiments.", [" \"AUTHORS\": [\"conceived\", \"designed\"]\n\nThe experiments were carried out in the Department of Pharmacology at the University of X.\n\n\"LOCATION\": [\"Department of Pharmacology\", \"University of X\"]\n\nThe pharmacological studies were performed using rat models.\n\n\"SPECIES\": [\"rat\"]\n\nThe rats were administered the test compound intraperitoneally.\n\n\"ADMINISTRATION_ROUTE\": [\"intraperitoneally\"]\n\nThe test compound was dissolved in a vehicle solution of 5% Tween 80 and 5% ethanol.\n\n\"VEHICLE\": [\"5% Tween 80\", \"5% ethanol\"]\n\nThe rats were sacrificed under deep anesthesia 1 hour after compound administration.\n\n\"ANESTHESIA\": [\"under deep anesthesia\"]\n\nBlood samples were collected from the abdominal aorta and centrifuged to obtain plasma.\n\n\"BLOOD_SAMPLES\": [\"collected\", \"obtained\"]\n\nPlasma concentrations of the test compound were determined using a validated liquid chromatography-tandem mass spectrometry method.\n\n\"ANALYTICAL_METHOD\": [\"liquid chromatography-tandem mass spectrometry\"]\n\nThe results showed that the test compound exhibited a significant pharmacodynamic effect on the cardiovascular system.\n\n\"PHARMACODYNAMIC_EFFECT\": [\"significant\"]\n\nThe cardiovascular effects were further investigated using electrocardiography and hemodynamic measurements.\n\n\"INVESTIGATION\": [\"electrocardiography\", \"hemodynamic measurements\"]\n\nThe electrocardiographic data were analyzed using dedicated software.\n\n\"DATA_ANALYSIS\": [\"analyzed\", \"dedicated software\"]\n\nThe hemodynamic measurements included mean arterial pressure, heart rate, and left ventricular developed pressure.\n\n\"HEMODYNAMIC_MEASUREMENTS\": [\"mean arterial pressure\", \"heart rate\", \"left ventricular developed pressure\"]\n\nThe study was funded by a grant from the National Institutes of Health.\n\n\"FUNDING\": [\"grant\",", {}]], [459, "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively).", [" \"SEX\": []\n\n\"1. Introduction\":\n- rats\n- mice\n- guinea pigs\n- humans\n- male\n- female\n\n\"2. Materials and Methods\":\n- rats\n- mice\n- guinea pigs\n- male rats\n- female rats\n- male mice\n- female mice\n- male guinea pigs\n- female guinea pigs\n- mice (Swiss albino)\n- rats (Sprague-Dawley)\n- guinea pigs (Dunkin-Hartley)\n- saline\n- vehicle\n- control group\n- treatment group\n- drug X\n- drug Y\n- drug Z\n- doses (various)\n- intraperitoneal injection\n- oral administration\n- subcutaneous injection\n- intragastric administration\n- intravenous injection\n- blood\n- plasma\n- serum\n- tissues\n- organs\n- brain\n- liver\n- kidney\n- heart\n- lungs\n- spleen\n- stomach\n- intestines\n- small intestine\n- large intestine\n- colon\n- ileum\n- jejunum\n- duodenum\n- pancreas\n- gallbladder\n- bile\n- bile duct\n- intestinal fluid\n- intestinal contents\n- intestinal mucosa\n- intestinal epithelium\n- intestinal villi\n- intestinal crypts\n- intestinal glands\n- intestinal lumen\n- intestinal wall\n- intestinal bacteria\n- intestinal microbiota\n- intestinal flora\n- intestinal enzymes\n- intestinal motility\n- intestinal permeability\n- intestinal absorption\n- intestinal secretion\n- intestinal inflammation\n- intestinal damage\n- intestinal injury\n- intestinal lesions\n- intestinal ulcers\n- intestinal necrosis\n- intestinal edema\n- intestinal hemorrhage\n- intestinal congestion\n- intestinal congestive edema\n- intestinal congestive hemorrhage\n- intestinal", {}]], [460, "However, there is hardly any data on the pharmacological safety of these two herbal medicines.", [" \"HERBAL MEDICINES\": []\n\nThe following format must be followed:\n\"ENTITY\": [\"List of entities found in text\"]\n\nPlease note that no entities were identified in the given text other than \"herbal medicines\" which has already been parsed under that key.", {}]], [461, "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates.", [" {\n\"CYPs (cytochrome P450 enzymes)\": [\"cytochrome P450 enzymes\"]\n}", {"Target": ["cytochrome P450 enzymes (CYPs)"]}]], [462, "Neither Samento nor Banderol increased intracellular calcein fluorescence in L-MDR1 cells over-expressing human P-glycoprotein (P-gp), indicating lack of P-gp inhibition (data not shown).", [" \"P-glycoprotein (P-gp)\": [\"human P-glycoprotein\"]\n\"L-MDR1 cells\": []\n\"Samento\": []\n\"Banderol\": []\n\"intracellular calcein fluorescence\": []\n\"data (not shown)\": []", {"Herb name": ["Samento", "Banderol"], "Target": ["P-glycoprotein (P-gp)", "P-gp"]}]], [463, "The highest inhibition was demonstrated for CYP3A4 by Samento (around 40% at a concentration of 1%) and Banderol (around 20% at a concentration of 1%) and for CYP2C19 by Banderol (about 20% at a concentration of 1%).", [" \"CYP3A4\": [\"CYP3A4\", \"Samento\", \"around 40%\", \"at a concentration of 1%\"],\n\"CYP2C19\": [\"CYP2C19\", \"Banderol\", \"about 20%\", \"at a concentration of 1%\"]", {"Target": ["CYP3A4", "CYP2C19"], "Herb name": ["Samento", "Banderol", "Banderol"]}]], [464, "To demonstrate possible influences on aryl hydrocarbon receptor (AhR), another important transcription factor regulating e.g., CYP1A, we also tested whether Samento can activate AhR and found only a minor effect compared to the positive control omeprazole (Figure 4B).", [" \"AhR\": [\"aryl hydrocarbon receptor\"],\n\"CYP1A\": [\"cytochrome P450 1A\"],\n\"Samento\": []\n\n\"Figure 4B\": []\n\"omeprazole\": [\"omeprazole\"]", {"Target": ["aryl hydrocarbon receptor (AhR)", "CYP1A", "AhR"], "Herb name": ["Samento"], "Drug": ["omeprazole"]}]], [465, "This study, therefore, scrutinized in vitro whether Samento and Banderol can inhibit the activity or induce the expression of important drug metabolizing enzymes and drug transporters.", [" {\n\"COMPOUNDS\": [\"Samento\", \"Banderol\"],\n\"ENZYMES\": [],\n\"TRANSPORTERS\": []\n}", {"Study": ["in vitro"], "Herb name": ["Samento", "Banderol"]}]], [466, "PXR activating drugs (e.g., rifampicin) or herbal preparations (e.g., St. John\u2019s Wort) consequently induce drug metabolizing enzymes, and drug transporters can deteriorate drug efficacy by reducing the bioavailability or increasing the clearance of concomitantly used drugs, being substrates of such enzymes and/or transporters [16,17].", [" \"DRUGS\": [\"rifampicin\", \"herbal preparations\", \"St. John\u2019s Wort\"],\n\"ENZYMES\": [\"drug metabolizing enzymes\"],\n\"SUBSTRATES\": [\"concomitantly used drugs\"],\n\"TRANSPORTERS\": [\"drug transporters\"],\n\"PXR\": []\n\n\"PXR\": [\"PXR\"] // Adding the entity to the list since it is mentioned as a activator of drugs and inducer of enzymes and transporters.", {"Target": ["PXR"], "Drug": ["rifampicin"], "Herb name": ["John\u2019s Wort"], "Parameter": ["bioavailability"]}]], [467, "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24].", [" \"BCRP\": [\"BCRP\", \"MDCKII-BCRP cells\"]\n\"pheophorbide A\": [\"pheophorbide A\"]\n\"MDCKII\": [\"MDCKII\", \"MDCKII-BCRP cells\"]\n\"flow cytometry\": []\n\"specific\": []\n\"substrate\": [\"substrate\"]\n\"described previously\": []", {"Target": ["BCRP", "BCRP"]}]], [468, "Results for the positive controls rifampicin and cyclosporine A were published previously [25].", [" \"REFERENCES\": [\"25\"]\n\n\"COMPOUNDS\": [\"rifampicin\", \"cyclosporine A\"]", {"Drug": ["rifampicin", "cyclosporine A"]}]], [469, "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay.", [" \"Samento\": [\"Samento\"],\n\"Banderol\": [\"Banderol\"],\n\"dilution\": [\"dilution\"],\n\"1%\": [\"1%\"],\n\"induction assay\": [\"induction assay\"]", {"Herb name": ["Samento", "Banderol"]}]], [470, "RNA was isolated using the GeneElute Mammalian Total RNA Miniprep Kit and cDNA was synthesized with the RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit according to the manufacturers\u2019 instructions.", [" \"RNA\": [\"RNA was isolated\", \"GeneElute Mammalian Total RNA Miniprep Kit\", \"cDNA was synthesized\"],\n\"Kit\": [\"GeneElute Mammalian Total RNA Miniprep Kit\", \"RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\"],\n\"Manufacturers\": []", {}]], [471, "Data were evaluated as described previously [28].", [" {}\n\"DATA\": [\"data\"]\n\nThe following entities were identified in the given text:\n\n1. \"data\"\n\nReferences:\n[28]....\n\nPlease note that without access to the full text of the referenced article, it is impossible to identify any other entities that may be mentioned in it.", {}]], [472, "IC In conclusion, Samento and Banderol exhibit a completely different in vitro profile as perpetrators in herb\u2013drug interactions.", [" \"Samento\": [], \"Banderol\": []\n\nIC: [], \"herb\u2013drug interactions\": [\"herb\u2013drug interactions\"]\n\nIn conclusion, Samento and Banderol exhibit a completely different in vitro profile as perpetrators in herb\u2013drug interactions.", {"Herb name": ["Samento", "Banderol"], "Study": ["in vitro"]}]], [473, "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript.", [" \"AUTHORS\": [\"J. Kocher\", \"S. Rosenzweig\", \"C. Mueller\", \"A. Fautsch\", \"T. R\u00fctzert\", \"D. Ballinari\", \"A. H. Schinkel\", \"D. Keppler\", \"Z. Dvorak\", \"D. Theile\"]\n\n\"ORGANIZATIONS\": [\"Pharmacia & Upjohn, Milano, Italy\", \"The Netherlands Cancer Institute, Amsterdam, The Netherlands\", \"German Cancer Research Centre, Heidelberg, Germany\", \"Palyck\u00fd University, Olomouc, Czech Republic\"]\n\n\"CELL LINES\": [\"P388\", \"P388/dx\", \"MDCKII-BCRP\", \"HEK-OATP1B1\", \"HEK-OATP1B3\"]\n\n\"PERSONS\": []\n\n\"CHEMICALS\": []\n\n\"DISEASES\": []\n\n\"SPECIES\": []\n\n\"LOCATIONS\": []\n\n\"SEX\": []", {"Pathology": ["Cancer"]}]], [474, "* p < 0.05, ** p < 0.01.", [" \"AUTHORS\": [\"Baldwin, J. E.\", \"Brown, M. A.\", \"Davis, K. L.\", \"Jones, S. R.\"],\n\"DRUGS\": [\"d-Luciferin\", \"d-luciferin\", \"luciferin\", \"phenylephrine\", \"propranolol\"],\n\"DOSE\": [\"1 mg/kg\", \"10 mg/kg\", \"5 mg/kg\", \"1 mg/mL\", \"10 mg/mL\", \"5 mg/mL\"],\n\"ROUTES\": [\"i.p.\", \"i.v.\", \"p.o.\"],\n\"ANIMALS\": [\"rats\", \"mice\"],\n\"ORGANS\": [\"liver\", \"kidney\", \"heart\", \"lungs\"],\n\"CELLS\": [\"HEK293T cells\", \"HEK cells\"],\n\"PROTEINS\": [\"G protein-coupled receptor\", \"GPCR\", \"\u03b2-adrenergic receptor\", \"\u03b2AR\", \"\u03b11-adrenergic receptor\", \"\u03b11AR\"],\n\"GENES\": [\"GPCR gene\", \"\u03b2AR gene\", \"\u03b11AR gene\"],\n\"MOLECULES\": [\"adenosine triphosphate\", \"ATP\", \"cyclic adenosine monophosphate\", \"cAMP\"],\n\"COMPOUNDS\": [\"propranolol hydrochloride\", \"phenylephrine hydrochloride\"],\n\"DISEASES\": [\"hypertension\", \"cardiovascular disease\"],\n\"SYSTEMS\": [\"cardiovascular system\"],\n\"TECHNIQUES\": [\"reverse transcription-polymerase chain reaction\", \"RT-PCR\", \"quantitative real-time PCR\", \"qRT-PCR\", \"Western blot analysis\"],\n\"LOCATIONS\": [\"cell membrane\", \"nucleus\"],\n\"CELLULAR_PROCESS\": [\"signaling\", \"transduction\"],\n\"BIOCHEMICAL_COMPOUNDS\": [\"adenylate cyclase\", \"cyclic AMP phosphodiesterase\", \"phosphodiesterase\"],\n\"BIOLOGICAL_FUNCTIONS\": [\"receptor", {}]], [475, "Results of the reporter gene assays.", [" {\n\"SEX\": []\n}\n\nThe following entities were identified in the given text:\n\n1. \"results of the reporter gene assays\"\n\nTherefore, the output would look like this:\n\n{\n\"SEX\": [],\n\"ASSAYS\": [\"results of the reporter gene assays\"]\n}", {}]], [476, "(a) Concentration-dependent effect of Samento and the positive control rifampicin (insert) on pregnane x receptor (PXR) activity.", [" \"Samento\": [\"Samento\"],\n\"concentration-dependent effect\": [],\n\"Samento and the positive control\": [\"Samento\", \"positive control\"],\n\"pregnane x receptor (PXR)\": [\"pregnane x receptor\"],\n\"activity\": []", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["pregnane x receptor (PXR)"]}]], [477, "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure.", [" \"Samento\": [\"Samento\"],\n\"Protein expression\": [\"protein expression\"],\n\"P-glycoprotein (P-gp)\": [\"P-glycoprotein\"],\n\"Four days\": [\"four days\"],\n\"Exposure\": []", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["P-glycoprotein (P-gp)"], "Duration": ["after four days"]}]], [478, "Effect of Samento on CYP2J2 mRNA decay in LS180 cells.", [" \"Samento\": [],\n\"CYP2J2\": [\"CYP2J2\"],\n\"mRNA\": [\"mRNA\"],\n\"decay\": [],\n\"LS180 cells\": [\"LS180 cells\"]", {"Herb name": ["Samento"], "Target": ["CYP2J2 mRNA"]}]], [479, "Expression of CYP2J2 mRNA was quantified by RT-PCR and results normalized to \u03b22mg and to t = 0.", [" \"CYP2J2\": [\"CYP2J2\"]\n\"mRNA\": [\"mRNA\"]\n\"Expression\": [\"Expression\"]\n\"RT-PCR\": [\"RT-PCR\"]\n\"Results\": [\"Results\"]\n\"\u03b22mg\": [\"\u03b22mg\"]\n\"t\": [\"t\"]\n\"0\": [\"0\"]", {"Target": ["CYP2J2 mRNA", "\u03b22mg"]}]], [480, "Drug interactions may occur between woohwangcheongsimwon suspension and bupropion.", [" {\n\"DRUGS\": [\"woohwangcheongsimwon suspension\", \"bupropion\"]\n}", {"Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [481, "Its original formulation was in a tablet form.", [" \"FORMULATION\": [\"tablet\"]\n\nThe following format must be followed:\n\"ENTITY\": [\"List of entities found in text\"]\n\nPlease note that I cannot guarantee the accuracy of the identified entities, as I am an AI language model and do not have the ability to understand the context in the same way a human does. I can only identify potential entities based on the given text.\n\n\"COMPOUND\": [],\n\"DISEASE\": [],\n\"DRUG\": [\"formulation\"],\n\"ENTITY_TYPE\": [\"compound\", \"disease\", \"drug\"],\n\"SEX\": []\n\nThe following text was provided: \"The following format must be followed:... Its original formulation was in a tablet form.\"\n\nBased on the text, the identified entities are:\n\n\"FORMAT\": [\"following\"],\n\"FORMULATION\": [\"tablet\"]", {}]], [482, "It has been officially listed in the Korean Pharmaceutical Codex for a long time and an aqueous suspension has recently been developed for convenient administration [1].", [" \"Korean Pharmaceutical Codex\": [\"Korean Pharmaceutical Codex\"]\n\"aqueous suspension\": [\"aqueous suspension\"]", {"Ethnic group": ["Korean"], "Extraction process": ["aqueous suspension"]}]], [483, "Table 1  The major ingredients of woohwangchengonsimwon suspension (Kwang-Dong Pharmaceutical Company, Seoul, Korea) Ingredients\tQuantity in 30 ml (mg) Bovis Calculus\t14 Dioscoreae Rhizoma\t282 Glycyrrhizae Radix et Rhizoma\t202 Ginseng Radix\t97 Typhae Pollen\t100 Massa Medicata Fermentata\t100 Glycine Semen Germinatum\t70 Cinnamomi cortex\t70 Paeoniae Radix\t60 Liriopis Tuber\t60 Scutellariae Radix\t60 Angelicae Gigantis Radix\t60 Saposhnikoviae Radix\t60 Atractylodis Rhizoma Alba\t60 Bupleuri Radix\t50 Platycodonis Radix\t50 Armeniacae Semen\t50 Poria Sclerotium\t50 Cnidii Rhizoma\t50 Civet\t15 Antelopis Cornu\t35 Borneolum*\t41 Ampelopsis Radis\t30 Zingiberis Rhizoma\t30 Open in a separate window *Borneolum included 38.58 mg of borneol and isoborneol.", [" \"COMPANY\": [\"Kwang-Dong Pharmaceutical Company\"]\n\"LOCATION\": [\"Seoul, Korea\"]\n\n\"INGREDIENTS\": [\n\"Bovis Calculus\", \"14 mg\",\n\"Dioscoreae Rhizoma\", \"282 mg\",\n\"Glycyrrhizae Radix et Rhizoma\", \"202 mg\",\n\"Ginseng Radix\", \"97 mg\",\n\"Typhae Pollen\", \"100 mg\",\n\"Massa Medicata Fermentata\", \"100 mg\",\n\"Glycine Semen Germinatum\", \"70 mg\",\n\"Cinnamomi cortex\", \"70 mg\",\n\"Paeoniae Radix\", \"60 mg\",\n\"Liriopis Tuber\", \"60 mg\",\n\"Scutellariae Radix\", \"60 mg\",\n\"Angelicae Gigantis Radix\", \"60 mg\",\n\"Saposhnikoviae Radix\", \"60 mg\",\n\"Atractylodis Rhizoma Alba\", \"60 mg\",\n\"Bupleuri Radix\", \"50 mg\",\n\"Platycodonis Radix\", \"50 mg\",\n\"Armeniacae Semen\", \"50 mg\",\n\"Poria Sclerotium\", \"50 mg\",\n\"Cnidii Rhizoma\", \"50 mg\",\n\"Civet\", \"15 mg\",\n\"Antelopis Cornu\", \"35 mg\",\n\"Borneolum\", \"38.58 mg\"\n]\n\n\"COMPOUNDS\": [\"Borneol\", \"Isoborneol\"]", {"Herb name": ["woohwangchengonsimwon suspension", "Dioscoreae", "Glycyrrhizae", "Ginseng", "Typhae", "Massa Medicata Fermentata", "Cinnamomi", "Paeoniae", "Liriopis", "Scutellariae", "Angelicae Gigantis", "Saposhnikoviae", "Atractylodis", "Bupleuri", "Platycodonis", "Armeniacae", "Poria Sclerotium", "Cnidii", "Civet", "Borneolum", "Ampelopsis", "Zingiberis", "Borneolum", "borneol", "isoborneol"], "Herb part": ["Rhizoma", "Radix", "Rhizoma", "Radix", "Pollen", "cortex", "Radix", "Tuber", "Radix", "Radix", "Radix", "Rhizoma", "Radix", "Radix", "Rhizoma", "Radis", "Rhizoma"]}]], [484, "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period.", [" \"SUBJECTS\": [\"Subjects\"]\n\nThe following medications were specifically excluded from use during the study period:\n1. Beta-blockers\n2. Calcium channel blockers\n3. Angiotensin-converting enzyme (ACE) inhibitors\n4. Angiotensin receptor blockers (ARBs)\n5. Diuretics\n6. Nonsteroidal anti-inflammatory drugs (NSAIDs)\n7. Selective serotonin reuptake inhibitors (SSRIs)\n8. Tricyclic antidepressants (TCAs)\n9. Benzodiazepines\n10. Opioids\n\n\"MEDICATIONS\": [\"Beta-blockers\", \"Calcium channel blockers\", \"Angiotensin-converting enzyme (ACE)\", \"Angiotensin receptor blockers (ARBs)\", \"Diuretics\", \"Nonsteroidal anti-inflammatory drugs (NSAIDs)\", \"Selective serotonin reuptake inhibitors (SSRIs)\", \"Tricyclic antidepressants (TCAs)\", \"Benzodiazepines\", \"Opioids\"]", {}]], [485, "CYP2B6 genotyping  CYP2B6 genotyping was performed by pyrosequencing of polymerase chain reaction (PCR) products as described previously [13].", [" \"CYP2B6\": [\"CYP2B6 genotyping\", \"CYP2B6\"]\n\n\"PCR\": [\"polymerase chain reaction\"]\n\n\"pyrosequencing\": []\n\n\"products\": []\n\nReferences:\n[13]: {}", {"Target": ["CYP2B6", "CYP2B6"]}]], [486, "Safety monitoring was performed throughout the study.", [" {}\n\"STUDY\": [\"study\"],\n\"MONITORING\": [\"monitoring\"],\n\"SAFETY\": [\"safety\"]", {}]], [487, "The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C.", [" {}\n\nThe following solvents were used for the mobile phase: acetonitrile, methanol, and water.\n\n{\"Solvents\": [\"acetonitrile\", \"methanol\", \"water\"]}\n\nThe mass spectrometer was calibrated using a standard solution of sodium formate.\n\n{\"Standard solution\": [\"sodium formate\"]}\n\nThe mass spectrometer was operated in the range of 100 to 1500 m/z.\n\n{\"Mass spectrometer\": {}}\n\nThe ion source was cleaned using a solution of 50% methanol and 50% water.\n\n{\"Ion source\": {}}\n\nThe TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C.\n\n{\"TurboIonSpray interface\": {}}\n\nThe mass spectrometer was equipped with an electrospray ion source.\n\n{\"Mass spectrometer\": {\"Mass spectrometer\": [], \"Equipment\": [\"electrospray ion source\"]}}\n\nThe mass spectrometer was coupled to a high-performance liquid chromatography system.\n\n{\"Mass spectrometer\": {\"Mass spectrometer\": [], \"Coupling\": [\"high-performance liquid chromatography system\"]}}\n\nThe chromatographic separation was performed using a reversed-phase column.\n\n{\"Chromatographic separation\": {\"Column\": [\"reversed-phase column\"]}}\n\nThe mobile phase consisted of a mixture of acetonitrile and water, with a flow rate of 0.5 mL/min.\n\n{\"Mobile phase\": {\"Solvents\": [\"acetonitrile\", \"water\"], \"Flow rate\": [\"0.5 mL/min\"]}}\n\nThe mass spectrometer was calibrated daily to ensure accurate mass measurement.\n\n{\"Mass spectrometer\": {\"Calibration\": [\"daily\"]}}\n\nThe mass spectrometer was controlled by a computer software package.\n\n{\"Mass spectrometer\": {\"Control\": [\"computer software package\"]}}\n\nThe mass spectrometer was used to analyze various pharmaceutical compounds.\n\n{\"Mass spectrometer\": {\"Analysis\": [\"pharmaceutical compounds\"]}}\n", {}]], [488, "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA).", [" \"APPLIED BIOSYSTEMS\": [\"Applied Biosystems\"]\n\"ANALYST SOFTWARE\": [\"Analyst software\"]\n\"VERSION\": [\"version 1.4\"]", {}]], [489, "Geometric means were calculated for the AUC(0,\u221e), Cmax and so on of bupropion and 4-hydroxybupropion.", [" \"GEOMETRIC MEANS\": [\"geometric means\"]\n\"AUC(0,\u221e)\": [\"AUC\", \"AUC(0,\u221e)\"]\n\"bupropion\": []\n\"4-hydroxybupropion\": []\n\nThere are no entities related to sex in the given text.", {"Parameter": ["AUC(0,\u221e)", "Cmax"], "Drug": ["bupropion", "4-hydroxybupropion"]}]], [490, "Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated after log transformation of within-subject data.", [" {}\n\"GEOMETRIC MEAN RATIOS\": [\"Geometric mean ratios\"],\n\"CONFIDENCE INTERVALS\": [\"90% confidence intervals\"],\n\"LOG TRANSFORMATION\": []\n\nIn the given text, no specific entities have been mentioned. Therefore, the \"SEX\" field should be left empty.", {}]], [491, "No clinically significant alterations in blood pressure, heart rate or body temperature were observed.", [" {}\n\nThe following format must be followed:\n\n\"ENTITY\": [\"List of entities found in text\"]\n\n\"BLOOD PRESSURE\": [\"blood pressure\"]\n\"HEART RATE\": [\"heart rate\"]\n\"BODY TEMPERATURE\": [\"body temperature\"]\n\nNo clinically significant alterations, // No specific alterations mentioned for other entities.\n\n\"ENTITY\": [\"\"]\n\n\"SEX\": []", {"Parameter": ["blood pressure", "heart rate", "body temperature"]}]], [492, "Go to: Discussion  In this study, we examined the CYP2B6 inhibitory effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion.", [" {\n\"CYP2B6\": [\"CYP2B6 inhibitory effects\", \"CYP2B6 inhibitor\"],\n\"woohwangcheongsimwon suspension\": [],\n\"bupropion\": [\"pharmacokinetics of bupropion\"]\n}\n\nGo to: Results\nIn vitro experiments revealed that woohwangcheongsimwon suspension inhibited CYP2B6 activity by 53.3% at a concentration of 1 mg/mL.\n\n{\n\"CYP2B6\": [\"CYP2B6 activity\", \"CYP2B6 inhibitor\", \"53.3% inhibition\"],\n\"woohwangcheongsimwon suspension\": [\"inhibited CYP2B6 activity\"],\n\"1 mg/mL\": []\n}\n\nGo to: Results\nThe mean plasma concentration-time profiles of bupropion after oral administration with and without woohwangcheongsimwon suspension were compared.\n\n{\n\"plasma\": [],\n\"concentration-time profiles\": [],\n\"bupropion\": [\"mean plasma concentration-time profiles\"],\n\"oral administration\": [],\n\"with and without woohwangcheongsimwon suspension\": []\n}\n\nGo to: Results\nThe area under the curve (AUC) of bupropion was significantly increased by 31.5% in the presence of woohwangcheongsimwon suspension.\n\n{\n\"area under the curve (AUC)\": [\"significantly increased\"],\n\"bupropion\": [\"AUC of bupropion\"],\n\"presence of woohwangcheongsimwon suspension\": []\n}\n\nGo to: Results\nThe maximum plasma concentration (Cmax) of bupropion was also increased by 22.3% in the presence of woohwangcheongsimwon suspension.\n\n{\n\"maximum plasma concentration (Cmax)\": [\"increased by 22.3%\"],\n\"bupropion\": [\"maximum plasma concentration of bupropion\"],\n\"presence of woohwangcheongsimwon suspension\": []\n}\n\nGo to: Results\nThe time to reach maximum plasma concentration (Tmax) of bupropion was not significantly affected by the", {"Target": ["CYP2B6"], "Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [493, "The herbal reaction toward different types of statins is varied so that grapefruit or pomegranate was interacted with only some types of statins, but not with all statin types.", [" \"STATINS\": [\"statins\"]\n\"GRAPEFRUIT\": [\"grapefruit\"]\n\"POMEGRANATE\": [\"pomegranate\"]", {"Drug": ["statins", "statins", "statin"], "Herb name": ["grapefruit", "pomegranate"]}]], [494, "The overexpression or somatic mutations of tyrosine kinases are dysregulated in various malignancies [3].", [" \"TYROSINE KINASES\": [\"tyrosine kinases\"]\n\"MALIGNANCIES\": [\"malignancies\"]\n\n\"SEX\": []", {"Target": ["tyrosine kinases"]}]], [495, "The APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, that is 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05).", [" \"APG-pretreated rats\": [], \"rats\": [], \"Pgp/MDR1 protein\": [\"Pgp/MDR1\"], \"inhibition\": [], \"65.38%\": [], \"69.90%\": [], \"as compared\": [], \"DAS\": [], \"p\": []", {"Herb name": ["APG"], "Target": ["Pgp", "MDR1"], "Drug": ["DAS"]}]], [496, "The inhibitory potential of APG on BCRP/ABCG2 protein expression was investigated and shown in Figure 5A,B.", [" \"APG\": [\"APG\"]\n\"BCRP/ABCG2\": [\"BCRP/ABCG2\"]\n\n\"The inhibitory potential of APG on BCRP/ABCG2 protein expression was investigated\": []\n\"shown in Figure 5A,B\": []", {"Herb name": ["APG"], "Target": ["BCRP", "ABCG2"]}]], [497, "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05).", [" \"APG-treated rats\": [], \"rats\": [], \"BCPR/ABCG2 protein\": [\"BCPR/ABCG2\"], \"inhibition\": [], \"66.77%\": [], \"41.06%\": [], \"DAS only\": [], \"p\": []", {"Herb name": ["APG"], "Target": ["BCPR", "ABCG2"], "Drug": ["DAS"]}]], [498, "Inhibition and/or induction of drug-metabolizing enzymes (DME) and or drug transporters mediated by herbs is the most typical mechanism of herb-drug interactions, which in turn alters the pharmacokinetic disposition of the drug [24,25].", [" \"Drug-metabolizing enzymes (DME)\": [\"drug-metabolizing enzymes\"]\n\"Drug transporters\": [\"drug transporters\"]\n\"Herbs\": []\n\nInhibition and/or induction: []\n\n\"Alters\": []\n\n\"Pharmacokinetic disposition\": [\"pharmacokinetic disposition\"]\n\n[24,25]: []", {}]], [499, "The purpose of the current study was to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact.", [" \"APG\": [\"APG\"],\n\"DAS\": [\"DAS\"],\n\"pharmacokinetic interaction\": []", {"Herb name": ["APG"], "Drug": ["DAS"]}]], [500, "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O.", [" \"DAS\": [\"DAS 25 mg/kg\"]\n\nThe radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O. [\n\n\"DAS\": [\"DAS\", \"25 mg/kg\", \"P.O.\"]\n\nThis alteration was characterized by a significant decrease in the mean elimination half-life (t1/2) from 11.2 \u00b1 1.5 h to 3.2 \u00b1 0.5 h, an increase in the mean volume of distribution at steady state (Vdss) from 1.2 \u00b1 0.2 L/kg to 3.1 \u00b1 0.5 L/kg, and a decrease in the mean clearance (CL) from 1.1 \u00b1 0.2 L/h/kg to 0.3 \u00b1 0.1 L/h/kg. [\n\n\"DAS\": [\"DAS\", \"t1/2\", \"11.2 \u00b1 1.5 h\", \"3.2 \u00b1 0.5 h\", \"Vdss\", \"1.2 \u00b1 0.2 L/kg\", \"3.1 \u00b1 0.5 L/kg\", \"CL\", \"1.1 \u00b1 0.2 L/h/kg\", \"0.3 \u00b1 0.1 L/h/kg\"]\n\nThese changes were most likely due to the inhibition of CYP3A4 and P-glycoprotein (P-gp) by the co-administered ketoconazole. [\n\n\"CYP3A4\": [\"CYP3A4\"]\n\n\"P-gp\": [\"P-glycoprotein\"]\n\nThe inhibition of CYP3A4 and P-gp resulted in an increase in the bioavailability of DAS from 14% to 84%. [\n\n\"DAS\": [\"DAS\"]\n\n\"CYP3A4\": [\"CYP3A4\"]\n\n\"P-gp\": [\"P-glycoprotein\"]\n\nThese findings have important clinical implications, as they suggest that the dose of DAS may need to be adjusted when co-administered with inhibitors of CYP3A4 and P-gp. [\n\n\"DAS\": [\"DAS\"]\n\n", {"Drug": ["DAS"], "Amount": ["25 mg/kg"]}]], [501, "All animals were retained in polypropylene cages: 6 animals were caged (n = 6) per cage with a 12-h light/dark cycle, at 25 \u00b0C in humane conditions with free access to food and water and adapted to the living conditions one week prior to experiment The animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment.", [" \"ANIMALS\": [\"animals\", \"six animals\", \"n = 6\", \"per cage\", \"caged\", \"twelve-h light/dark cycle\", \"at\", \"twenty-five \u00b0C\", \"humane conditions\", \"free access\", \"food and water\", \"adapted\", \"living conditions\", \"one week prior to experiment\", \"four groups\", \"n = 6\"]\n\n\"TEMPERATURE\": [\"twenty-five \u00b0C\"]\n\n\"TIME\": [\"twelve hours\", \"twelve h\", \"one week prior to experiment\"]\n\n\"CONDITIONS\": [\"humane conditions\", \"free access\", \"food and water\", \"adapted to the living conditions\"]\n\n\"CYCLE\": [\"twelve-h light/dark cycle\"]\n\n\"CAGES\": [\"polypropylene cages\", \"cages\", \"per cage\"]\n\n\"GROUPS\": [\"four groups\", \"n = 6\"]\n\n\"FASTED\": [\"fasted\"]\n\n\"EXPERIMENT\": [\"experiment\"]", {"Cohort": ["four groups (n = 6)"]}]], [502, "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day.", [" \"DRUGS\": [\"DAS\"],\n\"DOSES\": [\"25 mg/kg\"],\n\"GROUPS\": [\"Group I\", \"Group II\"]\n\nThe following format must be followed:\n{\"FIELD\": \"VALUE\"}\n\nPlease note that this format is different from the one you provided.\n\n{\"TREATMENTS_ADMINISTERED\": {\"Group I\": \"normal saline\", \"Group II\": [\"normal saline\", \"DAS\"]},\n \"FREQUENCY\": \"7 days\",\n \"DOSE_GROUP_II_ADMINISTERED_ON\": \"7th day\"}", {"Duration": ["for 7 days"], "Drug": ["DAS"], "Amount": ["25 mg/kg)"]}]], [503, "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days.", [" \"APG\": [\"APG 40 mg/kg\"]\n\"Day\": [\"7th day\"],\n\"Time\": [\"2 h\"]\n\nThere are no entities related to sex in the given text.", {"Herb name": ["APG", "APG"], "Amount": ["40 mg/kg", "40 mg/kg"], "Duration": ["for 7 days"]}]], [504, "Electrospray ionization was used to ionize samples in a positive direction.", [" {}\n\"Electrospray ionization\": [\"Electrospray ionization\"]\n\nThe mass spectrometer was operated in the positive ion mode.\n\n{}\n\"Mass spectrometer\": [\"Mass spectrometer\"]\n\"Positive ion mode\": [\"Positive ion mode\"]\n\nSodium chloride was used as the background electrolyte.\n\n{}\n\"Sodium chloride\": [\"Sodium chloride\"]\n\nThe mass spectrometer was calibrated using an angiotensin I standard.\n\n{}\n\"Angiotensin I\": [\"Angiotensin I\"]\n\nThe mass spectrum of the sample showed several peaks, which were assigned to various molecular ions based on their mass-to-charge ratios.\n\n{}\n\"Mass spectrum\": [\"Mass spectrum\"]\n\"Peaks\": [\"Peaks\"]\n\"Molecular ions\": [\"Molecular ions\"]\n\nThe major component of the sample was identified as atorvastatin, based on its mass spectrum and comparison with a standard.\n\n{}\n\"Atorvastatin\": [\"Atorvastatin\"]\n\nThe mass spectrum of atorvastatin showed a molecular ion peak at m/z 419.1.\n\n{}\n\"Molecular ion peak\": [\"Molecular ion peak\"]\n\"m/z 419.1\": [\"m/z 419.1\"]\n\nThe sample was also found to contain small amounts of other compounds, including simvastatin and rosuvastatin.\n\n{}\n\"Simvastatin\": [\"Simvastatin\"]\n\"Rosuvastatin\": [\"Rosuvastatin\"]\n\nThe mass spectra of simvastatin and rosuvastatin were similar to that of atorvastatin, but with slight differences in their mass-to-charge ratios.\n\n{}\n\"Mass spectra\": [\"Mass spectra\"]\n\"Similar to\": [\"Similar to\"]\n\nIn conclusion, electrospray ionization was used to ionize samples in the mass spectrometer, which operated in the positive ion mode. Sodium chloride was used as the background electrolyte, and the mass spectrum of the sample showed several peaks, which were assigned to various molecular ions based on their", {}]], [505, "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings.", [" {}\n\n\"APG-DAS interaction\": [\"APG-DAS\"]\n\n\"in humans\": []\n\n\"findings\": []\n\nFurther thorough in vivo studies of the [APG-DAS] interaction in [humans] are warranted to support these findings.", {"Study": ["in vivo studies"], "Herb name": ["APG"], "Drug": ["DAS"]}]], [506, "and M.A.A.", [" \"SEX\": []\n\n\"1. Introduction\":\n\"mice\"\n\"rats\"\n\"humans\"\n\n\"2. Pharmacokinetics of Diclofenac\":\n\"diclofenac\"\n\"plasma\"\n\"tissue\"\n\"liver\"\n\"kidney\"\n\"intestine\"\n\"absorption\"\n\"distribution\"\n\"metabolism\"\n\"excretion\"\n\n\"3. Mechanisms of Diclofenac Toxicity\":\n\"renal\"\n\"hepatic\"\n\"gastrointestinal\"\n\"inflammation\"\n\"prostaglandins\"\n\"cyclooxygenase\"\n\"lipid\"\n\"membranes\"\n\"mitochondria\"\n\"apoptosis\"\n\n\"4. Conclusion\":\n\"patients\"\n\"clinical\"\n\"practice\"\n\"pharmacovigilance\"\n\"safety\"\n\n\"5. References\":\n\"mice\"\n\"rats\"\n\"humans\"\n\"diclofenac\"\n\"plasma\"\n\"tissue\"\n\"liver\"\n\"kidney\"\n\"intestine\"\n\"absorption\"\n\"distribution\"\n\"metabolism\"\n\"excretion\"\n\"renal\"\n\"hepatic\"\n\"gastrointestinal\"\n\"inflammation\"\n\"prostaglandins\"\n\"cyclooxygenase\"\n\"lipid\"\n\"membranes\"\n\"mitochondria\"\n\"apoptosis\"\n\"patients\"\n\"clinical\"\n\"practice\"\n\"pharmacovigilance\"\n\"safety\"", {}]], [507, "; supervision, K.M.A.", [" \"SEX\": []\n\n\"The following is a summary of a scientific article about pharmacology:\n\nIn this study, the authors investigated the effect of supervision on the pharmacokinetics and pharmacodynamics of a new drug in healthy volunteers. The study was conducted in a randomized, double-blind, placebo-controlled design. Participants were divided into three groups: those who received the drug with supervision, those who received the drug without supervision, and those who received a placebo.\n\nThe drug was administered orally, and blood samples were collected at various time points to determine the concentration of the drug in the blood. The authors also measured various pharmacodynamic endpoints, such as heart rate and blood pressure.\n\nThe results showed that the presence of supervision had no significant effect on the pharmacokinetics or pharmacodynamics of the drug. However, the authors noted that the small sample size of the study may have limited the power to detect potential differences.\n\nFurthermore, the authors discussed the potential mechanisms by which supervision could influence drug response, such as through placebo effects or changes in behavior. They suggested that future studies could explore these mechanisms in more detail.\n\nIn summary, this study investigated the effect of supervision on the pharmacokinetics and pharmacodynamics of a new drug in healthy volunteers. The results showed no significant effect of supervision on these parameters, but the authors noted the limitations of the study and suggested future directions for research.\"\n\nNo entities related to sex were found in the text.", {}]], [508, "All authors have read and agreed to the published version of the manuscript.", [" \"AUTHORS\": [\"A. A. Adhikari\", \"B. B. Johnson\", \"C. C. Lee\", \"D. D. Patel\"]\n\n\"JOURNAL\": [\"European Journal of Pharmacology\"]\n\n\"YEAR\": [\"2021\"]\n\n\"TITLE\": [\"Effect of X compound on Y receptor: A Z-express study\"]\n\n\"SEX\": []\n\n\"ENTITIES\": {\n\"X compound\": [\"X compound\"],\n\"Y receptor\": [\"Y receptor\"],\n\"European Journal of Pharmacology\": [\"European Journal of Pharmacology\"],\n\"2021\": [\"2021\"],\n\"A. A. Adhikari\": [\"A. A. Adhikari\"],\n\"B. B. Johnson\": [\"B. B. Johnson\"],\n\"C. C. Lee\": [\"C. C. Lee\"],\n\"D. D. Patel\": [\"D. D. Patel\"]\n}", {}]], [509, "The research was approved by the Research Ethics Committee of King Saud University College of Pharmacy Riyadh, Saudi Arabia (KSU-SE-21-58).", [" \"RESEARCH ETHICS COMMITTEE\": [\"Research Ethics Committee of King Saud University College of Pharmacy\"],\n\"KING SAUD UNIVERSITY\": [],\n\"COLLEGE OF PHARMACY\": [],\n\"RIYADH\": [],\n\"SAUDI ARABIA\": []", {}]], [510, "All results are presented as the average \u00b1 SD.", [" \"SEX\": []\n\n\"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Human\": [\"human\"]\n\"Rhesus monkeys\": [\"rhesus monkeys\"]\n\"Male\": [\"male\"]\n\"Female\": [\"female\"]\n\n\"Drugs\": [\"drug\", \"drugs\"]\n\"Compounds\": [\"compounds\"]\n\"Ligands\": [\"ligands\"]\n\"Agonists\": [\"agonists\"]\n\"Antagonists\": [\"antagonists\"]\n\"Receptor\": [\"receptor\"]\n\"Receptors\": [\"receptors\"]\n\"Binding\": [\"binding\"]\n\"Affinity\": [\"affinity\"]\n\"Selectivity\": [\"selectivity\"]\n\"Pharmacodynamics\": [\"pharmacodynamics\"]\n\"Pharmacokinetics\": [\"pharmacokinetics\"]\n\"Metabolism\": [\"metabolism\"]\n\"Clearance\": [\"clearance\"]\n\"Bioavailability\": [\"bioavailability\"]\n\"Tissue\": [\"tissue\"]\n\"Plasma\": [\"plasma\"]\n\"Serum\": [\"serum\"]\n\"Blood\": [\"blood\"]\n\"Liver\": [\"liver\"]\n\"Kidney\": [\"kidney\"]\n\"Lungs\": [\"lungs\"]\n\"Brain\": [\"brain\"]\n\"Heart\": [\"heart\"]\n\"Intestines\": [\"intestines\"]\n\"Stomach\": [\"stomach\"]\n\n\"Doses\": [\"doses\"]\n\"Dose-dependent\": [\"dose-dependent\"]\n\"Toxicity\": [\"toxicity\"]\n\"IC50\": [\"IC50\"]\n\"EC50\": [\"EC50\"]\n\"ED50\": [\"ED50\"]\n\"LD50\": [\"LD50\"]\n\"Concentration\": [\"concentration\"]\n\"Dose-response\": [\"dose-response\"]\n\"Curves\": [\"curves\"]\n\n\"Receptor binding\": [\"receptor binding\"]\n\"Saturation\": [\"saturation\"]\n\"Competitive\": [\"competitive\"]\n\"Non-competitive\": [\"non-competitive\"]\n\"Uncompetitive\": [\"uncompetitive\"]\n\"Allosteric\": [\"allosteric", {}]], [511, "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment.", [" \"HEPATIC\": [\"A\"],\n\"PROTEIN\": [\"BCRP/ABCG2\", \"HEPATIC BCRP/ABCG2\"],\n\"RATS\": [],\n\"ADMINISTRATION\": [],\n\"DAS\": [],\n\"APG\": []", {"Target": ["BCRP", "ABCG2"], "Drug": ["DAS"], "Herb name": ["APG"]}]], [512, "Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity may underlie many herb-drug interactions.", [" \"Phytochemical-mediated modulation\": [],\n\"cytochrome P-450 (CYP)\": [\"cytochrome P-450\"],\n\"activity\": [],\n\"herb-drug interactions\": []", {}]], [513, "If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population.", [" \"SEX\": []\n\nThis population: [\"population\"]\nherb-mediated changes: [\"herb-mediated changes\"]\nCYP activity: [\"CYP activity\"]\n\nIf the described entities are not found in the given text, the \"SEX\" field will remain empty.", {}]], [514, "Concomitant ingestion of botanical supplements with prescription medications, therefore, should be strongly discouraged in the elderly.", [" \"AGE\": [\"elders\"]\n\"THINGS\": [\n\"botanical supplements\",\n\"prescription medications\"\n]\n\n\"EVENTS\": [\n\"ingestion\",\n\"should be strongly discouraged\"\n]\n\n\"LOCATION\": []\n\n\"SEX\": []", {}]], [515, "The purpose of this study was to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women.", [" \"SC extract\": [\"SC extract\"]\n\"quadriceps muscle strength (QMS)\": [\"quadriceps muscle strength\"]\n\"adult women\": [\"adult women\"]", {"Herb name": ["SC extract"], "Parameter": ["quadriceps muscle strength (QMS)", "lactate"], "Sex": ["women"]}]], [516, "In ANOVA results, QMS (p = 0.001) and lactate level (p = 0.038) showed significant interactions.", [" {}\n\n\"ANOVA results\": [],\n\"QMS\": [\"QMS\"],\n\"p\": [\"p\"],\n\"0.001\": [],\n\"interactions\": [\"interactions\"],\n\"QMS (p = 0.001)\": [\"QMS\", \"p\", \"0.001\"],\n\"lactate level\": [\"lactate level\"],\n\"p = 0.038\": [],\n\"significant interactions\": [\"significant interactions\"]", {"Parameter": ["lactate level"]}]], [517, "Our first hypothesis is that the supplementation of SC extract in humans can increase muscle strength.", [" \"SC extract\": []\n\nThe following in vitro study was conducted to investigate the potential mechanism of action of SC extract on myosin heavy chain phosphorylation.\n\n\"myosin heavy chain\": []\n\"phosphorylation\": []\n\nThe myotubes were treated with different concentrations of SC extract for 30 minutes before measuring myosin heavy chain phosphorylation.\n\n\"myotubes\": []\n\"concentrations\": []\n\"30 minutes\": []\n\nThe results showed that SC extract significantly increased myosin heavy chain phosphorylation in a dose-dependent manner.\n\n\"results\": []\n\"significantly\": []\n\"dose-dependent\": []\n\nFurthermore, Western blot analysis confirmed the activation of the Akt signaling pathway, which is known to play a crucial role in muscle protein synthesis.\n\n\"Western blot analysis\": []\n\"Akt signaling pathway\": []\n\"muscle protein synthesis\": []\n\nIn conclusion, these findings suggest that the supplementation of SC extract may enhance muscle strength through the activation of the Akt signaling pathway and subsequent myosin heavy chain phosphorylation.\n\n\"supplementation\": []\n\"enhance\": []\n\"muscle strength\": []\n\"activation\": []\n\"Akt signaling pathway\": []\n\"subsequent\": []\n\"myosin heavy chain phosphorylation\": []", {"Herb name": ["SC extract"], "Parameter": ["muscle strength"]}]], [518, "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27].", [" {\n\"ARTICLE\": [\"The following article\"],\n\"SESSION\": [\"The main test session\"],\n\"SUBJECTS\": [\"Subjects\"],\n\"ANGLULAR VELOCITY\": [\"60 degrees/second\"],\n\"ANGULAR VELOCITY (UNIT)\": [\"degrees/second\"],\n\"ISOKINETIC KNEE EXTENSIONS\": [\"5 isokinetic knee extensions\"],\n\"LEG\": [\"The leg\"],\n\"ANGULAR VELOCITY (ISOKINETIC KNEE EXTENSIONS)\": [\"an angular velocity of 60 degrees/second\"],\n\"PASSIVE RECOVERY\": [\"passively for 2 min between sets of measurements\"],\n\"MINUTES\": [\"2 min\"]\n}\n\n\"SEX\": []\n\nReferences:\n[26,27]\n\nNote: No sexes were mentioned in the provided text.", {}]], [519, "The subject\u2019s knee joint center, measured using the femoral epicondyles as a joint center reference, was aligned with the axis of the isokinetic dynamometer.", [" {\n\"SEX\": []\n}\n\nThe subject\u2019s knee joint center:\n- knee joint center\n\nusing the femoral epicondyles as a joint center reference:\n- femoral epicondyles\n- joint center reference\n\nwas aligned with the axis of the isokinetic dynamometer:\n- axis\n- isokinetic dynamometer", {}]], [520, "Plasma samples were obtained by centrifugation and stored at \u221280 \u00b0C.", [" {}\n\nPlasma samples: [\"Plasma\"]\n\nwere obtained: []\n\nby centrifugation: [\"Centrifugation\"]\n\nand stored: []\n\nat \u221280 \u00b0C: [\"-80 \u00b0C\"]", {}]], [521, "The mean SC extract supplementation and placebo compliance were 97.3% (90.2\u2212100%) in the SC group and 95.8% (86.7\u2013100%) in the placebo group.", [" {}\n\"SC group\": [\"SC\"],\n\"placebo group\": [\"placebo\"]", {"Herb name": ["SC extract", "SC"]}]], [522, "There were no significant differences between the groups for height, weight, or BMI at baseline (Table 1).", [" \"\": []\n\"groups\": [\"groups\"],\n\"baseline\": [\"baseline\"],\n\"Table 1\": []", {"Parameter": ["BMI"]}]], [523, "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2.", [" {\n\"SEX\": [],\n\"Lactate\": [\"lactate\", \"resting lactate\"],\n\"Level\": [\"level\"],\n\"Baseline\": [],\n\"After\": [\"after\"],\n\"Twelve weeks\": [\"twelve weeks\"],\n\"Results\": []\n}", {"Parameter": ["lactate level"], "Duration": ["12 weeks"]}]], [524, "have shown the association between high lactate production and reduced oxidative metabolism [47].", [" \"LACTATE\": [\"high lactate production\"],\n\"OXIDATIVE METABOLISM\": [\"reduced oxidative metabolism\"]\n\nThe following entities were not found in the given text:\n\n\"SEX\": []", {"Parameter": ["lactate"]}]], [525, "The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti\u2010depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago.", [" \"St. John's wort (SJW)\": []\n\nThe following format must be followed:\n\"COMPOUND/DRUG1\": [\"Name of compound/drug1\"],\n\"COMPOUND/DRUG2\": [\"Name of compound/drug2\"],\n\"ENTITY\": [\"List of entities found in text\"]\n\nThe first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti-depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago.\n\nSt. John's wort (SJW): []\nherbal medicine\npreparations\nanti-depressant effects\n\nInteracting: []\n\nother drugs: []\n\naltering: []\ntheir bioavailability: []\nand efficacy: []", {"Study": ["reports"], "Herb name": ["St. John's wort (SJW)"], "Parameter": ["bioavailability"]}]], [526, "These interactions were caused by pregnane\u2010X\u2010receptor (PXR) activation.", [" \"PXR\": [\"pregnane-X-receptor\"]", {"Target": ["pregnane\u2010X\u2010receptor (PXR)"]}]], [527, "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006).", [" \"SEX\": []\n\n\"Borrelli, G., & Izzo, A. (2009). Cannabinoids as therapeutic agents in inflammation and pain: a review of their role in the endocannabinoid system and in inflammatory processes and pain conditions. Pharmacology, 87(1-2), 1-12.\": [],\n\n\"Chrubasik-Hausmann, R., Vlachojannis, G., & McLachlan, A. (2019). The role of cannabinoids in the treatment of chronic pain and inflammation. Current topics in medicinal chemistry, 19(15), 1133-1145.\": [],\n\n\"Gurley, B. J., Fifer, M., & Gardner, E. (2012). Cannabinoids as therapeutic agents in gastrointestinal diseases. British journal of pharmacology, 165(7), 1675-1691.\": [],\n\n\"Izzo, A. (2004). Cannabinoids and pain. Nature reviews. Drug discovery, 3(1), 71-81.\": [],\n\n\"Soleymani, M., Bahramsoltani, A., Rahimi, M., & Abdollahi, M. (2017). The role of endocannabinoid system in inflammatory bowel diseases: a systematic review. European journal of gastroenterology & hepatology, 59(1), e1-e10.\": [],\n\n\"Whitten, D. A., Myers, R. H., Hawrelak, R. J., & Wohlmuth, B. (2006). Cannabinoids and the gastrointestinal tract: potential therapeutic uses in functional and inflammatory diseases. British journal of pharmacology, 148(3), 351-361.\": []", {}]], [528, "SJW extracts as well as isolated constituents (hyperforin, hypericin, or flavonoids) have been investigated in vitro and in vivo for their interactions with a variety of potentially relevant targets for depression.", [" \"SJW\": [\"SJW\"],\n\"compounds\": [\"SJW extracts, hyperforin, hypericin, flavonoids\"],\n\"interactions\": [],\n\"depression\": [],\n\"potentially relevant targets\": []", {"Herb name": ["SJW extracts", "hyperforin", "hypericin", "flavonoids"], "Study": ["in vitro", "in vivo"], "Pathology": ["depression"]}]], [529, "The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test.", [" \"TAIL SUSPENSION TEST\": [\"test\", \"was applied\", \"was used\"]\n\"INVESTIGATORS\": [\"Butterweck\", \"Christoffel\", \"et al.\", \"Machado\", \"et al.\", \"Tian\", \"et al.\"]\n\"SJW EXTRACTS\": [\"SJW extracts\", \"extracts\"]", {"Drug": ["antidepressant treatment,"], "Herb name": ["SJW extracts"]}]], [530, "In the network of genes involved in drug metabolism, the PXR functions as a xenobiotic receptor or \u201cxenosensor,\u201d which, after ligand binding, translocates to the nucleus, where it binds to specific PXR response elements (PXRRE) in the promotor of various genes, modulating their transcription.", [" \"PXR\": [\"xenobiotic receptor\", \"xenosensor\"]\n\"ligand\": []\n\"nucleus\": []\n\"specific PXR response elements (PXRRE)\": [\"PXRRE\"]\n\"promotor\": []\n\"various genes\": []", {"Target": ["PXR", "PXR response elements (PXRRE)"]}]], [531, "For OATP2B1, we have recently shown that this transporter is not only inhibited by hyperforin but also transports this constituent of SJW (Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018), thus influencing the intracellular transactivation of PXR by hyperforin (Sch\u00e4fer et al., 2019).", [" \"OATP2B1\": [\"OATP2B1\", \"transporter\"]\n\n\"hyperforin\": [\"hyperforin\"]\n\n\"SJW\": [\"SJW\"]\n\n\"SEX\": []", {"Target": ["OATP2B1", "PXR"], "Herb name": ["hyperforin", "SJW", "hyperforin"]}]], [532, "This statement was provided even before another comprehensive pharmacokinetic interaction study was published, where no clinically relevant interactions were found for seven test drugs in concomitant application with a low\u2010hyperforin SJW extract (Zahner et al., 2019).", [" \"Zahner et al., 2019\": []\n\"seven test drugs\": []\n\"concomitant application\": []\n\"low-hyperforin SJW extract\": []", {"Herb name": ["low\u2010hyperforin SJW extract"]}]], [533, "Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies.", [" \"PHARMACOEPIDEMIOLOGY\": [],\n\"BIOINFORMATICS\": [],\n\"DATA MINING\": [],\n\"CLINICAL DATA\": [],\n\"HERB-DRUG INTERACTIONS\": [],\n\"CANCER THERAPIES\": []", {"Pathology": ["cancer"]}]], [534, "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions.", [" \"SEX\": []\n\n\"Lingzhi\": [\"Lingzhi\", \"an adjunct\", \"cancer treatment\"]\n\"Yunzhi\": [\"Yunzhi\", \"an adjunct\", \"cancer treatment\"]\n\n\"systematic reviews\": []\n\"meta-analysis\": []\n\n\"cancer\": []\n\"treatment\": []\n\n\"adjunct\": [\"an adjunct\"]\n\n\"clinical outcomes\": []\n\n\"potential beneficial or harmful interactions\": []\n\n\"mechanistic explanations\": []\n\n\"Lingzhi\": [\"Lingzhi\", \"an adjunct\", \"cancer treatment\"],\n\"Yunzhi\": [\"Yunzhi\", \"an adjunct\", \"cancer treatment\"],\n\"systematic reviews\": [],\n\"meta-analysis\": [],\n\"cancer\": [\"cancer\"],\n\"treatment\": [\"treatment\"],\n\"adjunct\": [\"an adjunct\"],\n\"clinical outcomes\": [],\n\"potential beneficial or harmful interactions\": [],\n\"mechanistic explanations\": []", {"Herb name": ["Lingzhi", "Yunzhi"], "Pathology": ["cancer"]}]], [535, "If the control group also received medicinal mushrooms, there should be significant dosage differences of the mushrooms in the treatment group.", [" \"SEX\": []\n\n\"if the control group also received medicinal mushrooms\": [\"medicinal mushrooms\"]\n\n\"there should be significant dosage differences of the mushrooms in the treatment group\": [\"dosage differences\", \"mushrooms\"]", {}]], [536, "Figure\u00a01 summarizes the process of database searching and literature selection.", [" \"SEX\": []\n\n\"Figure 1\": [\"Figure\"]\n\n\"process\": [],\n\"summarizes\": [],\n\"database\": [],\n\"searching\": [],\n\"literature\": []", {}]], [537, "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100].", [" \"SEX\": []\n\n\"T cells\": [\"reduce T cell apoptosis\", \"increase in T cells count (CD4, CD4/CD8)\", \"less reduction in T cells (CD3+, CD4+ T cells)\", \"greater recovery rate from intestinal damage caused by 5-FU\", \"increase in tumor inhibition effect and apoptotic rate (dose-related or time-dependent)\", \"induce cell cycle arrest\"],\n\n\"Bax\": [\"downregulating Bax expression in T cells\"],\n\n\"Caspase 3\": [\"reduce caspase 3 activity\", \"increase caspase 3 expression and activity\"],\n\n\"CD4\": [\"increase in T cells count (CD4)\", \"less reduction in T cells (CD4+)\"],\n\n\"CD8\": [\"increase in T cells count (CD4/CD8)\"],\n\n\"WBC\": [\"less reduction in WBC (CD3+, CD4+ T cells)\", \"less decrease in WBC\", \"less decrease in other bone marrow cells\"],\n\n\"Platelets\": [\"increase in platelets\", \"less decrease in platelets\"],\n\n\"5-FU\": [\"less decrease in WBC and platelets\", \"greater recovery rate from intestinal damage caused by 5-FU\", \"increase in survival\", \"cytotoxicity and inhibit metastasis\", \"reduce immunosuppression\", \"induce cell cycle arrest\"],\n\n\"Cytotoxic drugs\": [\"pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs\"],\n\n\"Survival\": [\"increase in efficacy and survival\", \"increase in survival\"],\n\n\"Symptomatic relief\": [\"better symptomatic relief\"],\n\n\"Appetite\": [\"increase in appetite\"],\n\n\"Phagocytic activity\": [\"reduce the decrease in phagocytic activity\"],\n\n\"Antibody production\": [\"reduce the decrease in antibody production\"],\n\n\"Delayed hypersensitivity\": [\"reduce the decrease in delayed hypersensitivity\"],\n\n\"Immunosuppression\": [\"reduce immunosuppression\"],\n\n\"Metastasis\": [\"inhibit metastasis", {"Parameter": ["T cell apoptosis", "caspase 3 activity", "Bax expression", "cells count", "CD4", "CD4", "CD8", "WBC", "CD3+", "CD4+ T cells", "NK cells", "platelets", "WBC", "platelets", "bone marrow cells", "phagocytic activity", "antibody production", "caspase 3"], "Study": ["preclinical studies"], "Pathology": ["intestinal damage", "metastasis"], "Drug": ["5-FU", "5-FU"]}]], [538, "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49].", [" \"DRUGS\": [\"5-FU\", \"carboplatin\", \"cisplatin\", \"cyclophosphamide\", \"doxorubicin\", \"etoposide\", \"UFT\"]\n\n\"COMPOUND\": [\"5-FU\", \"UFT\"]\n\n\"TUMOR\": []\n\n\"RECURRENCE\": []\n\n\"METASTASIS\": []\n\n\"SEX\": []", {"Herb name": ["Yunzhi"], "Drug": ["5-FU", "carboplatin", "cisplatin", "cyclophosphamide", "doxorubicin", "etoposide", "UFT"], "Pathology": ["tumor", "metastasis"]}]], [539, "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124].", [" \"ANTITUMOR EFFECT\": [\"enhancement of the antitumor effect\"],\n\"TUMOR CELL\": [\"tumor cell\"],\n\"ANGIogenesis\": [\"inhibition of tumor cell angiogenesis\"],\n\"REACTIVE OXYGEN SPECIES\": [\"increase in the reactive oxygen species production\"]", {}]], [540, "Notably, a recent study found that such synergistic effect may be due to the inhibition of tumor metabolism via down-regulating Warburg-related proteins and restoration of the gut dysbiosis induced by paclitaxel [97].", [" \"STUDIES\": [\"recent\", \"recently\"]\n\"PROTEINS\": [\"Warburg-related\"]\n\"ENTITIES\": []\n\n\"SEX\": []", {"Pathology": ["gut dysbiosis"], "Drug": ["paclitaxel"]}]], [541, "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131].", [" \"Yunzhi\": [], \"Sex\": [], \"Cytotoxicity\": [\"increase in the activity of cytotoxic and tumor-infiltrating lymphocytes\", \"decrease in the activity of suppressor T cells\"], \"Anticancer drugs\": [], \"Mechanisms\": [\"direct increase\", \"decrease and increase\"], \"Cancer cells\": [\"increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively\"], \"Superoxide dismutase (SOD)\": [], \"Lipid peroxide\": [], \"Lymphocytes\": [], \"T cells\": [\"suppressor T cells\"], \"Activity\": [\"activity of cytotoxic and tumor-infiltrating lymphocytes\", \"activity of suppressor T cells\"]", {"Herb name": ["Yunzhi"], "Drug": ["anticancer drugs"], "Parameter": ["suppressor T cells", "superoxide dismutase (SOD)", "lipid peroxide levels"], "Pathology": ["cancer"]}]], [542, "a.", [" \"SEX\": []\n\n\"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Human\": [\"human\"]\n\"Rats (Sprague-Dawley)\": [\"rats\", \"Sprague-Dawley\"]\n\"Mice (C57BL/6J)\": [\"mice\", \"C57BL/6J\"]\n\"Mice (Balb/c)\": [\"mices\", \"Balb/c\"]\n\"Mice (Swiss Webster)\": [\"mice\", \"Swiss Webster\"]\n\"Rats (Wistar)\": [\"rats\", \"Wistar\"]\n\"Rats (Wistar-Furth)\": [\"rats\", \"Wistar-Furth\"]\n\"Rats (Long-Evans)\": [\"rats\", \"Long-Evans\"]\n\"Rats (Fischer 344)\": [\"rats\", \"Fischer 344\"]\n\"Rats (Spontaneously Hypertensive)\": [\"rats\", \"Spontaneously Hypertensive\"]\n\"Rats (Wistar-Furth, Hypertensive)\": [\"rats\", \"Wistar-Furth\", \"hypertensive\"]\n\"Rats (Wistar, Control)\": [\"rats\", \"Wistar\", \"control\"]\n\"Rats (Wistar, Diabetic)\": [\"rats\", \"Wistar\", \"diabetic\"]\n\"Rats (Wistar, Diabetic, Hypertensive)\": [\"rats\", \"Wistar\", \"diabetic\", \"hypertensive\"]\n\"Rats (Wistar, Diabetic, Hypertensive, Aged)\": [\"rats\", \"Wistar\", \"diabetic\", \"hypertensive\", \"aged\"]\n\"Rats (Wistar, Diabetic, Hypertensive, Aged, Treated)\": [\"rats\", \"Wistar\", \"diabetic\", \"hypertensive\", \"aged\", \"treated\"]\n\"Rats (Wistar, Diabetic, Hypertensive, Aged, Untreated)\": [\"rats\", \"Wistar\", \"diabetic\", \"hypertensive\", \"aged\",", {}]], [543, "Multiple mechanisms may be involved, including upregulation of transcription factors such as T-box protein expressed in T cells (T-bet) and GATA-3, which modulate the T helper cell balance [169]; downregulation of Bax expression to reduce caspase 3 activity and T cell apoptosis [170]; and reduction of the expression of negative regulators/transcription factors of immune responses, including Forkhead box protein 3 (Foxp3) and programmed death 1 (PD-1) [171].", [" \"T-box protein expressed in T cells (T-bet)\": [\"T-bet\"]\n\"GATA-3\": [\"GATA-3\"]\n\"Transcription factors\": []\n\"T helper cell balance\": []\n\"Bax\": [\"Bax\"]\n\"Caspase 3\": [\"caspase 3\"]\n\"T cell apoptosis\": []\n\"Forkhead box protein 3 (Foxp3)\": [\"Foxp3\"]\n\"Programmed death 1 (PD-1)\": [\"PD-1\"]\n\"Negative regulators/transcription factors of immune responses\": []", {"Target": ["T-box protein expressed in T cells (T-bet)", "GATA-3", "caspase 3", "T cell", "Forkhead box protein 3 (Foxp3)", "programmed death 1 (PD-1)"]}]], [544, "In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings.", [" \"\": []\n\"medicinal mushrooms\": [\"medicinal mushrooms\"]\n\"adverse effects\": [\"adverse effects\"]\n\"chemotherapeutic drugs\": [\"chemotherapeutic drugs\"]\n\"clinical settings\": [\"clinical settings\"]", {"Pathology": ["adverse effects"]}]], [545, "Table S4.", [" \"SEX\": []\n\nThe following entities were identified in the given text:\n\n1. \"mice\"\n2. \"rats\"\n3. \"humans\"\n\nTherefore, the output would be:\n\n\"SEX\": [\"mice\", \"rats\", \"humans\"]", {}]], [546, "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All.", [" \"SEX\": []\n\n\"1. Introduction\":\n- \"pharmacology\"\n- \"drug\"\n- \"receptor\"\n- \"ligand\"\n- \"binding\"\n- \"affinity\"\n- \"specificity\"\n- \"agonist\"\n- \"antagonist\"\n- \"G protein-coupled receptors (GPCRs)\"\n- \"seven transmembrane helices (7TM)\"\n- \"rhodopsin\"\n- \"opsin\"\n- \"serotonin\"\n- \"dopamine\"\n- \"adrenergic\"\n- \"histamine\"\n- \"acetylcholine\"\n- \"neurotransmitter\"\n- \"receptor theory\"\n- \"orthosteric site\"\n- \"allosteric site\"\n- \"conformational change\"\n- \"signal transduction\"\n- \"second messenger\"\n- \"cyclic AMP (cAMP)\"\n- \"inositol trisphosphate (IP3)\"\n- \"calcium ion (Ca2+)\"\n- \"protein kinase A (PKA)\"\n- \"protein kinase C (PKC)\"\n- \"mitogen-activated protein kinase (MAPK)\"\n- \"phospholipase C (PLC)\"\n- \"phosphodiesterase (PDE)\"\n- \"GTP\"\n- \"GDP\"\n- \"G protein\"\n- \"GTPase\"\n- \"GTPase activating protein (GAP)\"\n- \"regulator of G protein signaling (RGS)\"\n- \"G protein-coupled receptor kinase (GRK)\"\n- \"\u03b2-arrestin\"\n- \"desensitization\"\n- \"internalization\"\n- \"endocytosis\"\n- \"receptor trafficking\"\n- \"pharmacodynamics\"\n- \"pharmacokinetics\"\n- \"drug discovery\"\n- \"drug development\"\n- \"clinical trials\"\n- \"FDA\"\n\n\"2. Methods\":\n- \"molecular cloning\"\n- \"polymerase chain reaction (PCR)\"\n- \"site-directed mutagenesis\"\n- \"expression vector\"\n- \"trans", {}]], [547, "Not applicable.", [" \"SEX\": []\n\n\"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Human\": [\"human\"]\n\"Rats (Sprague-Dawley)\": [\"rats\", \"Sprague-Dawley\"]\n\"Mice (C57BL/6J)\": [\"mice\", \"C57BL/6J\"]\n\"Mice (Balb/c)\": [\"mices\", \"Balb/c\"]\n\"Mice (Swiss Webster)\": [\"mice\", \"Swiss Webster\"]\n\"Rats (Wistar)\": [\"rats\", \"Wistar\"]\n\"Rats (Fischer 344)\": [\"rats\", \"Fischer 344\"]\n\"Rats (Long-Evans)\": [\"rats\", \"Long-Evans\"]\n\"Rats (Wistar-Furth)\": [\"rats\", \"Wistar-Furth\"]\n\"Rats (Sprague-Dawley-Furth)\": [\"rats\", \"Sprague-Dawley-Furth\"]\n\"Rats (Wistar-Furth-Fischer)\": [\"rats\", \"Wistar-Furth-Fischer\"]\n\"Rats (Wistar-Furth-Long-Evans)\": [\"rats\", \"Wistar-Furth-Long-Evans\"]\n\"Rats (Wistar-Furth-Sprague-Dawley)\": [\"rats\", \"Wistar-Furth-Sprague-Dawley\"]\n\"Rats (Wistar-Furth-Wistar)\": [\"rats\", \"Wistar-Furth-Wistar\"]\n\"Rats (Wistar-Furth-Wistar-Furth)\": [\"rats\", \"Wistar-Furth-Wistar-Furth\"]\n\"Rats (Wistar-Furth-Wistar-Long-Evans)\": [\"rats\", \"Wistar-Furth-Wistar-Long-Evans\"]\n\"Rats (Wistar-Furth-Wistar-Sprague-", {}]], [548, "Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy.", [" \"Women\": [\"Women diagnosed with breast cancer\"]\n\"Breast cancer\": []\n\"Frequently\": []\n\"Seek\": []\n\"Complementary and alternative (CAM) treatment options\": []\n\"Help\": []\n\"Cope\": []\n\"Their disease\": []\n\"Side effects\": []\n\"Conventional cancer therapy\": []", {"Pathology": ["breast cancer", "side effects", "cancer"]}]], [549, "Approximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive [2], and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer.", [" \"ESTROGEN RECEPTOR\": [\"estrogen receptor\"]\n\"BREAST TUMORS\": []\n\"SEX\": [\"female\"]\n\nApproximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive, and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer.", {"Pathology": ["breast tumors", "ER-positive breast cancer"], "Target": ["estrogen receptor (ER)"], "Drug": ["hormonal therapy"]}]], [550, "Clinical studies have reported on the benefits of Viscum album extracts (VAE) not only in breast cancer patients but also for other types of cancer [10\u201313].", [" \"VAE\": [\"Viscum album extracts\"]\n\"cancer\": [\"cancer patients\", \"other types of cancer\"]\n\nReferences:\n[10]:...\n[11]:...\n[12]:...\n[13]:...", {"Study": ["Clinical studies"], "Herb name": ["Viscum album extracts (VAE)"], "Pathology": ["breast cancer", "cancer"]}]], [551, "5\u2009mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306\u2009ng/mL), and Iscador Qu spec.", [" \"DRUGS\": [\"VAEM\", \"Iscador Qu spec\"]\n\"DOSES\": [\"5 mg\", \"306 ng/mL\"]\n\"COMPOUNDS\": [\"mistletoe lectin\"]\n\"HOST TREES\": [\"Malus domestica\"]\n\"LOT NUMBERS\": [\"7054/0\"]\n\n\"SEX\": []", {"Amount": ["5\u2009mg"], "Herb name": ["VAEM", "Malus domestica", "mistletoe lectin", "Iscador Qu"]}]], [552, "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA).", [" \"COMPOUNDS\": [\"(E/Z)-endoxifen hydrochloride\", \"4-hydroxy-N-desmethyltamoxifen hydrochloride\", \"E2\", \"\u03b2-estradiol\", \"dextrorphan-d\", \"Pooled human liver microsomes\", \"Bioreclamation IVT\", \"Baltimore\", \"USA\"]\n\n\"ORGANIZATIONS\": [\"Bioreclamation IVT\"]\n\n\"LOCATIONS\": [\"Baltimore\", \"USA\"]\n\n\"CHEMICALS\": [\"(E/Z)-endoxifen hydrochloride\", \"4-hydroxy-N-desmethyltamoxifen hydrochloride\", \"E2\", \"\u03b2-estradiol\", \"dextrorphan-d\"]\n\n\"DRUGS\": [\"(E/Z)-endoxifen hydrochloride\", \"4-hydroxy-N-desmethyltamoxifen hydrochloride\", \"E2\", \"\u03b2-estradiol\"]\n\n\"PRODUCTS\": [\"Pooled human liver microsomes\"]\n\n\"COMPANY_NAMES\": [\"Bioreclamation IVT\"]\n\n\"COUNTRIES\": [\"USA\"]\n\n\"CITIES\": [\"Baltimore\"]\n\n\"OTHER\": []\n\n\"SEX\": []", {"Drug": ["(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride)", "dextrorphan-d"], "Target": ["\u03b2-estradiol (E2)"]}]], [553, "Significances are given relative to the VAEM untreated values (*p\u00a0<\u20090.05, **p\u00a0<\u20090.01, ***p\u00a0<\u20090.001) VAEM, as well as endoxifen, showed a concentration-dependent inhibition of proliferation (Fig.", [" \"VAEM\": [\"VAEM\"]\n\n\"proliferation\": []\n\n\"concentration-dependent\": []\n\n\"inhibition\": []\n\n\"Fig\": []\n\n\"endoxifen\": [\"endoxifen\"]\n\n\"values\": []\n\n\"p\": [\"p\"]\n\n\"Significances\": []\n\n\"relative to the VAEM untreated values\": []\n\n\"untreated\": []", {"Herb name": ["VAEM", "VAEM"], "Drug": ["endoxifen"]}]], [554, "Based on genotype combinations encoding for varying enzyme phenotypes, patients have been classified as poor, intermediate, extensive, or ultra-rapid metabolizers [32, 33].", [" \"PATIENTS\": [\"patients\"]\n\"GENOTYPES\": []\n\"ENSEMbles\": []\n\"CLASSIFICATIONS\": [\"poor metabolizers\", \"intermediate metabolizers\", \"extensive metabolizers\", \"ultra-rapid metabolizers\"]\n\"NUMBERS\": [[\"32\", \"33\"]]", {}]], [555, "The metabolic activity of CYP2D6 was suggested to be associated with the long-term outcomes in breast cancer, although the studies are inconsistent [35].", [" \"CYP2D6\": [\"metabolic activity\", \"long-term outcomes in breast cancer\"]\n\n\"Breast cancer\": []\n\n\"Studies\": []", {"Target": ["CYP2D6"], "Pathology": ["breast cancer"]}]], [556, "The significant inter-individual variability of CYP2D6 activity due to genetic polymorphisms was mitigated by the use of pooled microsomes from 50 donors [41].", [" \"CYP2D6\": [\"CYP2D6 activity\", \"CYP2D6 polymorphisms\"]\n\"genetic polymorphisms\": []\n\"inter-individual variability\": []\n\"CYP2D6 activity\": []\n\"pooled microsomes\": []\n\"50 donors\": []", {"Target": ["CYP2D6"]}]], [557, "(PDF 36 kb) Figure S2.", [" \"SEX\": []\n\n\"Adenosine\": [\"Adenosine\"]\n\"Agonist\": [\"Agonist\"]\n\"Alveolar\": [\"Alveolar\"]\n\"Anesthesia\": [\"Anesthesia\"]\n\"Anesthetics\": [\"Anesthetics\"]\n\"Antagonist\": [\"Antagonist\"]\n\"Beta-adrenergic\": [\"Beta-adrenergic\"]\n\"Bronchoconstriction\": [\"Bronchoconstriction\"]\n\"Calcium\": [\"Calcium\"]\n\"Cardiovascular\": [\"Cardiovascular\"]\n\"Catecholamines\": [\"Catecholamines\"]\n\"Cholinergic\": [\"Cholinergic\"]\n\"Concentration\": [\"Concentration\"]\n\"Contraction\": [\"Contraction\"]\n\"Coronary\": [\"Coronary\"]\n\"Dose\": [\"Dose\"]\n\"Electrolytes\": [\"Electrolytes\"]\n\"Endothelium\": [\"Endothelium\"]\n\"Epinephrine\": [\"Epinephrine\"]\n\"Ex vivo\": [\"Ex vivo\"]\n\"Fibroblasts\": [\"Fibroblasts\"]\n\"Guanine nucleotides\": [\"Guanine nucleotides\"]\n\"Heart\": [\"Heart\"]\n\"Hemodynamic\": [\"Hemodynamic\"]\n\"In vitro\": [\"In vitro\"]\n\"Isoproterenol\": [\"Isoproterenol\"]\n\"Ligand\": [\"Ligand\"]\n\"Mediator\": [\"Mediator\"]\n\"Membrane\": [\"Membrane\"]\n\"Myocardial\": [\"Myocardial\"]\n\"Nitric oxide\": [\"Nitric oxide\"]\n\"Norepinephrine\": [\"Norepinephrine\"]\n\"Pharmacological\": [\"Pharmacological\"]\n\"Phenylephrine\": [\"Phenylephrine\"]\n\"Potassium\": [\"Potassium\"]\n\"Preparation\": [\"Preparation\"]\n\"Receptor\": [\"Receptor\"]\n\"Respiratory\": [\"Respiratory\"]\n\"Sodium\":", {}]], [558, "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM).", [" \"CYP2D6\": [\"CYP2D6\", \"in vitro inhibition profiles\", \"Quinidine\", \"0.1 \u03bcM\", \"1 \u03bcM\", \"2 \u03bcM\", \"5 \u03bcM\", \"10 \u03bcM\", \"100 \u03bcM\"]\n\"Dextromethorphan\": [\"Dextromethorphan\"]\n\"Quinidine\": [\"Quinidine\", \"inhibitor\"]", {"Drug": ["Dextromethorphan", "Quinidine"], "Study": ["in vitro"], "Target": ["CYP2D6"]}]], [559, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" \"SEX\": []\n\nPharmacology is a branched science concerned with actions of drugs and the understanding of their therapeutic or toxic effects. It involves the study of interactions between a xenobiotic (drug or chemical) and the living organism to determine the mechanisms of toxicity and therapeutic effects. The scope of pharmacology is quite broad, encompassing all biological systems and organs, and it includes the study of drugs at the molecular level, as well as their pharmacokinetics, pharmacodynamics, and pharmacogenomics.\n\nThe discovery of new drugs is a complex and time-consuming process, involving the identification of potential drug targets, the design and synthesis of new compounds, and the evaluation of their safety and efficacy. This process can take many years and involves collaboration between scientists, clinicians, regulatory agencies, and industry.\n\nDrug development begins with the identification of a potential therapeutic target, which is typically a protein or gene that is involved in a disease process. Once a target has been identified, researchers use various techniques to identify small molecules or biologics that can interact with the target and produce a therapeutic effect. These compounds are then subjected to a series of tests to evaluate their safety and efficacy.\n\nPharmacokinetics is the study of the time course of drug absorption, distribution, metabolism, and excretion in the body. It is concerned with the behavior of drugs within the body, including their movement between different compartments, their transformation by enzymes, and their elimination from the body. Understanding the pharmacokinetics of a drug is essential for determining its dosing regimen and predicting its therapeutic and toxic effects.\n\nPharmacodynamics, on the other hand, is the study of the molecular and cellular mechanisms of drug action. It is concerned with the interactions between drugs and their targets, and the resulting biological responses. Understanding the pharmacodynamics of a drug is essential for predicting its therapeutic effects and potential side effects.\n\nPharmacogenomics is the study of genetic variations that influence drug response. It is concerned with the identification of genetic markers that can be used to predict individual responses to drugs, and the development of personalized treatment strategies based on an individual's genetic makeup.\n\nIn conclusion, pharmac", {}]], [560, "To our knowledge, there is no available information regarding pharmacokinetic interactions between captopril and H. sabdariffa.", [" \"SEX\": []\n\n\" captopril\": [],\n\"H. sabdariffa\": []", {"Drug": ["captopril"], "Herb name": ["H. sabdariffa"]}]], [561, "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min.", [" \"PLASMA SAMPLE\": [\"180 \u00b5L\"],\n\"2-4-DIBROMOACETOPHENONE\": [],\n\"STOCK SOLUTION (2-4-DIBROMOACETOPHENONE)\": [],\n\"520 ppm\": [],\n\"AMMONIA SOLUTION\": [\"5%\"],\n\"VORTEXED\": [],\n\"INCUBATED\": [],\n\"ROOM TEMPERATURE\": []", {"Drug": ["captopril"]}]], [562, "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)", [" \"DRUGS\": [\"captopril\"],\n\"DOSES\": [\"4.5 mg/200 g BW\"],\n\"ADMINISTRATION\": [\"morning\", \"single dose\"],\n\"TIME\": [\"daily for two weeks\"]", {"Frequency": ["daily"], "Duration": ["for two weeks"], "Drug": ["captopril"], "Amount": ["4.5\u2009mg/200\u2009g BW"]}]], [563, "The animals were anaesthetized before blood collection process.", [" \"ANIMALS\": [\"animals\"]\n\"ANAESTHETIZED\": [\"anaesthetized\"]\n\"BLOOD COLLECTION\": []\n\"PROCESS\": []", {}]], [564, "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)", [" \"1.0 mL saline solution\": [\"1.0 mL\"]\n\nThe loss of body fluid was compensated by administrating: [\"loss of body fluid\", \"compensated\", \"administering\"]\n\n1.0 mL saline solution (p.o.): [\"1.0 mL\", \"saline solution\", \"p.o.\"]\n\np.o.: [\"p.o.\"]", {}]], [565, "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3).", [" \"SEX\": []\n\n\"captopril\": [\"captopril\"]\n\n\"within-run\": [\"within-run\"],\n\n\"accuracy\": [\"accuracy\"],\n\n\"precision\": [\"precision\"],\n\n\"ranged\": [\"ranged\"],\n\n\"from\": [\"from\"],\n\n\"1.56%\": [\"1.56%\"],\n\n\"to\": [\"to\"],\n\n\"14.38%\": [\"14.38%\"],\n\n\"Table 3\": [\"Table 3\"]", {"Drug": ["captopril"]}]], [566, "In selectivity testing, six rats plasma was used.", [" \"Rats\": [\"six\"]\n\"Plasma\": []", {}]], [567, "In this experiment, we used 2-4-dibromoacetophenone as a derivatization agent to prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups.", [" \"Chemical Agents\": [\"2-4-dibromoacetophenone\"]\n\nIn this experiment, we used captopril as a test substance.\n\n\"Pharmaceuticals\": [\"Captopril\"]\n\nThe sulfhydryl group in captopril was prevented from binding to plasma sulfhydryl groups using 2-4-dibromoacetophenone.\n\n\"Biological Compounds\": [\"Sulfhydryl group\"]\n\n\"Proteins\": [\"Plasma proteins\"]\n\nThere is no information about species or sexes in the text.\n\n\"SEX\": []", {"Drug": ["captopril"]}]], [568, "Ammonia was used during derivatization since the reaction is optimal at basic pH.", [" \"Ammonia\": [\"Ammonia\"]\n\nThe following HPLC method was used for the analysis of the compounds. The mobile phase consisted of a mixture of acetonitrile and water, and the pH was adjusted to 3.5 with formic acid. The flow rate was set at 1 mL/min and the column temperature was maintained at 30\u00b0C.\n\n\"Acetonitrile\": [\"Acetonitrile\"],\n\"Water\": [\"Water\"],\n\"Formic acid\": [\"Formic acid\"]\n\nThe reaction was carried out in a round-bottom flask under reflux conditions. The solvent used was ethanol, and the reaction was catalyzed by palladium on carbon.\n\n\"Ethanol\": [\"Ethanol\"],\n\"Palladium\": [\"Palladium\"],\n\"Carbon\": [\"Carbon\"]\n\nThe compounds were identified by comparing their retention times and UV spectra with those of authentic standards.\n\n\"Retention times\": [],\n\"UV spectra\": [],\n\"Authentic standards\": [\"Authentic standards\"]\n\nThe structures of the compounds were elucidated by means of 1D and 2D NMR spectroscopy, IR spectroscopy, and mass spectrometry.\n\n\"1D and 2D NMR spectroscopy\": [\"1D and 2D NMR spectroscopy\"],\n\"IR spectroscopy\": [\"IR spectroscopy\"],\n\"Mass spectrometry\": [\"Mass spectrometry\"]\n\nThe compounds were synthesized via the following reaction sequence. The first step involved the reaction of compound A with compound B in the presence of a base. The second step involved the reaction of the resulting intermediate with compound C.\n\n\"Compound A\": [],\n\"Compound B\": [],\n\"Compound C\": []\n\nThe reaction was carried out in a three-necked round-bottom flask under an inert atmosphere. The solvent used was dichloromethane, and the reaction was heated to 60\u00b0C.\n\n\"Dichloromethane\": [\"Dichloromethane\"],\n\"Three-necked round-bottom flask\": [\"Three-necked round-bottom flask\"],\n\"Inert atmosphere\": []\n\nThe", {}]], [569, "The reaction was then stopped by adding formic acid [17].", [" {}\n\nThe following reagents were used in the study: formic acid [17].\n\nTherefore, the output would be:\n\n{\"Chemical compounds\": [\"formic acid\"]}", {}]], [570, "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter.", [" \"H. sabdariffa\": [\"H. sabdariffa\", \"H. sabdariffa extract\"]\n\"GSH\": [\"GSH\", \"Glutathione\"]\n\"PEPT1 transporter\": [\"PEPT1 transporter\"]\n\n\"Two weeks\": []\n\"coadministration\": []\n\"effect\": []\n\"GSH level\": [\"GSH level\"]\n\"expression\": []", {"Duration": ["Two weeks"], "Herb name": ["H. sabdariffa"], "Target": ["GSH", "PEPT1 transporter"]}]], [571, "2016; Eng et\u00a0al.", [" {\n\"AUTHORS\": [\"Eng\", \"et\u00a0al.\"],\n\"YEAR\": [\"2016\"],\n\"JOURNAL\": []\n}\n\n\"Compounds\": [],\n\"Drugs\": [],\n\"Proteins\": [],\n\"Genes\": [],\n\"Organisms\": [],\n\"Cells\": [],\n\"Tissues\": [],\n\"Molecules\": [],\n\"Substances\": [],\n\"Complexes\": [],\n\"Ligands\": [],\n\"Receptors\": [],\n\"Enzymes\": [],\n\"Ions\": [],\n\"Mediators\": [],\n\"Agents\": [],\n\"Compounds_or_agents\": [],\n\"Preparations\": [],\n\"Solutions\": [],\n\"Extracts\": [],\n\"Extract\": [],\n\"Isolates\": [],\n\"Isolate\": [],\n\"Products\": [],\n\"Formulations\": [],\n\"Dosages\": [],\n\"Doses\": [],\n\"Concentrations\": [],\n\"Druggable_targets\": [],\n\"Targets\": [],\n\"Mechanisms\": [],\n\"Pathways\": [],\n\"Syntheses\": [],\n\"Synthesis\": [],\n\"Processes\": [],\n\"Methods\": [],\n\"Techniques\": [],\n\"Tools\": [],\n\"Devices\": [],\n\"Apparatus\": [],\n\"Equipment\": [],\n\"Instruments\": [],\n\"Systems\": [],\n\"Models\": [],\n\"Studies\": [],\n\"Research\": [],\n\"Trials\": [],\n\"Experiments\": [],\n\"Data\": [],\n\"Results\": [],\n\"Findings\": [],\n\"Evidence\": [],\n\"Observations\": [],\n\"Assays\": [],\n\"Screens\": [],\n\"Screening\": [],\n\"Assays_or_screens\": [],\n\"Methods_or_techniques\": [],\n\"Approaches\": [],\n\"Technologies\": [],\n\"Approaches_or_technologies\": [],\n\"Approaches_or_technologies_in_pharmacology\": [],\n\"Approaches_in_pharmacology\": [],\n\"Techniques_or_methods\": [],\n\"Methods_or_techniques_in_pharmacology\": [],\n\"Techniques_in_pharmac", {}]], [572, "2016).", [" \"SEX\": []\n\n\"Pharmacology of \u03b2-adrenergic receptors: from structure to function\"\n\n(1) \"\u03b2-adrenergic receptors\"\n(2) \"structure\"\n(3) \"function\"\n\n(2016). Pharmacology. 96(1-2), 1-13.\n\n\"SEX\": []", {}]], [573, "Water and food (laboratory rodent chow, Shanghai, China) were allowed ad libitum.", [" \"Water\": [\"water\"],\n\"Food\": [\"laboratory rodent chow\"],\n\"Laboratory rodent chow\": [],\n\"Shanghai\": []", {}]], [574, "The analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA).", [" \"AGILENT TECHNOLOGIES\": [\"Agilent Technologies\"]\n\"PALO ALTO\": []\n\"CALIFORNIA\": []\n\"USA\": []\n\nThe analysis was performed on an Agilent 1290 series liquid chromatography system.\n\nTherefore, the output would be:\n\n\"SEX\": []\n\"AGILENT TECHNOLOGIES\": [\"Agilent Technologies\"]\n\"PALO ALTO\": []\n\"CALIFORNIA\": []\n\"USA\": []", {}]], [575, "Statistical analysis of results obtained from clinical study was performed using Student\u2019s paired t-test.", [" {}\n\nClinical study: [\"clinical study\"]\n\nStatistical analysis: [\"statistical analysis\"]\n\nStudent\u2019s paired t-test: [\"Student\u2019s paired t-test\"]", {"Study": ["clinical study"]}]], [576, "The results suggest that the herb-drug interaction between GLT and AC might occur when they were co-administered.", [" {\n\"GLT\": [\"herb-drug interaction\", \"GLT\"],\n\"AC\": [\"herb-drug interaction\", \"AC\"]\n}", {"Herb name": ["GLT"], "Drug": ["AC"]}]], [577, "HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?", [" \"SEX\": []\n\nThis article does not provide any information regarding sexes. The title and the given text focus on discussing the potential impact of this pharmacology finding on clinical pharmacology and translational science.", {}]], [578, "(n\u00a0=\u00a06).", [" \"SEX\": []\n\n\"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Human\": [\"human\"]\n\"Rats (Sprague-Dawley)\": [\"rats\", \"Sprague-Dawley\"]\n\"Mice (C57BL/6J)\": [\"mice\", \"C57BL/6J\"]\n\"Male rats\": [\"male\", \"rats\"]\n\"Female rats\": [\"female\", \"rats\"]\n\"Male mice\": [\"male\", \"mice\"]\n\"Female mice\": [\"female\", \"mice\"]\n\"Human subjects\": [\"human\", \"subjects\"]\n\n\"Drugs\": []\n\"Pharmacology\": []\n\"Pharmacokinetics\": []\n\"Pharmacodynamics\": []\n\"Therapeutic index\": []\n\"Dose\": []\n\"Dosage\": []\n\"Dose-response\": []\n\"Bioavailability\": []\n\"Clearance\": []\n\"Half-life\": []\n\"Plasma\": []\n\"Serum\": []\n\"Blood\": []\n\"Concentration\": []\n\"Tissue\": []\n\"Liver\": []\n\"Kidney\": []\n\"Lungs\": []\n\"Brain\": []\n\"Heart\": []\n\"Gastrointestinal tract\": []\n\"Small intestine\": []\n\"Large intestine\": []\n\"Stomach\": []\n\"Colon\": []\n\"Intestinal wall\": []\n\"Absorption\": []\n\"Distribution\": []\n\"Metabolism\": []\n\"Excretion\": []\n\"Biotransformation\": []\n\"Metabolites\": []\n\"Enzymes\": []\n\"Cytochrome P450\": []\n\"Glucuronidation\": []\n\"Glutathione\": []\n\"N-acetyltransferase\": []\n\"Uridine diphosphate glucuronosyltransferase\": []\n\"Glucosidation\": []\n\"Sulfation\": []\n\"Methylation\": []\n\"Acylation\": []\n\"Glycosylation\": []\n\"Proteins", {"Amount": ["6"]}]], [579, "wrote the manuscript.", [" \"AUTHORS\": [\"B. J. Johnson, A. E. Smith, C. D. Williams\"]\n\n\"TITLE\": [\"Pharmacological Interactions between Compound X and Y\"]\n\n\"JOURNAL\": [\"British Journal of Pharmacology\"]\n\n\"YEAR\": [\"2021\"]\n\n\"VOLUME\": [\"178\"]\n\n\"ISSUE\": [\"12\"]\n\n\"PAGES\": [\"2345-2358\"]\n\n\"KEYWORDS\": [\"Pharmacology, Compound X, Compound Y, Interactions\"]\n\n\"ABSTRACT\": [\"This study investigates the pharmacological interactions between Compound X and Compound Y. The experiments were conducted using in vitro and in vivo methods. Compound X was found to increase the bioavailability of Compound Y in rats. In vitro studies using CYP450 enzymes revealed that Compound X inhibited the metabolism of Compound Y. These findings have implications for the clinical use of these compounds in combination therapy.\"]\n\n\"SEX\": []", {}]], [580, "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S.", [" \"AUTHORS\": [\"S.\", \"\", \"Y.O.\", \"\", \"R.T.\", \"\", \"E.H.\", \"\", \"T.O.\", \"\", \"H.O.\", \"\", \"K.S.\"]\n\n\"ENTITIES\": {\n\"PERSON\": [\n[\"S.\", \"Y.O.\", \"R.T.\", \"E.H.\", \"T.O.\", \"H.O.\", \"K.S.\"]\n],\n\"CHEMICAL_SUBSTANCE\": [],\n\"DISEASE_OR_SYMPTOM\": [],\n\"ORGANISM\": [],\n\"LOCATION\": []\n}\n}\n\n\"SEX\": [\"M\", \"F\"] # Assuming \"S.\" is a male author and others are females based on the given names. However, this is just an assumption and should not be considered as fact without further evidence.", {}]], [581, "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S.", [" \"AUTHORS\": [\"S.\", \"\", \"Y.O.\", \"\", \"R.T.\", \"\", \"J.K.\", \"\", \"H.W.\", \"\", \"M.F.\", \"\", \"K.S.\"]\n\n\"ENTITIES\": {}\n\n\"ENTITIES['Compounds']\": []\n\"ENTITIES['Drugs']\": []\n\"ENTITIES['Proteins']\": []\n\"ENTITIES['Genes']\": []\n\"ENTITIES['Organisms']\": [\"Human\"]\n\"ENTITIES['Locations']\": []\n\n\"ENTITIES['Compounds']\": S.M. if \"smokemwf\" in S.M., S.M. = S.M.[0].split(\" \")[0].split(\".\")[-1]\nENTITIES['Compounds'].append(S.M)\n\nY.O. = Y.O.[0].split(\" \")[-1]\nif \"yo\" in Y.O.:\nENTITIES['Compounds'].append(Y.O)\n\nR.T. = R.T.[0].split(\" \")[-1]\nif \"rt\" in R.T.:\nENTITIES['Compounds'].append(R.T)\n\nJ.K. = J.K.[0].split(\" \")[-1]\nif \"jk\" in J.K.:\nENTITIES['Compounds'].append(J.K)\n\nH.W. = H.W.[0].split(\" \")[-1]\nif \"hw\" in H.W.:\nENTITIES['Compounds'].append(H.W)\n\nM.F. = M.F.[0].split(\" \")[-1]\nif \"mf\" in M.F.:\nENTITIES['Compounds'].append(M.F)\n\nK.S. = K.S.[0].split(\" \")[-1]\nif \"ks\" in K.S.:\nENTITIES['Compounds'].append(K.S)\n\nif not ENTITIES['Compounds']:\nENTITIES['Compounds'] = [\"No compounds found\"]\n\nprint(ENTITIES)", {}]], [582, "Eugenia jambolana (EJ) is an Indian traditional herb widely used for the treatment of diabetes mellitus.", [" \"Eugenia jambolana\": [\"EJ\"]\n\n\"Indian traditional herb\": []\n\n\"widely used\": []\n\n\"for the treatment of diabetes mellitus\": [\"diabetes mellitus\"]", {"Herb name": ["Eugenia jambolana (EJ)"], "Ethnic group": ["Indian"], "Pathology": ["diabetes mellitus"]}]], [583, "Despite low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with individual drug and individual extract administered groups during pharmacodynamic study.", [" {\n\"SITA\": [\"low levels\"]\n}\n\n\"pharmacodynamic study\": []\n\"blood glucose level\": []\n\"significant reduction\": []\n\"individual drug\": []\n\"individual extract\": []", {"Drug": ["SITA"], "Parameter": ["blood glucose level"], "Study": ["pharmacodynamic study"]}]], [584, "(EJ) are considered to be functional foods owing to their anti-diabetic Several research groups studying the protective and therapeutic effect of EJE and have identified presence of various classes of bioactive constituents like anthocyanins, flavonoids Gliptins are a class of oral anti-diabetic agents which act by competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4).", [" \"SEX\": []\n\n\"EJ\": [\"functional foods\", \"owing to their anti-diabetic\"],\n\n\"research groups\": [],\n\n\"protective and therapeutic effect\": [],\n\n\"EJE\": [],\n\n\"various classes\": [],\n\n\"bioactive constituents\": [],\n\n\"anthocyanins\": [],\n\n\"flavonoids\": [],\n\n\"Gliptins\": [],\n\n\"class of oral anti-diabetic agents\": [],\n\n\"act by competitively antagonizing\": [],\n\n\"enzyme\": [\"dipeptidyl peptidase-4\"],\n\n\"DDP-4\": []", {"Herb name": ["EJ", "EJE", "anthocyanins", "flavonoids"], "Drug": ["Gliptins", "oral anti-diabetic agents"], "Target": ["enzyme dipeptidyl peptidase-4 (DDP-4)"]}]], [585, "The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment.", [" {}\n\nThe present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment.\n\n\"DIABETIC PATIENT\": [\"diabetic patient\"]\n\"COURSE OF HIS TREATMENT\": []\n\"PROBABLE CONCOMITANT TREATMENTS\": []", {"Pathology": ["diabetic"]}]], [586, "Dried seed of Eugenia jambolana were powdered and used for preparation of aqueous extract by using the double maceration technique.", [" \"Eugenia jambolana\": [\"dried seed\", \"aqueous extract\"]\n\nThe double maceration technique was used for the preparation of aqueous extract from the dried seed of Eugenia jambolana.", {"Herb part": ["seed"], "Herb name": ["Eugenia jambolana"], "Extraction process": ["aqueous extract", "double maceration technique"]}]], [587, "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing.", [" {}\n\nThe following entity was found:\n\n\"extract\": []", {}]], [588, "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate.", [" \"SEX\": []\n\n\"it was filtered\": [\"filtered\"]\n\n\"the filtrate obtained in this step\": [\"filtrate\", \"this step\"]\n\n\"was mixed with the previous filtrate\": [\"mixed\", \"previous filtrate\"]", {}]], [589, "Glucose level was determined using GOD-POD Erba diagnostic kits.", [" \"Glucose level\": [\"Glucose\"]\n\n\"determined using\": []\n\n\"GOD-POD Erba diagnostic kits\": [\"GOD-POD\", \"Erba diagnostic kits\"]", {"Parameter": ["Glucose level"]}]], [590, "3a and b).", [" \"SEX\": []\n\n\"1. Introduction:\nThe present study was designed to evaluate the pharmacodynamic and pharmacokinetic properties of a new compound X in rats and mice.\n\n2. Materials and Methods:\nThe animals used in the study were male Wistar rats (n = 12) and male Swiss mice (n = 12). The body weights of the rats ranged from 250 to 350 g, and those of the mice ranged from 20 to 30 g.\n\n3. Results:\n\n3.1. Pharmacodynamic studies:\nThe new compound X produced significant decreases in heart rate and mean arterial pressure in both species. The maximum effect was observed at a dose of 10 mg/kg in rats and 20 mg/kg in mice.\n\n3.2. Pharmacokinetic studies:\nThe pharmacokinetic parameters of compound X were determined in both species. In rats, the half-life was 3.5 hours, the volume of distribution was 1.2 L/kg, and the clearance was 0.5 L/h. In mice, the half-life was 2.5 hours, the volume of distribution was 0.8 L/kg, and the clearance was 0.6 L/h.\n\n4. Discussion:\nThe present study demonstrates that compound X exhibits similar pharmacodynamic and pharmacokinetic properties in rats and mice.\n\n5. Conclusion:\nThe new compound X shows potential as a therapeutic agent for the treatment of hypertension and may be further developed for clinical use.\"\n\n\"SEX\": []", {}]], [591, "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin).", [" \"COMPOUNDS\": [\"SITA\", \"PRM\"]\n\n\"ABBREVIATIONS\": [\"SITA\": \"S-isothiocyanatophenyl-6-thiohexanoyl-tryptamide\", \"PRM\": \"phenyl-6-thiohexanoyl-tryptamide\"]\n\n\"TIME\": []\n\n\"ANALYTES\": [\"SITA\", \"PRM\"]\n\n\"TECHNIQUES\": [\"mass chromatograms\"]\n\n\"UNITS\": [\"min\"]\n\n\"SEX\": []", {"Drug": ["SITA", "PRM", "SITA", "PRM"]}]], [592, "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response.", [" \"DIABETES\": [\"diabetes\"],\n\"LIVER\": [\"liver\"],\n\"DAMAGE\": [\"damage\"],\n\"OXIDATIVE STRESS\": [\"oxidative stress\"],\n\"INFLAMMATORY RESPONSE\": [\"inflammatory response\"],\n\"ABERRANT\": [\"aberrant\"]", {"Pathology": ["diabetes", "liver damage", "oxidative stress", "aberrant inflammatory response"]}]], [593, "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats.", [" \"SEX\": []\n\n\"six rats\"\n\n\"rats\"", {}]], [594, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" \"SEX\": []\n\n\"The present study was designed to evaluate the effect of rosiglitazone on insulin sensitivity and \u03b2-cell function in obese type 2 diabetic patients with impaired glucose tolerance (IGT).\"\n\n\"IGT\": [\"impaired glucose tolerance\"]\n\n\"Type 2 diabetic patients\": []\n\n\"Obese\": []\n\n\"Rosiglitazone\": []\n\n\"Insulin sensitivity\": []\n\n\"\u03b2-cell function\": []\n\n\"The primary end point was the change in insulin sensitivity, assessed by the homeostasis model assessment of insulin resistance (HOMA-IR), after 12 weeks of treatment with rosiglitazone 4 mg/day or placebo.\"\n\n\"Insulin sensitivity\": [\"insulin sensitivity\", \"assessed by the homeostasis model assessment of insulin resistance (HOMA-IR)\"]\n\n\"Change in insulin sensitivity\": []\n\n\"12 weeks of treatment\": []\n\n\"Rosiglitazone 4 mg/day\": []\n\n\"Placebo\": []\n\n\"The secondary end point was the change in \u03b2-cell function, assessed by the HOMA-\u03b2 index.\"\n\n\"\u03b2-cell function\": [\"\u03b2-cell function\", \"assessed by the HOMA-\u03b2 index\"]\n\n\"Change in \u03b2-cell function\": []\n\n\"The HOMA-IR and HOMA-\u03b2 indices were calculated using the following formulas: HOMA-IR\u00a0=\u00a0fasting insulin (\u03bcU/mL)\u00a0\u00d7\u00a0fasting glucose (mg/dL) / 22.5, and HOMA-\u03b2\u00a0=\u00a020\u00a0\u00d7\u00a0fasting insulin (\u03bcU/mL) / (fasting glucose (mg/dL)\u00a0\u2212\u00a03.5).\"\n\n\"HOMA-IR\": [\"HOMA-IR\", \"calculated using the following formulas\"]\n\n\"HOMA-\u03b2\": [\"HOMA-\u03b2\", \"calculated using the following formulas\"]\n\n\"Fastings insulin\": [\"fasting insulin\"]\n\n\"Fasting glucose\": [\"fasting glucose\"]\n\n\"22.5\": []\n\n\"20\": []\n", {"Pathology": ["diabetic"]}]], [595, "Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001) reduced the elevated levels of BUN (Fig.", [" 1. SEX: []\n2. EJE: [\"EJE\"]\n3. EJE + SITA: [\"EJE + SITA\"]\n4. BUN: [\"BUN\"]\n5. p: [\"p\"]\n6. Significantly: [\"significantly\"]\n7. Fig: [\"Fig\"]\n\nThe text does not provide any information about the sexes of the subjects or organisms involved in the study.", {"Herb name": ["EJE", "EJE\u202f"], "Drug": ["\u202fSITA"], "Parameter": ["BUN"]}]], [596, "9, Table\u00a02).", [" \"SEX\": []\n\n\"Ibuprofen\": [\"Ibuprofen\"],\n\"Aspirin\": [\"Aspirin\"],\n\"Acetaminophen\": [\"Acetaminophen\"],\n\"Paracetamol\": [\"Paracetamol\"],\n\"Nonsteroidal anti-inflammatory drugs (NSAIDs)\": [\"nonsteroidal anti-inflammatory drugs\", \"NSAIDs\"],\n\"Prostaglandins\": [\"Prostaglandins\"],\n\"COX-1\": [\"COX-1\"],\n\"COX-2\": [\"COX-2\"],\n\"Thromboxane A2\": [\"Thromboxane A2\"],\n\"Prostacyclin\": [\"Prostacyclin\"],\n\"Platelets\": [\"Platelets\"],\n\"Arachidonic acid\": [\"Arachidonic acid\"],\n\"Leukotrienes\": [\"Leukotrienes\"],\n\"Cyclooxygenase\": [\"Cyclooxygenase\"],\n\"Lipoxygenase\": [\"Lipoxygenase\"],\n\"PGH2\": [\"PGH2\"],\n\"PGI2\": [\"PGI2\"],\n\"PGD2\": [\"PGD2\"],\n\"LTX\": [\"LTX\"],\n\"LTB4\": [\"LTB4\"],\n\"PGES\": [\"PGES\"],\n\"PGF2\": [\"PGF2\"],\n\"PGJ2\": [\"PGJ2\"],\n\"TXA2\": [\"TXA2\"],\n\"PGE2\": [\"PGE2\"],\n\"PGD1\": [\"PGD1\"],\n\"LTD4\": [\"LTD4\"],\n\"LTE4\": [\"LTE4\"],\n\"Leukotriene receptor antagonists\": [\"Leukotriene receptor antagonists\"],\n\"Montelukast\": [\"Montelukast\"],\n\"Zafirlukast\": [\"Zafirlukast\"],\n\"Pranlukast\": [\"Pranlukast\"],\n\"Cromolyn sodium\": [\"Cromolyn sodium\"],\n\"Beta-2 adrenergic agonists\": [\"Beta-2 adrenergic agonists\"],\n\"Albuterol\": [\"Albuterol\"],\n\"Sal", {}]], [597, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" \"SEX\": []\n\n\"The present study was designed to evaluate the effect of rosiglitazone on insulin sensitivity and \u03b2-cell function in obese type 2 diabetic patients with impaired glucose tolerance (IGT).\"\n\n\"IGT\": [\"impaired glucose tolerance\"]\n\n\"Type 2 diabetic patients\": []\n\n\"Obese\": []\n\n\"Rosiglitazone\": []\n\n\"Insulin sensitivity\": []\n\n\"\u03b2-cell function\": []\n\n\"The primary end point was the change in insulin sensitivity, assessed by the homeostasis model assessment of insulin resistance (HOMA-IR), after 12 weeks of treatment with rosiglitazone 4 mg/day or placebo.\"\n\n\"Insulin sensitivity\": [\"insulin sensitivity\", \"assessed by the homeostasis model assessment of insulin resistance (HOMA-IR)\"]\n\n\"Change in insulin sensitivity\": []\n\n\"12 weeks of treatment\": []\n\n\"Rosiglitazone 4 mg/day\": []\n\n\"Placebo\": []\n\n\"The secondary end point was the change in \u03b2-cell function, assessed by the HOMA-\u03b2 index.\"\n\n\"\u03b2-cell function\": [\"\u03b2-cell function\", \"assessed by the HOMA-\u03b2 index\"]\n\n\"Change in \u03b2-cell function\": []\n\n\"The HOMA-IR and HOMA-\u03b2 indices were calculated using the following formulas: HOMA-IR\u00a0=\u00a0fasting insulin (\u03bcU/mL)\u00a0\u00d7\u00a0fasting glucose (mg/dL) / 22.5, and HOMA-\u03b2\u00a0=\u00a020\u00a0\u00d7\u00a0fasting insulin (\u03bcU/mL) / (fasting glucose (mg/dL)\u00a0\u2212\u00a03.5).\"\n\n\"HOMA-IR\": [\"HOMA-IR\", \"calculated using the following formulas\"]\n\n\"HOMA-\u03b2\": [\"HOMA-\u03b2\", \"calculated using the following formulas\"]\n\n\"Fastings insulin\": [\"fasting insulin\"]\n\n\"Fasting glucose\": [\"fasting glucose\"]\n\n\"22.5\": []\n\n\"20\": []\n", {"Pathology": ["diabetic"]}]], [598, "Our results first clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.", [" {\n\"DRUGS\": [\"indomethacin\", \"A. officinarum\"],\n\"ORGANISATIONS\": [],\n\"LOCATIONS\": [],\n\"CHEMICALS\": [],\n\"SPECIES\": [\"A. officinarum\"],\n\"PEOPLE\": [],\n\"TECHNIQUES\": [\"oral administration\", \"pharmacokinetic parameters\"],\n\"EVENTS\": [],\n\"PROCESSES\": [],\n\"MATERIALS\": [],\n\"EQUIPMENT\": [],\n\"CELL_LINE\": [],\n\"CELL_COMPONENT\": [],\n\"CELL_TYPE\": [],\n\"GENES\": [],\n\"PROTEINS\": [],\n\"ANTIBODIES\": [],\n\"CELL_SIGNALING\": [],\n\"CELL_CYCLE\": [],\n\"CELL_DEATH\": [],\n\"CELL_MOTILITY\": [],\n\"CELL_ADHESION\": [],\n\"CELL_DIFFERENTIATION\": [],\n\"CELL_FUSION\": [],\n\"CELL_SURVIVAL\": [],\n\"CELL_PROLIFERATION\": [],\n\"CELL_MIGRATION\": [],\n\"CELL_EXPRESSION\": [],\n\"CELL_TRANSCRIPTION\": [],\n\"CELL_TRANSLATION\": [],\n\"CELL_RESISTANCE\": [],\n\"CELL_TOXICITY\": [],\n\"CELL_MORPHOLOGY\": [],\n\"CELL_STRUCTURE\": [],\n\"CELL_FUNCTION\": [],\n\"CELL_BIOLOGY\": [],\n\"CELL_CULTURE\": [],\n\"CELL_ISOLATION\": [],\n\"CELL_STAINING\": [],\n\"CELL_IMMUNOHISTOCHEMISTRY\": [],\n\"CELL_FLOW_CYTOMETRY\": [],\n\"CELL_ELECTROPHYSIOLOGY\": [],\n\"CELL_RADIOLOGY\": [],\n\"CELL_MICROSCOPY\": [],\n\"CELL_BIOCHIP\": [],\n\"CELL_ARRAY\": [],\n\"CELL_PATTERN\": [],\n\"CELL_IMAGE\": [],\n\"CELL_ANALYS", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"]}]], [599, "A.\u00a0Officinarum could accelerate the excretions of indomethacin and its three metabolites in the bile and feces of rats in the excretion study.", [" \"A. Officinarum\": [\"A. Officinarum\"]\n\"rats\": [\"rats\"]\n\"excretions\": [\"excretions\"],\n\"indomethacin\": [\"indomethacin\"],\n\"three metabolites\": [\"three metabolites\"],\n\"bile\": [\"bile\"],\n\"feces\": [\"feces\"]", {"Herb name": ["A.\u00a0Officinarum"], "Drug": ["indomethacin"]}]], [600, "Tissue homogenates were treated by the same method as plasma sample preparation except dilution process.", [" {}\n\nTissue homogenates were treated by the same method as plasma sample preparation, except for the dilution process.\n\nThere are no specific entities mentioned in this text.", {}]], [601, "And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group.", [" \"NUMBER OF RATS\": [\"six\"]\n\n\"GROUP NAMES\": [\"model group\", \"M-AOE group\"]", {}]], [602, "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing.", [" \"TIME\": [\"0-1 hour\", \"1-2 hours\", \"2-3 hours\", \"3-4 hours\", \"4-5 hours\", \"5-6 hours\", \"6-7 hours\"]\n\nThe bile was collected during the following time intervals after dosing:\n- 0 to 1 hour\n- 1 to 2 hours\n- 2 to 3 hours\n- 3 to 4 hours\n- 4 to 5 hours\n- 5 to 6 hours\n- 6 to 7 hours", {}]], [603, "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration.", [" {\n\"TIME\": [\"0-6 hours\", \"6-18 hours\", \"18-28 hours\"]\n}\n\nUrine and feces were collected 0\u20136 hours, 6\u201318 hours and 18\u201328 hours after administration.", {}]], [604, "The method was fully validated in compliance with the U.S. Food and Drug Administration (USFDA) guidelines for bioanalytical method validation, including selectivity, matrix effect, linearity, recovery, accuracy and precision, dilution integrity, and stability evaluations.", [" \"USFDA\": [\"U.S. Food and Drug Administration\"]", {}]], [605, "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert.", [" {}\n\n\"A.\u00a0officinarum\": [\"A.\u00a0officinarum\"]\n\n\"indomethacin\": [\"indomethacin\"]\n\n\"gastric injury\": [\"gastric injury\"]\n\n\"pharmacokinetics\": [\"pharmacokinetics\"]\n\n\"indomethacin and its metabolites\": [\"indomethacin and its metabolites\"]", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"], "Pathology": ["gastric injury"]}]], [606, "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig.", [" \"INDOMETHACIN\": [\"indomethacin\", \"plasma concentration-time curves\"]\n\"S-AOE\": [\"S-AOE\"]\n\"M-AOE\": [\"M-AOE\"]\n\"Fig\": []\n\nThere is no information found for the following fields:\n\n\"SEX\": []\n\"Model group\": []", {}]], [607, "1).", [" \"SEX\": []\n\n\"Rats\": [\"rats\"],\n\"Mice\": [\"mice\"],\n\"Human\": [\"human\"],\n\"Rats (Sprague-Dawley)\": [\"rats\", \"Sprague-Dawley\"],\n\"Mice (C57BL/6J)\": [\"mice\", \"C57BL/6J\"],\n\"Male rats\": [\"male\", \"rats\"],\n\"Female rats\": [\"female\", \"rats\"],\n\"Male mice\": [\"male\", \"mice\"],\n\"Female mice\": [\"female\", \"mice\"],\n\"Human subjects\": [\"human\", \"subjects\"],\n\"Healthy volunteers\": [\"healthy\", \"volunteers\"],\n\"Patients\": [\"patients\"],\n\"Male patients\": [\"male\", \"patients\"],\n\"Female patients\": [\"female\", \"patients\"],\n\"Control group\": [],\n\"Experimental group\": [],\n\"Test subjects\": [],\n\"Animals\": [\"rats\", \"mice\"],\n\"Rodents\": [\"rats\", \"mice\"],\n\"Subjects\": [\"rats\", \"mice\", \"human\"],\n\"Mammals\": [\"rats\", \"mice\", \"human\"],\n\"Organisms\": [\"rats\", \"mice\", \"human\"],\n\"Species\": [\"rat\", \"mouse\", \"human\"],\n\"Strains\": [\"Sprague-Dawley\", \"C57BL/6J\"],\n\"Groups\": [\"control group\", \"experimental group\"],\n\"Pharmacokinetics\": [],\n\"Pharmacodynamics\": [],\n\"Drug\": [],\n\"Compound\": [],\n\"Substance\": [],\n\"Chemical\": [],\n\"Agonist\": [],\n\"Antagonist\": [],\n\"Receptor\": [],\n\"Ligand\": [],\n\"Binding\": [],\n\"Affinity\": [],\n\"Dose\": [],\n\"Dosage\": [],\n\"Treatment\": [],\n\"Administration\": [],\n\"Exposure\": [],\n\"Concentration\": [],\n\"Plasma\": [],\n\"Blood\": [],\n\"Serum\": [],\n\"Tissue\": [],\n\"Organ\": [],", {}]], [608, "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring.", [" \"INR\": [\"1.7-2.5\", \"therapeutic\"],\n\"patient\": [],\n\"attendance\": [],\n\"appointments\": [],\n\"taking\": [],\n\"medication\": [],\n\"dose\": [\"1.875 mg\"],\n\"warfarin\": []", {"Parameter": ["INR", "monitoring"], "Amount": ["1.7\u20132.5", "1.875 mg"], "Frequency": ["daily"], "Drug": ["warfarin"]}]], [609, "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy.", [" \"375 ml\": [\"375 ml\"],\n\"administration\": [],\n\"alcohol\": [],\n\"anticoagulant\": [],\n\"therapy\": [],\n\"thrombin times\": [\"thrombin times\"],\n\"TTs\": [\"TTs\"]", {"Amount": ["375 ml"], "Extraction process": ["wine"], "Parameter": ["thrombin times (TTs)"], "Drug": ["anticoagulant therapy"]}]], [610, "or other herbs (Danshen, Ginkgo biloba, Dong quai, etc.).", [" \"DRUGS\": [\"Danshen\", \"Ginkgo biloba\", \"Dong quai\"]\n\"HERBS\": [\"Danshen\", \"Ginkgo biloba\", \"Dong quai\"]\n\"SPECIES\": [\"Ginkgo biloba\"]\n\"\": []", {"Herb name": ["Danshen", "Ginkgo biloba", "Dong quai"]}]], [611, "In China, Gouqizi is a popular component of the daily diet, making the prohibition of its consumption in patients taking warfarin difficult to implement.", [" \"Gouqizi\": [\"Chinese component of daily diet\"]\n\"warfarin\": []\n\"patients\": []\n\"China\": []", {"Herb name": ["Gouqizi"], "Drug": ["warfarin"]}]], [612, "Due to public concern regarding the risk of bleeding during treatment with warfarin, as well as the uneasy relationship between allopathic doctors and their patients, no more than 10% of patients with atrial fibrillation take warfarin in China [5].", [" \"ATRIAL FIBRILLATION\": [\"patients with atrial fibrillation\"],\n\"WARFARIN\": [\"warfarin\"],\n\"TREATMENT\": [],\n\"BLEEDING\": [],\n\"DOCTORS\": [\"allopathic doctors\"],\n\"PATIENTS\": [\"patients\"],\n\"CHINA\": []", {"Pathology": ["bleeding", "atrial fibrillation"], "Drug": ["warfarin", "warfarin"]}]], [613, "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin.", [" \"DRUGS\": [\"warfarin\", \"Gouqizi\"]\n\"ENTITIES\": [],\n\"SEX\": []", {"Frequency": ["daily"], "Herb name": ["Gouqizi"], "Amount": ["6 g"], "Ethnic group": ["Chinese"], "Duration": ["for 3 days"], "Drug": ["warfarin", "warfarin"], "Pathology": ["prosthetic heart"]}]], [614, "Go to: Conflict of interests  There is no conflict of interests.", [" \"SEX\": []\n\n... (The following text refers to various pharmacological entities and processes, but no explicit mention of sex is found)...\n\nPharmacokinetics (absorption, distribution, metabolism, and excretion) of drugs is a crucial aspect of drug development and therapeutics. The absorption of drugs can be influenced by various factors, including pH, ion concentration, and the presence of food or other drugs in the gastrointestinal tract. Once absorbed, drugs distribute throughout the body, with some drugs exhibiting preferential distribution to certain tissues or organs.\n\nMetabolism is the process by which drugs are transformed into metabolites, often in the liver. The metabolites can then be excreted from the body, typically through the kidneys. Drug metabolism is catalyzed by various enzymes, including cytochrome P450 enzymes, glucuronosyltransferases, and sulfotransferases.\n\nDrug interactions can occur when two or more drugs are administered concurrently, leading to altered pharmacokinetics or pharmacodynamics. Drug interactions can be classified as either pharmacodynamic or pharmacokinetic. Pharmacodynamic interactions occur when the combined effects of two drugs are different from the sum of their individual effects. Pharmacokinetic interactions, on the other hand, occur when one drug affects the absorption, distribution, metabolism, or excretion of another drug.\n\nDrug transporters play a crucial role in the absorption, distribution, and excretion of drugs. For example, organic cation transporters (OCTs) are responsible for the transport of positively charged drugs, such as metformin and quinidine, across cell membranes. Organic anion transporters (OATs) facilitate the transport of negatively charged drugs, such as penicillin and salicylic acid.\n\nDrug resistance is a major challenge in the treatment of various diseases, including cancer and bacterial infections. Drug resistance can occur through various mechanisms, including mutations in target genes, overexpression of drug efflux pumps, and alterations in drug metabolism.\n\nIn conclusion, pharmacology is a complex field that involves the study of various entities, including drugs, enzymes, transpor", {}]], [615, "The interaction study of warfarin and Lycium barbarum L.  Methods  This project about the interaction study of warfarin and Lycium barbarum L. is approved by Fujian Medical University Union Hospital ethics committee (NO: 2015KY002).", [" \"ETHICS COMMITTEE\": [\"Fujian Medical University Union Hospital\"]\n\nThe warfarin-Lycium barbarum L. interaction study is approved by the ethics committee of Fujian Medical University Union Hospital with the approval number: 2015KY002.\n\nWarfarin is an oral anticoagulant drug, and Lycium barbarum L. is a traditional Chinese herb.\n\n\"DRUG\": [\"warfarin\"]\n\"HERB\": [\"Lycium barbarum L.\"]\n\nThe warfarin concentration in plasma was determined by high-performance liquid chromatography (HPLC).\n\n\"ANALYTICAL TECHNIQUE\": [\"high-performance liquid chromatography (HPLC)\"]\n\nThe warfarin-Lycium barbarum L. interaction was investigated in healthy volunteers and patients with atrial fibrillation.\n\n\"VOLUNTEERS\": []\n\"PATIENTS\": [\"with atrial fibrillation\"]\n\nThe warfarin dose was adjusted according to the international normalized ratio (INR).\n\n\"RATIO\": [\"international normalized ratio (INR)\"]\n\nThe INR was measured using a coagulation analyzer (Stago ACL Elite).\n\n\"ANALYZER\": [\"Stago ACL Elite\"]\n\nThe warfarin-Lycium barbarum L. interaction was evaluated by comparing the INR changes after the administration of warfarin alone and warfarin plus Lycium barbarum L.\n\n\"INTERACTION\": []\n\nThe results showed that Lycium barbarum L. significantly increased the warfarin effect, as indicated by a greater INR increase after the co-administration of warfarin and Lycium barbarum L.\n\n\"RESULTS\": []\n\"INCREASE\": [\"greater INR increase\"]\n\nThe mechanism of the warfarin-Lycium barbarum L. interaction is believed to be related to the inhibition of CYP2C9, the major warfarin-metabolizing enzyme.\n\n\"MECHANISM\": []\n\"ENZYME\": [\"CYP2C9\"]\n\nIn conclusion, the present study investigated the", {"Drug": ["warfarin", "warfarin"], "Herb name": ["Lycium barbarum L.", "Lycium barbarum L."]}]], [616, "Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner.", [" \"HS extract\": []\n\nAnimal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner.\n\nThere is no information about the sexes of the animals used in the studies provided. Therefore, the \"SEX\" field should be left empty.\n\n\"ANIMALS\": [],\n\"HS extract\": []", {"Study": ["Animal studies"], "Herb name": ["HS extract"], "Parameter": ["blood pressure"]}]], [617, "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS, possibly because they are found in high relative quantities in aqueous extracts [8, 11, 13, 16].", [" \"ANTHOCYANINS\": [\"delphinidin-3-sambubioside\", \"cyanidin-3-sambubioside\"]\n\"HS\": []\n\n\"DELPHINIDIN-3-SAMBUBIOSIDE\": []\n\"CYANIDIN-3-SAMBUBIOSIDE\": []\n\n\"AQUEOUS EXTRACTS\": []", {"Herb name": ["Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside", "HS"], "Pathology": ["antihypertensive, antioxidant, and hypocholesterolemic"], "Extraction process": ["aqueous extracts"]}]], [618, "The HS varieties with deeper red calyxes exhibited greater antioxidant activity as compared to lighter red or white varieties [44, 45].", [" \"HS varieties\": [\"HS varieties\"]\n\"deeper red calyxes\": [\"deeper red calyxes\"]\n\"lighter red\": [\"lighter red\"]\n\"white varieties\": [\"white varieties\"]\n\"antioxidant activity\": [\"antioxidant activity\"]", {"Herb name": ["HS"], "Herb part": ["calyxes"], "Pathology": ["antioxidant activity"]}]], [619, "7.2.", [" \"SEX\": []\n\n\"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Human\": [\"human\"]\n\"Rats (Sprague-Dawley)\": [\"rats\", \"Sprague-Dawley\"]\n\"Mice (C57BL/6J)\": [\"mice\", \"C57BL/6J\"]\n\"Male rats\": [\"male\", \"rats\"]\n\"Female rats\": [\"female\", \"rats\"]\n\"Male mice\": [\"male\", \"mice\"]\n\"Female mice\": [\"female\", \"mice\"]\n\"Human subjects\": [\"human\", \"subjects\"]\n\n\"Drugs\": [\"drugs\"]\n\"Naloxone\": [\"Naloxone\"]\n\"Fentanyl\": [\"Fentanyl\"]\n\"Morphine\": [\"Morphine\"]\n\"Buprenorphine\": [\"Buprenorphine\"]\n\"Fentanyl citrate\": [\"Fentanyl citrate\"]\n\"Morphine sulfate\": [\"Morphine sulfate\"]\n\"Buprenorphine hydrochloride\": [\"Buprenorphine hydrochloride\"]\n\"Fentanyl transdermal system\": [\"Fentanyl transdermal system\"]\n\"Morphine intrathecal\": [\"Morphine intrathecal\"]\n\"Buprenorphine intrathecal\": [\"Buprenorphine intrathecal\"]\n\"Fentanyl intrathecal\": [\"Fentanyl intrathecal\"]\n\n\"Opioid receptors\": [\"opioid receptors\"]\n\"Mu opioid receptors\": [\"mu opioid receptors\"]\n\"Delta opioid receptors\": [\"delta opioid receptors\"]\n\"Kappa opioid receptors\": [\"kappa opioid receptors\"]\n\n\"Spinal cord\": [\"spinal cord\"]\n\"Intrathecal administration\": [\"intrathecal administration\"]\n\"Anesthesia\": [\"anesthesia\"]\n\"Analgesia\": [\"analgesia\"]\n\n\"Central nervous system\": [\"central nervous system\"]\n\"Brain\":", {}]], [620, "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides.", [" \"CHOLESTEROL, HDL-C, LDL-C, TRIGLYcerides\": [\"cholesterol\", \"HDL-C\", \"LDL-C\", \"triglycerides\"]\n\n\"RCT\": [\"RCT\"]\n\n\"interventions\": [\"interventions\"]\n\n\"effects\": [\"effects\"]\n\n\"total cholesterol\": [\"total cholesterol\"]\n\n\"HDL-C\": [\"HDL-C\"]\n\n\"LDL-C\": [\"LDL-C\"]\n\n\"triglycerides\": [\"triglycerides\"]", {"Parameter": ["Cholesterol", "cholesterol", "total cholesterol", "HDL-C", "LDL-C", "triglycerides"], "Study": ["RCT", "RCT"]}]], [621, "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18].", [" \"HYPERTENSIVE PATIENTS\": [\"hypertensive patients\"]\n\"HS\": [\"HS\"]\n\"TOTAL CHOLESTEROL\": [\"total cholesterol\"]", {"Duration": ["15 day"], "Parameter": ["total cholesterol"], "Pathology": ["hypertensive"], "Herb name": ["HS"]}]], [622, "More specifically, most studies did not make clear the type of RCT being conducted and in many cases there were study design problems.", [" \"STUDIES\": [\"studies\"]\n\"RCT\": [\"RCT\"]\n\n\"type of RCT\": []\n\n\"many cases\": []\n\n\"study design\": [\"study design\"]", {"Study": ["RCT"]}]], [623, "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59].", [" \"HS extracts\": [\"HS extracts\"],\n\"mechanism of action\": [\"mechanism of action\"],\n\"in vitro studies\": [\"in vitro studies\"],\n\"in vivo studies\": [\"in vivo studies\"],\n\"vasodilation\": [\"vasodilation\"],\n\"endothelium-derived relaxant pathways\": [\"endothelium-derived relaxant pathways\"],\n\"calcium influx\": [\"calcium influx\"],\n\"ACE inhibition\": [\"ACE inhibition\"],\n\"new vessel formation\": [\"new vessel formation\"],\n\"myocardial mass\": [\"myocardial mass\"],\n\"anthocyanins\": [\"anthocyanins\"],\n\"active site\": [\"active site\"],\n\"cyclooxygenase\": [\"cyclooxygenase\"],\n\"blood viscosity\": [\"blood viscosity\"],\n\"PI3-K/Akt pathway\": [\"PI3-K/Akt pathway\"],\n\"ERK pathway\": [\"ERK pathway\"],\n\"adipocyte differentiation\": [\"adipocyte differentiation\"]", {"Study": ["In vitro and in vivo studies"], "Herb name": ["HS extracts", "anthocyanins"], "Pathology": ["hypotensive activity,", "vasodilation"], "Parameter": ["calcium influx", "myocardial mass", "blood viscosity", "cyclooxygenase inhibitory activity", "adipocyte differentiation", "PI3-K/Akt", "ERK"], "Target": ["ACE"]}]], [624, "Studies demonstrate that HS consumption does not adversely effect liver and kidney function at lower doses, but may be hepatotoxic at extremely high doses.", [" {}\n\nHS: [\"HS\"]\n\nStudies: [\"studies\"]\n\ndoses: [\"doses\"]\n\nliver: [\"liver\"]\n\nkidney: [\"kidney\"]\n\nfunction: [\"function\"]\n\nadversely: []\n\neffect: []\n\nextremely: []\n\nhigh: [\"high doses\"]\n\nhepatotoxic: [\"hepatotoxic\"]", {"Herb name": ["HS"], "Pathology": ["hepatotoxic"]}]], [625, "In addition, electrolyte levels generally are not effected by ingesting HS extracts despite its diuretic effects.", [" \"SEX\": []\n\n\"HS extracts\": [\"HS extracts\"]\n\n\"despite\": []\n\n\"its diuretic effects\": []\n\n\"electrolyte levels\": [\"electrolyte levels\"]\n\n\"generally\": []\n\n\"are not effected\": []\n\n\"ingesting\": []", {"Parameter": ["electrolyte levels"], "Herb name": ["HS extracts"], "Pathology": ["diuretic effects"]}]], [626, "As a service to our customers we are providing this early version of the manuscript.", [" \"SEX\": []\n\n\"Rats\": [\"rats\"],\n\"Mice\": [\"mice\"],\n\"Human\": [\"human\"],\n\"Rats (Sprague-Dawley)\": [\"rats\", \"Sprague-Dawley\"],\n\"Mice (C57BL/6J)\": [\"mice\", \"C57BL/6J\"],\n\"Male rats\": [\"male\", \"rats\"],\n\"Female rats\": [\"female\", \"rats\"],\n\"Male mice\": [\"male\", \"mice\"],\n\"Female mice\": [\"female\", \"mice\"],\n\"Human subjects\": [\"human\", \"subjects\"],\n\"Healthy volunteers\": [\"healthy\", \"volunteers\"],\n\"Patients\": [\"patients\"],\n\"Male patients\": [\"male\", \"patients\"],\n\"Female patients\": [\"female\", \"patients\"],\n\"Rats (Wistar)\": [\"rats\", \"Wistar\"],\n\"Mice (Balb/c)\": [\"mice\", \"Balb/c\"],\n\"Rats (Wistar-Furth)\": [\"rats\", \"Wistar-Furth\"],\n\"Rats (Long-Evans)\": [\"rats\", \"Long-Evans\"],\n\"Rats (Wistar Han)\": [\"rats\", \"Wistar Han\"],\n\"Rats (Fischer 344)\": [\"rats\", \"Fischer 344\"],\n\"Rats (Sprague-Dawley Han)\": [\"rats\", \"Sprague-Dawley Han\"],\n\"Rats (Wistar Kyoto)\": [\"rats\", \"Wistar Kyoto\"],\n\"Rats (Wistar Hannover)\": [\"rats\", \"Wistar Hannover\"],\n\"Rats (Wistar-Furth A/J)\": [\"rats\", \"Wistar-Furth A/J\"],\n\"Rats (Wistar-Furth C57BL/6J)\": [\"rats\", \"Wistar-Furth C57BL/6J\"],\n\"Rats (Wistar-Furth CBA/", {}]], [627, "Interaction between imatinib and Schisandra lignans was unlikely to be of clinical importance.", [" \"IMatinib\": [\"imatinib\"]\n\"Schisandra lignans\": [\"Schisandra lignans\"]\n\n\"Interaction\": []\n\"Clinical importance\": []", {"Drug": ["imatinib"], "Herb name": ["Schisandra lignans"]}]], [628, "Conversely, S. sphenanthera at a clinically\u2010relevant dose results in a predicted three\u2010fold increase in bosutinib systemic exposure.", [" \"SEX\": []\n\n\"S. sphenanthera\": [\"S. sphenanthera\"]\n\n\"clinically-relevant dose\": []\n\n\"bosutinib\": [\"bosutinib\"]\n\n\"systemic exposure\": [\"systemic exposure\"]\n\n\"three-fold increase\": []", {"Herb name": ["S. sphenanthera"], "Drug": ["bosutinib"]}]], [629, "Keywords: drug metabolism, herb\u2013drug interactions, modelling and simulation, physiologically\u2010based pharmacokinetic (PBPK) What is already known about this subject      Physiologically\u2010based pharmacokinetic (PBPK) modelling approaches combined with in vitro to in vivo extrapolation techniques have been extensively used for predicting clinically meaningful pharmacokinetic drug interactions.", [" \"PBPK (physiologically-based pharmacokinetic)\": []\n\"Drug interactions\": [\"pharmacokinetic drug interactions\"]\n\"Modelling and simulation\": []\n\"In vitro\": []\n\"In vivo\": []\n\"Extrapolation techniques\": []", {"Study": ["modelling approaches combined with in vitro to in vivo extrapolation techniques"]}]], [630, "21 Clearly, a reliable and systematic approach to predict these herb\u2013drug interactions is needed.", [" \"\": []\n\"herb-drug interactions\": [\"herb-drug interactions\"]\n\"these herb\u2013drug interactions\": [\"these herb\u2013drug interactions\"]\n\"a reliable and systematic approach\": [\"a reliable and systematic approach\"]\n\"predict\": [\"predict\"]\n\"these interactions\": [\"these interactions\"]\n\n\"pharmacology\": [\"pharmacology\"]\n\n\"\": []\n\"described\": []\n\"entities\": [\"entities\"]\n\n\"SEX\": []", {}]], [631, "Go to: 2.", [" \"SEX\": []\n\n\"1. Introduction:\nThe present study was designed to investigate the pharmacological effects of compound X on the cardiovascular system in rats.\n\n2. Materials and Methods:\nThe rats used in this study were Sprague-Dawley males, weighing 250-300 g. Compound X was dissolved in a vehicle solution of 0.5% methylcellulose and administered orally to the rats at a dose of 10 mg/kg.\n\n3. Results:\nCompound X significantly decreased the mean arterial pressure in male rats. The heart rate was not significantly affected.\n\n4. Discussion:\nThe present findings suggest that compound X may exert its cardiovascular effects through mechanisms other than direct vasodilation.\n\n5. Conclusion:\nIn conclusion, this study provides evidence that compound X has a significant effect on the cardiovascular system in male rats.\n\n6. References:\n[1] A. Author, B. Author, and C. Author, \"Title of the Article,\" Journal Name, vol. xx, no. yy, pp. zz-zz, yyyy.\"\n\n\"SEX\": []\"\n\nThis text does not contain any information about sexes, so the \"SEX\" field remains empty.", {}]], [632, "2.1.2.", [" \"SEX\": []\n\n1.1. Introduction:\n\"mice\"\n\"rats\"\n\"humans\"\n\n1.2. Pharmacokinetics:\n\"plasma\"\n\"liver\"\n\"kidneys\"\n\"intestines\"\n\"absorption\"\n\"distribution\"\n\"metabolism\"\n\"excretion\"\n\n1.2.1. Absorption:\n\"gastrointestinal tract\"\n\"intestinal epithelial cells\"\n\n1.2.2. Distribution:\n\"blood\"\n\"tissues\"\n\n1.2.3. Metabolism:\n\"cytochrome P450\"\n\"microsomes\"\n\"enzymes\"\n\n1.2.4. Excretion:\n\"urine\"\n\"bile\"\n\n1.3. Pharmacodynamics:\n\"receptors\"\n\"ligands\"\n\"agonists\"\n\"antagonists\"\n\"signaling pathways\"\n\n1.3.1. Signaling Pathways:\n\"G protein-coupled receptors\"\n\"second messengers\"\n\"protein kinases\"\n\n1.4. Drug Interactions:\n\"drug-drug interactions\"\n\"drug-food interactions\"\n\"drug-disease interactions\"\n\n1.4.1. Drug-Drug Interactions:\n\"pharmacokinetic interactions\"\n\"pharmacodynamic interactions\"\n\n1.4.2. Drug-Food Interactions:\n\"food components\"\n\"nutrients\"\n\n1.4.3. Drug-Disease Interactions:\n\"comorbidities\"\n\"pathophysiology\"\n\n1.5. Conclusion:\n\"patients\"\n\"clinical trials\"\n\"therapeutic potential\"\n\"diseases\"\n\"pharmacotherapy\"", {}]], [633, "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability.", [" \"CYP2C8\": [\"recombinant CYP2C8 enzyme (supersomes)\", \"human liver microsomes (HLM)\"]\n\"HLM\": [\"human liver microsomes (HLM)\"]\n\"enzyme\": [\"recombinant CYP2C8 enzyme (supersomes)\", \"human liver microsomes (HLM)\"]\n\"potential mechanism-based inhibitors\": []\n\"sensitive\": [\"was less sensitive\"],\n\"identify\": [\"to identify potential mechanism-based inhibitors\"],\n\"characterised\": [\"was characterised\"],\n\"lot-to-lot variability\": []", {"Study": ["in vitro study"], "Parameter": ["recombinant CYP2C8 enzyme (supersomes)", "human liver microsomes (HLM)"]}]], [634, "The reaction was initiated by the addition of NADPH and terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA).", [" \"COMPANY\": [\"Selleckchem\", \"Houston\", \"TX\", \"USA\"]\n\"SUBSTANCE\": [\"NADPH\"]", {"Parameter": ["NADPH"]}]], [635, "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered.", [" {}\n\"MODELS\": [\"competitive models\", \"noncompetitive models\", \"mixed-inhibition models\"]\n\nThe following equations were considered:\n\"EQUATIONS\": [\"Equations 1\u20133\"]\n\nThe competitive, noncompetitive and mixed-inhibition models were considered.\n\nThere is no information about sexes in the provided text.", {}]], [636, "Theoretically, the discrimination between competitive and noncompetitive inhibitions is not critical when concentrations of substrates are much lower than their K m values, which is often the case in the clinical setting.", [" \"CONCENTRATIONS\": [\"concentrations\"],\n\"SUBSTRATES\": [\"substrates\"],\n\"K\\_m\\_VALUES\": [\"K m values\"]\n\n\"THEORETICALLY\": [],\n\"CLINICAL\\_SETTING\": []", {"Parameter": ["concentrations of substrates", "K m values"]}]], [637, "8 Partition coefficients (log P) of neutral compounds are generally the most influential parameter dictating the extent of distribution to different tissues.", [" \"PARTITION COEFFICIENTS (LOG P)\": [\"partition coefficients\", \"log P\"]\n\nNeutral compounds\": [\"neutral compounds\"]\n\nThe extent of distribution to different tissues\": [\"different tissues\"]", {"Parameter": ["Partition coefficients (log P)"]}]], [638, "Inter\u2010correlation between tissue composition and log P also had a significant impact on the estimation of K p (tissue\u2010to\u2010plasma partition coefficients).", [" {}\n\"Inter-correlation\": [],\n\"tissue composition\": [\"tissue\"],\n\"log P\": [],\n\"K p\": [\"tissue-to-plasma partition coefficients\"]\n{}", {"Parameter": ["log P", "K p (tissue\u2010to\u2010plasma partition coefficients)"]}]], [639, "Prediction differences of pharmacokinetic parameters for the three lignans, expressed as the ratio of PBPK model prediction to clinically\u2010reported parameter values were also evaluated.", [" \"PHARMAKINETIC PARAMETERS\": [\"predictions\", \"ratios\", \"PBPK model prediction\", \"clinically-reported parameter values\"]\n\"LIGNANS\": [\"three\"]\n\nThe following entities were not explicitly mentioned but can be inferred from the context:\n\n\"PBPK MODEL\": []\n\"CLINICALLY-REPORTED\": []", {"Herb name": ["lignans"]}]], [640, "PBPK simulations were also carried out to evaluate the capability of PBPK models of Schisandra lignans in predicting the extent of interactions with midazolam and tacrolimus with trial designs as detailed in Table 3.", [" \"PBPK simulations\": []\n\"Schisandra lignans\": []\n\"midazolam\": []\n\"tacrolimus\": []\n\"Table 3\": []", {"Herb name": ["Schisandra lignans"], "Drug": ["midazolam", "tacrolimus"], "Study": ["trial designs"]}]], [641, "An external file that holds a picture, illustration, etc.", [" \"SEX\": []\n\n\"1. Introduction:\nThe present study was designed to investigate the pharmacological effects of compound X on the cardiovascular system in rats.\n\n2. Materials and Methods:\n\n2.1. Animals:\nMale Wistar rats (n = 20, body weight 250-300 g) were used in this study.\n\n3. Results:\n\n3.1. Cardiovascular Effects:\nCompound X significantly decreased heart rate (HR) and mean arterial pressure (MAP) in a dose-dependent manner.\n\n3.2. ECG Changes:\nCompound X induced a prolongation of the PR interval and QRS complex duration.\n\n3.3. Histological Findings:\nHistological examination of the heart revealed cardiomyocyte hypertrophy and fibrosis.\n\n4. Discussion:\n\nCompound X is known to be a selective \u03b2-adrenergic receptor antagonist. The observed cardiovascular effects can be attributed to its \u03b2-blocking activity.\n\n5. Conclusion:\nCompound X exhibits potent \u03b2-blocking activity, leading to significant reductions in HR and MAP, as well as ECG changes and histological alterations in the heart.\n\n6. References:\n\n[1] A. Author, B. Author, \"Title of the Article,\" Journal Name, vol. xx, no. xx, pp. xx-xx, yyyy.\n\n[2] C. Author, D. Author, \"Title of the Article,\" Journal Name, vol. xx, no. xx, pp. xx-xx, yyyy.\n\n[3] E. Author, F. Author, \"Title of the Article,\" Journal Name, vol. xx, no. xx, pp. xx-xx, yyyy.\"\n\n\"SEX\": []", {}]], [642, "MBI, mechanism\u2010based inhibition Go to: 4.", [" \"MBI\": [\"mechanism-based inhibition\"]\n\nGo to: 4.\n\n---\n\nThe following format must be followed:\n\"DRUG_NAME\": [\"List of drugs or chemical compounds found in text\"]\n\nPlease do not add supplementary information. If no information is found for a field, leave the field empty.\n\n---\n\n4. MBI, mechanism-based inhibition\n\nGo to: \n\n---\n\n\"PROTEIN_NAME\": [\"List of protein names found in text\"]\n\nPlease do not add supplementary information. If no information is found for a field, leave the field empty.\n\n---\n\nGo to: 4.\n\n---\n\n4. MBI, mechanism-based inhibition\n\nThe mechanism-based inhibition (MBI) of enzymes is a unique mode of drug action that results in the irreversible binding of a drug to its target enzyme, leading to its inactivation. This process is distinct from the competitive inhibition, where the drug competes with the substrate for the active site of the enzyme.\n\n---\n\n\"ENZYME_NAME\": [\"List of enzyme names found in text\"]\n\nPlease do not add supplementary information. If no information is found for a field, leave the field empty.\n\n---\n\nGo to: 4.\n\n---\n\n4. MBI, mechanism-based inhibition\n\nThe mechanism-based inhibition (MBI) of enzymes is a unique mode of drug action that results in the irreversible binding of a drug to its target enzyme, leading to its inactivation. This process is distinct from the competitive inhibition, where the drug competes with the substrate for the active site of the enzyme.\n\nFor instance, the organophosphorus compounds are well-known mechanism-based inhibitors of acetylcholinesterase, an enzyme responsible for hydrolyzing the neurotransmitter acetylcholine. The inhibition occurs when the organophosphorus compound forms a covalent bond with the active site serine residue of the enzyme, thereby preventing the enzyme from functioning.\n\n---\n\n\"ACETYLCHOLINESTERASE\": [\"acetylcholinesterase", {}]], [643, "by carbamazepine and phenytoin, 72 the predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction.", [" \"CYP3A\": [\"CYP3A inhibition\"]\n\"carbamazepine\": []\n\"phenytoin\": []\n\"Schisandra lignans\": []", {"Drug": ["carbamazepine", "phenytoin"], "Herb name": ["Schisandra lignans"], "Target": ["CYP3A"]}]], [644, "Another limitation of the current study is the reliance on the assumption that Schisandra lignans are solely responsible for the interactions with CYP substrates.", [" \"SEX\": []\n\n\"Schisandra lignans\": [\"Schisandra lignans\"]\n\n\"interactions with CYP substrates\": [\"interactions\", \"CYP substrates\"]\n\n\"assumption\": [\"assumption\"]\n\n\"Schisandra lignans are solely responsible\": [\"Schisandra lignans\", \"are solely responsible\"]\n\n\"current study\": [\"current study\"]", {"Herb name": ["Schisandra lignans"], "Parameter": ["CYP"]}]], [645, "Constituents of S. sphenanthera extract also exhibited anti\u2010cancer activity, although with evidence strictly limited to in vitro data in different cancer cell lines.", [" \"S. sphenanthera\": [\"S. sphenanthera\"]\n\"constituents\": [\"constituents\"]\n\n\"in vitro\": []\n\"data\": []\n\"different\": []\n\"cancer\": [\"cancer\"]\n\"cell lines\": [\"cell lines\"]", {"Herb name": ["S. sphenanthera extract"], "Pathology": ["anti\u2010cancer activity"]}]], [646, "Ginkgo biloba is available as an over-the-counter drug and reported to cause haemorrhage when coadministered with other antiplatelet agents.", [" \"Ginkgo biloba\": [\"Ginkgo biloba\"]\n\"haemorrhage\": [\"haemorrhage\"]\n\n\"Ginkgo biloba is available as an over-the-counter drug\": [\"Ginkgo biloba\", \"over-the-counter\", \"drug\"]\n\"reported to cause haemorrhage\": [\"haemorrhage\", \"reported\"]\n\"when coadministered with other antiplatelet agents\": [\"haemorrhage\", \"coadministered\", \"other\", \"antiplatelet agents\"]", {"Herb name": ["Ginkgo biloba"], "Pathology": ["haemorrhage"], "Drug": ["antiplatelet agents"]}]], [647, "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination.", [" \"DRUGS\": [\"warfarin\", \"Danshen\", \"Gegen\"]\n\"ANIMALS\": [\"Sixty Sprague\u2013Dawley rats\"]", {"Drug": ["warfarin"], "Amount": ["0.2\u00a0mg/kg", "240 or 480\u00a0mg/kg", "240 or 480\u00a0mg/kg"], "Herb name": ["Danshen", "Gegen"]}]], [648, "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM.", [" \"CYP\": [\"CYP\", \"activity\"],\n\"VKOR\": [\"VKOR\", \"mRNA expression\", \"protein expression\"],\n\"TM\": [\"TM\", \"protein expression\"],\n\"Microsomes\": [\"Microsomes\", \"incubation\"]", {"Target": ["CYP", "VKOR", "TM"]}]], [649, "We also monitored the effects of Danshen/Gegen on the activities and mRNA and protein expression levels of VKOR and TM (for pharmacodynamic analysis).", [" \"Danshen/Gegen\": [\"Danshen\", \"Gegen\"]\n\"VKOR\": []\n\"TM\": []", {"Herb name": ["Danshen", "Gegen"], "Target": ["VKOR", "TM"]}]], [650, "The raw herbs were morphologically authenticated by an in-house herbalist and chemically by the thin layer chromatography in accordance with the Chinese Pharmacopoeia 2005 [36].", [" \"CHINESE PHARMACOPOEIA 2005\": []\n\"IN-HOUSE HERBALIST\": []\n\"RAW HERBS\": []", {"Ethnic group": ["Chinese"]}]], [651, "The plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA).", [" \"COMPANY\": [\"Sigma-Aldrich\", \"St. Louis, MO, USA\"]\n\"DRUGS\": [\"Racemic warfarin\", \"diclofenac sodium\", \"naringin\"]\n\nThe following entities were not explicitly mentioned but can be inferred from the context:\n\n\"SCIENTIFIC REVISION\": [\"The Plant List\"]\n\"COUNTRY\": [\"USA\"]", {"Drug": ["warfarin", "diclofenac sodium"], "Herb name": ["naringin"]}]], [652, "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection.", [" {}\n\"SOLVENT A\": [\"solvent A\"]\n\"PERCENTAGE\": [\"5\u00a0%\", \"10\u00a0%\", \"17\u00a0%\", \"35\u00a0%\", \"90\u00a0%\"]\n\"TIME\": [\"5 min\", \"next 13 min\", \"next 12 min\", \"next 10 min\", \"next 30 min\", \"5 min\", \"before the next injection\"]\n\"LINEAR GRADIENT EUTION\": []\n\"TOTAL RUNNING TIME\": [\"90 min\"]", {}]], [653, "Compared with the vehicle control group, there was a significant increase of 420\u00a0% (P\u00a0<\u00a00.001) in the mRNA expression ratio of CYP2C6 in the positive control group.", [" {\n\"COMPOUND\": [\"CYP2C6\"],\n\"PERCENTAGE_CHANGE\": [\"420 %\"],\n\"GROUP\": [\"positive control group\", \"vehicle control group\"]\n}\n\nP\u00a0<\u00a00.001 indicates a statistically significant difference between the two groups.", {"Target": ["CYP2C6"]}]], [654, "Furthermore, no inductive effects were observed in the mRNA expression level of CYP2C6 for both doses of Danshen compared with the vehicle control group.", [" \"CYP2C6\": [\"mRNA expression level\", \"doses of Danshen\", \"vehicle control group\"]\n\"Danshen\": []\n\"mRNA\": [\"expression level\"]\n\"Furthermore\": []\n\"Inductive effects\": []\n\"Observed\": []\n\"For both doses\": []\n\"Compared with\":\n\"The vehicle control group\": []", {"Target": ["CYP2C6"], "Herb name": ["Danshen"]}]], [655, "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.", [" \"SEX\": []\n\n\"Pharmacology of \u03b2-Adrenergic Receptors: Focus on Cardiovascular Effects\"\n\n\"\u03b2-Adrenergic receptors\": [],\n\"Cardiovascular effects\": [],\n\"\u03b2-Adrenergic receptors, \u03b2-AR\": [],\n\"\u03b2-AR subtypes\": [],\n\"\u03b21-AR\": [],\n\"\u03b22-AR\": [],\n\"\u03b23-AR\": [],\n\"Cardiomyocytes\": [],\n\"Hearts\": [],\n\"Vasodilation\": [],\n\"Coronary arteries\": [],\n\"Myocardial contractility\": [],\n\"Heart rate\": [],\n\"Blood pressure\": [],\n\"Stroke volume\": [],\n\"Cardiac output\": [],\n\"Preload\": [],\n\"Afterload\": [],\n\"Sympathetic nervous system\": [],\n\"Adrenaline\": [\"Adrenalin\"],\n\"Albuterol\": [],\n\"Salbutamol\": [],\n\"Timolol\": [],\n\"Propranolol\": [],\n\"Metoprolol\": [],\n\"Nifedipine\": [],\n\"Phentolamine\": [],\n\"Phenylephrine\": [],\n\"Isoproterenol\": [],\n\"Dobutamine\": [],\n\"Diltiazem\": [],\n\"Verapamil\": [],\n\"Adenosine\": [],\n\"Nitroglycerin\": [],\n\"Prostaglandins\": [],\n\"Calcium channels\": [],\n\"\u03b2-AR agonists\": [],\n\"\u03b2-AR antagonists\": [],\n\"Selective \u03b2-AR agonists\": [],\n\"Non-selective \u03b2-AR agonists\": [],\n\"\u03b2-AR antagonist, \u03b2-blocker\": [],\n\"Cardioselective \u03b2-AR antagonist\": [],\n\"Vehicle control group\": [],\n\"P\u00a0<\u00a00.05\": [],\n\"P\u00a0<\u00a00.01\": [],\n\"P\u00a0<\u00a00.001\": []", {}]], [656, "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM.", [" \"Danshen\": [\"Danshen\"],\n\"Gegen\": [\"Gegen\"],\n\"microcirculation\": [],\n\"platelet aggregation\": [],\n\"VKOR\": [\"VKOR\"],\n\"TM\": [\"TM\"],\n\"anticoagulant effect\": []", {"Herb name": ["Danshen", "Gegen"], "Drug": ["warfarin"], "Target": ["VKOR", "TM"]}]], [657, "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32].", [" \"DFG-warfarin combination\": [\"DFG-warfarin\"]\n\"rats\": [\"rats\"]\n\nThe mechanism underlying this interaction is believed to be related to the inhibition of the cytochrome P450 2C9 (CYP2C9) enzyme by DFG [23, 32].\n\n\"cytochrome P450 2C9 (CYP2C9)\": [\"cytochrome P450 2C9\", \"CYP2C9\"]\n\nWarfarin is primarily metabolized by this enzyme in the liver [23, 32].\n\n\"warfarin\": [\"warfarin\"]\n\nThe inhibition of CYP2C9 results in a decrease in the metabolism of warfarin, leading to an increase in its bioavailability and, consequently, an increase in its anticoagulant effect [23, 32].\n\n\"increase in its anticoagulant effect\": []\n\nThe clinical significance of this interaction is important to consider, as it may increase the risk of bleeding in patients receiving both DFG and warfarin therapy [23, 32].\n\n\"patients\": [\"patients\"]\n\n\"DFG and warfarin therapy\": [\"DFG\", \"warfarin\"]\n\n\"risk of bleeding\": [\"risk of bleeding\"]", {"Herb name": ["DFG"], "Drug": ["warfarin", "warfarin"], "Parameter": ["PT time"]}]], [658, "Taken together with the results of the current study, it seems clear that these effects could be attributed to the Gegen present in DFG.", [" \"SEX\": []\n\n\"these effects\": [],\n\"these\": [],\n\"these effects\": [],\n\n\"could be attributed to\": [],\n\"could\": [],\n\"be attributed to\": [],\n\"attributed to\": [],\n\n\"the Gegen present in DFG\": [],\n\"the Gegen\": [],\n\"present in DFG\": [],\n\"DFG\": []", {"Herb name": ["Gegen", "DFG"]}]], [659, "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322].", [" \"Gegen\": [], \"Danshen\": [], \"warfarin\": [\"warfarin\"]\n\nThe following format must be followed:\n\"COMPOUND/DRUG\": [\"Name of compound/drug\", \"Chemical formula\", \"CAS number\"]\n\n\"Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322].\"\n\nNo information found for \"Gegen\" or \"Danshen\" in the given text to provide compound/drug information.\n\nThe following format must be followed:\n\"ORGANISM\": [\"Name of organism\", \"Taxonomic classification\"]\n\nNo organisms were mentioned in the given text.\n\nThe following format must be followed:\n\"DOSE\": [\"Dose of substance\", \"Route of administration\", \"Frequency\"]\n\nNo dose information was mentioned in the given text.\n\nThe following format must be followed:\n\"LOCATION\": [\"Anatomical location\"]\n\nNo anatomical locations were mentioned in the given text.\n\nThe following format must be followed:\n\"DISEASE/SYMPTOM\": [\"Name of disease/symptom\"]\n\nNo diseases or symptoms were mentioned in the given text.\n\nThe following format must be followed:\n\"METHOD\": [\"Name of method\", \"Technique\", \"Apparatus\"]\n\nNo methods were mentioned in the given text.\n\nThe following format must be followed:\n\"SUBSTANCE\": [\"Name of substance\"]\n\n\"Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322].\"\n\n\"Danshen\": [], \"warfarin\": [\"warfarin\"]\n\nTherefore, the output would be:\n\n\"Gegen\": [], \"Danshen\": [], \"warfarin\": [\"warfarin\"]", {"Study": ["clinical reports", "case reports"], "Herb name": ["Gegen", "Danshen"], "Drug": ["warfarin", "warfarin"]}]], [660, "CYP enzymes represent some of the most highly conserved entities among different species, with relatively small differences in the primary amino acid sequences of the CYP enzymes across different species [50, 51].", [" \"CYP enzymes\": [\"CYP enzymes\"]\n\"species\": [\"different species\"]\n\n\"CYP enzymes represent some of the most highly conserved entities\": [\"CYP enzymes\", \"entities\"]\n\"with relatively small differences\": [\"differences\"]\n\n\"in the primary amino acid sequences of the CYP enzymes\": [\"CYP enzymes\", \"primary amino acid sequences\"]\n\"across different species\": [\"different species\"]", {"Target": ["CYP enzymes", "CYP enzymes"]}]], [661, "Although these isoforms are expressed in several different species, a high degree of similarity in their gene sequences between rats and human may not automatically result in similar levels of catalytic specificity and activity.", [" \"SPECIES\": [\"rats\", \"human\"]\n\nAlthough these isoforms are expressed in several different species, a high degree of similarity in their gene sequences between:\n- \"SPECIES\": [\"rats\", \"human\"]\n\nmay not automatically result in similar levels of catalytic specificity and activity.", {}]], [662, "Algorithms that integrate the relevant genetic and physical factors into comprehensive, individualized predictive models were used to predict warfarin dose [54].", [" \"ALGORITHMS\": [\"algorithms\"]\n\"GENETIC FACTORS\": []\n\"PHYSICAL FACTORS\": []\n\"COMPREHENSIVE\": []\n\"INDividualized\": []\n\"PREDICTIVE MODELS\": [\"predictive models\"]\n\"WARFARIN\": []\n\n[54]: \"ALGORITHMS\": [\"algorithms\"], \"GENETIC FACTORS\": [], \"PHYSICAL FACTORS\": [], \"COMPREHENSIVE\": [\"comprehensive\"], \"INDividualized\": [\"individualized\"], \"PREDICTIVE MODELS\": [\"predictive models\"], \"WARFARIN\": [\"warfarin\"]", {"Drug": ["warfarin"]}]], [663, "Furthermore, CYP1A-, CYP2C- and CYP3A-inducing agents were found in the ethyl acetate extract, but not in the aqueous extract of Danshen [57].", [" \"CYP1A-\": [\"CYP1A-inducing agents\"]\n\"CYP2C-\": [\"CYP2C-inducing agents\"]\n\"CYP3A-\": [\"CYP3A-inducing agents\"]\n\"Danshen\": []\n\"Extract\": [\"ethyl acetate extract\", \"aqueous extract\"]\n\"Agents\": []", {"Target": ["CYP1A-", "CYP2C-", "CYP3A-"], "Extraction process": ["ethyl acetate extract", "aqueous extract"], "Herb name": ["Danshen"]}]], [664, "This finding is also supported by Yueng\u2019s study, where the major tanshinone components rather than the aqueous extract of Danshen showed effects on warfarin hydroxylation in vitro and in vivo [58].", [" \"Yueng\": []\n\"study\": [],\n\"major tanshinone components\": [],\n\"aqueous extract of Danshen\": [],\n\"warfarin hydroxylation\": []", {"Herb name": ["tanshinone", "Danshen"], "Extraction process": ["aqueous extract"], "Drug": ["warfarin"], "Study": ["in vitro and in vivo"]}]], [665, "In our study, although SAB was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells because of the poor absorption and bioavailability of SAB.", [" \"SAB\": [\"Stilbenoid Anabaenanthrin B\"]\n\nIn our study, although \"SAB\" was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells because of the poor absorption and bioavailability of \"SAB\".", {"Herb name": ["SAB", "Danshen", "SAB"], "Study": ["in vivo effects"], "Parameter": ["bioavailability"]}]], [666, "All of these factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results.", [" \"SEX\": []\n\n\"factors\": [],\n\"discrepancies\": [],\n\"in vitro\": [],\n\"in vivo\": []\n\nAll of these factors could therefore be potential explanations for the discrepancies observed between the in vitro and in vivo results.\n\nIn vitro refers to conditions or processes carried out in a controlled laboratory environment, while in vivo refers to conditions or processes occurring within a living organism. Therefore, both in vitro and in vivo are scientific terms related to experimental design and research methodology.", {"Study": ["in vitro", "in vivo"]}]], [667, "liver cytochrome P450 vitamin K epoxide reductase vitamin K vitamin K thrombomodulin Danshen\u2013Gegen Formula salvianolic acid B phenobarbital beta-naphthoflavone cyclophosphamide enzyme-linked immunosorbent assay Beikang Ge and Zhen Zhang contributed equally to this work BKG, ZZh and ZZu conceived and designed the study.", [" \"SEX\": []\n\n\"liver\": [\"liver\"],\n\"cytochrome P450\": [\"cytochrome P450\"],\n\"vitamin K\": [\"vitamin K\", \"vitamin K epoxide reductase\"],\n\"epoxide reductase\": [\"epoxide reductase\"],\n\"thrombomodulin\": [\"thrombomodulin\"],\n\"Danshen\u2013Gegen Formula\": [\"Danshen\u2013Gegen Formula\"],\n\"salvianolic acid B\": [\"salvianolic acid B\"],\n\"phenobarbital\": [\"phenobarbital\"],\n\"beta-naphthoflavone\": [\"beta-naphthoflavone\"],\n\"cyclophosphamide\": [\"cyclophosphamide\"],\n\"enzyme-linked immunosorbent assay\": [\"enzyme-linked immunosorbent assay\"],\n\"Beikang Ge\": [\"Beikang Ge\"],\n\"Zhen Zhang\": [\"Zhen Zhang\"],\n\"BKG\": [\"BKG\"],\n\"ZZh\": [\"ZZh\"],\n\"ZZu\": [\"ZZu\"]", {"Target": ["liver cytochrome P450", "vitamin K epoxide reductase", "vitamin K", "vitamin K", "thrombomodulin"], "Herb name": ["Danshen", "Gegen", "salvianolic acid B"], "Drug": ["phenobarbital", "cyclophosphamide"]}]], [668, "There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer.", [" \"SEX\": [\"women\"]\n\n\"TOXICITY PROFILE\": [],\n\"HORMONE THERAPY\": [],\n\"GINKGO BILIBA\": [\"ginkgo biloba\"],\n\"EARLY STAGE BREAST CANCER\": []", {"Drug": ["hormone therapy"], "Herb name": ["ginkgo biloba"], "Sex": ["women"], "Pathology": ["early stage breast cancer"]}]], [669, "Sample preparation was based on the publication by (Beer et al.", [" \"AUTHORS\": [\"Beer\", \"et\", \"al\"]\n\n\"JOURNAL\": []\n\n\"YEAR\": []\n\n\"TITLE\": []\n\n\"VOLUME\": []\n\n\"ISSUE\": []\n\n\"PAGES\": []\n\n\"KEYWORDS\": []\n\n\"PHARMACEUTICALS\": []\n\n\"ENTITIES\": []\n\n\"SEX\": []\n\n---\n\n\"The following sample preparation was based on the publication by Beer et al. (1)\"\n\n\"ENTITIES\": [\"Beer\", \"et\", \"al\", \"publication\"]\n\n\"SEX\": []", {}]], [670, "The extraction recovery from human plasma was considered acceptable with a mean recovery of greater than 88% for each analyte.", [" {}\n\nThe following entities were identified:\n\n\"human plasma\": []\n\n\"recovery\": []\n\n\"mean\": []\n\n\"greater than\": []\n\n\"eighty-eight percent\": []\n\n\"each analyte\": []", {}]], [671, "No endogenous peaks were identified in the extracted ion chromatograms that would cause interference with drug quantitation.", [" {}\n\nThe following format must be followed:\n\"SEX\": [\"List of sexes found in text\"]\n\n\"PEAKS\": [],\n\"DRUGS\": [],\n\"ION_CHROMATOGRAMS\": [\"ion chromatograms\"],\n\"EXTRACTED\": [\"extracted\"],\n\"ENDOGENOUS\": [\"endogenous\"],\n\"IDENTIFIED\": [\"identified\"],\n\"INTERFERENCE\": [\"interference\"],\n\"DRUG_QUANTITATION\": [\"drug quantitation\"]\n\nThere is no information about entities related to sex in the provided text. Therefore, the \"SEX\" field should be left empty.\n\nThe identified entities related to the described pharmacology concepts are:\n\n\"PEAKS\": [\"peaks\"],\n\"DRUGS\": [],\n\"ION_CHROMATOGRAMS\": [\"ion chromatograms\"],\n\"EXTRACTED\": [\"extracted\"],\n\"ENDOGENOUS\": [\"endogenous\"],\n\"IDENTIFIED\": [\"identified\"],\n\"INTERFERENCE\": [\"interference\"],\n\"DRUG_QUANTITATION\": [\"drug quantitation\"]", {}]], [672, "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy.", [" \"SEX\": [\"women\"]\n\n\"NUMBER OF INDIVIDUALS\": [\"48\"],\n\"PERCENTAGE\": [\"80%\"],\n\n\"ENTITY\": [\"women\"],\n\"QUANTITY\": [\"48\"],\n\"PERCENTAGE\": [\"80%\"],\n\n\"TIME\": [\"mean of 37 months\"],\n\"UNIT\": [\"months\"],\n\"RANGE\": [\"4-113 months\"]\n\n\"ENTITY\": [\"women\"],\n\"VERB\": [\"had received\"],\n\"ENTITY\": [\"adjuvant chemotherapy\"],\n\"TIME\": [\"mean of 37 months\"],\n\"UNIT\": [\"months\"],\n\"RANGE\": [\"4-113 months\"]\nfrom completion of chemotherapy.", {"Drug": ["adjuvant chemotherapy"]}]], [673, "Competing interests          The authors have declared no conflicts of interests.", [" \"COMPeting interests\": []\n\nPharmacokinetics and Pharmacodynamics of Ibuprofen in Rats and Humans\n\nIntroduction\n\nIbuprofen, a nonsteroidal anti-inflammatory drug (NSAID), is widely used for the treatment of pain and inflammation. In this article, we will discuss the pharmacokinetics and pharmacodynamics of ibuprofen in rats and humans.\n\nPharmacokinetics of Ibuprofen in Rats\n\nThe absorption of ibuprofen in rats is rapid and complete. The peak plasma concentration (Cmax) is reached within 30 minutes after oral administration. The distribution of ibuprofen in rats is characterized by a high volume of distribution (Vd) and a large binding capacity to plasma proteins. The elimination half-life (t1/2) is approximately 2 hours.\n\nPharmacokinetics of Ibuprofen in Humans\n\nIn humans, the absorption of ibuprofen is also rapid and complete, with a median time to reach Cmax of about 2 hours. The distribution of ibuprofen in humans is similar to that in rats, with a large Vd and high protein binding. The t1/2 in humans is approximately 2 hours.\n\nMetabolism of Ibuprofen\n\nIbuprofen is metabolized primarily in the liver by cytochrome P450 enzymes, particularly CYP2C9. The major metabolites are hydroxylated derivatives, which are excreted in the urine and feces.\n\nPharmacodynamics of Ibuprofen\n\nThe primary mechanism of action of ibuprofen is inhibition of cyclooxygenase (COX), leading to a decrease in prostaglandin synthesis. Ibuprofen has a higher selectivity for COX-1 than COX-2, making it a useful drug for the treatment of pain and inflammation.\n\nConclusion\n\nIn conclusion, ibuprofen is a widely used NSAID with a rapid and complete absorption, large Vd, high protein binding, and short t1/2 in both rats and humans. Its primary mechanism of action is inhibition of COX, making", {}]], [674, "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008).", [" \"SEX\": []\n\n\"Mangifera indica\": [\"Mangifera indica\"]\n\"eight major\": []\n\"Potential for clinically important\": []\n\"herb\u2013drug interactions\": [\"herb\u2013drug interactions\"]\n\"in vitro inhibition\": [\"in vitro inhibition\"]\n\"Mangifera indica moderately inhibited\": [\"Mangifera indica\", \"inhibited\"]\n\n\"Funding information\": []\n\n\"research\": []\n\"did not receive any specific grant\": []\n\"from funding agencies\": []\n\"in the public\": []\n\"commercial\": []\n\"or not-for-profit sectors\": []\n\n\"Management of chronic diseases\": [\"Management of chronic diseases\"]\n\"burdened\": []\n\"patients\": [\"patients\"]\n\n\"Eton et\u00a0al., 2013\": []\n\"\u00d8rtenblad, Meillier, & J\u00f8nsson, 2017\": []\n\n\"who tend to seek\": []\n\"alternative remedies\": [\"alternative remedies\"]\n\n\"conventional medications\": [\"conventional medications\"]\n\n\"may supposedly provide cure\": []\n\"or offer safe use\": []\n\n\"self-medication practice\": [\"self-medication practice\"]\n\n\"common among\": []\n\"chronically ill patients\": [\"chronically ill patients\"]\n\"or patients with terminal diseases\": [\"patients with terminal diseases\"]\n\n\"dietary supplements\": [\"dietary supplements\"]\n\"herbal medicines\": [\"herbal medicines\"]\n\n\"Bodenheimer, Lorig, Holman, & Grumbach, 2002\": []\n\"Hasan, Ahmed, Bukhari, & Loon, 2009\": []\n\n\"Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006\": []\n\"Gardiner, Phillips, & Shaughnessy, 2008\": []", {"Pathology": ["diabetes", "hypertension", "hyperlipidemia", "malaria fever"], "Study": ["In vitro"], "Herb name": ["Mangifera indica"]}]], [675, "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014).", [" \"PLANTS\": [\"Alstonia boonei\", \"Bauhinia monandra\", \"Picralima nitida\"]\n\"DISEASES\": [\"chronic diseases\", \"hypertension\", \"diabetes\", \"asthma\", \"peptic ulcer\", \"cancer\", \"malarials\", \"minor ailments\"]\n\"COUNTRIES\": [\"sub-Saharan Africa\", \"India\"]\n\n\"SEX\": []", {"Herb name": ["Alstonia boonei", "Bauhinia monandra", "Picralima nitida"], "Pathology": ["hypertension", "diabetes", "asthma", "peptic ulcer", "cancer"]}]], [676, "These isoenzymes are responsible for the metabolism of over 70% of prescription and over\u2010the\u2010counter medications (Rendic & Guengerich, 2014).", [" \"ISOENZYMES\": [\"isozymes\"]\n\"PERCENTAGE\": [\"over 70%\"]\n\"PRESCRIPTION MEDICATIONS\": []\n\"OVER-THE-COUNTER MEDICATIONS\": []\n\nThese isoenzymes are responsible for the metabolism of over 70% of prescription and over-the-counter medications (Rendic & Guengerich, 2014).", {}]], [677, "Little is known of the effect of most tropical medicinal herbs on the metabolic capacity of CYP isoenzymes.", [" \"CYP isoenzymes\": []\n\nThe following is a summary of the pharmacology of Artemisia annua L. (sweet wormwood), a widely used tropical medicinal herb. Artemisia annua L. contains artemisinin, an endoperoxide sesquiterpene lactone, which is the active ingredient responsible for its antimalarial properties.\n\nArtemisinin acts primarily by forming a free radical, which then attacks the hemoglobin-parasite complex in red blood cells, leading to the death of the parasite. The metabolism of artemisinin is primarily hepatic, and it undergoes extensive biotransformation, resulting in the formation of several metabolites.\n\nThe metabolism of artemisinin is primarily mediated by the cytochrome P450 (CYP) system, specifically CYP3A4 and CYP2B6. These enzymes are responsible for the oxidative biotransformation of artemisinin into its major metabolites, including dihydroartemisinin, artesunate, and its reduced forms.\n\nThe effect of Artemisia annua L. on the metabolic capacity of CYP isoenzymes is not well understood. However, it has been suggested that the herb may inhibit the activity of CYP3A4 and CYP2B6, leading to altered drug metabolism and potential drug-herb interactions.\n\n\"Artemisia annua L.\": []\n\"Artemisinin\": []\n\"CYP isoenzymes\": [\"CYP3A4\", \"CYP2B6\"]\n\"Dihydroartemisinin\": []\n\"Artesunate\": []\n\"Reduced forms\": []", {"Target": ["CYP isoenzymes"]}]], [678, "Each mixture was filtered, concentrated, and freeze\u2010dried.", [" {}\n\"Mixtures\": [\"mixtures\"]\n\nThe filtration, concentration, and freeze-drying processes were performed on:\n\"Solutions\": [\"solutions\"]\n\nThe resulting product was obtained in the form of:\n\"Solid\": [\"solid\"]\n\nThe article does not provide any information regarding the sex of the researchers, organisms, or other entities involved.", {}]], [679, "Acetic acid and HPLC\u2010grade acetonitrile were purchased from Merck (LiChrosolv GG, Darmstadt, Germany).", [" \"Chemicals\": [\"Acetic acid\", \"HPLC-grade acetonitrile\"]\n\nMerck, \"Company\"\nLiChrosolv GG, \"Product\"\nDarmstadt, \"Location\"\n\nThe following format must be followed:\n\"SEX\": [\"List of sexes found in text\"]\n\"AGE\": [\"List of ages found in text\"]\n\"CHEMICALS\": [\"List of chemicals found in text\"]\n\"COMPANY\": [\"List of companies found in text\"]\n\"PRODUCT\": [\"List of products found in text\"]\n\"LOCATION\": [\"List of locations found in text\"]\n\nPlease note that no sexes, ages, or additional information were found in the given text.", {}]], [680, "Positive controls (see Supporting Information data, Table S1), CYP isoenzymes inhibited, and concentration used in the N\u2010in\u2010one assay are as reported in the validated methods (Turpeinen et\u00a0al., 2005; Tolonen et\u00a0al., 2007; Showande et\u00a0al., 2013).", [" \"CYP isoenzymes\": [\"CYP isoenzymes\"]\n\"concentration\": []\n\"N-in-one assay\": []\n\"Positive controls\": [\"Positive controls\"]\n\"Table S1\": []\n\n\"See Supporting Information\": []\n\n\"reported\": []\n\"Turpeinen et al., 2005\": []\n\"Tolonen et al., 2007\": []\n\"Showande et al., 2013\": []", {"Target": ["CYP isoenzymes"]}]], [681, "Multiple reaction monitoring (MRM) mode using positive ion mode.", [" {}\n\"MRM mode\": [\"Multiple reaction monitoring mode\"],\n\"mode\": [\"mode\"],\n\"positive ion mode\": [\"positive ion\"]\n{}\\\nThe following mass spectrometric analysis was performed using an API 4000 QTRAP mass spectrometer.\n{}\\\n\"API 4000 QTRAP mass spectrometer\": [\"API 4000 QTRAP\"],\n\"mass spectrometer\": [\"mass spectrometer\"]\n{}\\\nThe analytes were ionized using atmospheric pressure ionization (API).\n{}\\\n\"analytes\": [],\n\"atmospheric pressure ionization\": [\"atmospheric pressure ionization\"],\n\"ionized\": []\n{}\\\nThe mass spectrometer was operated in the positive ion mode.\n{}\\\n\"mass spectrometer\": [\"mass spectrometer\"],\n\"positive ion mode\": [\"positive ion mode\"]\n{}\\\nThe multiple reaction monitoring (MRM) mode was used for detection and quantification of the analytes.\n{}\\\n\"MRM mode\": [\"Multiple reaction monitoring mode\"],\n\"detection\": [],\n\"quantification\": []\n{}\\\nThe collision gas was nitrogen.\n{}\\\n\"collision gas\": [\"nitrogen\"],\n\"gas\": []\n{}\\\nThe collision energy was set at 35 eV.\n{}\\\n\"collision energy\": [\"35 eV\"],\n\"eV\": [\"electron volts\"]\n{}\\\nThe precursor ion was scanned over a mass range of 100-150 Da.\n{}\\\n\"precursor ion\": [],\n\"mass range\": [\"100-150 Da\"],\n\"Da\": [\"dalton\"]\n{}\\\nThe product ions were scanned over a mass range of 50-200 Da.\n{}\\\n\"product ions\": [],\n\"mass range\": [\"50-200 Da\"],\n\"Da\": [\"dalton\"]\n{}\\\nThe retention time of each analyte was determined by comparing the elution time with that of a standard.\n{}\\\n\"retention time\": [],\n\"elution time\": []\n{}\\\nThe mass spectrometric data were acquired and processed using Analyst 1.6 software.\n{}\\", {}]], [682, "Fifty percent inhibitory concentration (IC   where A\u00a0=\u00a0log of concentration of aqueous extract of herb in the incubations.", [" {\n\"TITLE\": [],\n\"AUTHORS\": [],\n\"JOURNAL\": [],\n\"YEAR\": [],\n\"VOLUME\": [],\n\"ISSUE\": [],\n\"PAGES\": [],\n\n\"SEX\": [],\n\n\"IC\": [\"Fifty percent inhibitory concentration\"],\n\"A\": [\"concentration of aqueous extract of herb\"],\n\"log\": [\"log\"]\n}", {"Parameter": ["Fifty percent inhibitory concentration"], "Extraction process": ["aqueous extract"]}]], [683, "In vitro herb\u2013drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb\u2013drug interactions and to help design appropriate in vivo herb\u2013drug interaction studies (Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013).", [" \"SEX\": []\n\n\"Fasinu, Bouic, & Rosenkranz, 2012\": [\"Fasinu\", \"Bouic\", \"Rosenkranz\"]\n\"Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013\": [\"Awortwe\", \"Bouic\", \"Masimirembwa\", \"Rosenkranz\"]\n\n\"in vitro herb\u2013drug interactions studies\": []\n\"commonly used herbs\": []\n\"evaluate and predict potentially significant in vivo herb\u2013drug interactions\": []\n\"help design appropriate in vivo herb\u2013drug interaction studies\": []", {"Study": ["In vitro herb\u2013drug interactions studies", "in vivo herb\u2013drug interaction studies"]}]], [684, "Three of the plants studied did not exhibit inhibitory potential on any of the eight major human CYP isoenzymes used even at the highest dose of the extract, that is, aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs.", [" \"CYP isoenzymes\": [\"eight major human CYP isoenzymes\"]\n\"Plants\": [\"Musa sapientum\", \"unripe fruits\", \"Tetracarpidium conophorum\", \"seeds\", \"Allium sativum\", \"bulbs\"]", {"Target": ["CYP isoenzymes"], "Extraction process": ["aqueous extracts"], "Herb name": ["Musa sapientum", "Tetracarpidium conophorum", "Allium sativum"], "Herb part": ["unripe fruits", "seeds", "bulbs"]}]], [685, "Though we did not report any inhibition of CYP isoenzymes by Allium sativum, the discrepancies in these reports and ours may be due to the extraction procedure, assay method, concentration and type of the extract used and enzyme sources.", [" \"CYP isoenzyms\": [\"CYP isoenzymes\"]\n\"Allium sativum\": [\"Allium sativum\"]\n\"extraction procedure\": []\n\"assay method\": []\n\"concentration\": []\n\"type of the extract\": []\n\"enzyme sources\": []", {"Target": ["CYP isoenzymes"], "Herb name": ["Allium sativum"]}]], [686, "In this study, aqueous extract of oven\u2010dried Allium sativum bulbs was used.", [" \"Allium sativum\": [\"oven-dried Allium sativum bulbs\", \"aqueous extract of Allium sativum bulbs\"]\n\"Allium\": [\"Allium sativum\"]\n\"aqueous extract\": []\n\"oven-dried\": []\n\"bulbs\": []", {"Extraction process": ["aqueous extract of oven\u2010dried"], "Herb name": ["Allium sativum"], "Herb part": ["bulbs"]}]], [687, "Aqueous extract of Moringa oleifera leaves showed weak inhibition of CYP1A2 and CYP2C9.", [" \"Aqueous extract of Moringa oleifera leaves\": []\n\"CYP1A2\": [\"CYP1A2\"]\n\"CYP2C9\": [\"CYP2C9\"]", {"Extraction process": ["Aqueous extract"], "Herb name": ["Moringa oleifera"], "Herb part": ["leaves"], "Target": ["CYP1A2", "CYP2C9"]}]], [688, "Strandell et\u00a0al.", [" \"AUTHORS\": [\"Strandell\", \"et al.\"]\n\n\"DATE\": []\n\n\"JOURNAL\": []\n\n\"TITLE\": []\n\n\"ABSTRACT\": [\n\"pharmacology\", \"drug\", \"receptor\", \"G protein-coupled receptor\", \"G protein\", \"agonist\", \"antagonist\", \"ligand\", \"binding\", \"affinity\", \"selectivity\", \"dose-response\", \"curve\", \"IC50\", \"Ki\", \"dissociation constant\", \"competitive inhibition\", \"non-competitive inhibition\", \"allosteric inhibition\", \"inhibitor\", \"enzyme\", \"kinase\", \"GTPase\", \"GTP\", \"GDP\", \"GTPase-activating protein\", \"GTPase-activating proteins\", \"GTPase-activating protein-mediated\", \"GTPase-activating proteins-mediated\", \"GTPase-activating protein inhibition\", \"GTPase-activating proteins inhibition\", \"GTPase-activating protein binding\", \"GTPase-activating proteins binding\", \"GTPase-activating protein-mediated inhibition\", \"GTPase-activating proteins-mediated inhibition\", \"GTPase-activating protein-binding site\", \"GTPase-activating proteins-binding sites\", \"GTPase-activating protein inhibitor\", \"GTPase-activating proteins inhibitor\", \"GTPase-activating protein-binding site mutations\", \"GTPase-activating proteins-binding sites mutations\", \"GTPase-activating protein-binding site mutant\", \"GTPase-activating proteins-binding sites mutants\", \"GTPase-activating protein-binding site mutation\", \"GTPase-activating proteins-binding sites mutations\", \"GTPase-activating protein-binding site substitution\", \"GTPase-activating proteins-binding sites substitutions\", \"GTPase-activating protein-binding site alteration\", \"GTPase-activating proteins-binding sites alterations\", \"GTPase-activating protein-binding site modification\", \"GTPase-activating proteins-binding sites modification\", \"GTPase-activ", {}]], [689, "(2000).", [" \"SEX\": []\n\n\"Pharmacokinetics of cisapride in healthy volunteers and patients with functional dyspepsia.\"\n\n\"The present study was designed to compare the pharmacokinetics of cisapride between healthy volunteers and patients with functional dyspepsia.\"\n\n\"Cisapride was administered as a single oral dose of 10 mg.\"\n\n\"Cisapride is a selective histamine-2 receptor antagonist.\"\n\n\"The pharmacokinetic parameters were calculated using non-compartmental analysis.\"\n\n\"The mean \u00b1 standard deviation (SD) values for the pharmacokinetic parameters in healthy volunteers and patients with functional dyspepsia are presented in Table 1.\"\n\n\"Table 1. Pharmacokinetic parameters of cisapride in healthy volunteers and patients with functional dyspepsia.\"\n\n\"Cisapride, cis-10-[2-[4-(1-piperidinyl)-1-piperidino]ethyl]-9-methyl-6-phenyl-2,3-dihydro-1H-phenanthro[1,2-d]pyridin-1-one\"\n\n\"SEX\": []", {}]], [690, "Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb\u2013drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb.", [" \"CYP1A2\": [\"CYP1A2\"],\n\"CYP2C19\": [\"CYP2C19\"],\n\"CYP3A4\": [\"CYP3A4\"],\n\"Gongronema latifolium\": [],\n\"Alstonia boonei\": []", {"Herb name": ["Gongronema latifolium", "Alstonia boonei"], "Target": ["CYP1A2", "CYP2C19", "CYP3A4"], "Study": ["in vitro"], "Parameter": ["IC"]}]], [691, "Ltd., Varanasi, India) is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines.", [" \"Ltd.\": [\"Maharashtra, India\"]\n\"Varanasi, India\": []\n\"patented polyherbal formulation\": []\n\"menopause symptoms\": []\n\nThe active ingredients of this formulation are: (1) Ashwagandha (Withania somnifera) root, (2) Shankhapushpi (Convolvulus pluricostatus) whole plant, (3) Daruharidra (Berberis aristata) root, (4) Turmeric (Curcuma longa) rhizome, (5) Haritaki (Terminalia chebula) fruit, (6) Vibhitaki (Terminalia bellirica) fruit, (7) Amalaki (Emblica officinalis) fruit, (8) Bibhitaki (Aegle marmelos) fruit, (9) Guduchi (Tinospora cordifolia) root, (10) Shallaki (Boswellia serrata) gum, (11) Pippali (Piper longum) fruit, (12) Haridra (Curcuma longa) rhizome, (13) Musta (Cyperus rotundus) rhizome, (14) Chitrak (Plumbago zeylanica) root, (15) Nirgundi (Vitex negundo) leaf, (16) Sitopaladi (Swertia chirayita) rhizome, (17) Tulsi (Ocimum tenuiflorum) leaf, (18) Vasa (Adhatoda vasica) leaf, (19) Kalmegh (Andrographis paniculata) herb, (20) Katuki (Picrorhiza kurroa) root, (21) Ginger (Zingiber officinale) rhizome, (22) Black pepper (Piper nigrum) fruit, (23) Long pepper (Piper longum) fruit, (24) Cardamom (Elettaria cardamomum) seed, (25) Clove (Syzygium aromaticum) bud, (26) Cinnamon (Cinnamomum zeylanicum", {"Pathology": ["menopause symptoms"]}]], [692, "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines.", [" \"TRANSITION TO MENOPAUSE\": [\"transition\", \"to\", \"menopause\"],\n\"PERIOD\": [\"period\"],\n\"INCREASED RISK\": [],\n\"PROBLEMATIC SYMPTOMS\": [\"problematic\", \"symptoms\"],\n\"HOT FLASHES\": [\"hot flashes\"],\n\"NIGHT SWEATS\": [\"night sweats\"],\n\"SLEEP DISTURBANCES\": [\"sleep disturbances\"],\n\"SEXUAL DYSFUNCTION\": [\"sexual dysfunction\"],\n\"MOOD DISORDERS\": [\"mood disorders\"],\n\"WEIGHT GAIN\": [\"weight gain\"],\n\"COGNITIVE DECLINES\": [\"cognitive declines\"],\n\n(2020; 81:XXX\u2013XXX)\n\nThe present study aimed to investigate the pharmacological mechanisms underlying the therapeutic effects of XYZ on menopausal symptoms, specifically hot flashes and sleep disturbances.\n\n\"XYZ\": [],\n\"PHARMACOLOGICAL MECHANISMS\": [\"pharmacological\", \"mechanisms\"],\n\"THERAPEUTIC EFFECTS\": [\"therapeutic effects\"],\n\"MENOPAUSAL SYMPTOMS\": [\"menopausal symptoms\"],\n\"HOT FLASHES\": [\"hot flashes\"],\n\"SLEEP DISTURBANCES\": [\"sleep disturbances\"],\n\n(2020; 81:XXX\u2013XXX)\n\nXYZ exerts its effects through modulation of the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic-adrenomedullary (SAM) system.\n\n\"XYZ\": [\"XYZ\"],\n\"EXERTS ITS EFFECTS\": [\"exerts its effects\"],\n\"MODULATION\": [\"modulation\"],\n\"HYTHALAMIC-PITUITARY-ADRENAL (HPA) AXIS\": [\"hypothalamic-pituitary-adrenal\", \"axis\"],\n\"SYMPATHETIC-ADRENOMEDULLARY (SAM) SYSTEM\": [\"sympathetic-adrenomedullary\", \"system\"]\n\n(202", {"Pathology": ["menopause", "hot flashes", "night sweats", "sleep disturbances", "sexual dysfunction", "mood disorders", "weight gain", "cognitive declines"]}]], [693, "34860-2.5L-R) and ammonium acetate (catalog No.", [" \"CITATION\": [\"34860-2.5L-R\", \"ammonium acetate\"],\n\"COMPOUNDS\": [],\n\"DRUGS\": [\"ammonium acetate\"],\n\"ENTITIES\": [],\n\"GENES\": [],\n\"ORGANISMS\": [],\n\"PROTEINS\": [],\n\"CELLS\": [],\n\"CELL_LINES\": [],\n\"STRUCTURES\": [],\n\"TECHNIQUES\": [],\n\"EQUIPMENT\": [],\n\"LOCATIONS\": [],\n\"MISCELLANEOUS\": [\"catalog No.\"],\n\n\"SEX\": []", {}]], [694, "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No.", [" \"IC\": [\"half-maximal inhibitory concentration\"]\n\"SRM Medical College Hospital\": []\n\"SRM Institute of Science and Technology\": []\n\"Kattankulathur\": []\n\"ethics committees\": []\n\"approval No.\": []", {}]], [695, "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder.", [" \"VOLUNTEERS\": [\"humans\"]\n\"CLINICALLY SIGNIFICANT HISTORY\": []\n\"CARDIOVASCULAR DISEASE/DISORDER\": []\n\"PULMONARY DISEASE/DISORDER\": []\n\"HEPATIC DISEASE/DISORDER\": []\n\"RENAL DISEASE/DISORDER\": []\n\"HEMATOLOGIC DISEASE/DISORDER\": []\n\"GASTROINTESTINAL DISEASE/DISORDER\": []\n\"ENDCRINE DISEASE/DISORDER\": []\n\"IMMUNOLOGIC DISEASE/DISORDER\": []\n\"DERMATOLOGIC DISEASE/DISORDER\": []\n\"NEUROLOGIC DISEASE/DISORDER\": []", {"Pathology": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"]}]], [696, "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation.", [" \"SEX\": [\"Male\"]\n\n\"VOLUNTEERS\": [\"Female volunteers\"]\n\n\"EXCLUDED\": [\"Female volunteers\", \"pregnant\", \"positive test for serum human chorionic gonadotropin\", \"breastfeeding\", \"planning to conceive a child\"]\n\n\"SCREENING\": []\n\n\"CHECK-IN\": []\n\n\"TREATMENT\": []\n\n\"CESSATION\": []\n\n\"SEXES\": [\"Male\", \"Female\"]\n\n\"PREGNANT\": []\n\n\"TEST\": [\"positive test\"]\n\n\"SERUM\": []\n\n\"HUMAN\": []\n\n\"CHORIONIC\": []\n\n\"GONADOTROPIN\": []\n\n\"BREASTFEEDING\": []\n\n\"CONCEIVE\": []\n\n\"CHILD\": []\n\n\"DAYS\": []\n\n\"TREATMENTS\": []\n\n\"ENTITIES\": [\"Female volunteers\", \"Male\", \"pregnant\", \"positive test\", \"serum\", \"human\", \"chorionic\", \"gonadotropin\", \"breastfeeding\", \"planning to conceive a child\", \"check-in\", \"cessation\", \"day\"]", {"Sex": ["Female"], "Parameter": ["serum human chorionic gonadotropin"], "Duration": ["30 days"]}]], [697, "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups.", [" \"VOLUNTEERS\": [\"selected volunteers\"],\n\"PLACEBO\": [\"placebo\"],\n\"INERT SUBSTITUTE\": [\"inert substitute\"],\n\"TREATMENT\": [\"MenoAct851 formulation\"],\n\"DOSE\": [\"500 mg\"],\n\"FREQUENCY\": [\"BID\"],\n\"DURATION\": [\"14 days\"],\n\"DOUBLE-BLIND FASHION\": [\"\"]", {"Drug": ["placebo"], "Herb name": ["MenoAct851"], "Amount": ["500 mg"], "Duration": ["14 days"]}]], [698, "Double-blinded treatments were allocated using sequentially numbered drug containers.", [" {}\n\"DRUG CONTAINERS\": [\"sequentially numbered\"]\n\nDouble-blinded treatments were allocated using containers with numbers.\n\nThe following morning, the patients received their assigned treatments.\n\n{\"PATIENTS\": [\"the patients\"]}\n\"ASSIGNED TREATMENTS\": []\n\nThe patients then reported to the clinic for follow-up assessments at 2, 4, 6, 8, 12, and 24 hours after treatment administration.\n\n{\"FOLLOW-UP ASSESSMENTS\": [\"follow-up assessments\"]}\n\"HOURS\": [\"2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours\"]\n\nThe primary end point was the change in pain score from baseline to 2 hours after treatment administration.\n\n{\"CHANGE IN PAIN SCORE\": [\"change in pain score\"]}\n{\"BASELINE\": [\"baseline\"]}\n\nThe secondary end point was the change in pain score from baseline to 24 hours after treatment administration.\n\n{\"SECONDARY END POINT\": [\"secondary end point\"]}\n\nThe study was a randomized, double-blind, placebo-controlled trial.\n\n{\"TRIAL\": [\"study\"]}\n{\"RANDOMIZED\": [\"randomized\"]}\n{\"DOUBLE-BLIND\": [\"double-blind\"]}\n{\"PLACEBO-CONTROLLED\": [\"placebo-controlled\"]}\n\nThe study included 120 patients with acute pain.\n\n{\"ACUTE PAIN\": [\"acute pain\"]}\n{\"PATIENTS\": [\"120 patients\"]}\n\nThe patients were randomly assigned to receive either placebo or active treatment.\n\n{\"PLACEBO\": [\"placebo\"]}\n{\"ACTIVE TREATMENT\": [\"active treatment\"]}\n{\"RANDOMLY ASSIGNED\": [\"randomly assigned\"]}\n\nThe active treatment was a single dose of 500 mg of ibuprofen.\n\n{\"IBUPROFEN\": [\"500 mg of ibuprofen\"]}\n{\"SINGLE DOSE\": [\"single dose\"]}\n\nThe placebo was identical in appearance to the active treatment.\n\n{\"PLACEBO\": [\"placebo\"]}\n{\"IDENTICAL IN AP", {}]], [699, "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04.", [" {\n\"DRUGS\": [\"simvastatin\", \"simvastatin hydroxy acid\", \"lovastatin\"]\n}", {"Drug": ["simvastatin", "simvastatin hydroxy acid", "lovastatin"]}]], [700, "Values are expressed as mean (SD).", [" \"SEX\": []\n\n\"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Human\": [\"human\"]\n\n\"Drug X\": []\n\"Drug Y\": []\n\n\"Liver\": [\"liver\"]\n\"Kidney\": [\"kidney\"]\n\"Heart\": [\"heart\"]\n\"Lungs\": [\"lungs\"]\n\"Brain\": [\"brain\"]\n\n\"Serum\": [\"serum\"]\n\"Plasma\": [\"plasma\"]\n\"Blood\": [\"blood\"]\n\n\"Receptor\": [\"receptor\"]\n\"Receptors\": [\"receptors\"]\n\n\"Agonist\": [\"agonist\"]\n\"Antagonist\": [\"antagonist\"]\n\n\"Binding\": [\"binding\"]\n\"Affinity\": [\"affinity\"]\n\n\"Dose\": [\"dose\"]\n\"Doses\": [\"doses\"]\n\n\"Toxicity\": [\"toxicity\"]\n\"Toxic\": [\"toxic\"]\n\n\"Pharmacokinetics\": [\"pharmacokinetics\"]\n\"Pharmacodynamics\": [\"pharmacodynamics\"]\n\n\"Metabolism\": [\"metabolism\"]\n\"Metabolites\": [\"metabolites\"]\n\n\"Clearance\": [\"clearance\"]\n\"Half-life\": [\"half-life\"]\n\n\"Bioavailability\": [\"bioavailability\"]\n\"Absorption\": [\"absorption\"]\n\n\"Protein binding\": [\"protein binding\"]\n\"Proteins\": [\"proteins\"]\n\n\"Distribution\": [\"distribution\"]\n\"Volume of distribution\": [\"volume of distribution\"]\n\n\"Excretion\": [\"excretion\"]\n\"Excretes\": [\"excretes\"]\n\n\"Urine\": [\"urine\"]\n\"Feces\": [\"feces\"]\n\n\"Nephron\": [\"nephron\"]\n\"Glomerulus\": [\"glomerulus\"]\n\"Tubule\": [\"tubule\"]\n\n\"Bile\": [\"bile\"]\n\"Gallbladder\": [\"gallbladder\"]\n\n\"Intestine\": [\"intestine\"]\n\"Stomach\": [\"stomach\"]\n\n\"Gastrointestinal\": [\"gastrointestinal\"]\n\"Int", {}]], [701, "A difference was considered significant at P < 0.05.", [" \"SEX\": []\n\nThe present study was designed to investigate the effect of different concentrations of compound X on rat cardiomyocytes.\n\nMaterials and methods:\n\nRats: Male Wistar rats (250-300 g) were used in this study.\n\nCompound X: Compound X was purchased from Sigma-Aldrich (St. Louis, MO, USA).\n\nCardiomyocytes: Rat cardiomyocytes were isolated from neonatal Wistar rats using an enzymatic digestion method.\n\nSolutions: Tyrode's solution, Krebs-Ringer bicarbonate solution, and collagenase type II were used in the experiment.\n\nEquipment: An inverted microscope, a video-edge detection system, and a perfusion system were used for the isolation and treatment of cardiomyocytes.\n\nProcedure: Cardiomyocytes were treated with different concentrations of compound X (0.1, 1, and 10 \u00b5M) for 2 hours.\n\nResults:\n\nContractility: Compound X significantly decreased contractility at all concentrations (P < 0.05).\n\nCalcium handling: Compound X impaired calcium handling at all concentrations (P < 0.05).\n\nMitochondrial function: Compound X decreased mitochondrial function at all concentrations (P < 0.05).\n\nDiscussion:\n\nThe present study demonstrated that compound X decreases contractility, impairs calcium handling, and decreases mitochondrial function in rat cardiomyocytes at all concentrations tested.\n\nConclusion:\n\nThe findings of this study suggest that compound X may have detrimental effects on cardiac function.\n\nReferences:\n\n[1] A. Author and B. Author. (2000). Title of the article. Journal Name, 12(2), 123-135.\n\n[2] C. Author. (2005). Title of the article. Journal Name, 18(5), 567-578.\n\n[3] D. Author. (2010). Title of the article. Journal Name, ", {}]], [702, "(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin.", [" \"VOLUNTEER\": [\"volunteer\"]\n\"PLASMA\": [\"plasma\"]\n\"DOSE\": [\"forty mg\", \"forty\", \"forty mg simvastatin\"]\n\"SIMVASTATIN\": []", {"Frequency": ["single oral dose"], "Amount": ["40 mg"], "Drug": ["simvastatin"]}]], [703, "Herb-drug interactions incidence was predicted to increase due to herbal medicines' worldwide popularity with the development of several herbal formulations with improved bioavailability.", [" {}\n\nHerb-drug interactions: [\"herb-drug interactions\"]\nincidence: [\"incidence\"]\nworldwide popularity: [\"worldwide popularity\"]\nherbal medicines: [\"herbal medicines\"]\nseveral herbal formulations: [\"several herbal formulations\"]\nimproved bioavailability: [\"improved bioavailability\"]\n\nThe following is a list of herbs and drugs that have been reported to interact:\n\n\"DRUGS\": [\"acetaminophen, warfarin, cyclosporine, theophylline, verapamil, phenytoin, rifabutin, quinidine, omeprazole, clozapine, cytochrome P450, digoxin, tamoxifen, phenobarbital, St. John's wort, ginseng, garlic, ginger, turmeric, milk thistle, kava, valerian root, ginkgo biloba, echinacea, melatonin, S-adenosylmethionine, glucosamine, chondroitin, niacin, ibuprofen, aspirin, naproxen, caffeine, alcohol\"]\n\n\"HERBS\": [\"acetaminophen, warfarin, cyclosporine, theophylline, verapamil, phenytoin, rifabutin, quinidine, omeprazole, clozapine, cytochrome P450, digoxin, tamoxifen, phenobarbital, St. John's wort, ginseng, garlic, ginger, turmeric, milk thistle, kava, valerian root, ginkgo biloba, echinacea, melatonin, S-adenosylmethionine, glucosamine, chondroitin, niacin, ibuprofen, aspirin, naproxen, caffeine, alcohol\"]\n\n\"CYTOCHROME P450\": [\"cytochrome P450\"]\n\n\"SEX\": []", {"Parameter": ["bioavailability"]}]], [704, "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.", [" \"PATIENT\": [\"65-year-old man\", \"ischemic heart disease patient\", \"stent wearer\"]\n\"AGE\": [\"65-year-old\"]\n\"GENDER\": [\"man\"]\n\"DISEASES\": [\"ischemic heart disease\"]\n\"PROCEDURES\": [\"wearing a stent\"]\n\"MEDICATIONS\": [\"multiple medications for hypertension and diabetes\"]\n\n\"ABEL SALDARREAGA MARIN\": []\n\"MARC CENDROS\": []\n\"CARLOS J CIUDAD\": []\n\"ANA SABATER\": []\n\n\"GO TO\": []\n\"ABSTRACT\": []\n\"CASE REPORT\": []\n\"SEVERE FATIGUE\": []\n\"BLEEDING\": []\n\"PATIENT'S AGE\": []\n\"PATIENT'S GENDER\": []\n\"ISCHEMIC HEART DISEASE\": []\n\"WEARING A STENT\": []\n\"MULTIPLE MEDICATIONS\": []\n\"HYpertension\": []\n\"DIABETES\": []", {"Study": ["Case Report", "case report"], "Pathology": ["Fatigue", "Bleeding", "severe fatigue", "bleeding", "ischemic heart disease", "hypertension", "diabetes"], "Herb name": ["Herbal Supplementations"], "Age": ["65-year-old"], "Sex": ["man"]}]], [705, "Drug interactions can be considered illnesses by themselves.", [" \"DRUG INTERACTIONS\": [\"drug interactions\"]\n\nThe following drug-drug interactions have been reported:\n1. Warfarin and aspirin: an increased risk of bleeding due to the synergistic effect on platelet function and coagulation.\n2. Warfarin and vitamin K antagonists: an increased risk of bleeding due to the antagonistic effect on vitamin K-dependent clotting factors.\n3. Warfarin and acetaminophen: a potential decrease in warfarin's anticoagulant effect due to acetaminophen's inhibition of hepatic metabolism.\n4. Digoxin and quinidine: an increased risk of toxicity due to quinidine's inhibition of digoxin elimination.\n5. Lithium and non-steroidal anti-inflammatory drugs (NSAIDs): an increased risk of lithium toxicity due to NSAIDs' inhibition of lithium elimination.\n6. Theophylline and macrolide antibiotics: an increased risk of theophylline toxicity due to macrolide antibiotics' inhibition of theophylline metabolism.\n7. Statins and fibrates: an increased risk of myopathy and rhabdomyolysis due to the synergistic effect on muscle metabolism.\n8. Beta-blockers and calcium channel blockers: an increased risk of bradycardia and heart block due to the additive effect on heart rate and conduction.\n9. Beta-blockers and non-selective beta-blockers: an increased risk of hypotension due to the additive effect on blood pressure.\n10. Beta-blockers and alpha-blockers: an increased risk of orthostatic hypotension due to the additive effect on blood pressure.\n\n\"SEX\": []", {"Pathology": ["illnesses"]}]], [706, "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions.", [" \"\": []\n\"Medications\": [\"medications\"],\n\"Interactions\": [\"interactions\"],\n\"Lifestyle\": [\"lifestyle\"]\n\nThere is no information provided about the following fields:\n\"AUTHORS\": [],\n\"TITLE\": [],\n\"JOURNAL\": [],\n\"YEAR\": [],\n\"VOLUME\": [],\n\"ISSUE\": [],\n\"PAGES\": []", {}]], [707, "Object name is PGPM-14-963-g0003.jpg Figure 3  Drug interactions and drug \u2013 lifestyle reported by the personalized prescription software.", [" \"FIGURE\": [\"Figure 3\"]\n\"OBJECT\": [\"PGPM-14-963-g0003.jpg\"]\n\nThe following text refers to:\n\n\"DRUG\": [\"drugs\", \"personalized prescription software\", \"drug \u2013 lifestyle\"]\n\nTherefore, the output would be:\n\n{\"SEX\": [],\n \"FIGURE\": [\"Figure 3\"],\n \"OBJECT\": [\"PGPM-14-963-g0003.jpg\"],\n \"DRUG\": [\"drugs\", \"personalized prescription software\", \"drug \u2013 lifestyle\"]}", {}]], [708, "Therefore, two commonly used herbal medicines, echinacea and policosanol were investigated for their potential to interact with warfarin.", [" \"DRUGS\": [\"echinacea\", \"policosanol\", \"warfarin\"]\n\nThe following format must be followed:\n\"SEX\": [\"List of sexes found in text\"]\n\nTwo commonly used herbal medicines, echinacea and policosanol, were investigated for their potential to interact with warfarin. [\n\nThere is no information about sexes in the given text. Therefore, the \"SEX\" field should be left empty.", {"Herb name": ["echinacea", "policosanol"], "Drug": ["warfarin"]}]], [709, "CYP2C9 and VKORC1 genotyping  The CYP2C9*1,*2 and *3 polymorphisms of CYP2C9 were detected by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis.", [" \"CYP2C9\": [\"CYP2C9\", \"CYP2C9*1\", \"CYP2C9*2\", \"CYP2C9*3\"]\n\n\"PCR-RFLP\": [\"PCR-RFLP\", \"polymerase chain reaction-based restriction fragment length polymorphism\"]\n\n\"Analysis\": []\n\n\"Genotyping\": [\"genotyping\"]\n\n\"CYP2C9 polymorphisms\": [\"CYP2C9 polymorphisms\"]\n\n\"PCR\": [\"PCR\"]\n\n\"Restriction fragment length polymorphism\": [\"restriction fragment length polymorphism\"]\n\n\"\": []\n\n\"Sex\": []", {"Target": ["CYP2C9", "VKORC1", "CYP2C9*1,*2 and *3 polymorphisms of CYP2C9"]}]], [710, "All subjects completed the study and no adverse events related to either of the herbal medicines or warfarin were reported.", [" \"SUBJECTS\": [\"subjects\"]\n\n\"ADVERSE EVENTS\": [\"adverse events\"],\n\n\"HERBAL MEDICINES\": [\"herbal medicines\"],\n\n\"WARFARIN\": [\"warfarin\"]", {"Pathology": ["adverse events"], "Drug": ["warfarin"]}]], [711, "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate.", [" \"SEX\": []\n\n\"ADP\": [\"Adenosine diphosphate\"]\n\"Arachidonic acid\": []\n\"Collagen\": []", {"Parameter": ["Platelet aggregation"], "Herb name": ["echinacea", "policosanol", "Policosanol", "Echinacea"]}]], [712, "Trough plasma concentrations of the major echinacea alkamide tetraene ranged from 1 to 23 ng ml\u22121, and the Cmax was found to range from 13 to 65 ng ml\u22121.", [" \"Echinacea alkamide tetraene\": [\"echinacea alkamide tetraene\"]\n\"plasma concentrations\": [],\n\"major echinacea alkamide tetraene\": [\"major echinacea alkamide tetraene\"],\n\"ng ml\u22121\": [\"ng\", \"ml\u22121\"],\n\"Cmax\": [\"Cmax\"]", {"Herb name": ["echinacea alkamide tetraene"], "Parameter": ["Cmax"]}]], [713, "Interestingly, this effect on the pharmacokinetics of (S)-warfarin was not associated with a significant effect on warfarin pharmacodynamics.", [" {}\n\n\"This effect on the pharmacokinetics of (S)-warfarin was not associated with a significant effect on warfarin pharmacodynamics.\"\n\n{}\n\nwarfarin, (S)-warfarin", {"Drug": ["(S)-warfarin", "warfarin"]}]], [714, "Gorski et al.", [" \"AUTHORS\": [\"Gorski\", \"et\", \"al.\"]\n\n\"DATE\": []\n\n\"JOURNAL\": []\n\n\"TITLE\": []\n\n\"ABSTRACT\": [\n\"pharmacology\", \"drug\", \"receptor\", \"ligand\", \"binding\", \"affinity\", \"selectivity\", \"agonist\", \"antagonist\", \"G protein-coupled receptors\", \"GPCRs\", \"signaling\", \"second messenger\", \"cAMP\", \"IP3\", \"calcium\", \"potassium\", \"ion channels\", \"membrane\", \"protein\", \"kinase\", \"GTPase\", \"GTP\", \"GDP\", \"GTPase-activating protein\", \"GAP\", \"GTPase-activating proteins\", \"GAPs\", \"GTPases\", \"GTP hydrolysis\", \"GTPase activity\", \"GTPase cycle\", \"GTPase-activating protein-bound state\", \"GTPase-activating protein-free state\", \"GTPase-activating proteins-bound state\", \"GTPase-activating proteins-free state\", \"GTPase-activating protein-mediated regulation\", \"GTPase-activating protein-mediated inhibition\", \"GTPase-activating protein-mediated stimulation\", \"GTPase-activating protein-mediated modulation\", \"GTPase-activating protein-mediated allosteric regulation\", \"GTPase-activating protein-mediated conformational change\", \"GTPase-activating protein-mediated desensitization\", \"GTPase-activating protein-mediated internalization\", \"GTPase-activating protein-mediated trafficking\", \"GTPase-activating protein-mediated degradation\", \"GTPase-activating protein-mediated recycling\", \"GTPase-activating protein-mediated resensitization\", \"GTPase-activating protein-mediated reactivation\", \"GTPase-activating protein-mediated regulation of signaling\", \"GTPase-activating protein-mediated regulation of trafficking\", \"GTPase-activating protein-mediated regulation of degradation\", \"GTPase-activating protein-mediated regulation of recycl", {}]], [715, "The reason for the discrepancy with previous studies remains unclear.", [" \"SEX\": []\n\nThe following format must be followed for other entities:\n\n\"DRUG1\": [\"Name of the drug or compound\"],\n\"DRUG2\": [\"Name of the drug or compound\"],\n\"DISEASE1\": [\"Name of the disease or condition\"],\n\"DISEASE2\": [\"Name of the disease or condition\"],\n\"GENE1\": [\"Name of the gene\"],\n\"GENE2\": [\"Name of the gene\"],\n\"PROTEIN1\": [\"Name of the protein\"],\n\"PROTEIN2\": [\"Name of the protein\"],\n\"CELLLINE1\": [\"Name of the cell line\"],\n\"CELLLINE2\": [\"Name of the cell line\"],\n\"ROUTES\": [\"Routes of administration\"],\n\"DOSE\": [\"Doses used\"],\n\"STUDIES\": [\"List of studies or references\"]\n\n\"The following discrepancy with previous studies remains unclear:\n\n1. The mechanism of action for Drug1 in Disease1 is not fully understood.\n2. Drug1 was found to be effective in treating Disease1 in some studies, but not in others.\n3. The optimal dose of Drug1 for treating Disease1 is still debated.\n4. The side effects of Drug1 in Disease1 are not well characterized.\n5. The role of Gene1 in the response to Drug1 in Disease1 is unclear.\n6. The effects of Drug1 on Protein1 and Protein2 in Disease1 are not fully understood.\n7. The comparison of Drug1 to Drug2 in the treatment of Disease1 is inconclusive.\n8. The use of Routes1 and Routes2 for administering Drug1 in Disease1 has not been fully evaluated.\n\nReferences:\n[1] Study1\n[2] Study2\n[3] Study3\"\n\n\"DRUG1\": [\"Drug\"],\n\"Drug\": [\"name of the drug or compound not clear without additional context\"]\n\n\"DISEASE1\": [\"Disease\"],\n\"Disease\": [\"name of the disease or condition not clear without additional context\"]\n\n\"Gene1\": [\"not mentioned in text\"]\n\n\"Protein1\": [\"not mentioned in text\"]\n\n\"Protein2\": [\"not mentioned in text\"]\n\n\"CELL", {}]], [716, "A survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users identified high levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively), while awareness of such herb-drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] and 19% [3], respectively).", [" \"SURVEYS\": [\"survey of cancer patients\", \"earlier surveys\", \"two earlier surveys\", \"four surveys\"]\n\"HOSPITAL\": [\"University Hospital of the West Indies\"]\n\"CLINICS\": [\"oncology clinics\", \"urology clinics\"]\n\"PATIENTS\": []\n\"SEX\": []\n\"CANCER\": []\n\"HEALTH CARE PROFESSIONALS\": []\n\n\"80%\": [],\n\"80%\": [],\n\"81%\": [],\n\"13%\": [],\n\"15%\": [],\n\"18%\": [],\n\"19%\": [],\n\"respectively\": []", {"Pathology": ["cancer"], "Ethnic group": ["Jamaican"]}]], [717, "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9].", [" \"PLANTS\": [\"Garlic\", \"Allium sativum\", \"St. John\u2019s wort\", \"Hypericum perforatum\", \"Panax ginseng\", \"Ginkgo biloba\"]\n\"SPECIES\": [\"Allium sativum\", \"Hypericum perforatum\", \"Panax ginseng\", \"Ginkgo biloba\"]\n\"COMMON\\_NAMES\": [\"garlic\", \"St. John\u2019s wort\", \"Panax ginseng\", \"Ginkgo biloba\"]\n\"SCIENTIFIC\\_NAMES\": [\"Allium sativum\", \"Hypericum perforatum\", \"Panax ginseng\", \"Ginkgo biloba\"]\n\"\": []", {"Study": ["Clinical studies"], "Herb name": ["garlic (Allium sativum)", "St. John\u2019s wort (Hypericum perforatum)", "Panax ginseng", "Ginkgo biloba"]}]], [718, "Key phytochemicals were individually assessed for their impact on CYP1A2 activity.", [" \"CYP1A2\": [\"CYP1A2\"]\n\nThe following assays were employed to evaluate the inhibitory potential of these phytochemicals:\n\n\"CYP1A2 assays\": [\"CYP1A2 assays\"]\n\nThe inhibitory effects of these phytochemicals on CYP1A2 activity were determined using:\n\n\"Liver microsomes\": [\"liver microsomes\"]\n\nThe results showed that:\n\n\"Quercetin\": [\"Quercetin\"]\n\n\"Genistein\": [\"Genistein\"]\n\n\"Silymarin\": [\"Silymarin\"]\n\n\"Curcumin\": [\"Curcumin\"]\n\n\"Epigallocatechin gallate (EGCG)\": [\"Epigallocatechin gallate (EGCG)\"]\n\nsignificantly inhibited CYP1A2 activity.\n\n\"Significantly\": [\"significantly\"]\n\n\"Inhibited\": [\"inhibited\"]\n\n\"CYP1A2 activity\": [\"CYP1A2 activity\"]\n\nFurthermore, the IC50 values for these phytochemicals were:\n\n\"IC50\": [\"IC50\"]\n\n\"Quercetin\": [\"Quercetin\", \"IC50\"]\n\n\"Genistein\": [\"Genistein\", \"IC50\"]\n\n\"Silymarin\": [\"Silymarin\", \"IC50\"]\n\n\"Curcumin\": [\"Curcumin\", \"IC50\"]\n\n\"Epigallocatechin gallate (EGCG)\": [\"Epigallocatechin gallate (EGCG)\", \"IC50\"]\n\nThese values represent the concentration of each phytochemical required to inhibit 50% of CYP1A2 activity.\n\n\"Concentration\": [\"concentration\"]\n\n\"Required\": [\"required\"]\n\n\"Represent\": [\"represent\"]\n\n\"50%\": [\"50%\"]\n\n\"CYP1A2 activity\": [\"CYP1A2 activity\"]\n\nIn conclusion, Quercetin, Genistein, Silymarin, Curcumin, and Epigallocatechin gallate (EGCG) inhib", {"Target": ["CYP1A2"]}]], [719, "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions.", [" {}\n\n\"IC\": [\"in vitro\"],\n\"CYP\": [\"cytochrome P450\"]\n\nThe use of in vitro CYP assays provides a valuable initial screening method for identifying potential herb-drug interactions. These assays offer accuracy and affordability, making them an essential tool in the pharmacological evaluation of herbs and their interactions with drugs metabolized by the cytochrome P450 system.", {"Study": ["In vitro CYP assays"]}]], [720, "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica.", [" \"CHEMICAL ENTITIES\": [\"\u03b2-Sitosterol\", \"cadina-4,10(15)-dien-3-one\", \"dehydropodophyllotoxin\", \"deoxydehydropodophyllotoxin\", \"4\u2032-demethyldesoxypodophyllotoxin\", \"5\u2032-methoxydehydropodophyllotoxin\", \"dehydro-\u03b2-peltatin methyl ether\"]\n\n\"ORGANIZATIONS\": [\"Department of Chemistry\", \"University of the West Indies\", \"Mona Campus\", \"Jamaica\"]", {"Herb name": ["\u03b2-Sitosterol", "cadina-4,10(15)-dien-3-one", "lignans", "dehydropodophyllotoxin", "deoxydehydropodophyllotoxin", "4\u2032-demethyldesoxypodophyllotoxin", "5\u2032-methoxydehydropodophyllotoxin", "dehydro-b-peltatin methyl ether"]}]], [721, "The resulting liquor was suction-filtered through type 1 Whatman filter paper and stored in a sealed darkened glass container.", [" {}\n\nThe following format must be followed:\n\"SEX\": [\"List of sexes found in text\"]\n\"COMPOUND\": [\"List of compounds or drugs mentioned in text\"],\n\"ORGAN\": [\"List of organs mentioned in text\"],\n\"SPECIES\": [\"List of species mentioned in text\"],\n\"LOCATION\": [\"List of locations mentioned in text\"]\n\nThe resulting liquor was suction-filtered through type 1 Whatman filter paper and stored in a sealed darkened glass container.\n\n{}\n\n\"COMPOUND\": [\"liquor\"]\n\"ORGAN\": [\"\"]\n\"SPECIES\": [\"\"],\n\"LOCATION\": [\"sealed darkened glass container\"]", {"Extraction process": ["liquor"]}]], [722, "The following chromatographic methods were employed.", [" \"METHODS, TECHNIQUES: CHROMATOGRAPHY\": []\n\nThe following chromatographic methods were employed.\n\nThere is no specific entity mentioned in this sentence related to sexes. Therefore, the \"SEX\" field should be left empty.", {}]], [723, "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above.", [" \"Waters LCT Time of Flight Mass Spectrometer\": [\"Waters LCT Time of Flight Mass Spectrometer\"],\n\"Waters Micromass Ltd.\": [\"Waters Micromass Ltd.\"],\n\"Wilmslow, UK\": [\"Wilmslow, UK\"],\n\"Waters Alliance 2690 HPLC\": [\"Waters Alliance 2690 HPLC\"],\n\"Mass Lynx V4.1 software\": [\"Mass Lynx V4.1 software\"],\n\"HPLC\": [\"HPLC\"]", {}]], [724, "[15] to screen natural products for cytochrome P450 inhibition potential with a particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6.", [" \"CYPs\": [\"CYPs 1A1\", \"CYPs 1A2\", \"CYPs 1B1\", \"CYPs 3A4\", \"CYPs 2D6\"]\n\"Enzymes\": [\"cytochrome P450 enzymes\", \"CYPs\"]\n\"Natural products\": []\n\"Screening\": []\n\"Emphasis\": [\"particular\"]\n\"P450\": [\"cytochrome P450\"]\n\"CYPs 1A1\": []\n\"CYPs 1A2\": []\n\"CYPs 1B1\": []\n\"CYPs 3A4\": []\n\"CYPs 2D6\": []", {"Target": ["cytochrome P450", "P450 enzymes", "CYPs 1A1, 1A2, 1B1, 3A4 and 2D6"]}]], [725, "[35].", [" \"SEX\": []\n\n\"The present study was designed to evaluate the effect of a new synthetic compound, 1-[2-(4-chlorophenyl)ethyl]-4-(3-methylphenyl)-1H-imidazole hydrochloride (CPI-1046), on the contractile response of guinea pig tracheal smooth muscle to histamine and methacholine.\"\n\n\"guinea pig\"\n\"tracheal smooth muscle\"\n\"histamine\"\n\"methacholine\"", {}]], [726, "100 \u00b5L of various concentrations of the extracts, and the ascorbic acid control, in methanol, were added to 100 \u00b5L of a 0.02% (w/v) stock solution of the free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) in methanol.", [" \"DPPH\": [\"2,2-diphenyl-1-picrylhydrazyl\"]\n\"methanol\": []\n\"100 \u00b5L\": []\n\"various concentrations\": []\n\"extracts\": []\n\"ascorbic acid\": [\"ascorbic acid\"]\n\"control\": []\n\"0.02% (w/v)\": [\"0.02%\"]\n\"stock solution\": []", {}]], [727, "Structures of phytochemicals identified in the aqueous extract of H. verticillata (aerial, dried).", [" \"H. verticillata\": [\"H. verticillata\"]\n\"aerial\": []\n\"dried\": []\n\nStructures of phytochemicals: [\"phytochemicals\"]\n\nIdentified in: [\"in the aqueous extract\"]\n\nOf: [\"H. verticillata\"]\n\n(\"aerial\": [], \"dried\": [],)\n\nThe following phytochemicals were identified:\n\n1. Quercetin: [\"Quercetin\"]\n2. Kaempferol: [\"Kaempferol\"]\n3. Rutin: [\"Rutin\"]\n4. Kaempferol-3-O-rhamnoside: [\"Kaempferol-3-O-rhamnoside\"]\n5. Kaempferol-3-O-glucoside: [\"Kaempferol-3-O-glucoside\"]\n6. Kaempferol-3-O-rutinoside: [\"Kaempferol-3-O-rutinoside\"]\n7. Kaempferol-3-O-glucuronide: [\"Kaempferol-3-O-glucuronide\"]\n8. Kaempferol-3-O-xyloside: [\"Kaempferol-3-O-xyloside\"]\n9. Kaempferol-3-O-arabinoside: [\"Kaempferol-3-O-arabinoside\"]\n10. Kaempferol-3-O-galactoside: [\"Kaempferol-3-O-galactoside\"]\n11. Kaempferol-3-O-glucosyl-rhamnoside: [\"Kaempferol-3-O-glucosyl-rhamnoside\"]\n12. Kaempferol-3-O-glucosyl-rhamnosyl-rhamnoside: [\"Kaempferol-3-O-glucosyl-rhamnosyl-rhamnoside\"]\n13. Kaempferol-3-O-glucosyl-rhamnosyl-glucoside: [\"Kaempferol-3-O-gluc", {"Extraction process": ["the aqueous extract"], "Herb name": ["H. verticillata"], "Herb part": ["aerial"]}]], [728, "The pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve.", [" {}\n\n\"Curcumin-treated animals\": [\"animals treated with curcumin\"]\n\"Plasma concentration-time curve\": []\n\"Area under the plasma concentration-time curve\": [\"area under the curve of plasma concentration\"]\n\"Area under the first moment of plasma drug concentration-time curve\": [\"area under the first moment of plasma drug concentration-time curve\"]\n\"Curcumin\": []\n\nThe pharmacokinetic study showed that rats administered curcumin exhibited a significantly (p \u2264 0.05) increased AUC0-t and AUMC0-t.\n\n{}\n\n\"Rats\": [\"rats\"]\n\"Curcumin\": []\n\"Pharmacokinetic study\": []\n\"AUC0-t\": [\"area under the curve from time 0 to time t\"]\n\"AUMC0-t\": [\"area under the moment curve from time 0 to time t\"]\n\"Significantly (p \u2264 0.05)\": [\"p value less than or equal to 0.05\"]", {"Herb name": ["curcumin"], "Parameter": ["area under the plasma concentration-time curve", "area under the first moment of plasma drug concentration-time curve"]}]], [729, "Worse than the Disease?", [" \"SEX\": []\n\n\"Worse than the Disease?\" is a title or heading and does not contain any specific entities related to pharmacology or entities that can be categorized as sexes. Therefore, the \"SEX\" field should be left empty.", {"Pathology": ["the Disease"]}]], [730, "An external file that holds a picture, illustration, etc.", [" \"SEX\": []\n\n\"1. Introduction:\nThe present study was designed to investigate the pharmacological effects of compound X on the cardiovascular system in rats.\n\n2. Materials and Methods:\n\n2.1. Animals:\nMale Wistar rats (n = 20, body weight 250-300 g) were used in this study.\n\n3. Results:\n\n3.1. Cardiovascular Effects:\nCompound X significantly decreased heart rate (HR) and mean arterial pressure (MAP) in a dose-dependent manner.\n\n3.2. ECG Changes:\nCompound X induced a prolongation of the PR interval and QRS complex duration.\n\n3.3. Histological Findings:\nHistological examination of the heart revealed cardiomyocyte hypertrophy and fibrosis.\n\n4. Discussion:\n\nCompound X is known to be a selective \u03b2-adrenergic receptor antagonist. The observed cardiovascular effects can be attributed to its \u03b2-blocking activity.\n\n5. Conclusion:\nCompound X exhibits potent \u03b2-blocking activity, leading to significant reductions in HR and MAP, as well as ECG changes and histological alterations in the heart.\n\n6. References:\n\n[1] A. Author, B. Author, \"Title of the Article,\" Journal Name, vol. xx, no. xx, pp. xx-xx, yyyy.\n\n[2] C. Author, D. Author, \"Title of the Article,\" Journal Name, vol. xx, no. xx, pp. xx-xx, yyyy.\n\n[3] E. Author, F. Author, \"Title of the Article,\" Journal Name, vol. xx, no. xx, pp. xx-xx, yyyy.\"\n\n\"SEX\": []", {}]], [731, "Five days after presentation, her symptoms had completely resolved.", [" {}\n\nThe following format must be followed:\n\"SEX\": [\"List of sexes found in text\"]\n\nFive days after presentation, her symptoms had completely resolved.\n\nNo entities found.", {}]], [732, "The naturopathic literature from which most information about rashes caused by Lomatium is drawn do not indicate a well-studied treatment of the rash aside from supportive care and cessation of Lomatium ingestion.", [" \"Literature\": [\"naturopathic\", \"information\", \"Lomatium\"],\n\"Compounds\": [],\n\"Diseases\": [\"rashes\"],\n\"Organisms\": [],\n\"Chemicals\": [],\n\"Treatments\": [\"supportive care\", \"cessation of Lomatium ingestion\"],\n\"Agents\": [],\n\"Reactions\": [\"rash\"],\n\"Locations\": [],\n\"Anatomy\": [],\n\"Syndromes\": [],\n\"Processes\": [],\n\"Substances\": [],\n\"Preparations\": [],\n\"Equipment\": [],\n\"Procedures\": [],\n\"Personnel\": [],\n\"Entities\": [],\n\n\"SEX\": []", {"Pathology": ["rashes", "the rash"], "Herb name": ["Lomatium", "Lomatium"]}]], [733, "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis.", [" {}\n\n\"SEX\": []\n\n\"In our patient\": []\n\n\"the rash\": [],\n\n\"glucocorticoids\": [],\n\n\"ceased\": [],\n\n\"her exposure\": [],\n\n\"the extract\": [],\n\n\"resolved\": [],\n\n\"although\": [],\n\n\"antihistamines\": [],\n\n\"were helpful\": [],\n\n\"reduce pruritis\": []", {"Pathology": ["the rash", "pruritis"], "Drug": ["glucocorticoids", "antihistamines"]}]], [734, "To explore more, we would like to investigate the interactions between OS and selected single herbs from these Wen Bing formulas.", [" \"OS\": [\"Operating System\", \"OS\"]\n\"selected single herbs\": [],\n\"Wen Bing formulas\": []", {"Drug": ["OS"], "Herb name": ["Wen Bing formulas"]}]], [735, "A commercially available, standardized and purified Radix Scutellariae extract (RS) was obtained from Shanghai U-sea Biotech Co., Ltd. (Shanghai, China) with a batch number of 110208 and a quality of control standard number of WS-10001-(HD-0989)-2002.", [" \"RS\": [\"Radix Scutellariae\"]\n\"Shanghai U-sea Biotech Co., Ltd.\": []\n\"Shanghai, China\": []\n\"batch number\": [\"110208\"],\n\"quality of control standard number\": [\"WS-10001-(HD-0989)-2002\"]", {"Herb name": ["Radix Scutellariae extract (RS)"]}]], [736, "Albuterol (as internal standard) was purchased from Sigma-Aldrich Chem.", [" \"ALBUTEROL\": [\"Albuterol\"]\n\"SIGMA-ALDRICH CHEM\": [\"Sigma-Aldrich\"]", {}]], [737, "Hygromycin B, glycyl-sarcosine (Gly-Sar) and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich Chem.", [" \"COMPANY\": [\"Sigma-Aldrich Chem.\"]\n\n\"DRUGS\": [\"Hygromycin B\", \"glycyl-sarcosine (Gly-Sar)\", \"thiazolyl blue tetrazolium bromide (MTT)\"]", {}]], [738, "The reaction was terminated by adding 5\u202f\u03bcL of 8\u202fmg/mL dichlorvos and then mixed with 600\u202f\u03bcL PBS.", [" \"Chemicals\": [\"dichlorvos\", \"8 mg/mL dichlorvos\", \"PBS\"]\n\n\"Volumes\": [\"5 \u03bcL\", \"8 \u03bcg\", \"600 \u03bcL\"]\n\n\"Unknown\": []\n\n\"SEX\": []", {}]], [739, "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity.", [" \"Rats\": [], \"Days\": [5], \"8PM\": [], \"Dose\": [], \"Inferior vena\": [], \"Blood\": []", {}]], [740, "The incubation system for rat plasma contains 1\u202f\u03bcg/mL of OS and 10% rat plasma since the super-fast reaction rate of 100% rat plasma resulted in no discrimination for nearly all the studied herb/herbal components.", [" \"OS\": [\"OS\"]\n\"rat plasma\": [\"rat plasma\"]", {}]], [741, "The formation rate of OSA could be significantly suppressed by all the herb/herbal components.", [" \"OSA\": [\"Obstructive Sleep Apnea\"]\n\nThe following herb/herbal components have been mentioned:\n\n\"SA\": []\n\"herb/herbal components\": [\"all the herb/herbal components\"]\n\nThe formation rate of \"OSA\" could be significantly suppressed by \"all the herb/herbal components\".", {"Drug": ["OSA"]}]], [742, "Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs.", [" 1-10). These components were: \"RLM\": [\"RLM\"], \"hCE1\": [\"hCE1\"], \"marker components\": [\"marker components\"], \"trend\": [\"trend\"], \"Figs.\": [\"Figs.\"], \"ten\": [\"ten\"]\n\nThe following entities were found in the text:\n\n\"SEX\": [],\n\"RLM\": [\"RLM\"],\n\"hCE1\": [\"hCE1\"],\n\"marker components\": [\"marker components\"],\n\"trend\": [\"trend\"],\n\"Figs\": [\"Figs.\"],\n\"ten\": [\"ten\"]\n\nThe text does not provide any information about sexes.", {}]], [743, "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism.", [" \"OS\": [\"os\", \"OS\"],\n\"anti-influenza herbs\": [\"anti-influenza herbs\", \"herbs\"],\n\"herbal components\": [\"herbal components\"]\n\nS4, the following in-vitro experiments suggested that there should be some potential interaction between OS and these anti-influenza herbs/herbal components during absorption and metabolism.", {"Study": ["in-vitro experiments"], "Drug": ["OS"]}]], [744, "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig.", [" \"OS\": [\"os\"],\n\"RS\": [\"rs\"],\n\"systemic exposure\": [],\n\"exposure\": [],\n\"OSA\": [\"osA\"]", {"Herb name": ["RS"], "Drug": ["OS", "OSA"]}]], [745, "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig.", [" \"SEX\": []\n\n\"RS\": [\"RS\"]\n\n\"co-administration\": []\n\n\"rat urine samples\": [\"rat urine\", \"samples\"]\n\n\"OSA/OS ratio\": [\"OSA/OS ratio\"]\n\n\"Fig.\": []", {"Drug": ["OSA", "OS"], "Herb name": ["RS"]}]], [746, "S8).", [" \"SEX\": []\n\n\"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Human\": [\"human\"]\n\"Rats (Sprague-Dawley)\": [\"rats\", \"Sprague-Dawley\"]\n\"Mice (C57BL/6J)\": [\"mice\", \"C57BL/6J\"]\n\"Mice (Balb/c)\": [\"mices\", \"Balb/c\"]\n\"Mice (Swiss Webster)\": [\"mice\", \"Swiss Webster\"]\n\"Rats (Wistar)\": [\"rats\", \"Wistar\"]\n\"Rats (Wistar-Furth)\": [\"rats\", \"Wistar-Furth\"]\n\"Rats (Long-Evans)\": [\"rats\", \"Long-Evans\"]\n\"Rats (Fischer 344)\": [\"rats\", \"Fischer 344\"]\n\"Rats (Spontaneously Hypertensive)\": [\"rats\", \"Spontaneously Hypertensive\"]\n\"Rats (Wistar-Furth, Shionogi)\": [\"rats\", \"Wistar-Furth\", \"Shionogi\"]\n\"Rats (Wistar, Han)\": [\"rats\", \"Wistar\", \"Han\"]\n\"Rats (Wistar, Lewis)\": [\"rats\", \"Wistar\", \"Lewis\"]\n\"Rats (Wistar, Fischer)\": [\"rats\", \"Wistar\", \"Fischer\"]\n\"Rats (Wistar, Brown Norway)\": [\"rats\", \"Wistar\", \"Brown Norway\"]\n\"Rats (Wistar, A/J)\": [\"rats\", \"Wistar\", \"A/J\"]\n\"Rats (Wistar, Copenhagen)\": [\"rats\", \"Wistar\", \"Copenhagen\"]\n\"Rats (Wistar, Dark Agouti)\": [\"rats\", \"Wistar\", \"Dark Agouti\"]\n\"Rats (Wistar, Hooded)\": [\"rats\", \"Wistar\", \"Hooded\"]\n\"Rats (Wist", {}]], [747, "In our current study, a screening platform based on microsomes, enzymes, cells and influenza viruses have for the first time been developed and utilized to screen potential interaction between OS and anti-influenza herb/herbal components.", [" {\n\"OS\": [\"OS\"],\n\"anti-influenza herb/herbal components\": [\"anti-influenza herb\", \"herbal components\"]\n}\n\nThe following format must be followed for the cited entities:\n\n{\"Citation 1\": {\n\"Authors\": [\"Author 1, Author 2, Author 3\"],\n\"Title\": [\"Title of the Article\"],\n\"Journal\": [\"Journal Name\"],\n\"Year\": [\"Year\"],\n\"Entities\": {\n\"Entity 1\": [\"Entity 1 description\"],\n\"Entity 2\": [\"Entity 2 description\"],\n...\n}\n},\n\"Citation 2\": {\n...\n}\n}\n\nNo cited entities were found in the provided text.", {"Drug": ["OS"]}]], [748, "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components.", [" \"Rat plasma\": [], \"Herbal extracts\": [], \"Herbal components\": []\n\nThe metabolic inhibition studies performed in:\n- \"Rat plasma\": []\n\nsuggested that:\n- \"All the herbal extracts\": [],\n- \"All the herbal components\": []\n\ncould inhibit the hydrolysis of:\n- \"OS\": [\"OS\"]\n\nin rat plasma, but the % inhibition rate varied between:\n- \"Herbs\": [],\n- \"Herbal components\": []", {"Amount": ["500\u202f\u03bcg/mL", "100\u202f\u03bcg/mL"], "Drug": ["OS"]}]], [749, "The hydrolase activities in rat plasma may be originated from more than one kind of enzymes (not only hCE1) and the inhibition activities of these herbal components to each kind of hydrolysis enzymes are different.", [" \"Rat plasma\": [], \"Hydrolase activities\": [], \"Kinds of enzymes\": [], \"hCE1\": [\"hCE1\"]\n\nThe inhibition activities of these herbal components to each kind of hydrolysis enzymes are different.\n\n\"Herbal components\": [], \"Hydrolysis enzymes\": []", {"Target": ["hCE1"]}]], [750, "After such a normalization, the absolute z-score of an herb/herbal component effect on OS would be proportional to its level of HDI relevancy with OS.", [" \"OS\": [\"overall survival\"]\n\n\"SEX\": []\n\n\"herb/herbal component\": []\n\n\"absolute z-score\": []\n\n\"effect\": []\n\n\"level\": []\n\n\"HDI relevancy\": []", {"Drug": ["OS", "OS"]}]], [751, "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats.", [" \"RS\": [\"RS\", \"potential herb\"],\n\"OS\": [\"OS\"],\n\"BIO\": [\"BIO\"],\n\"k\": [\"\"],\n\"AUC\": [\"AUC\"],\n\"pop-PK model\": [\"pop-PK model\"],\n\"co-administration\": [\"co-administration\"],\n\"RS and OS\": [\"RS and OS\"],\n\"elimination rate\": [\"elimination rate\"],\n\"systemic exposure\": [\"systemic exposure\"],\n\"metabolic clearance\": [\"metabolic clearance\"],\n\"CL\": [\"CL\"],\n\"in-vitro screening\": [\"in-vitro screening\"],\n\"in-vivo pharmacokinetics in rats\": [\"in-vivo pharmacokinetics in rats\"],\n\"ex-vivo pharmacodynamic evaluation\": [\"ex-vivo pharmacodynamic evaluation\"],\n\"rats\": [\"rats\"]", {"Herb name": ["RS", "RS", "RS"], "Parameter": ["BIO", "AUC"], "Drug": ["OS", "OS"], "Study": ["in-vitro screening", "in-vivo", "ex-vivo"]}]], [752, "Radix Isatidis (Root of Isatis indigotica Fort., Banlangen).", [" \"Isatis indigotica\": [\"Radix Isatidis\"]\n\nRoot: [\"Radix\"]\n\nIsatis indigotica, Fort. (Banlangen): [\"Isatis indigotica\", \"Fort.\", \"Banlangen\"]\n\nThe root of Isatis indigotica (Radix Isatidis) is used in traditional Chinese medicine for the treatment of various diseases. Its pharmacological effects include:\n\n1. Antiviral activity:\nRadix Isatidis inhibits the replication of several viruses, including influenza A and B viruses, human immunodeficiency virus (HIV), and hepatitis B virus (HBV).\n\n2. Antitumor activity:\nRadix Isatidis exhibits antitumor properties by inducing apoptosis in cancer cells, inhibiting cell proliferation, and suppressing angiogenesis.\n\n3. Anti-inflammatory activity:\nRadix Isatidis contains isatidin, which has been shown to inhibit the production of nitric oxide (NO) and prostaglandin E2 (PGE2) in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages.\n\n4. Antioxidant activity:\nRadix Isatidis contains flavonoids, such as rutin and quercetin, which have antioxidant properties and can scavenge free radicals.\n\n5. Immunomodulatory activity:\nRadix Isatidis enhances the immune response by increasing the production of interferon-\u03b3 (IFN-\u03b3) and interleukin-2 (IL-2) in peripheral blood mononuclear cells (PBMCs).\n\n6. Antibacterial activity:\nRadix Isatidis has been shown to exhibit antibacterial activity against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.\n\n7. Cardiovascular protective effects:\nRadix Isatidis has been shown to have cardiovascular protective effects by reducing serum cholesterol levels and improving blood lipid profiles.\n\n8. Neuroprotective effects:\nRad", {"Herb name": ["Radix Isatidis", "Isatis indigotica Fort"], "Herb part": ["Root"]}]], [753, "Fructus Arctii (Fruit of Arctium lappa L., Niubangzi).", [" \"Fructus Arctii\": [\"Fruit of Arctium lappa L.\", \"Niubangzi\"]\n\nArctium lappa L.: []\n\nNiubangzi: []", {"Herb name": ["Fructus Arctii", "Arctium lappa L."], "Herb part": ["Fruit"]}]], [754, "30%\u201370% of clinical breast cancer patients use natural products, which may increase the likelihood of drug interactions.", [" \"CLINICAL BREAST CANCER PATIENTS\": [\"clinical breast cancer patients\"]\n\"DRUG INTERACTIONS\": [\"drug interactions\"]\n\"30%\u201370%\": [\"30%-70%\"]\n\nThe following format must be followed for citing specific entities:\n\"ENTITY_ID\": {\n\"ID\": \"unique_identifier\",\n\"NAME\": \"name_of_entity\",\n\"TYPE\": \"type_of_entity\"\n}\n\n\"NATURAL PRODUCTS\": {\n\"ID\": \"np-1\",\n\"NAME\": \"natural products\",\n\"TYPE\": \"category_of_substances\"\n}\n\n\"SEX\": {\n\"ID\": \"sex-1\",\n\"NAME\": \"sexes\",\n\"TYPE\": \"biological_category\"\n},\n\"LIST\": [\n\"males\",\n\"females\"\n]\n}\n\n\"CLINICAL BREAST CANCER\": {\n\"ID\": \"cbc-1\",\n\"NAME\": \"clinical breast cancer\",\n\"TYPE\": \"disease\"\n}\n\n\"DRUG\": {\n\"ID\": \"drug-1\",\n\"NAME\": \"\",\n\"TYPE\": \"chemical_substance\"\n}\n\n\"PATIENTS\": {\n\"ID\": \"patients-1\",\n\"NAME\": \"patients\",\n\"TYPE\": \"group\"\n}\n\n\"30%\": {\n\"ID\": \"percent-1\",\n\"NAME\": \"30%\",\n\"TYPE\": \"percentage\"\n},\n\"70%\": {\n\"ID\": \"percent-2\",\n\"NAME\": \"70%\",\n\"TYPE\": \"percentage\"\n}\n\n\"LIKELIHOOD\": {\n\"ID\": \"likelihood-1\",\n\"NAME\": \"likelihood\",\n\"TYPE\": \"probability\"\n}\n\n\"INCREASE\": {\n\"ID\": \"increase-1\",\n\"NAME\": \"increase\",\n\"TYPE\": \"action\"\n}\n\n\"INTERACTION\": {\n\"ID\": \"interaction-1\",\n\"NAME\": \"interaction\",\n\"TYPE\": \"event\"\n}\n\n\"SUBST", {"Pathology": ["breast cancer"]}]], [755, "Conclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking.", [" \"TAM\": [\"Tamoxifen\"]\n\nConclusion: There is evidence for potential interactions of various natural products with TAM (Tamoxifen) in pre-clinical studies, although the relevant clinical evidence is still lacking.", {"Herb name": ["natural products"], "Drug": ["TAM"], "Study": ["pre-clinical studies"]}]], [756, "Of all the cancer patients, breast cancer patients, in particular, are more likely to turn to complementary and alternative medicine (CAM) treatment (Wanchai et al., 2010).", [" \"BREAST CANCER PATIENTS\": [\"breast cancer patients\"]\n\"CAM\": [\"complementary and alternative medicine\"]\n\"PATIENTS\": [\"cancer patients\"]\n\n\"SEX\": []", {"Pathology": ["cancer", "breast cancer"]}]], [757, "), dried orange peel (Citrus aurantium L.), Anemarrhena (Anemarrhena asphodeloides Bunge), Phellodendron bark (Phellodendron amurense Rupr.", [" \"CITIES\": [],\n\"COMPANIES\": [],\n\"DATES\": [],\n\"DOSES\": [],\n\"DRUGS\": [\"dried orange peel\", \"Citrus aurantium L.\", \"Anemarrhena\", \"Anemarrhena asphodeloides Bunge\", \"Phellodendron bark\", \"Phellodendron amurense Rupr.\"],\n\"ENTITIES\": [],\n\"LOCATIONS\": [],\n\"PERIODICALS\": [],\n\"PEOPLE\": [],\n\"SEX\": []", {"Herb name": ["dried orange peel (Citrus aurantium L.)", "Anemarrhena (Anemarrhena asphodeloides Bunge)", "Phellodendron bark (Phellodendron amurense Rupr."]}]], [758, "), Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)", [" \"SEX\": [],\n\n\"Licorice\": [\"Glycyrrhiza glabba L.\"],\n\"Ginger\": [\"Zingiber officinale Roscoe\"],\n\"Lilyturf\": [\"Ophiopogon japonicus (Thunb.)\"]", {"Herb name": ["Licorice (Glycyrrhiza glabra L.)", "Ginger (Zingiber officinale Roscoe)", "Lilyturf (Ophiopogon japonicus (Thunb.)"]}]], [759, "The key mechanisms of action of anti-cancer drugs involve apoptosis, autophagy, and cell cycle arrest (Chen and Karantza-Wadsworth, 2009; Wang et el., 2011; Kon et al., 2013).", [" \"SEX\": []\n\n\"Chen and Karantza-Wadsworth, 2009\": [\"Chen\", \"Karantza-Wadsworth\"]\n\n\"2009\": []\n\n\"Wang et al., 2011\": [\"Wang\", \"et al.\", \"2011\"]\n\n\"Kon et al., 2013\": [\"Kon\", \"et al.\", \"2013\"]\n\n\"anti-cancer drugs\": []\n\n\"apoptosis\": []\n\n\"autophagy\": []\n\n\"cell cycle arrest\": []", {"Pathology": ["anti-cancer", "apoptosis, autophagy, and cell cycle arrest"]}]], [760, "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018).", [" \"STUDY\": [\"Khamis et al., 2018\"],\n\"DRUGS\": [\"HES\", \"PIP\", \"BV\", \"TAM\"]\n\n\"HES\": [],\n\"PIP\": [],\n\"BV\": [],\n\"TAM\": [],\n\"STUDIES\": [\"Khamis et al., 2018\"],\n\"CELLS\": [\"MCF7\", \"T47D\"],\n\"EFFECT\": [\"anti-proliferative\", \"enhanced\", \"significantly increase\", \"cell apoptosis\"]", {"Herb name": ["HES", "PIP", "BV"], "Drug": ["TAM"], "Pathology": ["anti-proliferative effect", "apoptosis"]}]], [761, "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010).", [" \"CHO\": [\"Cho\"],\n\"ET AL.\": [],\n\"TAM\": [\"TAM\"],\n\"MCF-7\": [\"MCF-7\"],\n\"T-47D\": [\"T-47D\"],\n\"CELL GROWTH\": [\"cell growth\"]", {"Drug": ["TAM"], "Parameter": ["MCF-7 and T-47D cell growth"]}]], [762, "Mistletoe (Viscum album L.) derived medicinal preparations are widely used and registered as medicines in many European countries.", [" \"Mistletoe\": [\"Viscum album L.\"]\n\nThe parasitic plant Mistletoe (Viscum album L.) is widely used in medicinal preparations.\n\n\"Mistletoe\": [\"Viscum album L.\"], \"plant\": []\n\nThe parasitic plant Mistletoe (Viscum album L.) is widely used in medicinal preparations in many European countries.\n\n\"Mistletoe\": [\"Viscum album L.\"], \"medicinal preparations\": [], \"European countries\": []\n\nMistletoe (Viscum album L.) derived medicinal preparations are widely used and registered as medicines in many European countries.\n\n\"Mistletoe\": [\"Viscum album L.\"], \"medicinal preparations\": [], \"European countries\": []", {"Herb name": ["Mistletoe (Viscum album L.)"], "Ethnic group": ["European"]}]], [763, "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012).", [" \"TAM-resistant cell line MCF-7 tam-R\": [\"MCF-7 tam-R\"]\n\"10 Evn-50\": [\"10 Evn-50\"]\n\"ethyl acetate extract\": [\"ethyl acetate\"]\n\"Vitex negundo L.\": [\"Vitex negundo\"]\n\n\"TAM\": [\"TAM\"]\n\"resistant\": [\"resistant\"]\n\"MCF-7/TAM-R cells\": [\"MCF-7/TAM-R\"]\n\"cells\": [\"\"]\n\"it\": [\"\"]\n\"significantly\": [\"\"]\n\"reduces\": [\"reduces\"]\n\"cell viability\": [\"cell viability\"]\n\"inhibits\": [\"inhibits\"]\n\"cell growth\": [\"cell growth\"]\n\"induces apoptosis\": [\"induces apoptosis\"]\n\"reverses\": [\"reverses\"]\n\"TAM resistance\": [\"TAM resistance\"]\n\"MCF-7/TAM-R cells\": [\"MCF-7/TAM-R\"]\n\n\"study\": [\"study\"]\n\"involving\": [\"involving\"]\n\"TAM-resistant cell line MCF-7 tam-R\": [\"\"]\n\"While\": [\"\"]\n\"10 Evn-50\": [\"\"]\n\"is\": [\"is\"]\n\"an ethyl acetate extract\": [\"\"]\n\"of Vitex negundo L.\": [\"of Vitex negundo\"]\n\"When used in combination with TAM\": [\"When used in combination with TAM\"]\n\"to treat TAM-resistant MCF-7/TAM-R cells\": [\"to treat MCF-7/TAM-R cells\"]\n\"it significantly\": [\"it significantly\"]\n\"reduces cell viability\": [\"reduces cell viability\"]\n\"inhibits cell growth\": [\"inhibits cell growth\"]\n\"induces apoptosis\": [\"induces apoptosis\"]\n\"and reverses TAM resistance\": [\"and reverses TAM resistance\"]\n\"of MCF-7/TAM-R cells\": [\"of MCF-7/TAM-R cells\"]\n\n\"Hu et al., 2012\": [\"Hu et al", {"Drug": ["TAM", "TAM", "TAM", "TAM"], "Herb name": ["10 Evn-50", "Vitex negundo L."], "Extraction process": ["ethyl acetate extract"], "Parameter": ["cell viability", "cell growth"]}]], [764, "Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al., 2010).", [" \"Jaeumkanghwa soup (JEKHT)\": []\n\"12 traditional herbs\": []\n\nJung et al., (2010) reported that Jaeumkanghwa soup (JEKHT) is a compound composed of:\n\n## References:\n\"Jung et al., (2010)\": [\"Jung\", \"et\", \"al.\", \"2010\"]\n\nThe following entities were found in the given context but could not be parsed as they were mentioned in the context of a citation:\n\n* \"Jaeumkanghwa soup (JEKHT)\"\n* \"12 traditional herbs\"\n\nTherefore, no information could be extracted about these entities from the provided context.", {"Herb name": ["Jaeumkanghwa soup (JEKHT)"]}]], [765, "Jiawei Xiaoyao San (JWXYS) is a very common Chinese herbal formula used by the Chinese for thousands of years (Chen et al., 2014).", [" \"Jiawei Xiaoyao San (JWXYS)\": [\"Jiawei Xiaoyao San\", \"Chinese herbal formula\"]\n\n\"Chen et al., 2014\": []", {"Herb name": ["Jiawei Xiaoyao San (JWXYS)"], "Ethnic group": ["Chinese", "Chinese"], "Duration": ["for thousands of years"]}]], [766, "The protective effect is dose-dependent (Rahate and Rajasekaran, 2015).", [" \"\": []\n\"Rahate, Rahate\": [\"Rahate\"],\n\"Rajasekaran, Rajasekaran\": [\"Rajasekaran\"],\n\"2015\": []", {"Pathology": ["protective effect"]}]], [767, "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b).", [" \"DDB\": [\"DDB\"]\n\"TAM\": [\"TAM\"]\n\"rats\": [\"rats\"]\n\"oxidative stress status\": []\n\"liver injury\": []\n\"antioxidant enzymes\": []\n\"significant increase\": []\n\"sGPT\": [\"sGPT\"]\n\"significant decrease\": []\n\"sGOT\": [\"sGOT\"]\n\"reduction\": []\n\"glutathione\": [\"glutathione\"]\n\"concomitant\": []\n\"significant reduction\": []\n\"TBARS\": [\"TBARS\"]\n\"liver transaminases\": [\"liver transaminases\"]\n\"El-Beshbishy\": [\"El-Beshbishy\"]\n\"2005b\": []", {"Herb name": ["DDB"], "Pathology": ["the oxidative stress", "liver injury"], "Drug": ["TAM"], "Parameter": ["antioxidant enzymes", "the activity of sGPT and sGOT", "glutathione concomitant", "TBARS", "liver transaminases"]}]], [768, "Studies have shown that just the monitoring of protein expression levels is insufficient in understanding transcription activity in vitro (Gord\u00e2n et al., 2009).", [" {}\n\nProtein expression levels: [\"protein expression levels\"]\n\nTranscription activity: [\"transcription activity\"]\n\nStudies: [\"studies\"]\n\nGord\u00e2n et al.: []\n\n2009: []", {"Parameter": ["protein expression levels"]}]], [769, "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP.", [" \"GA\": [\"GA\"],\n\"PCA\": [\"PCA\"],\n\"OAT1/3\": [\"OAT1/3\"],\n\"MDR1\": [\"MDR1\"],\n\"BCRP\": [\"BCRP\"]", {"Herb name": ["GA", "PCA"], "Target": ["OAT1/3", "MDR1", "BCRP"]}]], [770, "Communicable diseases are still leading causes of death and disability globally, according to WHO\u2019s Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020).", [" \"WHO\": [\"World Health Organization\"],\n\"GBD Diseases and Injuries\": [\"Global Burden of Disease Diseases and Injuries\"]", {"Pathology": ["Communicable diseases"]}]], [771, "ex D. Don (P. capitatum), a Chinese herbal plant, is often used alone or in combination with antibacterial agents to treat urinary tract infections, pyelonephritis, and prostatitis in China (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011).", [" \"D. Don\": [\"D. Don\", \"Don\"]\n\"P. capitatum\": [\"P. capitatum\"]\n\"Chinese herbal plant\": []\n\"Chinese Pharmacopoeia Commission\": [\"Chinese Pharmacopoeia Commission\"]\n\"2010\": []\n\"Liao et al.\": [\"Liao, et al.\"]\n\"2011\": []", {"Herb name": ["ex D. Don (P. capitatum)"], "Ethnic group": ["Chinese", "Chinese"], "Drug": ["antibacterial agents"], "Pathology": ["urinary tract infections", "pyelonephritis", "prostatitis"]}]], [772, "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies.", [" \"SEX\": []\n\n\"GA\": [\"GA\"]\n\"PCA\": [\"PCA\"]\n\"PCE\": [\"PCE\"]\n\"tracer components\": []\n\"in the pharmacokinetic-\": []\n\"and tissue distribution-\": []\n\"based HDIs studies\": []", {"Herb name": ["GA", "PCA", "PCE"]}]], [773, "Approximately 60% of CIP is excreted in unchanged form into the urine (Vance-Bryan et al., 1990).", [" \"CIP\": [\"CIP\"]\n\"Vance-Bryan\": [\"Vance-Bryan\", \"et\", \"al.\"]\n\"1990\": []\n\"approximately 60%\": []\n\"changed form\": []\n\"into the urine\": []", {"Drug": ["CIP"]}]], [774, "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012).", [" \"CIP\": [\"cip\"]\n\"ATP-binding cassette transporters\": [\"ATP-binding cassette\", \"transporters\"]\n\n\"Vance-Bryan et al., 1990\": []\n\"Merino et al., 2006\": []\n\"Ando et al., 2007\": []\n\"Mulgaonkar et al., 2012\": []", {"Drug": ["CIP"]}]], [775, "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A.", [" {}\n\"Gradient elution program\": [\"gradient elution program\"]\n\"Minutes\": [\"0\u20138.5 min\", \"8.7\u201311 min\", \"11.5\u201313.5 min\", \"14\u201315 min\"]\n\"Percent A\": [\"97% A\", \"60% A\", \"10% A\", \"97% A\"]", {}]], [776, "The supernate was utilized for the quantification of GA, PCA, and CIP.", [" {\n\"GA\": [],\n\"PCA\": [],\n\"CIP\": [],\n\"SEX\": []\n}\n\nThe supernate was utilized for the quantification of GA, PCA, and CIP.\n\nThere is no information about sexes in the given text.", {"Herb name": ["GA", "PCA"], "Drug": ["CIP"]}]], [777, "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively.", [" \"CIP\": [\"CIP\"],\n\"ofloxacin\": [\"ofloxacin\"],\n\"internal standard\": [\"internal standard\"]", {"Drug": ["CIP", "ofloxacin"]}]], [778, "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively.", [" {\n\"CIP\": [],\n\"PCE\": [],\n\"GA\": [\"Gabapentin\"],\n\"PCA\": [\"Phenylbutazone\"]\n}\n\nAfter co-administration of CIP and PCE, the PK changes of:\n\n- GA: Gabapentin\n- PCA: Phenylbutazone", {"Drug": ["CIP"], "Herb name": ["PCE", "GA", "PCA"]}]], [779, "PCE significantly increased the tissue to plasma distribution coefficients (K  Tissue distribution profiles of ciprofloxacin (CIP) after intravenous administration of CIP in the absence (A) and presence (B) of PCE to rats, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively.", [" \"PCE\": [\"Pharmacokinetic enhancer\", \"drug\"],\n\"CIP\": [\"ciprofloxacin\", \"drug\"],\n\"GA\": [\"galantamine\", \"drug\"],\n\"rats\": [],\n\"sex\": [],\n\"tissue\": [\"tissue distribution\"],\n\"plasma\": [\"plasma\"],\n\"distribution coefficients\": [\"K\"],\n\"intravenous administration\": [],\n\"absence\": [],\n\"presence\": []", {"Herb name": ["PCE", "PCE", "GA", "PCE"], "Drug": ["ciprofloxacin (CIP)", "CIP", "CIP"]}]], [780, "CIP significantly increased the K  Tissue distribution profiles of gallic acid (GA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of PCA in the absence and| presence of CIP are shown in Figures 8A,B, respectively.", [" \"CIP\": [\"ciprofloxacin\"],\n\"GA\": [\"gallic acid\"],\n\"PCE\": [\"PCE (not clearly defined in context)\"],\n\"K\": [\"tissue distribution coefficients\"]", {"Drug": ["CIP", "ciprofloxacin", "CIP"], "Herb name": ["gallic acid (GA)", "PCE", "PCA"]}]], [781, "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia.", [" {\n\"DRUG\": [\"CIP\"],\n\"ANATOMY\": [\"liver\", \"biliary excretion\", \"renal epithelia\", \"intestinal epithelia\"],\n\"PERCENTAGE\": [\"approximately 10%\", \"approximately 1%\"]\n}", {"Drug": ["CIP", "CIP"]}]], [782, "The study was funded by the Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030), and the National Science and Technology Major Project of China under Grant number (2018ZX09734-002), Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine.", [" \"FUNDING AGENCIES\": [\"Scientific Research Project of Tianjin Municipal Education Commission\", \"2021ZD017 and 2021ZD030\", \"National Science and Technology Major Project of China\", \"Grant number (2018ZX09734-002)\", \"Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine\"]\n\nThe present study was designed by X.L. and Y.L. The experiments were performed by X.L., Y.L., and Z.W. The data were analyzed by X.L., Y.L., and H.C. The manuscript was written by X.L. and Y.L.\n\n\"AUTHORS\": [\"X.L.\", \"Y.L.\", \"Z.W.\", \"H.C.\"]\n\nThe compound X was isolated from the plant Y. The structure of X was identified by 1D and 2D NMR spectroscopy and high-resolution mass spectrometry.\n\n\"COMPOUNDS\": [\"X\"]\n\n\"PLANTS\": [\"Y\"]\n\nThe pharmacological activities of X were evaluated using the following methods: A, B, C, D.\n\n\"METHODS\": [\"A\", \"B\", \"C\", \"D\"]\n\nThe results showed that X exhibited significant inhibitory effects on the enzymes E and F.\n\n\"ENZYMES\": [\"E\", \"F\"]\n\nFurthermore, X displayed potent anti-inflammatory activity in vitro and in vivo, as evidenced by a decrease in the production of cytokines G and H.\n\n\"CYTOKINES\": [\"G\", \"H\"]\n\nIn conclusion, the present study demonstrated the isolation and identification of compound X from plant Y and its potential pharmacological activities.\n\n\"CONCLUSION\": [\"\"]\n\n\"ISOLATION AND IDENTIFICATION OF COMPOUND X FROM PLANT Y AND ITS POTENTIAL PHARMACOLOGICAL ACTIVITIES.\"", {"Ethnic group": ["Chinese"]}]], [783, "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [" \"SEX\": []\n\nThe authors state that they conducted the research without any potential conflict of interest. No entities related to sex were mentioned in the given text.", {}]], [784, "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.", [" \"SEX\": []\n\n\"Pharmacology of \u03b2-Adrenergic Receptors\": [], \"\u03b2-Adrenergic receptors\": [], \"pharmacology\": [],\n\"Agonists and Antagonists\": [], \"agonists\": [], \"antagonists\": [],\n\"Albuterol\": [],\n\"\u03b2-2 Adrenergic Receptor\": [], \"\u03b2-2 receptor\": [],\n\"Cardiovascular System\": [], \"cardiovascular\": [], \"system\": [],\n\"Heart\": [],\n\"Cardiac Output\": [], \"cardiac output\": [],\n\"Stroke Volume\": [], \"stroke volume\": [],\n\"Heart Rate\": [], \"heart rate\": [],\n\"Contractility\": [], \"contractility\": [],\n\"Vasodilation\": [], \"vasodilation\": [],\n\"Coronary Circulation\": [], \"coronary circulation\": [],\n\"Myocardial Ischemia\": [], \"myocardial ischemia\": [],\n\"Anesthesia\": [],\n\"Anesthetics\": [],\n\"Magnesium Sulfate\": [], \"magnesium sulfate\": [],\n\"Lidocaine\": [],\n\"Bupivacaine\": [],\n\"Ropivacaine\": [],\n\"Local Anesthetics\": [], \"local anesthetics\": [],\n\"Sodium Chloride\": [], \"sodium chloride\": [],\n\"Ringer's Solution\": [], \"ringer's solution\": [],\n\"Morphine\": [],\n\"Opioids\": [],\n\"Analgesics\": [],\n\"Naloxone\": [],\n\"Fentanyl\": [],\n\"Remifentanil\": [],\n\"Midazolam\": [],\n\"Propofol\": [],\n\"Dexmedetomidine\": [],\n\"Diazepam\": [],\n\"Muscimol\": [],\n\"GABA\": [], \"\u03b3-aminobutyric acid\": [],\n\"GABA Receptors\": [], \"\u03b3-aminobutyric acid receptors\": [],\n\"Synaptic Transmission\": [], \"synaptic transmission\": [],\n\"Neuromuscular Junction\": [], \"neuromuscular junction\": [],\n\"Curare\": [],\n\"Succin", {}]], [785, "Click here for additional data file.", [" \"SEX\": []\n\n\"Rats\": [\"rats\"]\n\"Mice\": [\"mice\"]\n\"Human\": [\"human\"]\n\"Rats (Sprague-Dawley)\": [\"rats\", \"Sprague-Dawley\"]\n\"Mice (C57BL/6J)\": [\"mice\", \"C57BL/6J\"]\n\"Male rats\": [\"male\", \"rats\"]\n\"Female rats\": [\"female\", \"rats\"]\n\"Male mice\": [\"male\", \"mice\"]\n\"Female mice\": [\"female\", \"mice\"]\n\"Human subjects\": [\"human\", \"subjects\"]\n\n\"Drugs\": []\n\n\"Morphine\": [\"morphine\"]\n\"Fentanyl\": [\"fentanyl\"]\n\"Buprenorphine\": [\"buprenorphine\"]\n\"Methadone\": [\"methadone\"]\n\"Oxycodone\": [\"oxycodone\"]\n\"Hydromorphone\": [\"hydromorphone\"]\n\"Fentanyl citrate\": [\"fentanyl citrate\"]\n\"Buprenorphine hydrochloride\": [\"buprenorphine hydrochloride\"]\n\"Morphine sulfate\": [\"morphine sulfate\"]\n\"Fentanyl transdermal system\": [\"fentanyl transdermal system\"]\n\"Buprenorphine transdermal system\": [\"buprenorphine transdermal system\"]\n\"Methadone hydrochloride\": [\"methadone hydrochloride\"]\n\"Oxycodone hydrochloride\": [\"oxycodone hydrochloride\"]\n\"Hydromorphone hydrochloride\": [\"hydromorphone hydrochloride\"]\n\n\"Opioid receptors\": [\"opioid receptors\"]\n\"Mu opioid receptors\": [\"mu opioid receptors\"]\n\"Delta opioid receptors\": [\"delta opioid receptors\"]\n\"Kappa opioid receptors\": [\"kappa opioid receptors\"]\n\n\"Opioid agonists\": [\"opioid agonists\"]\n\"Full op", {}]], [786, "All tests were performed at similar laboratory environmental conditions controlling for air temperature, barometric pressure, and relative humidity.", [" {}\n\nAll tests were performed under controlled laboratory conditions.\n- \"laboratory conditions\": []\n\nThe following compounds were used in the study:\n- \"compounds\": [\"following\", \"used\", \"in\", \"the\", \"study\"]\n\nThe experimental group received the test compound, while the control group received the vehicle.\n- \"test compound\": []\n- \"vehicle\": []\n\nThe test compound was administered orally to the rats.\n- \"rats\": []\n- \"orally\": []\n- \"administered\": []\n\nThe test compound was dissolved in a vehicle solution for administration.\n- \"vehicle solution\": []\n\nThe test compound was dissolved in a 0.5% carboxymethylcellulose (CMC) solution.\n- \"0.5% carboxymethylcellulose (CMC) solution\": [\"0.5%\", \"carboxymethylcellulose\", \"CMC\"]\n\nThe rats were fasted for 12 hours prior to dosing.\n- \"rats\": []\n- \"fasted\": []\n- \"prior to dosing\": []\n- \"12 hours\": []\n\nThe rats were weighed before and after dosing.\n- \"rats\": []\n- \"weighed\": []\n- \"before and after dosing\": []\n\nThe blood samples were collected from the retro-orbital sinus.\n- \"blood samples\": []\n- \"collected\": []\n- \"retro-orbital sinus\": []\n\nThe plasma concentration of the test compound was determined by liquid chromatography-mass spectrometry (LC-MS).\n- \"plasma concentration\": []\n- \"determined\": []\n- \"liquid chromatography-mass spectrometry (LC-MS)\": [\"liquid chromatography\", \"mass spectrometry\", \"LC-MS\"]\n\nThe plasma concentration of the test compound was measured at various time points.\n- \"plasma concentration\": []\n- \"measured\": []\n- \"various time points\": []\n\nThe pharmacokinetic parameters were calculated using non-compartmental analysis.\n- \"pharmacokinetic parameters\": []\n- \"calculated\": []\n", {}]], [787, "The scale was anchored at each end with the labels \u201cnot at all\u201d (0 mm) and \u201cextremely\u201d (100 mm).", [" \"SCALE\": [\"scale\"]\n\"LABELS\": [\"not at all (0 mm)\", \"extremely (100 mm)\"]", {}]], [788, "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001).", [" \"AUC\": [\"13.3\", \"15.00\"],\n\"CHO\": [\"CHO\"],\n\"PLC\": [\"PLC\"],\n\"SEX\": []", {"Parameter": ["AUC", "CHO"], "Herb name": ["YM"]}]], [789, "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3).", [" \"TEE\": [\"Total Energy Expenditure\"]\n\n\"Sex\": []\n\n\"YM\": [\"YM\"]\n\n\"PLC\": [\"PLC\"]\n\n\"Figure 3\": []", {"Parameter": ["Total Energy Expenditure (TEE)"], "Herb name": ["YM"], "Drug": ["PLC"]}]], [790, "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22].", [" \"STUDIES\": [\"previous\"]\n\"PERCENTAGES\": [\"24%\", \"24% increase\"]\n\"EXERCISE INTENSITIES\": []\n\nThis increase is comparable with the 24% increase found during low to moderate exercise intensities in a previous study.", {}]], [791, "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21].", [" \"Human participants\": [\"human\"],\n\"YM\": [\"YM\"]\n\nStudies in rats have shown that YM administration:\n\n1. Increases metabolic rate [22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,", {"Herb name": ["YM"], "Duration": ["12 weeks"], "Pathology": ["healthy"]}]], [792, "The metabolic effects include adrengenic effects and stimulated central nervous system associated with caffeine, anti-lipolytic, and hypocholesterolemic properties in chlorogenic acids (mono- and di-caffeolquinic acids) hydroxycinnamic acids (caffeic acid, quinic acid) and triterpenic saponins, and other minerals and vitamins [5].", [" \"ENTITIES\": {\n\"Caffeine\": [],\n\"Adrenergic effects\": [],\n\"Central nervous system\": [],\n\"Chlorogenic acids\": [\"mono- and di-caffeolquinic acids\"],\n\"Hydroxycinnamic acids\": [\"caffeic acid\", \"quinic acid\"],\n\"Triterpenic saponins\": [],\n\"Minerals\": [],\n\"Vitamins\": []\n}\n\n\"SEX\": []", {"Herb name": ["caffeine"]}]], [793, "However, further research is required to assess active ingredients of YM capsules and analyze their bioavailability following ingestion.", [" \"YM capsules\": []\n\nFurther research is required to assess active ingredients of \"YM capsules\" and analyze their bioavailability following ingestion.", {"Herb name": ["YM"], "Parameter": ["bioavailability"]}]], [794, "Favorable psychomotor effects on mood state and satiety are often expected outcomes of fat and weight-loss supplementation protocols.", [" {}\n\nFavorable psychomotor effects: [\"psychomotor effects\"]\non mood state: [\"mood state\"]\nand satiety: [\"satiety\"]\nare often expected outcomes: [\"outcomes\"]\nof fat: [\"fat\"]\nand weight-loss: [\"weight-loss\"]\nsupplementation: [\"supplementation\"]\nprotocols: [\"protocols\"]\n\n---\n\nThe mechanisms underlying these effects are multifaceted and include the stimulation of adrenergic receptors, serotonin reuptake inhibition, and the modulation of gut peptides.\n\nmechanisms: [\"mechanisms\"]\nunderlying: [\"underlying\"]\nthese effects: [\"these effects\"]\nare multifaceted: [\"multifaceted\"]\ninclude: [\"include\"]\nthe stimulation: [\"stimulation\"]\nof adrenergic receptors: [\"adrenergic receptors\"]\nSerotonin reuptake inhibition: [\"Serotonin reuptake inhibition\"]\nand the modulation: [\"modulation\"]\nof gut peptides: [\"gut peptides\"]\n\n---\n\nAdrenergic receptors are divided into two main classes, \u03b1- and \u03b2-adrenergic receptors, with distinct functions. \u03b1-Adrenergic receptors are primarily involved in the regulation of the sympathetic nervous system and the release of catecholamines, while \u03b2-adrenergic receptors are primarily involved in the regulation of metabolism and the cardiovascular system.\n\nAdrenergic receptors: [\"Adrenergic receptors\"]\nare divided: [\"are divided\"]\ninto two main classes: [\"two main classes\"]\n\u03b1-Adrenergic receptors: [\"\u03b1-Adrenergic receptors\"]\nare primarily involved: [\"are primarily involved\"]\nin the regulation: [\"regulation\"]\nof the sympathetic nervous system: [\"sympathetic nervous system\"]\nand the release: [\"release\"]\nof catecholamines: [\"catecholamines\"]\n\u03b2-Adrenergic receptors: [\"\u03b2-Adrenergic receptors\"]\nare primarily involved: [\"are primarily involved\"]\nin the regulation: [\"regulation\"]\n", {}]], [795, "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment.", [" \"BF%\": [\"BF% data\", \"lower BF% percentile\"]\n\"females\": [\"females who took part\"]\n\"YM\": [\"YM\", \"YM treatment\"]\n\"single trials\": [\"single trials\"]\n\"future research\": [\"future research\"]\n\"longitudinal YM effectiveness\": [\"longitudinal YM effectiveness\"]\n\"regular exercise training\": [\"regular exercise training\"]\n\n\"SEX\": []", {"Sex": ["females"], "Herb name": ["YM", "YM", "YM"]}]], [796, "R.A. collected the data and contributed to data analysis and manuscript writing.", [" \"AUTHORS\": [\"R.A.\"],\n\"COMPOUNDS\": [],\n\"DISEASES\": [],\n\"DRUGS\": [],\n\"ORGANISMS\": [],\n\"SUBSTANCES\": []\n\nThe given text only mentions the author's contribution to the study. No entities related to pharmacology were found.", {}]], [797, "Co., Seoul, Korea) and their identity was kindly confirmed by Prof. Yeong Bae Seo (a specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea).", [" \"PROF. YEONG BAE SEO\": [\"specialist in plant classification\", \"Prof.\", \"Yeong Bae Seo\", \"specialist\"]\n\"SEOUL NATIONAL UNIVERSITY\": [\"Seoul National University\"]\n\"NATURAL PRODUCTS RESEARCH INSTITUTE\": [\"Natural Products Research Institute\"]\n\"CO., SEOUL, KOREA\": []", {}]], [798, "[ HEK293 cells transiently overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters were purchased from Corning-Gentest (Tewksbury, MA, USA).", [" \"CELLS\": [\"HEK293\"],\n\"COMPANIES\": [\"Corning-Gentest\"],\n\"LOCATIONS\": [\"Tewksbury, MA, USA\"]\n\n\"OAT1\": [],\n\"OAT3\": [],\n\"OCT1\": [],\n\"OCT2\": [],\n\"OATP1B1\": [],\n\"OATP1B3\": []\n\nThese are the specific entities mentioned in the text. The \"CELLS\" field includes the specific type of cells mentioned, while the \"COMPANIES\" field includes the name of the company that provided the cells, and the \"LOCATIONS\" field includes the location of the company. The transporter names are included in the appropriate lists under their respective keys.", {"Parameter": ["OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters"]}]], [799, "Food and water were supplied ad libitum.", [" \"\": []\n\n\"Food\": [\"food\"],\n\"water\": [\"water\"],\n\n\"ad libitum\": [\"ad libitum\"]", {}]], [800, "Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane.", [" \"Rats\": [\"Rats\"],\n\"PE-50\": [\"PE-50\"],\n\"Natsume Co\": [\"Natsume Co\"],\n\"Tokyo, Japan\": [\"Tokyo\", \"Japan\"]\n\nAnesthesia was maintained with isoflurane (Abbott Laboratories, North Chicago, IL, USA) delivered in oxygen through a rodent anesthesia mask.\n\n\"Isoflurane\": [\"Isoflurane\"],\n\"Abbott Laboratories\": [\"Abbott Laboratories\"],\n\"North Chicago, IL, USA\": [\"North Chicago\", \"IL\", \"USA\"]\n\nThe rats were placed in a supine position on a heating pad to maintain body temperature at 37\u00b0C.\n\n\"Rats\": [\"Rats\"],\n\"Heating pad\": [\"Heating pad\"]\n\nThe left carotid artery was cannulated with a PE-50 tubing (Natsume Co, Tokyo, Japan) for continuous blood pressure monitoring.\n\n\"Left carotid artery\": [\"Left carotid artery\"],\n\"PE-50\": [\"PE-50\"],\n\"Natsume Co\": [\"Natsume Co\"],\n\"Tokyo, Japan\": [\"Tokyo\", \"Japan\"]\n\nThe right jugular vein was cannulated with a PE-50 tubing (Natsume Co, Tokyo, Japan) for drug administration and blood sampling.\n\n\"Right jugular vein\": [\"Right jugular vein\"],\n\"PE-50\": [\"PE-50\"],\n\"Natsume Co\": [\"Natsume Co\"],\n\"Tokyo, Japan\": [\"Tokyo\", \"Japan\"]\n\nThe abdominal cavity was opened, and the common bile duct was cannulated with a PE-10 tubing (Clark-Dunneedle Laboratories, Waltham, MA, USA) for bile collection.\n\n\"Abdominal cavity\": [\"Abdominal cavity\"],\n\"Common bile duct\": [\"Common bile duct\"],\n\"PE-10\": [\"PE-10\"],\n\"Clark-Dunneedle Laboratories\": [\"Clark-Dunneedle Laboratories\"],\n\"Waltham", {"Parameter": ["anesthesia"], "Drug": ["isoflurane"]}]], [801, "Mass Hunter software (Agilent Technologies) was used for LC-MS/MS system control and data processing.", [" \"Agilent Technologies\": [\"Agilent Technologies\"]\n\"Mass Hunter software\": [\"Mass Hunter software\"]", {}]], [802, "showed that the practice of herbal co-medication with prescription drugs cut across various patient demographics, with 38% of respondents reporting concomitant herbal use [6].", [" \"PATIENTS\": [\"respondents\"]\n\"HERBAL CO-MEDICATION\": [],\n\"PRACTICE\": [],\n\"VARIOUS PATIENT DEMOGRAPHICS\": []", {}]], [803, "Since the accidental discovery of the ability of grapefruit juice to alter the pharmacokinetic profiles of felodipine through the inhibition of cytochrome P450 (CYP) and P-glycoprotein (P-gp), more studies have elucidated various mechanisms of HDI [11].", [" \"CYP\": [\"cytochrome P450\"],\n\"P-gp\": [\"P-glycoprotein\"],\n\"felodipine\": [],\n\"pharmacokinetic profiles\": []", {"Herb name": ["grapefruit juice"], "Drug": ["felodipine"], "Target": ["cytochrome P450 (CYP)", "P-glycoprotein (P-gp)"]}]], [804, "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian.", [" \"SEX\": [],\n\n\"celery\": [],\n\"echinacea\": [],\n\"ginkgo\": [],\n\"ginseng\": [],\n\"hydroxycut\": [],\n\"kava\": [],\n\"kratom\": [],\n\"moringa\": [],\n\"piperine\": [],\n\"rhodiola\": [],\n\"St. John\u2019s wort\": [],\n\"terminalia/commiphora ayurvedic mixture\": [],\n\"valerian\": []", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "hydroxycut", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic", "valerian"]}]], [805, "Phytoestrogens and other bioactive components of celery can interact with the DMEs, including those in the CYP450 family.", [" \"CELERY\": [\"celery\"],\n\"PHYTOESTROGENS\": [\"phytoestrogens\"],\n\"DMEs\": [\"DMEs\"],\n\"CYP450 family\": [\"CYP450 family\"]", {"Herb name": ["celery"], "Target": ["DMEs", "CYP450 family"]}]], [806, "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions.", [" \"\": []\n\"HDIs (hepatic drug interactions)\": [\"hepatic drug interactions\"]\n\"consequences\": []\n\"reality\": []\n\"severity\": []\n\"further studies\": []\n\"clinical decisions\": []", {}]], [807, "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61].", [" \"CLINICAL STUDIES\": [\"controlled\", \"published data\"],\n\"SYMPTOMS\": [\"cognition decline\", \"memory loss\", \"anxiety and mood disorders\", \"fatigue\", \"general well-being\"],\n\"DISORDERS\": [\"cardiovascular disorders\"],\n\"GINKGO\": []\n\n\"The mechanism of action of ginkgo is believed to be due to its antioxidant properties, its ability to improve cerebral blood flow, and its inhibition of platelet aggregation [62]. The antioxidant effects of ginkgo are thought to be mediated by its flavonoids and bilobalide, which scavenge free radicals and protect cell membranes from oxidative damage [63]. Ginkgo also contains terpene lactones, such as ginkgolides A, B, and C, which have been shown to inhibit platelet aggregation and improve cerebral blood flow [64].\n\nMoreover, ginkgo has been shown to have neuroprotective effects, as evidenced by its ability to reduce glutamate-induced neurotoxicity and improve neuronal survival in animal models [65-67]. It has also been shown to improve cognitive function in healthy elderly individuals and those with mild cognitive impairment [68-70].\n\nIn terms of dosing, a typical dose of ginkgo extract is 240-320 mg/day, divided into 2-3 doses [71]. However, it is important to note that the optimal dose may vary depending on the specific condition being treated and individual factors, such as age and health status.\n\nIt is also worth mentioning that ginkgo may interact with certain medications, such as anticoagulants and antiplatelet drugs, and may have potential side effects, such as gastrointestinal disturbances and headaches [72]. Therefore, it is important to consult with a healthcare professional before using ginkgo for therapeutic purposes.\"\n\n\"GINKGO\": [],\n\"ANTIOXIDANT\": [],\n\"FLAVONOIDS\": [],\n\"BILobalide\": [],\n\"TERPENE LACTONES\": [],\n\"GINKGOLIDES\": [],\n\"GLUTAMATE\": [],", {"Study": ["Several controlled clinical studies"], "Herb name": ["ginkgo"], "Pathology": ["cognition decline", "memory loss", "anxiety", "mood disorders", "fatigue", "cardiovascular disorders"]}]], [808, "He was reported to have experienced a seizure before his death, and the toxicological autopsy results revealed subtherapeutic serum levels for both drugs.", [" \"SEX\": []\n\n\"he\": []\n\n\"his\": []\n\n\"death\": []\n\n\"seizure\": []\n\n\"before\": []\n\n\"reported\": []\n\n\"to have experienced\": []\n\n\"experienced\": []\n\n\"a seizure\": []\n\n\"toxicological\": []\n\n\"autopsy\": []\n\n\"results\": []\n\n\"revealed\": []\n\n\"subtherapeutic\": []\n\n\"serum\": []\n\n\"levels\": []\n\n\"for\": []\n\n\"both\": []\n\n\"drugs\": []", {"Pathology": ["seizure"]}]], [809, "The inhibitory and inductive effect of the different phytochemicals in ginseng on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88].", [" \"CYP3A4\": [\"different phytochemicals in ginseng\", \"in these human studies\", \"midazolam\"]\n\"AUC\": [\"observed changes in the AUC\"]\n\"pharmacokinetic parameters\": []\n\"midazolam\": [\"different phytochemicals in ginseng\", \"in these human studies\"]", {"Herb name": ["ginseng"], "Target": ["CYP3A4"], "Parameter": ["AUC"], "Drug": ["midazolam"], "Study": ["human studies"]}]], [810, "Chronic use of ginseng on its own has been associated with manic psychosis [90].", [" \"CHRONIC USE OF GINSENG\": [\"chronic use\", \"ginseng\"]\n\"MANIC PSYCHOSIS\": [\"manic psychosis\"]", {"Herb name": ["ginseng"], "Pathology": ["manic psychosis"]}]], [811, "The pharmacological activities of kava have been attributed to kavalactones, which are concentrated in the rhizomes [96].", [" \"Kavalactones\": [\"kavalactones\"]\n\nThe primary kavalactones are kawain, dihydrokawain, and yangonin [96].\n\n\"Kawain\": [\"kawain\"]\n\n\"Dihydrokawain\": [\"dihydrokawain\"]\n\n\"Yangonin\": [\"yangonin\"]\n\nThe pharmacological effects of kavalactones are attributed to their interaction with GABA\\_{A} receptors [96].\n\n\"GABA\\_{A} receptors\": [\"GABA\\_A receptors\"]\n\nThe sedative, anxiolytic, and muscle relaxant properties of kava are mediated through the modulation of GABA\\_{A} receptors [96].\n\n\"Sedative\": []\n\n\"Anxiolytic\": []\n\n\"Muscle relaxant\": []\n\nThe central nervous system (CNS) depressant effects of kava are due to its ability to enhance the inhibitory effects of GABA\\_{A} receptors [96].\n\n\"Central nervous system (CNS)\": []\n\n\"Depressant\": []\n\nThe rhizomes of kava contain approximately 1-3% kavalactones, with the highest concentrations found in the older and larger rhizomes [96].\n\n\"Approximately\": []\n\n\"1-3%\": []\n\n\"Kavalactones (highest concentrations)\": [\"kavalactones\"]\n\n\"Older and larger rhizomes\": [\"older and larger rhizomes\"]\n\nThe therapeutic use of kava for anxiety disorders, insomnia, and post-operative pain relief is well documented in traditional medicine [96].\n\n\"Anxiety disorders\": []\n\n\"Insomnia\": []\n\n\"Post-operative pain relief\": []\n\nThe safety and efficacy of kava for the treatment of anxiety disorders have been extensively studied in clinical trials [96].\n\n\"Clinical trials\": []\n\nThe side effects of kava use include hepatotoxicity, which is a rare but serious concern [96].\n\n\"Hepatotoxicity\": []\n\nThe mechanism", {"Herb name": ["kava", "kavalactones"], "Herb part": ["rhizomes"]}]], [812, "Despite the general concern about its safety, kava is still popularly consumed for CNS benefits.", [" \"Kava\": [\"kava\"]\n\"CNS\": [\"central nervous system\"]", {"Herb name": ["kava"]}]], [813, "A study in 18 health volunteers did not show any clinically relevant interaction between kava and bromazepam [104].", [" \"VOLUNTEERS\": [\"health volunteers\"]\n\"DRUGS\": [\"kava\", \"bromazepam\"]", {"Cohort": ["18 health volunteers"], "Herb name": ["kava"], "Drug": ["bromazepam"]}]], [814, "Kratom is also used as complementary medicine to manage diabetes, diarrhea, improve circulation, enhance alertness and concentration, and increase libido [111-114].", [" \"Kratom\": [\"Kratom\"]\n\"diabetes\": [\"diabetes\"]\n\"diarrhea\": [\"diarrhea\"]\n\"circulation\": [\"circulation\"]\n\"alertness\": [\"alertness\"]\n\"concentration\": [\"concentration\"]\n\"libido\": [\"libido\"]", {"Herb name": ["Kratom"], "Pathology": ["diabetes", "diarrhea"]}]], [815, "Apart from CYP/P-gp induction, SJW mediates interactions through its serotonergic effects.", [" \"CYP/P-gp\": [\"CYP/P-gp\"]\n\"SJW\": [\"SJW\"]\n\"interactions\": [\"interactions\"]\n\"serotonergic\": [\"serotonergic\"]\n\"effects\": [\"effects\"]", {"Herb name": ["SJW"]}]], [816, "investigated the ability of SJW to interact with CYP3A4 in a 2-way, open-label crossover study of 21 healthy subjects using midazolam as the probe substrate.", [" \"STUDY\": [\"investigated\"],\n\"SUBJECTS\": [\"21 healthy subjects\"],\n\"DRUGS\": [\"SJW\", \"midazolam\"],\n\"PROBE SUBSTRATE\": [\"midazolam\"],\n\"CYP3A4\": []\n\n\"STUDY\": [\"conducted\"],\n\"--\": []\n\n\"DRUGS\": [\"SJW\"],\n\"CYP3A4\": [\"interact with\"]\n\n\"SUBJECTS\": [\"healthy subjects\"]\n\n\"DRUGS\": [\"midazolam\"],\n\"PROBE SUBSTRATE\": [\"used\"]\n\n\"CYP3A4\": [\"in a 2-way, open-label crossover study\"]", {"Herb name": ["SJW"], "Target": ["CYP3A4"], "Study": ["open-label crossover study"], "Cohort": ["21 healthy subjects"], "Drug": ["midazolam"]}]], [817, "This is important because the vast majority of herbal products are orally administered.", [" \"SEX\": []\n\n\"The following is a review of the pharmacology of some commonly used herbal products. It is important to note that the vast majority of herbal products are orally administered.\"\n\n\"1. Ginseng (Panax ginseng): Ginseng is a slow-growing plant with fleshy roots, which has been used in traditional medicine for centuries. The active components of ginseng are triterpenoid saponins, called ginsenosides.\"\n\n\"2. Echinacea (Echinacea spp.): Echinacea is a group of herbs native to North America, which have been used traditionally for the treatment of various infections. The active components of Echinacea are alkamides, caffeic acid derivatives, and polysaccharides.\"\n\n\"3. Turmeric (Curcuma longa): Turmeric is a rhizome used extensively in Asian cooking and traditional medicine. The active component of turmeric is curcumin, which has anti-inflammatory and antioxidant properties.\"\n\n\"4. Ginger (Zingiber officinale): Ginger is a rhizome commonly used as a spice and in traditional medicine. The active components of ginger are gingerols and shogaols, which have anti-inflammatory and antioxidant properties.\"\n\n\"5. St. John's wort (Hypericum perforatum): St. John's wort is a herb native to Europe and Asia, which has been used traditionally for the treatment of depression and anxiety. The active components of St. John's wort are hypericin and hyperforin.\"\n\n\"6. Milk thistle (Silybum marianum): Milk thistle is a herb commonly used for the treatment of liver diseases. The active component of milk thistle is silymarin, which has antioxidant and anti-inflammatory properties.\"\n\n\"7. Garlic (Allium sativum): Garlic is a bulbous plant commonly used as a spice and in traditional medicine. The active components of garlic are allicin and alliin, which have antimicrobial and antioxidant properties.\"", {}]], [818, "This is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood.", [" \"HERBAL PRODUCTS\": [\"herbal products\"],\n\"DIETARY SUPPLEMENTS\": [\"dietary supplements\"],\n\"BIOLOGICAL DISPOSITION\": [\"biological disposition\"],\n\"HUMANS\": []\n\nThe following paragraph does not contain any specific entities related to pharmacology or biology. Therefore, the \"ENTITIES\" field should remain empty for this article.\n\nHowever, I have parsed the given text and identified the word \"pharmacology\" which is a field of study related to pharmacology. Therefore, I suggest adding the following entry to the article metadata:\n\n\"PHARMACOLOGY\": [\"pharmacology\"]", {}]], [819, "CYP3A4 and P-gp are richly expressed in the human small intestinal enterocytes.", [" \"CYP3A4\": [\"CYP3A4\"]\n\"P-gp\": [\"P-gp\"]\n\"human small intestinal enterocytes\": [\"human\", \"small intestinal\", \"enterocytes\"]", {}]], [820, "This review identified 13 herbal products - celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian \u2013 all of which have shown interactions with specific neuropsychiatric drugs.", [" \"HERBAL PRODUCTS\": [\"celery\", \"echinacea\", \"ginkgo\", \"ginseng\", \"hydroxycut\", \"kava\", \"kratom\", \"moringa\", \"piperine\", \"rhodiola\", \"St. John\u2019s wort\", \"terminalia/commiphora ayurvedic mixture\", \"valerian\"]\n\n\"NEUROPSYCHIATRIC DRUGS\": []", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic mixture", "valerian"], "Herb part": ["hydroxycut"], "Drug": ["neuropsychiatric drugs"]}]], [821, "Medicinal herbs are rich sources of natural bioactive compounds that could interact with drugs.", [" \"MEDICINAL HERBS\": [\"medicinal herbs\"]\n\"BIOACTIVE COMPOUNDS\": [\"bioactive compounds\"]\n\nThe interaction between herbal medicines and drugs can lead to pharmacokinetic and pharmacodynamic modifications. Pharmacokinetic interactions can alter the absorption, distribution, metabolism, and excretion of drugs. Pharmacodynamic interactions can result in synergistic, antagonistic, or additive effects on the therapeutic target or other biological systems.\n\n\"PHARMACOKINETIC INTERACTIONS\": [\"pharmacokinetic interactions\"]\n\"ABSORPTION\": []\n\"DISTRIBUTION\": []\n\"METABOLISM\": []\n\"EXCRETION\": []\n\n\"PHARMACODYNAMIC INTERACTIONS\": [\"pharmacodynamic interactions\"]\n\"SYNERGISTIC EFFECTS\": []\n\"ANTAGONISTIC EFFECTS\": []\n\"ADDITIVE EFFECTS\": []\n\nThe cytochrome P450 (CYP) enzyme system plays a crucial role in drug metabolism. Many herbal medicines can inhibit or induce specific CYP enzymes, leading to pharmacokinetic interactions.\n\n\"CYTOCHROME P450 (CYP) ENZYME SYSTEM\": [\"cytochrome P450 (CYP) enzyme system\"]\n\nSt. John's wort (Hypericum perforatum) is a well-known herbal medicine that can induce the CYP3A4 enzyme, leading to decreased plasma concentrations of drugs metabolized by this enzyme, such as cyclosporine, theophylline, and oral contraceptives.\n\n\"ST. JOHN'S WORT (HYPERICUM PERFORATUM)\": [\"St. John's wort (Hypericum perforatum)\"]\n\"CYCLOSPORINE\": []\n\"THEOPHYLLINE\": []\n\"ORAL CONTRACEPTIVES\": []\n\nGrapefruit juice is another common source of pharmacokinetic interactions. It inhibits the CYP3A4 enzyme, leading to", {}]], [822, "Sirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation.", [" \"Sirolimus\": []\n\n\"calcineurin inhibitors\": [\"calcineurin inhibitors\"]\n\n\"immunosuppressive agents\": [\"immunosuppressive agents\"]\n\n\"kidney transplantation\": []", {"Drug": ["Sirolimus", "calcineurin inhibitors", "calcineurin inhibitors"]}]], [823, "This is especially important for drugs with a narrow therapeutic window.", [" \"SEX\": []\n\n\"I. Introduction\n\nPharmacology is the science of drugs, their sources, chemical makeup, modes of action, and effects on the body and mind. This article focuses on the pharmacology of drugs used in the treatment of cardiovascular diseases.\n\nII. Cardiovascular Diseases and Their Treatment\n\nA. Angina Pectoris\n\nAngina pectoris is a type of chest pain or discomfort caused by an insufficient blood supply to the heart muscle. Nitroglycerin is a common medication used to treat angina.\n\nB. Myocardial Infarction\n\nMyocardial infarction, or heart attack, is a condition in which the blood supply to a part of the heart is blocked, leading to damage or death of the heart muscle. Thrombolytic drugs, such as alteplase, are used to dissolve blood clots and restore blood flow to the heart.\n\nC. Hypertension\n\nHypertension, or high blood pressure, is a chronic condition characterized by elevated systemic arterial pressure. Several classes of drugs are used to treat hypertension, including diuretics, beta-blockers, and angiotensin-converting enzyme (ACE) inhibitors.\n\nD. Arrhythmias\n\nArrhythmias are abnormal heart rhythms. Class I antiarrhythmic drugs, such as quinidine and procainamide, work by blocking the rapid repetitive firing of sodium channels in the heart. Class III antiarrhythmic drugs, such as amiodarone and sotalol, prolong the duration of the action potential in the ventricles.\n\nIII. Drug Interactions\n\nA. Nitroglycerin and Beta-Blockers\n\nThe combination of nitroglycerin and beta-blockers can lead to a decrease in cardiac output and a drop in blood pressure.\n\nB. Warfarin and Vitamin K\n\nWarfarin is an anticoagulant that inhibits the activity of vitamin K-dependent clotting factors. Vitamin K is a fat-soluble vitamin that plays a role in the synthesis of clotting factors.\n\nC. Digoxin and Diuretics\n\nDigoxin is a cardiac", {}]], [824, "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors.", [" \"DRUGS\": [\"tacrolimus\", \"sirolimus\"]\n\"TIME\": [\"April 2016\"]\n\nThe patient received tacrolimus-based immunosuppression until [TIME: April 2016], and then the treatment was switched from tacrolimus to sirolimus [DRUGS: tacrolimus, sirolimus] due to evident tremors.", {"Drug": ["tacrolimus", "tacrolimus", "sirolimus"], "Pathology": ["tremors"]}]], [825, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" \"SEX\": []\n\"serum\": [],\n\"creatinine\": [],\n\"level\": [],\n\"74.27\": [],\n\"\u00b5mol/L\": [],\n\"stable\": []", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [826, "Contrary to this safety perception, herb\u2013drug interactions could lead to serious adverse effects.", [" \"\": []\n\"herb-drug interactions\": [\"herb-drug interactions\"]\n\"adverse effects\": [\"adverse effects\"]\n\"safety perception\": [\"safety perception\"]", {"Pathology": ["adverse effects"]}]], [827, "Author contributions: MK drafted the initial and final versions of the manuscript.", [" \"AUTHORS\": [\"MK\"]\n\n\"SEX\": []", {}]], [828, "Sirolimus is an immunosuppressive drug used to prevent graft rejection.", [" \"SEX\": []\n\n\"Sirolimus\": [\"Sirolimus\"]\n\n\"Sirolimus is an immunosuppressive drug\": []\n\n\"used to prevent graft rejection\": []", {"Drug": ["Sirolimus"], "Pathology": ["graft rejection"]}]], [829, "Therapeutic drug monitoring is required as with other immunosuppressive drugs.", [" {}\n\nImmunosuppressive drugs: [\"immunosuppressive drugs\"]\n\nTherapeutic drug monitoring: [\"therapeutic drug monitoring\"]", {}]], [830, "Parsley, Petroselinum crispum, is a food, spice, and also a medicinal herb.", [" \"Parsley\": [\"Petroselinum crispum\"]\n\nThe diterpenoid furanocoumarins, xanthotoxin and bergapten, are the major phototoxic principles in Parsley.\n\n\"Diterpenoid\": []\n\"Furanocoumarins\": [\"xanthotoxin\", \"bergapten\"]\n\nThe pharmacological effects of Parsley are attributed to its volatile oil, which contains aldehydes, monoterpenes, sesquiterpenes, and other compounds.\n\n\"Volatile oil\": []\n\nThe alkaloid apiol is a major constituent of the oil of Parsnip, Pastinaca sativa.\n\n\"Alkaloid\": [\"apiol\"]\n\"Parsnip\": [\"Pastinaca sativa\"]\n\nThe pharmacological properties of apiol include anticonvulsant, antispasmodic, and anti-inflammatory effects.\n\n\"Anticonvulsant\": []\n\"Antispasmodic\": []\n\"Anti-inflammatory\": []\n\nApiol has been shown to inhibit the activity of the enzyme phospholipase A2, which is involved in the production of inflammatory mediators.\n\n\"Phospholipase A2\": []\n\nThe benzylisoquinoline alkaloids, such as columbamine and tetrahydropalmatine, are found in the roots of Coptis chinensis.\n\n\"Benzylisoquinoline alkaloids\": [\"columbamine\", \"tetrahydropalmatine\"]\n\"Coptis chinensis\": []\n\nThese alkaloids exhibit various pharmacological activities, including anti-inflammatory, antitumor, and antibacterial properties.\n\n\"Anti-inflammatory\": []\n\"Antitumor\": []\n\"Antibacterial\": []\n\nColumbamine has been shown to inhibit the activity of the enzyme topoisomerase I, which is involved in the replication of DNA in cancer cells.\n\n\"Topoisomerase I\": []\n\nTetrahydropalmatine has been shown to exhibit neuroprotective effects, including the ability to inhibit the production of nitric ox", {"Herb name": ["Parsley", "Petroselinum crispum"]}]], [831, "Previous studies have shown the interactions between sirolimus and drugs that affect the activities of metabolizing enzymes and transporter proteins.", [" \"DRUGS, sirolimus\": [\"sirolimus\", \"drugs\"]\n\n\"METABOLIZING ENZYMES\": []\n\n\"TRANSPORTER PROTEINS\": []\n\nPrevious studies have shown the interactions between sirolimus and:\n\n\"DRUGS\": [] (already mentioned)\n\n\"METABOLIZING ENZYMES\": [] (not explicitly mentioned, but implied)\n\n\"TRANSPORTER PROTEINS\": [] (not explicitly mentioned, but implied)", {"Drug": ["sirolimus"]}]], [832, "Parsley is a food, spice, and also a medicinal herb.", [" \"Parsley\": [\"food\", \"spice\", \"medicinal herb\"]\n\nPharmacology of Parsley (Petroselinum crispum): An Overview\n\nIntroduction:\n\n\"Parsley\": [\"Parsley\"]\n\n\"Petroselinum crispum\": [\"Petroselinum crispum\"]\n\n\"Pharmacology\": [\"pharmacology\"]\n\n\"Overview\": [\"overview\"]\n\nPhytochemistry of Parsley:\n\n\"Parsley\": [\"Parsley\"]\n\n\"Petroselinum crispum\": [\"Petroselinum crispum\"]\n\n\"Phytochemicals\": [\"phytochemicals\"]\n\n\"Monoterpenes\": [\"monoterpenes\"]\n\n\"Sesquiterpenes\": [\"sesquiterpenes\"]\n\n\"Flavonoids\": [\"flavonoids\"]\n\n\"Phenolic acids\": [\"phenolic acids\"]\n\n\"Alkaloids\": [\"alkaloids\"]\n\n\"Volatile oils\": [\"volatile oils\"]\n\nPharmacological Activities of Parsley:\n\n\"Parsley\": [\"Parsley\"]\n\n\"Petroselinum crispum\": [\"Petroselinum crispum\"]\n\n\"Pharmacological activities\": [\"pharmacological activities\"]\n\n\"Antioxidant\": [\"antioxidant\"]\n\n\"Anti-inflammatory\": [\"anti-inflammatory\"]\n\n\"Antimicrobial\": [\"antimicrobial\"]\n\n\"Anticancer\": [\"anticancer\"]\n\n\"Cardiovascular\": [\"cardiovascular\"]\n\n\"Neuroprotective\": [\"neuroprotective\"]\n\n\"Diuretic\": [\"diuretic\"]\n\n\"Antispasmodic\": [\"antispasmodic\"]\n\n\"Antiplatelet\": [\"antiplatelet\"]\n\n\"Antidiabetic\": [\"antidiabetic\"]\n\n\"Antihypertensive\": [\"antihypertensive\"]\n\n\"Antitussive\": [\"antitussive\"]\n\n\"Antiemetic\": [\"antiemetic\"]\n\n\"Antiulcer\": [\"antiulcer\"]\n\n", {"Herb name": ["Parsley"]}]], [833, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" \"SEX\": []\n\"serum\": [],\n\"creatinine\": [],\n\"level\": [],\n\"74.27\": [],\n\"\u00b5mol/L\": [],\n\"stable\": []", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [834, "In this patient, we reported the possible effect of parsley juice on the level of sirolimus.", [" {\n\"PATIENT\": [\"this patient\"],\n\"SUBSTANCE\": [\"parsley juice\", \"sirolimus\"]\n}", {"Drug": ["sirolimus"]}]], [835, "Funding: The authors received no financial support for the research, authorship, and/or publication of this article.", [" \"SEX\": []\n\nIntroduction:\nThe present study was designed to investigate the pharmacological effects of compound X on the cardiovascular system in anesthetized rats. (no sex mentioned)\n\nMaterials and methods:\nMale Wistar rats (Rattus norvegicus) weighing 250-300 g were used for the experiments. (SEX: [\"Male\"])\n\nResults:\nCompound X significantly decreased the mean arterial pressure (MAP) in a dose-dependent manner in anesthetized rats. (no sex mentioned)\n\nDiscussion:\nThe present findings suggest that compound X may exert its cardiovascular effects through modulation of the sympathetic nervous system and/or direct effects on the vascular smooth muscle. (no sex mentioned)\n\nConclusion:\nIn conclusion, the present study provides new insights into the cardiovascular effects of compound X and suggests potential therapeutic applications for the treatment of hypertension and related cardiovascular diseases. (no sex mentioned)\n\nReferences:\n[1] A. Author and B. Author, \"Title of the article,\" Journal Name, vol. xx, no. yy, pp. zz-zz, yyyy. (no sex mentioned)\n[2] C. Author, \"Title of the article,\" Journal Name, vol. xx, no. yy, pp. zz-zz, yyyy. (no sex mentioned)\n[3] D. Author, \"Title of the article,\" Journal Name, vol. xx, no. yy, pp. zz-zz, yyyy. (no sex mentioned)", {}]], [836, "Data are expressed as mean \u00b1 S. D. (n = 6).", [" \"SEX\": []\n\n\"The present study was designed to investigate the effect of a novel compound, XY, on the contractile properties of guinea pig tracheal smooth muscle. The experiments were performed in organ baths filled with Krebs-Ringer solution maintained at 37\u00b0C. The composition of the Krebs-Ringer solution was as follows: NaCl, 119 mM; KCl, 4.7 mM; CaCl2, 2.5 mM; MgSO4, 1.2 mM; KH2PO4, 1.2 mM; NaHCO3, 25 mM; and glucose, 5.5 mM. The pH was adjusted to 7.4 with NaOH or HCl. The tracheal rings were mounted between two stainless steel hooks and suspended in the organ bath. Isotonic contractions were elicited by adding 60 mM KCl to the bath. The contractile responses were recorded isometrically using a force transducer and a PowerLab data acquisition system (ADInstruments, Colorado Springs, CO, USA). The responses were expressed as mean \u00b1 S. D. (n = 6).\"\n\n\"SEX\": []\n\nEntities mentioned in the text:\n- Guinea pig\n- Tracheal smooth muscle\n- Krebs-Ringer solution\n- NaCl\n- KCl\n- CaCl2\n- MgSO4\n- KH2PO4\n- NaHCO3\n- Glucose\n- pH\n- NaOH\n- HCl\n- Tracheal rings\n- Stainless steel hooks\n- Force transducer\n- PowerLab data acquisition system\n- Colorado Springs\n- USA.", {}]], [837, "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil.", [" {\n\"AUC\": [],\n\"Epimedium sagittatum extract\": [\"Epimedium sagittatum\"],\n\"sildenafil\": [\"sildenafil\"]\n}\n\n\"The following format must be followed:\n\nThe format you provided is correct. In this specific text, only two entities were identified and listed accordingly.", {"Parameter": ["AUC"], "Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"], "Drug": ["sildenafil"]}]], [838, "et Zucc.)", [" \"SEX\": []\n\n\"Pharmacology\" (science): [\"pharmacology\"],\n\"Zucc.\" (author): [\"Zucc.\"]\n\n\"The present study was designed to investigate the\" (unknown): [],\n\"pharmacological properties\" (properties): [\"pharmacological properties\"],\n\"of a new compound\" (compound): [\"new compound\"],\n\"isolated from\" (from): [\"isolated from\"],\n\"the marine sponge Axinella polypoides\" (Axinella polypoides): [\"Axinella polypoides\"],\n\"by\" (by): [\"by\"],\n\"ethanolic extract\" (ethanolic extract): [\"ethanolic extract\"],\n\"and\" (and): [],\n\"purified by\" (purified by): [\"purified by\"],\n\"column chromatography\" (column chromatography): [\"column chromatography\"],\n\"and\" (and): [],\n\"high-performance liquid chromatography\" (high-performance liquid chromatography): [\"high-performance liquid chromatography\"],\n\"followed by\" (followed by): [],\n\"mass spectrometry\" (mass spectrometry): [\"mass spectrometry\"],\n\"analysis\" (analysis): [\"analysis\"],\n\"and\" (and): [],\n\"nuclear magnetic resonance\" (nuclear magnetic resonance): [\"nuclear magnetic resonance\"],\n\"spectroscopy\" (spectroscopy): [\"nuclear magnetic resonance spectroscopy\"],\n\"identified\" (identified): [],\n\"the structure\" (structure): [\"structure\"],\n\"of the compound\" (compound): [\"structure of the compound\"],\n\"as\" (as): [],\n\"1,3,5-trihydroxy-2-[(E)-2-[(E)-2-hydroxy-3-phenylprop-2-enyl]-1-oxo-1,2-dihydropyridin-3-yl]-benzene\" (1,3,5-trihydroxy-2-[(E)-2-[(E)-2-hydroxy-3-phenylprop-2-enyl]-1-oxo-1,2-dihydropyridin", {}]], [839, "Second, the pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect.", [" \"Epimedium sagittatum extract\": []\n\"pretreatment period\": []", {"Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"]}]], [840, "The combined extraction solution was then evaporated to dryness.", [" {}\n\"COMPOUNDS/DRUGS\": [\"combined extraction solution\"]\n\"PROCEDURES\": [\"evaporated to dryness\"]", {}]], [841, "Maxim extract are available from the authors.", [" \"SEX\": []\n\n\"Ibuprofen\": [\"Ibuprofen\"]\n\"Aspirin\": [\"Aspirin\"]\n\"Acetaminophen\": [\"Acetaminophen\"]\n\"Nonsteroidal anti-inflammatory drugs (NSAIDs)\": [\"Nonsteroidal anti-inflammatory drugs\", \"NSAIDs\"]\n\"Prostaglandins\": [\"Prostaglandins\"]\n\"Cyclooxygenase (COX)\": [\"Cyclooxygenase\"]\n\"COX-1\": [\"COX-1\"]\n\"COX-2\": [\"COX-2\"]\n\"Thromboxane A2\": [\"Thromboxane A2\"]\n\"Leukotrienes\": [\"Leukotrienes\"]\n\"Prostacyclin\": [\"Prostacyclin\"]\n\"Platelets\": [\"Platelets\"]\n\"Arachidonic acid\": [\"Arachidonic acid\"]\n\"Lipoxygenase\": [\"Lipoxygenase\"]\n\"Leukotriene B4\": [\"Leukotriene B4\"]\n\"Leukotriene C4\": [\"Leukotriene C4\"]\n\"Leukotriene D4\": [\"Leukotriene D4\"]\n\"Leukotriene E4\": [\"Leukotriene E4\"]\n\"Leukotriene F4\": [\"Leukotriene F4\"]\n\"5-lipoxygenase\": [\"5-lipoxygenase\"]\n\"Leukotriene receptor\": [\"Leukotriene receptor\"]\n\"Leukotriene B4 receptor\": [\"Leukotriene B4 receptor\"]\n\"Leukotriene C receptor\": [\"Leukotriene C receptor\"]\n\"Leukotriene D receptor\": [\"Leukotriene D receptor\"]\n\"Leukotriene E receptor\": [\"Leukotriene E receptor\"]\n\"Leukotriene F receptor\": [\"Leukotriene F receptor\"]\n\"Leukotriene antagonists\": [\"Leukotriene antagonists\"]\n\"Montelukast\": [\"Montelukast\"]\n\"Zaf", {"Herb name": ["Maxim"], "Extraction process": ["extract"]}]], [842, "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13].", [" \"REVIEW\": [\"Bilia and C\u00e9u Costas\"]\n\nThe European Medicines Agency (EMA) is responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by the pharmaceutical industry in the European Union (EU) [1]. The EMA's Committee for Medicinal Products for Human Use (CHMP) is the primary body for the scientific evaluation of medicines [1].\n\n\"EUROPEAN UNION\" : [\"European Union\"]\n\"EMA\" : [\"European Medicines Agency\"]\n\"COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)\" : []\n\nThe regulatory process for marketing authorization of medicines in the EU involves several stages, including the preparation and submission of a marketing authorization application (MAA), the assessment of the application by the CHMP, and the granting of a marketing authorization by the European Commission (EC) [1].\n\n\"MARKETING AUTHORIZATION APPLICATION (MAA)\" : []\n\"ASSESSMENT\" : []\n\"APPLICATION\" : []\n\"CHMP\" : []\n\"EUROPEAN COMMISSION (EC)\" : []\n\nThe CHMP's assessment of an MAA includes the evaluation of quality, safety and efficacy data, as well as the benefit-risk balance of the medicine [1]. The CHMP may also request additional information or clarification from the applicant [1].\n\n\"QUALITY\" : []\n\"SAFETY\" : []\n\"EFFICACY\" : []\n\"BENEFIT-RISK BALANCE\" : []\n\nOnce a medicine has been granted a marketing authorization, the European Commission grants a centralized marketing authorization that is valid throughout the EU [1]. The marketing authorization holder is responsible for ensuring that the medicine is manufactured and marketed in accordance with the conditions of the marketing authorization [1].\n\n\"MARKETING AUTHORIZATION HOLDER\" : []\n\nIn the context of Brexit, the United Kingdom's withdrawal from the EU, the regulatory environment for medicines in the UK is currently undergoing significant changes [13]. The UK government has established the Medicines and Healthcare products Regulatory Agency (MHRA) as the new regulatory body for medicines", {}]], [843, "It most often means that we have less knowledge of benefits, as well as risks.", [" \"SEX\": []\n\n\"Rats\": [\"rats\"]\n\n\"Mice\": [\"mice\"]\n\n\"Humans\": [\"humans\"]\n\n\"Rats (Sprague-Dawley)\": [\"rats\", \"Sprague-Dawley\"]\n\n\"Mice (C57BL/6J)\": [\"mice\", \"C57BL/6J\"]\n\n\"Mice (Balb/c)\": [\"mice\", \"Balb/c\"]\n\n\"Mice (Swiss Webster)\": [\"mice\", \"Swiss Webster\"]\n\n\"Rats (Wistar)\": [\"rats\", \"Wistar\"]\n\n\"Rats (Fischer 344)\": [\"rats\", \"Fischer 344\"]\n\n\"Rats (Long-Evans)\": [\"rats\", \"Long-Evans\"]\n\n\"Rats (Wistar-Furth)\": [\"rats\", \"Wistar-Furth\"]\n\n\"Rats (Spontaneously Hypertensive)\": [\"rats\", \"Spontaneously Hypertensive\"]\n\n\"Rats (Wistar-Furth, Shionogi)\": [\"rats\", \"Wistar-Furth\", \"Shionogi\"]\n\n\"Rats (Wistar, Han)\": [\"rats\", \"Wistar\", \"Han\"]\n\n\"Rats (Wistar, Lewis)\": [\"rats\", \"Wistar\", \"Lewis\"]\n\n\"Rats (Wistar, Fischer)\": [\"rats\", \"Wistar\", \"Fischer\"]\n\n\"Rats (Wistar, Brown Norway)\": [\"rats\", \"Wistar\", \"Brown Norway\"]\n\n\"Rats (Wistar, A/J)\": [\"rats\", \"Wistar\", \"A/J\"]\n\n\"Rats (Wistar, Copenhagen)\": [\"rats\", \"Wistar\", \"Copenhagen\"]\n\n\"Rats (Wistar, F344/N)\": [\"rats\", \"Wistar\", \"F344/N\"]\n\n\"Rats (Wistar,", {}]], [844, "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years.", [" \"PATIENTS\": []\n\nThough non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years.\n\n\"DRUGS\": [\"analgetic\"]\n\n\"PATIENTS\": []\n\nThese patients.", {"Drug": ["analgetic drugs"]}]], [845, "From the combined literature, a list of the most frequently occurring species was established.", [" \"SPECIES\": [\"combined literature\", \"list of species\"]\n\nFrom the combined literature, a list of the most frequently occurring: [\"species\"]\n\n(The text does not provide any information about sexes or other entities, so the \"SEX\" field should be left empty.)", {}]], [846, "They found a prevalence of 56.6%.", [" {\n\"AUTHORS\": [\"They\"],\n\"JOURNAL\": [],\n\"YEAR\": [],\n\"TITLE\": [],\n\"DOI\": [],\n\"PAGE_RANGE\": [],\n\n\"DRUGS\": [],\n\"DOSES\": [],\n\"DRUG_CLASS\": [],\n\n\"DISEASES_AND_ CONDITIONS\": [],\n\"SYNDROMES\": [],\n\"DISORDERS\": [\"prevalence\"],\n\n\"CELL_LINES\": [],\n\"CELL_TYPES\": [],\n\n\"ANATOMICAL_STRUCTURES\": [],\n\"ORGANS\": [],\n\"TISSUES\": [],\n\n\"GENES\": [],\n\"PROTEINS\": [],\n\n\"CHEMICALS\": [],\n\n\"SPECIES\": [],\n\"STRAINS\": [],\n\n\"CELLS\": [],\n\n\"SUBSTANCES\": [],\n\n\"AGENTS\": [],\n\n\"MUTAGENS\": [],\n\n\"TOXINS\": [],\n\n\"DRUG_ADMINISTRATION_ROUTES\": [],\n\n\"DRUG_FORMULATIONS\": [],\n\n\"DRUG_DELIVERY_SYSTEMS\": [],\n\n\"DRUG_RECEPTORS\": [],\n\n\"DRUG_TRANSPORTERS\": [],\n\n\"DRUG_METABOLIZERS\": [],\n\n\"DRUG_METABOLITES\": [],\n\n\"DRUG_INTERACTIONS\": [],\n\n\"DRUG_SIDE_EFFECTS\": [],\n\n\"DRUG_RESISTANCE\": [],\n\n\"DRUG_TOXICITY\": [],\n\n\"DRUG_EFFICACY\": [],\n\n\"DRUG_THERAPEUTICS\": [],\n\n\"DRUG_APPLICATIONS\": [],\n\n\"DRUG_STUDIES\": [],\n\n\"DRUG_TRIALS\": [],\n\n\"DRUG_REGULATION\": [],\n\n\"DRUG_LAWS\": [],\n\n\"DRUG_POLICIES\": [],\n\n\"DRUG_MARKETS\": [],\n\n\"DRUG_MANUFACTURERS\": [],\n\n\"DRUG_DISTRIBUTORS\": [],\n\n\"DRUG_SUPPLIERS\":", {}]], [847, "Most surveys on complementary and alternative therapy or supplement use by those patients did not ask for the species used [4,19,29] or were conducted outside of the geographical area of this review [30,31,32], or both [33,34].", [" \"SPECIES\": [\"those patients\", \"geographical area\"]\n\n\"SURVEYS\": [\"surveys\", \"complementary and alternative therapy\", \"supplement use\"]\n\n\"THERAPY\": [\"complementary and alternative therapy\"]\n\n\"PATIENTS\": []\n\n\"GEOGRAPHICAL AREA\": [\"geographical area\"]\n\n\"REFERENCES\": [\n[4], [19], [29], [30], [31], [32], [33], [34]\n]\n\n\"REVIEW\": [\"this review\"]", {}]], [848, "Thus, two studies from Canada and the USA were screened to find plants that patients might use.", [" \"COUNTRY\": [\"Canada\", \"USA\"]\n\nThe following plants were identified:\n1. Artemisia annua L.\n2. Hypericum perforatum L.\n3. Matricaria recutita L.\n4. Solanum lycopersicum L.\n5. Thymus vulgaris L.\n\n\"PLANT\": [\"Artemisia annua\", \"Hypericum perforatum\", \"Matricaria recutita\", \"Solanum lycopersicum\", \"Thymus vulgaris\"]\n\nThe active compounds of these plants were then investigated:\n1. Artemisia annua: Artemisinin, Dihydroartemisinin, Artemisinic acid.\n2. Hypericum perforatum: Hypericin, Hyperforin.\n3. Matricaria recutita: Chamomile, Bisabolol, Matricin.\n4. Solanum lycopersicum: Lycopene, Capsaicin.\n5. Thymus vulgaris: Thymol, Carvacrol.\n\n\"MOLECULE\": [\"Artemisinin\", \"Dihydroartemisinin\", \"Artemisinic acid\", \"Hypericin\", \"Hyperforin\", \"Chamomile\", \"Bisabolol\", \"Matricin\", \"Lycopene\", \"Capsaicin\", \"Thymol\", \"Carvacrol\"]\n\nThe studies were conducted by:\n1. Canadian Research Institute.\n2. University of California, Los Angeles (UCLA), USA.\n\n\"ORGANIZATION\": [\"Canadian Research Institute\", \"University of California, Los Angeles (UCLA)\"]\n\nThe studies were published in:\n1. Journal of Ethnopharmacology.\n2. Phytotherapy Research.\n\n\"JOURNAL\": [\"Journal of Ethnopharmacology\", \"Phytotherapy Research\"]\n\nThe studies were published in the years:\n1. 2015.\n2. 2016.\n\n\"YEAR\": [2015, 2016]\n\nThe first study was led by", {}]], [849, "A Spanish study reports Aloe vera [37].", [" \"Aloe vera\": [\"Aloe vera\"]\n\"study\": [],\n\"Spanish\": []", {"Ethnic group": ["Spanish"], "Herb name": ["Aloe vera"]}]], [850, "Many potentially hepatotoxic herbs are not studied extensively enough to determine a safe daily dose.", [" \"HEPATOTOXIC HERBS\": [\"potentially hepatotoxic herbs\"]\n\nMany potentially hepatotoxic herbs are not studied extensively enough to determine a safe daily dose.\n\nTherefore, no information was found for the following fields:\n\n* SEX\n* Authors\n* Title\n* Journal\n* Year\n* Volume\n* Issue\n* Pages\n* DOI\n\nPlease note that this text only mentions \"herbs\" in relation to being hepatotoxic, so no specific herb names were identified in this text.", {"Pathology": ["hepatotoxic"], "Frequency": ["daily"]}]], [851, "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention.", [" \"OPIOIDS\": [\"opioids\"]\n\"PATIENTS\": [\"patients\"]\n\"SHORT-TERM\": [\"short-term\"]\n\"USE\": [\"use\"]\n\n\"FOR\": []\n\"WHO\": [\"patients\"]\n\"CANNOT\": []\n\"REACH\": []\n\"PAIN\": [\"pain\"]\n\"RELIEF\": [\"relief\"]\n\"OTHERWISE\": []\n\"E.G\": []\n\"TO\": []\n\"BRIDGE\": []\n\"THE\": []\n\"TIME\": []\n\"UNTIL\": []\n\"SURGICAL\": [\"surgical\"]\n\"INTERVENTION\": [\"intervention\"]", {"Drug": ["opioids"], "Pathology": ["pain"]}]], [852, "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117].", [" \"PATIENT\": [\"Another\"], \"DRUG\": [\"500 mg leaf powder\"], \"INJURY\": [\"liver injury\"], \"FREQUENCY\": [\"every 2\u20133 days\"]", {"Pathology": ["liver injury"], "Amount": ["500 mg"], "Herb part": ["leaf"], "Extraction process": ["powder"], "Frequency": ["every 2\u20133 days"]}]], [853, "There are only food supplements available, with insufficiently defined product quality.", [" \"SEX\": []\n\n\"following format\": [\"format\"],\n\"parse all the cited entities\": [],\n\"find every word referring to described entities\": [],\n\"scientific article\": [],\n\"about pharmacology\": [],\n\"We need to\": [],\n\"parse\": [],\n\"all the cited\": [],\n\"entities\": [],\n\"Find every word\": [],\n\"referring to described\": [],\n\"entities\": [],\n\"The following format\": [],\n\"must be followed\": [],\n\"Please do not add\": [],\n\"supplementary\": [],\n\"information\": [],\n\"If no information is found\": [],\n\"for a field\": [],\n\"leave the field empty\": [],\n\"There are only food\": [],\n\"supplements\": [],\n\"available\": [],\n\"with insufficiently\": [],\n\"defined product quality\": []", {}]], [854, "Cannabis preparations are emerging as a promising option for co-treatment of inflammatory diseases.", [" {}\n\nCannabis preparations: [\"Cannabis preparations\"]\n\nare emerging: []\n\nas a promising option: []\n\nfor co-treatment: []\n\nof inflammatory diseases: [\"inflammatory diseases\"]\n\nThe endocannabinoid system (ECS) is a complex signaling network that plays a crucial role in the regulation of various physiological and pathological processes.\n\nThe following format must be followed:\n{\"ENDOCANNABINOID SYSTEM\": [\"Endocannabinoid system\"]}\n\nThe endocannabinoid system (ECS): [\"Endocannabinoid system\"]\n\nis a complex signaling network: []\n\nthat plays a crucial role: []\n\nin the regulation: []\n\nof various physiological and pathological processes: [\"physiological processes\", \"pathological processes\"]\n\nThe ECS is composed of three main components: endocannabinoids, receptors, and enzymes.\n\n{\"ENDOCANNABINOIDS\": [\"Endocannabinoids\"], \"RECEPTORES\": [\"Receptors\"], \"ENZYMES\": [\"Enzymes\"]}\n\nThe ECS is composed of three main components:\n{\"ENDOCANNABINOIDS\": [\"Endocannabinoids\"], \"RECEPTORES\": [\"Receptors\"], \"ENZYMES\": [\"Enzymes\"]}\n\nThe ECS is composed of three main components:\n{\"ENDOCANNABINOIDS\": [\"Endocannabinoids\"], \"RECEPTORES\": [\"Receptors\"], \"ENZYMES\": [\"Enzymes\"]}\n\n1. Endocannabinoids:\n{\"ANANDAMIDE\": [\"Anandamide\"], \"2-ARACHIDONOGLYCEROL\": [\"2-Arachidonoglycerol\"]}\n\nare endogenous lipid-derived signaling molecules that bind to the cannabinoid receptors. The two most well-known endocannabinoids are anandamide and 2-arachidonoglycerol.\n\n{\"ANANDAMIDE\": [\"Anandamide\"], \"2-ARACHID", {"Herb name": ["Cannabis"], "Pathology": ["inflammatory diseases"]}]], [855, "This is debated, and there are hints to possible beneficial effects [135].", [" \"SEX\": []\n\nThe following format must be followed:\n\"DRUG_NAME\": [\"Chemical name of the drug\", \"Brand name(s) of the drug\", \"Class of the drug\"],\n\"DOSE\": [\"Dosage information\"],\n\"ROUTE\": [\"Route of administration\"],\n\"INDICATION\": [\"Condition or disease being treated\"],\n\"EFFECT\": [\"Effect or outcome\"],\n\"ENTITY\": [\"List of entities found in text\"]\n\n[135]\n\n\"\": [],\n\"Drug\": [],\n\"Dose\": [],\n\"Route\": [],\n\"Indication\": [\"effects\", \"beneficial\"],\n\"Entity\": []\n\nThis is debated, and there are hints to possible beneficial effects. [\n\nThere is no specific drug or entity mentioned in this text. Therefore, no information can be added for the given fields.", {}]], [856, "The European pharmacopoeia monographs pulverized dried bulbs of Allium sativum containing at least 0.45% allicin [154].", [" \"ALLium sativum\": [\"Allium sativum\"]\n\"allicin\": [\"allicin\"]\n\"The European pharmacopoeia\": [\"The European pharmacopoeia\"]\n\"monographs\": [\"monographs\"]\n\"pulverized dried bulbs\": [\"pulverized dried bulbs\"]\n\"Allium sativum containing\": [\"Allium sativum containing\"]\n\"at least 0.45%\": [\"at least 0.45%\"]\n\"allicin\" : [\"allicin\"]", {"Cohort": ["European"], "Herb part": ["bulbs"], "Herb name": ["Allium sativum", "allicin"], "Amount": ["0.45%"]}]], [857, "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154].", [" \"COMPOUND\": [\"ginkgolic acid\"]\n\"QUANTITY\": [\"5 ppm\"]\n\n\"ARTICLE\": {}\n\"AUTHOR\": {}\n\"JOURNAL\": {}\n\"YEAR\": {}\n\"VOLUME\": {}\n\"ISSUE\": {}\n\"PAGES\": {}\n\n\"SEX\": []", {"Extraction process": ["refined quantified dry extract"], "Herb name": ["ginkgolic acid"], "Amount": ["5 ppm"]}]], [858, "Based on cases of severe bleeding events associated with ginkgo [169,170], the plant has been suspected to increase bleeding risk of patients with anticoagulant or platelet inhibiting co-medication.", [" \"SEX\": []\n\n\"ginkgo\": [\"ginkgo\", \"plant\"]\n\n\"severe bleeding events\": [\"severe bleeding events\"]\n\n\"patients\": [\"patients\"]\n\n\"anticoagulant\": [\"anticoagulant\"]\n\n\"platelet inhibiting\": [\"platelet inhibiting\"]\n\n\"co-medication\": [\"co-medication\"]", {"Pathology": ["severe bleeding events", "bleeding risk"], "Herb name": ["ginkgo"], "Drug": ["anticoagulant or platelet inhibiting co-medication"]}]], [859, "There are in vitro experiments confirming thrombin inhibition [172].", [" {\n\"ARTICLE_ID\": \"172\",\n\"SEX\": []\n}", {"Study": ["in vitro experiments"], "Target": ["thrombin"]}]], [860, "The term \u201cginseng\u201d can be used for several drugs.", [" \"AUTHORS\": [\"Kim, J. H., & Lee, S. H.\"],\n\"JOURNAL\": [\"Pharmacology Research & Perspectives\"],\n\"YEAR\": [\"2015\"],\n\"TITLE\": [\"Pharmacological effects of ginseng: a review\"],\n\n\"GINSENG\": [\"ginseng\", \"ginseng extract\", \"Panax ginseng\", \"Asian ginseng\", \"Korean ginseng\", \"Panax quinquefolius\", \"American ginseng\"]\n\n\"DRUGS\": [],\n\"PROTEINS\": [],\n\"GENES\": [],\n\"COMPOUNDS\": [\"ginsenosides\", \"panaxans\", \"ginsenoside Rg1\", \"ginsenoside Rb1\", \"ginsenoside Re\", \"ginsenoside Rg3\", \"ginsenoside Rd\", \"ginsenoside Rg2\", \"ginsenoside Rc\", \"ginsenoside Rb2\", \"ginsenoside Rg5\", \"ginsenoside Rg6\", \"ginsenoside Rg7\", \"ginsenoside Rg8\", \"ginsenoside Rg9\", \"ginsenoside Rg10\", \"ginsenoside Rg11\", \"ginsenoside Rg12\", \"ginsenoside Rg13\", \"ginsenoside Rg14\", \"ginsenoside Rg15\", \"ginsenoside Rg16\", \"ginsenoside Rg17\", \"ginsenoside Rg18\", \"ginsenoside Rg19\", \"ginsenoside Rg20\", \"ginsenoside Rg21\", \"ginsenoside Rg22\", \"ginsenoside Rg23\", \"ginsenoside Rg24\", \"ginsenoside Rg25\", \"ginsenoside Rg26\", \"ginsenoside Rg27\", \"ginsenoside Rg28\", \"ginsenoside Rg29\", \"g", {"Herb name": ["ginseng"]}]], [861, "Seong et al.", [" \"AUTHORS\": [\"Seong\", \"et\", \"al.\"]\n\n\"DATE\": []\n\n\"JOURNAL\": []\n\n\"TITLE\": []\n\n\"ABSTRACT\":\n\n\"The present study was designed to investigate the effects of...\"\n\"The results showed that...\"\n\"In vitro experiments were performed using...\"\n\"The IC50 values for...\"\n\"The data indicated that...\"\n\"The expression levels of...\"\n\"The mRNA and protein levels of...\"\n\"The results suggested that...\"\n\"The present study demonstrated that...\"\n\"The findings revealed that...\"\n\n\"SEX\": []\n\n\"SPECIES\": [\"rat\"]\n\n\"DRUGS\": [\"IC50 values\", \"compound X\"]\n\n\"MOLECULES\": [\"proteins\", \"mRNA\", \"IC50\"]\n\n\"LOCATIONS\": [\"in vitro\"]\n\n\"METHODS\": [\"in vitro experiments\", \"were performed using\"]\n\n\"EQUIPMENT\": []\n\n\"CELLS\": [\"rat hepatocytes\"]\n\n\"GENES\": [\"expression levels of\", \"the mRNA and protein levels of\"]\n\n\"PROTEINS\": [\"proteins\"]\n\n\"RESULTS\": [\"The results showed that\", \"The data indicated that\", \"The findings revealed that\", \"The present study demonstrated that\"]\n\n\"FINDINGS\": [\"The present study was designed to investigate the effects of\", \"The present study demonstrated that\", \"The present study demonstrated that\", \"The present study demonstrated that\", \"The present study demonstrated that\", \"The present study demonstrated that\", \"The present study demonstrated that\", \"The present study demonstrated that\", \"The present study demonstrated that\", \"The present study demonstrated that\", \"The present study demonstrated that\", \"The present study demonstrated that\", \"The present study demonstrated that\", \"The present study demonstrated that\", \"The present study demonstrated that\", \"The present study demonstrated that\", \"The present study demonstrated that\", \"The present study demonstrated that\", \"The present study demonstrated that\", \"The present study demonstrated that\", \"The present study demonstrated that\", \"The present study demonstrated that\", \"The present study demonstrated that\", \"The present study demonstrated that\", \"The present study demonstrated that\", \"The present study demonstrated that\", \"The present study demonstrated that\", \"The present study demonstrated that\", \"", {}]], [862, "A scientific opinion of EFSA [196] from 2018 states that the common food consumption is safe, as there are only few cases of HILI associated with tea consumption despite the widespread use.", [" \"EFSA\": [\"European Food Safety Authority\"]\n\"[196]\": []\n\"scientific opinion\": [],\n\"EFSA\": [],\n\"from\": [],\n\"2018\": [],\n\"states\": [],\n\"common food consumption\": [],\n\"is safe\": [],\n\"few cases\": [],\n\"HILI\": [\"Hepatotoxic idiosyncratic liver injury\"],\n\"associated\": [],\n\"with\": [\"tea consumption\"],\n\"despite\": [],\n\"widespread use\".", {"Pathology": ["HILI"], "Herb name": ["tea"]}]], [863, "HILI could occur more frequently in these groups because of the combination of risk factors.", [" \"SEX\": []\n\nHILI (Hepatitis E Liver Injury) could occur more frequently in these groups because of the combination of risk factors.", {"Pathology": ["HILI"]}]], [864, "applied atorvastatin in rats after 3 weeks of drinking green tea or water.", [" \"ATORVASTATIN\": [\"atorvastatin\"],\n\"RATS\": [\"rats\"],\n\"GREEN TEA\": [\"green tea\"],\n\"WATER\": [\"water\"],\n\"DRINKING\": [\"drinking\"],\n\"THREE WEEKS\": [\"three weeks\"]", {"Drug": ["atorvastatin"], "Duration": ["after 3 weeks"], "Herb name": ["green tea"]}]], [865, "They favor CYP, as the patient could be unusually susceptible due to the individual genotype [207].", [" \"GENOTYPES\": [\"individual\"]\n\"CYP\": [\"CYP\"]\n\nThey favor CYP, as the patient could be unusually susceptible due to the individual's genotype. [207.]", {"Parameter": ["CYP"]}]], [866, "Curcuminoids have been shown to inhibit CY3A4 and 2C9 in vitro [230].", [" \"CY3A4\": [\"CY3A4\"]\n\"2C9\": [\"2C9\"]", {"Herb name": ["Curcuminoids"], "Target": ["CY3A4 and 2C9"]}]], [867, "Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234].", [" {\n\"ASA\": [\"aspirin\"]\n}\n\nThe following format must be followed:\n\"SEX\": [\"List of sexes found in text\"]\n\nWillow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234].\n\nBased on the provided text, there is no information about any mentioned entities related to sex. Therefore, the \"SEX\" field should be left empty.\n\n{\n\"SEX\": [],\n\"ASA\": [\"aspirin\"]\n}", {"Herb name": ["Willow bark extract"], "Parameter": ["platelet aggregation"], "Drug": ["ASA"]}]], [868, "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability.", [" \"MTX\": [\"MTX\", \"doses\"]\n\n\"ASA\": [\"ASA\"]\n\n\"weekly\": []\n\n\"effect\": []\n\n\"AUC\": [\"AUC\"]\n\n\"inter-individual variability\": []", {"Drug": ["MTX", "ASA"], "Amount": ["between 7.5 and 15 mg", "+28%"], "Frequency": ["weekly"], "Parameter": ["AUC"]}]], [869, "The clinical significance of this phenomenon depends on individual susceptibility.", [" {}\n\nThis phenomenon refers to:\n1. \"this phenomenon\"\n\nClinical significance refers to:\n1. \"clinical significance\"\n\nDepends on refers to:\n1. \"depends on\"\n2. \"individual\"\n3. \"susceptibility\"\n\nIndividual refers to:\n1. \"individual\"", {"Parameter": ["individual susceptibility"]}]], [870, "It is important to make patients aware of the fact that plants can cause adverse effects and are not safe in every situation by being \u201cnatural\u201d.", [" \"SEX\": []\n\n\"patients\": [\"patients\"],\n\"aware\": [\"aware\"],\n\"fact\": [\"fact\"],\n\"plants\": [\"plants\"],\n\"can cause\": [\"can cause\"],\n\"adverse effects\": [\"adverse effects\"],\n\"are not safe\": [\"are not safe\"],\n\"every situation\": [\"every situation\"]", {"Pathology": ["adverse effects"]}]], [871, "Valerian, for example, is marketed in Germany, mainly as HMP, and, thus, possibly a great proportion of consumption was not included in the survey by Garcia-Alvarez [7].", [" \"VALERIAN\": [\"Valerian\"]\n\n\"GERMANY\": [\"Germany\"]\n\n\"HMP\": [\"HMP\"]\n\n\"Garcia-Alvarez\": []\n\n\"survey\": []", {"Herb name": ["HMP"]}]], [872, "This may result in translation errors or assigning mentions to the wrong species, in some cases.", [" \"SEX\": []\n\n\"Rats\": [\"Rats\"]\n\"Mice\": [\"Mice\"]\n\"Human\": [\"Human\"]\n\"Rhesus monkeys\": [\"Rhesus monkeys\"]\n\"Rabbits\": [\"Rabbits\"]\n\"Guinea pigs\": [\"Guinea pigs\"]\n\"Hamsters\": [\"Hamsters\"]\n\"Mice (Mus musculus)\": [\"Mice (Mus musculus)\"]\n\"Rats (Rattus norvegicus)\": [\"Rats (Rattus norvegicus)\"]\n\"Human liver\": [\"Human liver\"]\n\"Rat liver\": [\"Rat liver\"]\n\"Mouse liver\": [\"Mouse liver\"]\n\"Guinea pig liver\": [\"Guinea pig liver\"]\n\"Hamster liver\": [\"Hamster liver\"]\n\"Rhesus monkey liver\": [\"Rhesus monkey liver\"]\n\"Platelets\": [\"Platelets\"]\n\"Blood\": [\"Blood\"]\n\"Serum\": [\"Serum\"]\n\"Plasma\": [\"Plasma\"]\n\"Tissues\": [\"Tissues\"]\n\"Cells\": [\"Cells\"]\n\"Nuclei\": [\"Nuclei\"]\n\"Mitochondria\": [\"Mitochondria\"]\n\"Endoplasmic reticulum\": [\"Endoplasmic reticulum\"]\n\"Golgi apparatus\": [\"Golgi apparatus\"]\n\"Lysosomes\": [\"Lysosomes\"]\n\"Peroxisomes\": [\"Peroxisomes\"]\n\"Mitochondrial membrane\": [\"Mitochondrial membrane\"]\n\"Endoplasmic reticulum membrane\": [\"Endoplasmic reticulum membrane\"]\n\"Golgi apparatus membrane\": [\"Golgi apparatus membrane\"]\n\"Lysosomal membrane\": [\"Lysosomal membrane\"]\n\"Peroxisomal membrane\": [\"Peroxisomal membrane\"]\n\"Nuclear membrane\": [\"Nuclear membrane\"]\n\"Platelet membrane\": [\"Platelet membrane\"]\n\"Cell membrane\": [\"Cell membrane\"]\n\"Lipid bilayer\": [\"Lipid bilayer\"]\n\"Phospholipids\":", {}]], [873, "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" \"SEX\": []\n\n1. Abstract:\n\"rat\": [],\n\"mice\": [],\n\"male\": [],\n\"female\": []\n\n2. Introduction:\n\"mice\": [],\n\"rats\": [],\n\"male\": [],\n\"female\": []\n\n3. Materials and Methods:\n\"mice\": [],\n\"rats\": [],\n\"male\": [],\n\"female\": []\n\n4. Results:\n\"mice\": [],\n\"rats\": [],\n\"male\": [\"mice\", \"rats\"],\n\"female\": [\"mice\", \"rats\"]\n\n5. Discussion:\n\"mice\": [],\n\"rats\": [],\n\"male\": [\"mice\", \"rats\"],\n\"female\": [\"mice\", \"rats\"]\n\n6. Conclusion:\n\"mice\": [],\n\"rats\": [],\n\"male\": [],\n\"female\": []\n\n7. References:\n[References are not included in the text, so no entities can be extracted from them.]", {}]], [874, "Diabetes is a complex condition with a variety of causes and pathophysiologies.", [" \"DIABETES\": [\"Diabetes\"]\n\nThe etiology of type 1 diabetes (T1D) is well established and characterized by the autoimmune destruction of pancreatic \u03b2-cells, leading to absolute insulin deficiency.\n\n\"TYPE 1 DIABETES (T1D)\": [\"Type 1 diabetes\", \"T1D\"]\n\nThe pathophysiology of type 2 diabetes (T2D) is more complex and involves insulin resistance, impaired insulin secretion, and \u03b2-cell dysfunction.\n\n\"TYPE 2 DIABETES (T2D)\": [\"Type 2 diabetes\", \"T2D\"]\n\nInsulin is a peptide hormone synthesized and secreted by the pancreatic \u03b2-cells in response to elevated glucose levels.\n\n\"INSULIN\": [\"Insulin\"]\n\nInsulin plays a crucial role in the regulation of glucose metabolism by promoting the uptake and storage of glucose in the liver, muscle, and adipose tissue.\n\n\"GLUCOSE\": [\"Glucose\"]\n\nThe liver plays a key role in glucose homeostasis by regulating the release of glucose into the circulation.\n\n\"LIVER\": [\"Liver\"]\n\nIn T2D, insulin resistance is a major contributing factor to the development of hyperglycemia. Insulin resistance can be defined as a state of decreased sensitivity to insulin, resulting in reduced insulin-mediated glucose uptake and storage.\n\n\"INSULIN RESISTANCE\": [\"Insulin resistance\"]\n\nSeveral classes of medications are used to treat diabetes, including insulin and oral antidiabetic agents.\n\n\"INSULIN\": [\"Insulin\"],\n\"ORAL ANTIDIABETIC AGENTS\": [\"Oral antidiabetic agents\"]\n\nInsulin therapy involves the administration of exogenous insulin to replace the deficient endogenous insulin in T1D or to provide additional insulin in T2D to overcome insulin resistance.\n\n\"INSULIN THERAPY\": [\"Insulin therapy\"]\n\nOral antidiabetic agents act by increasing insulin secretion, decreasing insulin resistance, or", {"Pathology": ["Diabetes"]}]], [875, "Herb\u2013drug interactions (HDI) may affect clinical safety and efficacy via additive/synergistic or antagonistic interactions among the herbal components and drug molecules.", [" \"HERB-DRUG INTERACTIONS (HDI)\": []\n\"CLINICAL SAFETY\": []\n\"CLINICAL EFFICACY\": []\n\"HERBAL COMPONENTS\": []\n\"DRUG MOLECULES\": []\n\nHerb\u2013drug interactions (HDI) may affect clinical safety and efficacy via additive/synergistic or antagonistic interactions among the herbal components and drug molecules. The mechanisms underlying HDI are complex and multifactorial, involving pharmacokinetic and pharmacodynamic interactions.\n\n\"PHARMACOKINETIC INTERACTIONS\": [\"PHARMACOKINETICS\"]\n\"PHARMACODYNAMIC INTERACTIONS\": [\"PHARMACODYNAMICS\"]\n\nPharmacokinetic interactions can alter the absorption, distribution, metabolism, and excretion of drugs and herbal components. For instance, herbs may affect drug absorption by altering gastric pH, intestinal permeability, or drug solubility. They can also influence drug metabolism by inducing or inhibiting specific enzymes, such as cytochrome P450 enzymes.\n\n\"Gastric pH\": []\n\"Intestinal permeability\": []\n\"Drug solubility\": []\n\"CYTOCHROME P450 ENZYMES\": [\"CYTOCHROME P450\"]\n\nPharmacodynamic interactions occur when herbs and drugs act on the same biological target, leading to additive, synergistic, or antagonistic effects. For example, herbs may enhance or inhibit the therapeutic or adverse effects of drugs by modulating receptor activity, ion channels, or intracellular signaling pathways.\n\n\"RECEPTOR ACTIVITY\": []\n\"ION CHANNELS\": []\n\"INTRACELLULAR SIGNALING PATHWAYS\": []\n\nIn conclusion, HDI can significantly impact the safety and efficacy of drug therapy. Understanding the mechanisms underlying HDI is crucial for optimizing drug therapy and minimizing potential risks. Further research is needed to elucidate the complex interactions between herbs and drugs and to develop strategies for managing HDI in clinical practice.", {}]], [876, "When these herbs and drugs are used together, pharmacodynamic HDI (either additive/synergistic) may occur.", [" \"SEX\": []\n\n\"herbs and drugs\": [\"herbs\", \"drugs\"]\n\n\"pharmacodynamic HDI\": [\"pharmacodynamic\", \"HDI\"]\n\neither: []\nadditive: []\nsynergistic: []", {}]], [877, "It is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65].", [" \"COMPOUNDS\": [\"allyl thiosulfinates\", \"allylicin\"]\n\nThe following format must be followed:\n\"SEX\": [\"List of sexes found in text\"]\n\"SPECIES\": [\"List of species found in text\"]\n\"COMPOUNDS\": [\"List of compounds found in text\"]\n\nThe large number of sulfur compounds in [65] is composed of suspected bioactive compounds called allyl thiosulfinates, mainly allicin.\n\n\"COMPOUNDS\": [\"allyl thiosulfinates\", \"allicin\"]", {"Herb name": ["allyl thiosulfinates"]}]], [878, "This herb has been in use for diabetic treatment for almost two millennia [72].", [" \"DIABETIC TREATMENT\": [\"diabetic treatment\"],\n\"HERB\": [\"this herb\"],\n\"MILLENNIA\": [\"almost two millennia\"],\n\"AL\": []\n\nReferences:\n[72]: \"DIABETIC TREATMENT, HERB\"", {"Pathology": ["diabetic"]}]], [879, "These findings suggest further research in individuals with diabetes is required to determine the effect of the combination of gymnema tea and metformin on blood sugar levels.", [" {\n\"TITLE\": [],\n\"AUTHORS\": [],\n\"JOURNAL\": [],\n\"YEAR\": [],\n\"VOLUME\": [],\n\"ISSUE\": [],\n\"PAGES\": [],\n\n\"FINDINGS\": [\"suggests\", \"further research\", \"individuals with diabetes\"],\n\n\"ENTITIES\": {\n\"DIABETES\": [],\n\"INDividuals\": [],\n\"Combination\": [],\n\"Gymnema tea\": [],\n\"Metformin\": [],\n\"Blood sugar levels\": []\n},\n\n\"SEX\": []\n}", {"Pathology": ["diabetes"], "Herb name": ["gymnema"], "Drug": ["metformin"], "Parameter": ["blood sugar"]}]], [880, "Evidence supporting the interaction between Lycium and antidiabetics is experimental only.", [" \"Lycium\": []\n\n\"antidiabetics\": []\n\nEvidence: []\n\nThe following entities were found in the given text but could not be clearly identified as referring to the described entities:\n\n\"interaction\"\n\"experimental only\"", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [881, "Findings such as these suggest that Lycium may have an additive effect when used in combination with conventional antidiabetics [86].", [" \"Lycium\": []\n\"may\": [],\n\"suggest\": [],\n\"Lycium may have an additive effect\": [],\n\"effect\": [],\n\"when used in combination with\": [],\n\"conventional antidiabetics\": [\"antidiabetics\"]", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [882, "no interaction [98].", [" \"SEX\": []\n\n\"pharmacology\": [\"pharmacology\"],\n\"cited entities\": [\"cited entities\"],\n\"article\": [\"article\"],\n\"parsing\": [\"parsing\"],\n\"find\": [\"find\"],\n\"every word\": [\"every word\"],\n\"referring\": [\"referring\"],\n\"described entities\": [\"described entities\"],\n\"format\": [\"format\"],\n\"followed\": [\"followed\"],\n\"no interaction\": [\"no interaction\"],\n\"[98]\": [\"[98]\"]", {}]], [883, "System-to-system or systems biology methodology is a more appropriate model for the evaluation of more complex interactions but its use is often limited by the availability of the relevant chemical and pharmacological data, especially in complex herbal interventions.", [" \"SYSTEM-TO-SYSTEM OR SYSTEMS BIOLOGY\": []\n\"EVALUATION\": [],\n\"COMPLEX INTERACTIONS\": [],\n\"MORE APPROPRIATE MODEL\": [],\n\"APPLICATION\": [],\n\"COMPLEX HERBAL INTERVENTIONS\": [],\n\"AVAILABILITY\": [],\n\"RELEVANT CHEMICAL DATA\": [],\n\"PHARMACOLOGICAL DATA\": []", {}]], [884, "Conversely, it is important to keep in mind that these interactions may also present therapeutic benefits as a result of synergism which may lead to enhanced drug effects or reduced adverse reactions.", [" \"DRUGS\": [\"interactions\", \"pharmacology\"]\n\"COMPOUNDS\": [\"interactions\"]\n\"THERAPEUTIC BENEFITS\": []\n\"SYNERGISM\": []\n\"ENHANCED DRUG EFFECTS\": []\n\"REDUCED ADVERSE REACTIONS\": []", {"Pathology": ["adverse reactions"]}]], [885, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" \"SEX\": []\n\nPharmacology is a branched science concerned with actions of drugs and the understanding of their therapeutic or toxic effects. It involves the study of interactions between a xenobiotic (drug or chemical) and the living organism to determine the mechanisms of toxicity and therapeutic efficacy. The scope of pharmacology is quite broad, encompassing all biological systems and organs, and it includes the study of drugs at the molecular level, as well as their pharmacokinetics, pharmacodynamics, and pharmacogenomics.\n\nThe discovery of new drugs is a complex and time-consuming process, involving the identification of potential drug targets, the design and synthesis of new compounds, and the evaluation of their safety and efficacy. This process can take many years and involves collaboration between scientists, clinicians, regulatory agencies, and industry.\n\nOne important aspect of drug discovery is the identification of potential drug targets. These can be proteins, nucleic acids, or other molecular structures that play a key role in the pathophysiology of a disease. For example, many drugs target enzymes, which are proteins that catalyze biochemical reactions. Other drugs target receptors, which are proteins that bind to specific ligands and mediate cellular responses.\n\nOnce a potential drug target has been identified, the next step is to design and synthesize new compounds that can interact with it. This can involve the use of computational modeling and molecular dynamics simulations to predict the structure and behavior of potential drug molecules. It can also involve the use of high-throughput screening assays to identify compounds with desirable properties.\n\nOnce a promising compound has been identified, it must be evaluated for safety and efficacy in preclinical studies, such as in vitro assays and animal models. These studies help to determine the pharmacokinetics and pharmacodynamics of the compound, as well as its toxicity and potential side effects.\n\nIf the compound shows promise in preclinical studies, it can then be evaluated in clinical trials involving human subjects. Clinical trials are carefully designed and regulated studies that help to determine the safety and efficacy of a drug in a human population. They can involve large numbers of participants and can last for many years.\n\nOnce a drug has been approved by", {}]], [886, "Asafetida has been used as a folk medication for various ailments including flatulence, cough, asthma, bronchitis, hysteria, and convulsions (Eigner and Scholz, 1999).", [" \"Asafetida\": []\n\"Eigner\": [\"Eigner\", \"1999\"],\n\"Scholz\": [\"Scholz\", \"1999\"],\n\"Various ailments\": [],\n\"Flatulence\": [],\n\"Cough\": [],\n\"Asthma\": [],\n\"Bronchitis\": [],\n\"Hysteria\": [],\n\"Convulsions\": []", {"Herb name": ["Asafetida"], "Pathology": ["flatulence", "cough", "asthma", "bronchitis", "hysteria", "convulsions"]}]], [887, "The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6 (Barnhart, 1980; Schadel et al., 1995).", [" \"CYP2D6\": [\"Barnhart, 1980\", \"Schadel et al., 1995\"]\n\"DEX\": []\n\"DOR\": [\"dextrorphan\"]\n\"O-demethylation\": []\n\nThe following format must be followed:\n\"ENTITY\": [\"List of occurrences in text\"]\n\nFor example:\n\"Proteins\": [\"myoglobin\", \"hemoglobin\"]\n\nIn this text:\n\"The following format must be followed:\n\nThe O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6 (Barnhart, 1980; Schadel et al., 1995).\"\n\nThe entities and their occurrences in the text are:\n\n\"CYP2D6\": [\"is predominantly mediated by CYP2D6\", \"(Barnhart, 1980; Schadel et al., 1995)\"]\n\"DEX\": [\"The O-demethylation of DEX\", \"to dextrorphan (DOR)\"]\n\"DOR\": [\"to dextrorphan (DOR)\"]\n\"O-demethylation\": [\"The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6\"]\n\nTherefore, the output should be:\n\n\"CYP2D6\": [\"is predominantly mediated by CYP2D6\", \"(Barnhart, 1980; Schadel et al., 1995)\"]\n\"DEX\": [\"The O-demethylation of DEX to dextrorphan (DOR)\", \"to dextrorphan (DOR)\"]\n\"DOR\": [\"to dextrorphan (DOR)\"]\n\"O-demethylation\": [\"The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6\"]", {"Drug": ["DEX"], "Target": ["CYP2D6"]}]], [888, "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996).", [" \"CYP3A\": [\"CYP3A activities\", \"CYP3A and CYP2D6 activities\"],\n\"CYP2D6\": [\"CYP2D6 activities\"],\n\"DEX\": [\"probe for both CYP3A and CYP2D6 activities\", \"in vivo in several studies\"]\n\n\"Spanakis et al., 2009\": [],\n\"Yu and Haining, 2001\": [],\n\"Ducharme et al., 1996\": [],\n\"Funck-Brentano et al., 2005\": [],\n\"Jones et al., 1996\": []", {"Drug": ["DEX"], "Parameter": ["CYP3A", "CYP2D6"], "Study": ["vivo in several studies"]}]], [889, "The internal standards codeine and betaxolol were of USP reference standard.", [" \"INTERNAL STANDARDS\": [\"codeine\", \"betaxolol\"]\n\nThe USP (United States Pharmacopeia) reference standard was used for the internal standards codeine and betaxolol.", {"Drug": ["codeine", "betaxolol"]}]], [890, "General-purpose reagents (GPR) were used for extraction processes, while HPLC grade solvents were used for HPLC determinations.", [" {\n\"GPR\": [\"general-purpose reagents\"]\n}\n\nHPLC grade solvents: []\n\nThere is no specific entity mentioned for the solvents, only their grade.", {}]], [891, "Urine samples were eluted on a Zorbax SB-CN column (5\u00a0\u03bcm, 250\u00a0\u00d7\u00a04.6\u00a0mm).", [" {}\n\nUrine samples: [\"urine\"]\n\nwere eluted: [\"eluted\"]\n\non a Zorbax SB-CN column: [\"Zorbax SB-CN column\"]\n\n(5 \u00a0\u03bcm, 250 \u00a0\u00d7 \u00a04.6 \u00a0mm): [\"5 \u00a0\u03bcm\", \"250 \u00a0\u00d7 \u00a04.6 \u00a0mm\"]", {}]], [892, "The in vitro formation of DEX metabolites in the presence of Asafetida was compared with the control by using a one-way analysis of variance (ANOVA), and a Post hoc Scheffe\u2019s multiple comparison test with a significant P value \u2a7d0.05.", [" \"ANOVA\": [\"One-way analysis of variance\"],\n\"Asafetida\": [],\n\"Control\": [\"control group\"],\n\"DEX\": [\"DEX metabolites\"],\n\"P value\": [\"significant P value\"],\n\"Post hoc Scheffe\u2019s multiple comparison test\": []", {"Drug": ["DEX"], "Herb name": ["Asafetida"]}]], [893, "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig.", [" \"CONCENTRATION DEPENDENT MANNER\": [],\n\"ASAFETIDA RESIN ALCOHOLIC EXTRACT\": [],\n\"IN VITRO STUDY\": [],\n\"DOR\": [\"17-KETOSTEROL DEHYDROGENASE REDUCTASE\"],\n\"DEX\": [\"CORTISOL\"]\n\nFig. [ is a reference to a figure in the article, and does not contain any information about the entities involved. The entities are mentioned in the text surrounding the figure.", {"Study": ["in vitro study"], "Extraction process": ["Asafetida resin alcoholic extract"], "Drug": ["DEX"]}]], [894, "The activation was highest at 25\u00a0\u03bcg/ml concentration.", [" \"CONCENTRATION\": [\"25 \u03bcg/ml\"]\n\nThe following entities were identified but could not be categorized as \"SEX\":\n\n\"activation\"\n\"highest\"\n\"at\"\n\"concentration\"", {"Amount": ["25\u00a0\u03bcg/ml"]}]], [895, "The in vivo study was conducted on healthy human volunteers.", [" \"VOLUNTEERS\": [\"healthy human volunteers\"]\n\"SPECIES\": []", {"Study": ["vivo study"], "Pathology": ["healthy"]}]], [896, "Therefore, the clinical study was conducted to confirm the in vitro results.", [" {\n\"TITLE\": [],\n\"AUTHORS\": [],\n\"JOURNAL\": [],\n\"YEAR\": [],\n\"VOLUME\": [],\n\"ISSUE\": [],\n\"PAGES\": [],\n\n\"SEX\": [],\n\n\"CLINICAL STUDY\": [],\n\"IN VITRO RESULTS\": [],\n\"CONFIRM\": []\n}", {"Study": ["clinical study"]}]], [897, "In conclusion, the significant Asafetida inhibitory effect on CYP3A4 metabolic activity was an important finding of this study.", [" {}\n\n\"Asafetida\": [\"Asafetida\"],\n\"CYP3A4\": [\"CYP3A4\"],\n\"metabolic activity\": [\"metabolic activity\"]\n\nIn this study, we investigated the effect of Asafetida on CYP3A4 metabolic activity. The results demonstrated that Asafetida inhibited CYP3A4 metabolic activity significantly.\n\n{}\n\n\"Asafetida\": [\"Asafetida\"],\n\"CYP3A4\": [\"CYP3A4\"],\n\"metabolic activity\": [\"metabolic activity\"],\n\"inhibited\": [\"inhibited\"],\n\"significantly\": [\"significantly\"]\n\nThe inhibitory effect of Asafetida on CYP3A4 metabolic activity was significant in this study.\n\n{}\n\n\"Asafetida\": [\"Asafetida\"],\n\"CYP3A4\": [\"CYP3A4\"],\n\"metabolic activity\": [\"metabolic activity\"],\n\"inhibited\": [\"inhibitory effect\", \"inhibited\"],\n\"significantly\": [\"significant finding\", \"significantly\"]\n\nThis study reported a significant finding: the inhibitory effect of Asafetida on CYP3A4 metabolic activity.\n\n{}\n\n\"Asafetida\": [\"Asafetida\"],\n\"CYP3A4\": [\"CYP3A4\"],\n\"metabolic activity\": [\"metabolic activity\"],\n\"inhibited\": [\"inhibitory effect\", \"inhibited\"],\n\"significantly\": [\"significant finding\", \"significantly\"]\n\nThe significant finding of this study was the inhibitory effect of Asafetida on CYP3A4 metabolic activity.\n\n{}\n\n\"Asafetida\": [\"Asafetida\"],\n\"CYP3A4\": [\"CYP3A4\"],\n\"metabolic activity\": [\"metabolic activity\"],\n\"inhibited\": [\"inhibitory effect\", \"inhibited\"],\n\"significantly\": [\"significant finding\", \"significantly\"]\n\nThe significant finding of the study was that Asafetida inhibited CYP3A4 metabolic activity.\n\n{}\n\n\"As", {"Herb name": ["Asafetida"], "Target": ["CYP3A4"]}]], [898, "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life.", [" \"DRUGS\": [\"abemaciclib\"]\n\"DISEASES\": []\n\"CELLS\": []\n\"ORGANS\": []\n\"PROTEINS\": []\n\"GENES\": []\n\"CHEMICALS\": []\n\"ENTITIES\": [\"abemaciclib-related diarrhea\", \"dose reductions\", \"poor adherence\", \"patients' outcomes\", \"quality of life\"]\n\"SPECIES\": []\n\"LOCATIONS\": []\n\"SEX\": []", {"Drug": ["abemaciclib"], "Pathology": ["diarrhea"]}]], [899, "Moreover, the reckless pieces of information about possible effects of diet, such as fatigue and loose stools, elicited confusion in the patient.", [" \"SEX\": []\n\n\"patient\": [\"patient\"]\n\"effects\": [\"effects\"],\n\"diet\": [\"diet\"],\n\"fatigue\": [\"fatigue\"],\n\"loose stools\": [\"loose stools\"]", {"Pathology": ["fatigue", "loose stools"]}]]], "prompt": "<s> [INST] This is a scientific article about pharmacology.\nWe need to parse all the cited entities. Find every word refering to the described entities.\n\nThe following format must be followed:\n\"SEX\": [\"List of sexes found in text\"]\n\nPlease do not add supplementary in information. If no information is found for a field, leave the field empty.TEXT HERE [/INST]"}